Smoking and Health 2021: a coming of age for tobacco control? by Tobacco Advisory Group (Barker, A.B.), & Tobacco Advisory Group
Smoking and  
health 2021 
A coming of age  
for tobacco control?
A report by the Tobacco Advisory Group  
of the Royal College of Physicians
May 2021
Smoking and  
health 2021 
A coming of age  
for tobacco control?
A report by the Tobacco Advisory Group  
of the Royal College of Physicians
May 2021
Acknowledgements
The Tobacco Advisory Group acknowledges the help of 
the UK Centre for Tobacco and Alcohol Studies and Cancer 
Research UK (CRUK) for supporting some of the original 
research and literature reviews contained in this report; and 
thanks Lynsey Hanvey, Karen Porter and Keith Whitlock in 
the Royal College of Physicians Publications Department 
for their work in producing the report. 
The Royal College of Physicians 
The Royal College of Physicians (RCP) plays a leading 
role in the delivery of high-quality patient care by setting 
standards of medical practice and promoting clinical 
excellence. The RCP provides physicians in over 30 medical 
specialties with education, training and support throughout 
their careers. As an independent charity representing over 
40,000 fellows and members worldwide, the RCP advises 
and works with government, patients, allied healthcare 
professionals and the public to improve health and 
healthcare.
Citation for this document 
Royal College of Physicians. Smoking and health 2021:  
a coming of age for tobacco control? London: RCP, 2021.
Copyright 
All rights reserved. No part of this publication may be 
reproduced, distributed, or transmitted in any form or by 
any means, including photocopying, recording or other 
electronic or mechanical methods, without the written 
permission of the copyright owner. Applications to 
reproduce any part of this publication should be addressed 
to the publisher.
Copyright © Royal College of Physicians 2021
ISBN 978-1-86016-847-5 
eISBN 978-1-86016-848-2
Royal College of Physicians 
11 St Andrews Place 
Regent’s Park 
London NW1 4LE 
www.rcplondon.ac.uk 
Registered Charity No 210508
© Royal College of Physicians 2021 iv
Contents 
Contributors vi
Declaration of contributors’ interests viii
Members of the Tobacco Advisory Group ix
Foreword x
Abbreviations xi
Executive summary and recommendations xii
1. Introduction 1
 1.1 The evolution of tobacco control 1
 1.2  Tobacco industry response to tobacco control 2
 1.3  Objectives of this report 3
2  Impact of tobacco control policy  
on smoking prevalence from 2000  
and modelling to 2050 5
 2.1 Introduction 5
  2.2  Effects of the WHO Framework Convention on 
Tobacco Control policies on smoking behaviour 6
 2.3  Effects of FCTC policies on socio-economic 
inequalities 7
 2.4  UK tobacco control policy and smoking  
prevalence 8
 2.5  Inequalities in smoking in the UK 9
 2.6 Projecting future trends in smoking prevalence 10
3.  Education: policymakers, the public  
and the healthcare workforce 18
 3.1 Introduction 18
  3.2  The evolution of advocacy, lobbying and 
campaigning for policy change 19
  3.3 Health warnings and product labelling 21
  3.4 Mass media and social marketing campaigns 24
  3.5 Medical guidelines   26
 3.6 The healthcare workforce 28
4. Preventing uptake of smoking by children 39
 4.1 Introduction 39
 4.2 Trends in young people’s smoking 40
 4.3 Drivers of youth smoking 41
  4.4  How has progress to date in reducing smoking 
uptake been achieved? 42
  4.5 The role of e-cigarettes 43
  4.6  Future directions in reducing young people’s  
uptake of tobacco 43
5 Tobacco advertising and promotion 48
 5.1  The evolution of tobacco promotion and its 
regulation in the UK 49
 5.2  Effect of media smoking imagery on smoking 
behaviour 50
 5.3  Smoking in films 51
 5.4  Smoking in UK television and on-demand media 57
 5.5  Alibi marketing 59
 5.6  Smoking and the arts 60
 5.7  Point-of-sale advertising 61
 5.8  Standardised tobacco packaging 64
 5.9  Pack inserts 65
 5.10  Flavours and flavour capsules 66
 5.11  Dissuasive cigarettes 66
6 Public space smoking restrictions 73
 6.1 Introduction 73
 6.2  The evolution of public and workplace  
 on smoking in the UK 73
 6.3 Effects of smoke-free policies 74
 6.4 Smoke-free policies in hospital settings 75
 6.5  Effectiveness of further restrictions – outdoor  
public and commercial places and social housing 77
 6.6  Use of vaping in public places to facilitate  
smoking bans 78
v© Royal College of Physicians 2021
7 Economics of tobacco 82
 7.1 Introduction 82
 7.2  The price elasticity of demand for tobacco 
products 83
 7.3  Historic overview of tobacco prices and 
affordability in the UK 85
 7.4  Tobacco industry tactics to mitigate tax rises 87
 7.5  Future directions for tobacco price and  
taxation policy 89
 7.6  Taxation and price elasticity of smoking cessation 
medication, non-tobacco nicotine consumer 
products and heated tobacco products 90
 7.7 A smoke-free dividend 91
8  Tobacco content, nicotine products and 
regulation 95
 8.1 Introduction 95
 8.2  Components, design, and use of  
tobacco products 95
 8.3 Filter ventilation on tobacco cigarettes 100
 8.4  Labelling – tar, nicotine and carbon monoxide 
(TNCO) levels 100
 8.5  Reporting requirements on the  
tobacco industry   100
 8.6 Nicotine product regulation 101
 8.7 ‘Fire safer’ cigarettes 104
9 Treatment of tobacco addiction 108
 9.1 Introduction 108
 9.2 The cycle of addiction in a smoker 108
 9.3 Triggering quit attempts 111
 9.4  Treatment of tobacco dependency  
in healthcare   114
 9.5 Primary care 122
 9.6  The role of e-cigarettes and heated  
tobacco products 125
10  Tobacco industry tactics to undermine 
tobacco control 136
 10.1  Introduction 137
 10.2   Tobacco industry interference in UK  
tobacco control 137
 10.3   Undermining UK tobacco control policy:  
current and future concerns 142
11 Ethical aspects of tobacco control 150
 11.1 Introduction 150
 11.2 Autonomy 151
 11.3 Justice 151
© Royal College of Physicians 2021 vi
Contributors 
Sanjay Agrawal  Professor of respiratory medicine,  
University of Leicester
Deborah Arnott  Chief executive, Action on Smoking  
and Health 
Richard Ashcroft  Professor of bioethics,  
City University, London
Paul Aveyard  Professor of behavioural medicine, 
University of Oxford 
Linda Bauld  Professor of public health, University  
of Edinburgh
Alex B Barker  Research fellow, University of Nottingham
Virginia Berridge  Professor of history and health policy, 
London School of Hygiene and Tropical Medicine
Emma Beard  Principal research fellow, University  
College London
Ilze Bogdanovica  Principal research fellow, University  
of Nottingham
J Robert Branston Senior lecturer, University of Bath
John Britton  Emeritus professor of epidemiology, 
University of Nottingham
Jamie Brown  Professor of behavioural science and  
health, University College London
Phil Chamberlain  Managing editor of Tobacco  
Tactics, University of Bath
Tim Coleman  Professor of primary care, University  
of Nottingham
Lorraine Craig  International tobacco control project 
dissemination manager, University of Waterloo, Canada
Martin Dockrell  Tobacco control lead, Public Health 
England
Richard Edwards  Professor of public health, University  
of Otago, New Zealand
Matthew Evison  Consultant in respiratory medicine, 
Manchester University NHS Foundation Trust
Winifred Ekezie  Research associate, University of Leicester
Becky Freeman  Associate professor, University of  
Sydney, Australia
Geoffrey T Fong  Professor of psychology and public 
health and health systems, University of Waterloo, Canada
Duncan Gillespie  Research fellow, University of Sheffield
Anna B Gilmore  Professor of public health, University  
of Bath
Dave Hammond  Professor, University of Waterloo, 
Canada
Zeinab Hassanein  Postgraduate student, University  
of Nottingham
Summer Sherburne Hawkins  Associate professor,  
Boston College, USA
Thomas R Hird  Research fellow, University of Bath
Rosemary Hiscock  Research associate, University of Bath
Janet Hoek  Professor of public health, University of  
Otago, Wellington, New Zealand
Marie Horton  Senior public health intelligence analyst, 
Public Health England
Nick Hopkinson  Reader in respiratory medicine, Imperial 
College London
Sarah Jackson  Principal research fellow, University  
College London
Emma Knowles  Director of policy and research, 
Healthcare Financial Management Association
Lynn T Kozlowski  Professor of community health and 
health behaviour, University at Buffalo, USA
Mirte AG Kuipers  Research fellow, Amsterdam  
UMC – University of Amsterdam, Netherlands 
vii© Royal College of Physicians 2021
Contributors 
Tessa Langley  Associate professor in health economics, 
University of Nottingham
Jo Leonardi-Bee  Professor of medical statistics and 
epidemiology, University of Nottingham
Ann McNeill  Professor of tobacco addiction,  
King’s College London
Andrew Monahan  Policy and research manager, 
Healthcare Financial Management Association
Crawford Moodie  Senior research fellow, University  
of Stirling
Graham Moore  Professor of social sciences and  
public health, Cardiff University
Marcus Munafò  Professor of biological psychology, 
University of Bristol
Rachael Murray  Professor of population health, University 
of Nottingham
Richard J O’Connor  Professor of oncology, Roswell Park 
Comprehensive Cancer Center, Buffalo, USA
Rob Pryce  Research fellow, University of Sheffield
Elena Ratschen  Senior lecturer, University of York
Lion Shahab  Professor of health psychology, University 
College London
Niamh K Shortt  Professor of health geographies, 
University of Edinburgh
Judith Watt  Consultant for Action on Smoking and Health
Sarah Williams  Tobacco control programme manager, 
Public Health England
Luke B Wilson  Research associate, University of Sheffield
© Royal College of Physicians 2021 viii
Declaration of contributors’ interests
J Robert Branston owns 10 shares in Imperial Brands for 
research purposes. The shares were a gift from a public 
health campaigner and are not held for financial gain or 
benefit. All dividends received are donated to tobacco/
health-related charities, and proceeds from any future 
share sale or takeover will be similarly donated. He is 
the recipient of funding from Bloomberg Philanthropies, 
Stopping Tobacco Organizations and Products project 
funding as well as Cancer Research UK.
Jamie Brown has received unrestricted research funding 
to study smoking cessation from pharmaceutical 
companies (Johnson & Johnson and Pfizer) who 
manufacture smoking cessation medications. 
Geoffrey T Fong has served as an expert witness on 
behalf of governments in litigation involving the tobacco 
industry.
Lion Shahab has received honoraria for talks, an 
unrestricted research grant and travel expenses to 
attend meetings and workshops from Pfizer and an 
honorarium to sit on an advisory panel from Johnson 
& Johnson, both pharmaceutical companies that 
make smoking cessation products. He has acted as a 
paid reviewer for grant awarding bodies and as a paid 
consultant for healthcare companies.
All other contributors have no interests to declare.

















Members of the Tobacco Advisory Group 
of the Royal College of Physicians 
© Royal College of Physicians 2021 x
Foreword
Tobacco smoking is a blight on health and society. The 
ill health, premature death and financial toll caused by 
tobacco use touches all communities in the UK, and is 
typically concentrated in the most disadvantaged and 
vulnerable in our society. Any ward round or GP surgery  
is testament to the devastation it causes on human life.
The Royal College of Physicians (RCP) has been a strong 
advocate for ways to control tobacco use for almost 
60 years; from the initial and groundbreaking report 
Smoking and health in 1962, through constant lobbying, 
evidence collecting and reporting, to the modern day. Our 
work, though, is not done and the problem of smoking 
is far from solved. Across the UK smoking remains one 
of the leading causes of avoidable death and disease, 
exacerbating health inequalities and poverty, and blighting 
the ‘levelling up’ of our society. COVID-19, while not picking 
out smokers on its own rampage, has left a hidden iceberg 
of smoking-related disease that has been overlooked 
during the pandemic. Tobacco may still beat COVID-19 as 
the predominant cause of death and disease during the 
beginning of the 2020s.
Hence, this report is as timely as ones that have gone 
before it. Governments have not been idle but, as this 
report shows, without a fundamental renewal of our 
commitment to eradicating smoking, the UK will not 
meet the Smokefree 2030 ambitions to reduce smoking 
prevalence to less than 5% across all sociodemographic 
groups in the coming decade. However, there is much  
that can be done, and this report brings those practical 
solutions to the fore.
These include a suite of new measures to reduce uptake of 
smoking in children, targeting the drivers of youth smoking, 
most notably through taking radical measures to reduce 
exposure to and the effect of smoking imagery in the 
media; enhancing the use of health warnings on tobacco 
products; further reducing the affordability of tobacco 
products; and raising the minimum age of sale from  
18 to 21 years; together with a range of other measures 
designed to de-normalise smoking. Taxation and limitation 
of the tobacco industry’s ability to exploit loopholes, 
supporting the use of reduced risk nicotine products and 
treating tobacco dependency on an opt-out basis across 
the whole of the NHS will also be key to success. While none 
of these measures alone will put an end to tobacco use, 
their application together in a comprehensive package  
will deliver substantial health gains. 
Too many UK generations have been blighted by addiction 
to tobacco. To ensure that those born today live their  
lives tobacco-free we must take the necessary steps to 
make smoking obsolete. In a historic time of medicine 
showing it can solve the health crises that come its way,  
this is our opportunity to make smoking and tobacco 
addiction history.
Andrew Goddard 
President, Royal College of Physicians
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In 1962, when the Royal College 
of Physicians (RCP) published 
Smoking and health,1 tobacco 
smoking was the largest avoidable 
cause of premature death and 
disability in the UK. During the 
ensuing 6 decades the UK has 
moved from being a global leader 
in tobacco consumption to a global 
leader in tobacco control,2 and the 
subsequent reduction in smoking 
prevalence by about 75% from 1962 
levels is widely regarded as evidence 
of success. 
Yet tobacco smoking is entirely avoidable, so the 
persistence of smoking among almost 7 million regular 
smokers in the UK, and the fact that, as in 1962, smoking 
is still the largest avoidable cause of premature death 
and disability in the UK, actually represent an abject 
failure of public health policy. The ability of the UK and 
other countries to rise to major public health challenges is 
beyond doubt; the COVID-19 pandemic, by far the biggest 
new challenge to UK and global health in decades, has 
attracted a public health and economic response of a scale 
unique in the modern era. Yet in 2020, when COVID-19 
killed around 80,000 UK citizens,3 tobacco smoking killed 
94,000.4 Had the policies advocated by the RCP in 1962 
been adopted and followed through, smoking would – to 
practical purposes – have been eradicated from the UK 
years ago. Modelling of current tobacco control policies 
in this report identifies a failure to achieve a smoking 
prevalence of <5% until after 2050. To end the wholly 
preventable loss of life from tobacco use in the decades to 
come, it is essential to act, radically and comprehensively, 
now. To do otherwise would be unforgivable.
To meet these obligations our national tobacco control 
plans must be much more ambitious across the whole 
spectrum of policies available, and in particular must target 
the most disadvantaged communities. The measures 
necessary to deliver these needs have been identified in 
this report, and to varying extents act by reducing the 
appeal of smoking and encouraging smokers to quit. All 
are simple and inexpensive to implement. These measures 
are summarised below along with a series of policy 
recommendations that the RCP considers necessary to put 
an end to tobacco smoking in the UK. 
Executive summary  
and recommendations 
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1. Taxation
Increasing tobacco taxation is one of the 
most effective means of reducing smoking 
uptake and promoting quitting. UK 
tobacco tax structures need to be reformed 
with the aim of making smoked tobacco 
substantially less affordable and reduced harm nicotine 
alternatives much more affordable. This requires the 
imposition of large, above-inflation annual tax increases 
on smoked tobacco; reducing manufactured cigarette price 
differentials by imposing minimum prices and replacing 
ad valorem taxes with specific taxes; increasing the tax on 
hand rolling tobacco to close the current price differential 
between hand-rolled and manufactured cigarettes; and 
requiring all tax increases to be translated into retail prices 
simultaneously in a single annual increment. 
The strong relation between smoking and poverty makes 
tobacco tax increases regressive, and this concern has acted 
as a brake on more radical imposition of tobacco taxes since 
1962. For that reason alone it is essential that tax increases 
are used in combination with measures that make it as easy 
as possible for smokers to stop using tobacco, for example 
through the routine provision of stop smoking support in 
all NHS services, and by actively promoting the uptake 
of consumer alternatives to smoking such as electronic 
cigarettes. Tax increases are, however, also most effective 
among poorer smokers, so to hold back on their use only 
perpetuates health harms and health inequalities. On the 
other hand, eradicating tobacco use, even if tobacco is 
substituted with other nicotine products, could inject up to 
£7 billion of current tobacco spending directly back into the 
pockets of smokers and their communities.  
To incentivise and signal the importance of substituting 
tobacco with less harmful forms of nicotine, the level of 
taxation applied to non-tobacco nicotine products should 
be proportionate to their harm relative to tobacco. To this 
end, tax on medicinal nicotine should be abolished and tax 
on electronic cigarettes reduced. 
Recommendations
>  Tobacco product affordability is reduced by large, annual, 
above-inflation tax increases on all tobacco products that 
are translated immediately into retail prices, consideration is 
given to applying more radical increases aiming, for example, 
to double the price of cigarettes over a 5-year period.
>  Tax on hand rolling tobacco is increased to a greater 
extent to ensure that within 5 years the tax paid per 
cigarette, containing the typical weight of tobacco, is 
equivalent to that on manufactured cigarettes.
>  The regressive nature of higher taxes on tobacco is 
ameliorated by making easy access to cessation support 
universal to all smokers, and by encouraging those who 
continue to smoke to switch to non-tobacco nicotine.
>  To support this approach, tax on medicinal nicotine is 
reduced to zero and to 5% on consumer non-tobacco 
nicotine products such as electronic cigarettes. 
2. Health promotion 
Educating people about the harms of 
smoking, and encouraging quitting, have 
played major roles in reducing smoking 
prevalence since the mid-20th century, 
and this approach remains essential to 
further progress. Mass media campaigns are effective 
and relatively inexpensive but spending on mass media 
campaigns in the UK plummeted in 2010 and remains low. 
Restoring investment in media campaigns at the very least 
to the equivalent of the 2008 level of £23 million, the year 
that immediately preceded the highest uptake of NHS 
smoking cessation services by smokers,5 would provide a 
low-cost, highly effective method to incentivise smokers to 
quit. Media campaigns should also encourage switching 
from smoked tobacco to e-cigarettes and provide balanced 
information on other harm reduction options such as 
heated tobacco. Health warnings on tobacco packaging 
need to be strengthened and extended to individual 
cigarettes and hand rolling papers. 
Recommendations
>  Funding of mass media campaigns is increased to at 
least 2008 levels, to provide a low-cost, high-impact 
intervention to strengthen a comprehensive tobacco 
control strategy.
>  Mass media campaigns support the use of electronic 
cigarettes as a quitting aid or substitute for smoking, and 
redress false perceptions about the safety of e-cigarettes 
compared with cigarettes.
>  Health warnings on tobacco products are enhanced in 
size and supplemented by quit lines or web links that 
support cessation and by package inserts that provide 
information on health effects and quitting.
>  The use of dissuasive colours and health warnings is 
extended to individual cigarettes and hand rolling papers. 
>  Health warnings on e-cigarette packs include a statement 
that e-cigarette vapour is likely to be substantially less 
harmful than tobacco smoke. 
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3. Public space smoking 
restrictions
Smoke-free policies reduce exposure to 
tobacco smoke, encourage quit attempts, 
generate health benefits, protect children, 
de-normalise smoking and have strong 
public support. In healthcare settings, 
smoke-free premises and grounds are an essential 
component of a comprehensive approach to treating 
tobacco dependency among service users. Smoke-free 
policies in NHS settings should therefore be reinforced 
through legislation. 
Smoking in the home is a major source of involuntary 
exposure to tobacco smoke, particularly in disadvantaged 
households and should be reduced by interventions 
which target home smoking behaviour, including media 
campaigns and provision of cessation or temporary 
abstinence support, and particularly so in housing 
managed by local government and housing associations.
Use of non-tobacco nicotine, including e-cigarettes, is 
important as a means to support abstinence from smoking 
in public places, and in some circumstances also indoors. 
Therefore, smoke-free policies should not automatically be 
extended to include non-tobacco nicotine use.
Recommendations
>  Legislation prohibiting smoking in hospital grounds is 
adopted in England, thus aligning with laws adopted by 
the devolved nations. 
>  Smoking in the home is reduced by interventions which 
target home smoking behaviour, encouraging quitting 
and/or smoking only outdoors. 
>  Electronic cigarettes do not emit smoke, so smoke-free 
policies are not automatically extended to vaping.
>  Policies on vaping in indoor and outdoor areas are used 
to facilitate smoke-free policies, acknowledging that 
permitting vaping where smoking is prohibited may help 
indoor and outdoor smoke-free measures to succeed. 
4. Tobacco and nicotine 
product regulation
Nicotine product regulation should be used 
more proactively to reduce harm from 
smoked tobacco and promote substitution 
with alternative nicotine products. Hence, 
measures such as prohibiting cigarette 
filter vents, minimising filter porosity and imposing lower 
maximum standard tar, nicotine, and carbon monoxide 
yields, may be helpful in making cigarettes less desirable, 
and might encourage smoking cessation or substitution 
with less-hazardous nicotine delivery systems. Reporting 
requirements on the content and emissions of non-tobacco 
consumer nicotine products such as electronic cigarettes 
should be standardised and made easily available to the 
public. Substitution with non-tobacco nicotine products 
should be encouraged by allowing the use of comparative 
health claims in promotional materials. 
Recommendations
>  The toxicology of novel tobacco products is 
independently verified.
>  A review of the regulation of e-cigarettes in the UK is 
undertaken to assess the extent to which the regulations 
support switching from smoking, while limiting appeal to 
and use by youth, as well as the extent to which the current 
regulations ensure products on the market are safe.
5. Treating tobacco 
addiction
Treating tobacco addiction should become 
the norm in all areas of healthcare, with 
opt-out treatment services offered and 
provided at all points of NHS contact. 
Additional measures of proven efficacy 
should also be utilised, including financial incentives 
in maternal smoking cessation pathways and tailored 
treatment for tobacco dependency for patients with serious 
mental illness. There needs to be better access and services 
for the LGBT community. E-cigarettes are an effective 
treatment for tobacco dependency and their use should be 
included and encouraged in all treatment pathways.
The healthcare workforce needs targeted education to 
learn that treating smoking is a core duty, and healthcare 
delivery restructured to integrate smoking cessation 
treatment into all clinical contacts. Treating smoking 
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must be included in undergraduate, postgraduate and 
place-based training for clinicians and other healthcare 
professionals. 
Recommendations
>  The NHS provides opt-out smoking cessation services to 
all smokers at any point of contact with the NHS.
>  Financial incentives are provided in maternal smoking 
cessation pathways.
>  Patients with serious mental illness are offered tailored 
treatment for tobacco dependency.
>  Better access to services is provided for tobacco-
dependent members of the LGBT community. 
>  Training in the practical delivery of cessation and 
temporary abstinence advice and in prescribing smoking 
cessation medications is universal across the NHS and 
social care system.
>  Primary care practitioners treat tobacco dependency, 
supported by a reform to the system that rewards 
treatment and enhanced training in primary care.
>  E-cigarettes are included in standard protocols to treat 
tobacco dependency.
6. Preventing smoking 
uptake 
Smoking uptake occurs because children 
see others smoke. This role modelling 
can arise from personal encounters with 
smokers among family members, friends 
and peers, and from exposure to smoking 
imagery in the media. 
Exposure to smoking role models among family members, 
friends and peers occurs as a function of the general 
prevalence of smoking, and while not instantly preventable 
can be reduced by the many other measures described in 
this report to help smokers to quit smoking. 
Media exposure to smoking imagery, and particularly 
exposure occurring in mainstream media such as 
television and film, is entirely preventable in new content 
by extending to tobacco the regulations that currently 
and successfully protect young people from exposure to 
other harmful imagery, and can be ameliorated in existing 
content by following the example of India in requiring, 
among other measures, on-screen health warnings and 
anti-smoking health promotion messages in any television, 
film or on-demand media containing smoking. Measures 
are also required to prohibit all forms of alibi marketing, 
tobacco industry sponsorship and social media promotion. 
Dissuasive cigarettes offer a means to make media 
smoking imagery less appealing. Since there is evidence 
that the decline in youth smoking may be slowing, these 
measures are a particular priority. 
Other available policy options to make smoking uptake 
less likely are to reduce the availability of cigarettes by 
raising the minimum legal age of sale to 21 years, licensing 
tobacco vendors to discourage access to cigarettes 
through underage sale, extending standardised packaging 
legislation to include smoking paraphernalia such as 
cigarette papers, hand rolling filters and flavour cards, 
and extending point-of-sale legislation to remove tobacco 
gantries from sight. 
Recommendations
>  Exposure to tobacco imagery is included in the definition of 
online harm used in the forthcoming Online Safety Bill.
>  Regulation of film and television is reformed to ensure that 
children are not exposed to tobacco imagery in the media. 
>  New films showing smoking automatically receive an 
18 certificate, and television programmes containing 
smoking are not broadcast before the 9pm watershed. 
>  All existing and future films, television programmes, 
video-on-demand, music videos and print media that 
include tobacco imagery are required to display health 
warnings when tobacco imagery is present. 
>  Anti-smoking health promotion messages are screened 
before any film, television programming and video on-
demand service programmes containing smoking. 
>  Tobacco product imagery is not shown on online sales 
websites. 
>  Advertising legislation is reformed to end alibi marketing 
and all tobacco industry sponsorship.
>  Exposure to tobacco at point of sale is ended by taking 
all retail tobacco gantries and cabinets out of sight and 
removing all product imagery from online sales websites.
>  The tobacco display ban and standardised packaging 
regulations are extended to include tobacco 
paraphernalia such as hand rolling paper.
>  The minimum legal age of sale of tobacco products is 
raised to 21 years. 
>  Flavour infusion products are prohibited and flavour 
restrictions extended to filters and other tobacco 
paraphernalia. 
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>  Additional measures are introduced to reduce the uptake 
of smoking, including restricting access to tobacco 
vendors through tobacco licensing schemes, restrictions 
on the packaging of electronic cigarettes to make them 
less appealing to children, and school-based interventions 
targeting multiple risk behaviours simultaneously. 
7. Countering tobacco
industry tactics
The tobacco industry has been a lucrative 
business for more than a century, enjoying 
political influence and exemptions from 
rules and regulations that apply to other 
industries and consumer products. To 
protect profits the tobacco industry has consistently slowed, 
blocked, circumvented or overturned comprehensive 
tobacco control policies, often in contravention of 
measures to counteract tobacco industry interference 
set out in Article 5.3 of the Framework Convention on 
Tobacco Control. The policies advocated in this report must 
therefore be accompanied by measures to prevent the 
tobacco industry from deploying these tactics to oppose 
them, which to practical purposes means excluding the 
tobacco industry, industry lobbyists and advocates from all 
areas of government policymaking.
Recommendations 
>  The tobacco industry is excluded from all policymaking 
across government, from meeting with government 
officials and elected representatives, from making gifts 
or payments in kind and from any activity likely to or with 
the potential to promote tobacco use.
>  A lobbying register is established for the disclosure of any 
and all funding sources of individuals or organisations 
lobbying government on tobacco control. 
>  Contributions (monetary or otherwise) from the 
tobacco industry or tobacco industry-funded third party 
organisations to political parties, government officials at all 
levels and all-party parliamentary groups are prohibited.
>  Tobacco companies are statutorily required to provide 
information to government on their political activities 
and associated expenditure including the names of 
organisations they fund.
>  A tax or levy on tobacco companies is introduced to 
fund independent tobacco control research, including 
independent testing of tobacco industry product 
contents and emissions.
8. Ethical aspects of
tobacco control
Tobacco products are harmful, addictive, 
and are used predominantly by 
disadvantaged or marginalised people 
who in most cases become addicted while 
they are still children. The perpetuation 
of smoking in and by society thus contravenes the 
fundamental principles of autonomy and justice. Failure to 
do all that is possible to prevent young people from taking 
up smoking, and supporting and encouraging quitting 
among all existing smokers, is unethical.
9. Monitoring the
effects of tobacco 
policy
To evaluate the effects of tobacco control 
policies, and to enable the early detection 
and reversal of unwanted or unpredicted 
adverse effects of policy, it is essential that 
government continues carefully to measure 
smoking prevalence, in detail, across the UK population. 
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Key points
>  The publication of Smoking and health1 in 1962 
established the Royal College of Physicians (RCP) as a 
world leader in tobacco control policy.
>  The reluctance of the UK government to act on RCP 
recommendations led the RCP in 1971 to establish Action 
on Smoking and Health (ASH), a highly successful and 
effective advocacy organisation.
>  The policy recommendations set out in Smoking and 
health1 have formed the basis of comprehensive tobacco 
control frameworks used around the world. 
>  To the extent that they have been applied, these policies 
have led to significant reductions in smoking prevalence 
in the UK. 
>  Smoking is driven by the commercial interests of the 
tobacco industry, which over the years has sought to 
avoid or undermine comprehensive tobacco control 
measures. 
>  As a result, the tobacco industry remains highly profitable 
and has over 1.3 billion global consumers, including 
approximately 130 million children, addicted to its lethal 
product. 
>  Smoking prevalence remains stubbornly high in the UK, 
is concentrated in deprived communities and contributes 
significantly to health inequalities.
>  Achieving national aspirations to ‘level up’ society, 
establish a ‘smoke-free’ generation by 2030 and reduce 
health inequalities will require a much more ambitious 
programme of interventions than currently proposed.
>  We can achieve these goals if we adopt a new set of 
comprehensive tobacco control measures set out in this 
report.
1.1 The evolution of tobacco control
In 1962 among a UK population of 53 million, 56% of  
men and 42% of women smoked cigarettes. Still more 
people, mostly men, smoked cigars or pipes. The RCP, 
whose only previous intervention in public health was a 
1725 representation to the House of Commons on the 
disastrous consequences of rising consumption of cheap 
gin, elected in 1959 to establish a committee tasked 
to produce a report on ‘the question of smoking and 
atmospheric pollution in relation to carcinoma of the lung 
and other illnesses’. The report, Smoking and health,1 aimed 
at the public and policymakers as much as – if not more 
than – the medical profession, was published on 7 March 
1962. Within weeks it had sold 50,000 copies in the UK and 
30,000 in the USA. 
The 1962 report laid out a range of actions for government 
which formed the basis of modern tobacco control. On 
a limited but evolving evidence base, an array of key 
interventions was proposed to reduce the harm from 
smoking. In 1971, disappointed at how little had changed, 
the RCP set up Action on Smoking and Health (ASH) to 
advocate for the ‘decisive action’ called for by the RCP. 
This effective combination of academia and advocacy 
led, some 4 decades later, to the adoption of these 
interventions in the World Bank 1999 report,2 the landmark 
Framework Convention on Tobacco Control (FCTC)3 – the 
World Health Organization (WHO)’s first international 
health treaty, and the Tobacco Control Scale (TCS) – an 
approach to independent assessment developed for the 
Association of European Cancer Leagues4 (Table 1.1).
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Table 1.1 Tobacco control frameworks 
Sources
Domains











X X X X
Second-hand 
smoke
X X X X
Affordability X X X X
Regulation X X X X
Cessation support X X X X










Research and data X X
Protect health 
policy from vested 
interests 
X X
The only measure proposed by the RCP in the 1962 
report1 that has proved over time to be misdirected was a 
requirement to inform smokers of tar and nicotine levels 
in cigarettes. However, the RCP also recommended, in the 
text of the report, measures to reduce the harmful effects 
of cigarettes. Although at the time this concept involved 
using filters or modified tobacco, the principle of modifying 
tobacco products to reduce their risk is one that has in 
recent years attracted considerable new interest. This 
concept of harm reduction was not included in the FCTC3 
nor explored by the World Bank report.2 Since 1962 the RCP 
has continued to produce reports on aspects of tobacco 
control and to campaign on tobacco control matters in 
partnership with ASH and other organisations committed 
to tobacco control.
Nearly 60 years after the 1962 RCP report1 was published, 
smoking rates have fallen substantially in the UK – to 14.1% 
in 2019.5 However, this figure translates into an alarming 
total of almost 7 million UK citizens, predominantly the 
most disadvantaged and marginalised in our society, who 
are still smoking5 and hence on track to bear a substantial 
future burden of disease and premature death. Globally, 
the pattern is similar. Although the prevalence of smoking 
has declined substantially in most countries over the 
past 20 years (Fig 1.1), for a product that is known to be 
lethal to its consumers, it is shocking that over 20% of the 
world’s population, equivalent to around 1.3 billion people, 
currently use tobacco.6
Fig 1.1 Global trends in prevalence of tobacco use by sex.6 
© World Health Organization 2019
1.2 Tobacco industry response to tobacco 
control
The epidemic of smoking and of death and disease 
caused by tobacco use is a phenomenon driven by the 
commercial profit motive of the global tobacco industry. 
Over much of the 20th and all of the 21st centuries, 
tobacco companies have adapted to and where possible 
circumvented legislation and regulations intended to curb 
tobacco use through a number of mechanisms including: 
influencing politicians and using litigation to prevent 
or hold up tobacco control legislation;7 embracing new 
media and viewing habits to promote their products to 
vast audiences; 8–10  denying or misleading the public and 
politicians about the harmful and addictive nature of 
their products;11 supporting the illicit tobacco trade;12,13 
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on tobacco products;14 downplaying the environmental 
impact of tobacco production15 and introducing new 
tobacco products to keep current or entice new users, all 
while regularly reinventing themselves to portray corporate 
and social responsibility.16 These and other strategies 
have been successful in growing the global tobacco 
market: indeed, with a global total of over 1.3 billion users6 
including 130 million adolescents,17 6 trillion cigarettes 
manufactured worldwide in 201415 and estimated global 
revenues of around $767 billion in 2019,18 selling tobacco 
has never been more profitable. To maintain this successful 
commercial position, the tobacco industry has not been shy 
in shifting its consumer base to low- and middle-income 
countries,6 which now account for 80% of global sales, 
and to those who can least afford to smoke, exacerbating 
health inequalities and poverty.5 The success of the 
tobacco industry is acknowledged by global stock markets: 
tobacco industry stocks are viewed as a ‘defensive stock’ 
when there is economic turbulence and have enjoyed 
consistent investor support and sustained high prices over 
many decades.19 Despite comprehensive tobacco policies, 
tobacco use remains the leading cause of death in men 
worldwide, and is responsible for nearly 8% of all disability-
adjusted life years lost globally.20
The UK is home to two of the world’s four transnational 
tobacco companies. It was at the forefront of the global 
smoking epidemic in the 20th century, then became a 
world leader in implementing tobacco control measures in 
the 21st century.4 However, the UK is still failing to take all 
the necessary steps to bring the smoking epidemic to an 
end. Smoking rates remain unacceptably high, especially in 
disadvantaged communities.5 The current UK government 
ambition to achieve a ‘smoke-free’ generation,21 which 
they define as a smoking prevalence of less than 5% 
across the UK in the next 10–15 years is unattainable on 
the current trajectory.22 The renewed Tobacco Control 
Plan for England, due in 2021,23 provides an opportunity 
to introduce far more radical and effective tobacco control 
measures in the UK. 
1.3 Objectives of this report 
This report sets out to review the evidence on existing and 
potential new tobacco control policies and to propose a 
comprehensive suite of evidenced-based tobacco control 
measures to reduce smoking uptake in children and help 
existing smokers to quit. The measures include reforming 
tax policy, eradicating media promotion of smoking, 
prioritising the treatment of tobacco dependency, realising 
the potential of comprehensive public health campaigns to 
promote quitting, raising the legal age of sale for tobacco 
products, and silencing the voice of the tobacco industry. 
Critically, the effect of the sum of these measures is likely to be 
much greater than the individual parts and together can form 
the basis of a national ambition to make smoking obsolete 
within a generation. If implemented, the measures proposed 
in this report will prevent countless deaths, dramatically 
reduce the burden placed by tobacco use on health services 
and wider society, substantially reduce inequalities in health 
and, by alleviating poverty and improving health, contribute 
significantly to the levelling up of our society.
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Key points
>  Comprehensive implementation of Framework 
Convention on Tobacco Control (FCTC) policies has been 
demonstrated to reduce smoking prevalence.
>  Evidence on the effect of FCTC policies on inequalities in 
smoking prevalence is more limited; increasing tobacco 
prices has been found to be the most likely to reduce 
inequalities in smoking.
>  In the UK, comprehensive implementation of tobacco 
control policies over the past 20 years has been 
associated with substantial reductions in smoking 
prevalence in adults and young people; however, a 
significant proportion of adults continue to smoke.
>  Tobacco use in disadvantaged groups in the UK has 
declined but remains much higher than in other groups.
>  Modelling suggests that current tobacco control 
measures will not achieve a target smoking prevalence of 
less than 5% by 2030 and that people living in the most 
deprived socio-economic conditions are likely to lag far 
behind the 2030 target.
>  A sixfold increase in the odds of quitting among males 
living in the most deprived socio-economic conditions 
would be needed for smoking prevalence in this 
population subgroup to reach the 5% target by 2030.
Recommendation
>  A renewed set of tobacco control policies that supports 
quitting smoking is introduced to reduce prevalence 
across the general population and in particular in low 
income smokers.
2.1 Introduction 
Although UK tobacco control policies originated in the 1962 
Smoking and health report,1 national and international 
tobacco policy was revolutionised some 4 decades later 
by a legally binding global treaty – the World Health 
Organization (WHO) Framework Convention on Tobacco 
Control (FCTC). This came into force in 2005 and requires 
governments to implement evidence-based measures 
to curb the tobacco epidemic.2 The UK was among early 
adopters of the treaty, and as of May 2020, the FCTC has 
been ratified by 182 Parties (181 countries and the EU), 
covering more than 90% of the world’s population. 
The FCTC calls on parties to implement measures to 
reduce both the demand for and supply of tobacco 
products by implementing cost-effective tobacco control 
measures including price and tax measures; bans on 
tobacco advertising, promotion and sponsorship; smoke-
free policies; health warnings on tobacco packages; 
monitoring and surveillance; and measures to combat illicit 
trade in tobacco products. In 2008, these measures were 
summarised and repackaged under the acronym MPOWER 
(see Box 1).3
Monitor tobacco use and prevention policies Protect 
people from tobacco use Offer help to quit tobacco use 
Warn about the dangers of tobacco use Enforce bans on 
tobacco advertising, promotion and sponsorship Raise 
taxes on tobacco
Box 1 MPOWER measures.
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2.2.  Effects of the WHO Framework 
Convention on Tobacco Control policies on 
smoking behaviour
Several major studies published over the last 5 years 
have examined the relation between the extent of 
implementation of MPOWER policies in different countries 
and smoking prevalence; quitting; and consumption. 
Some studies focus only on the POWER policies because 
monitoring is not in itself a demand-reduction policy. 
Most identify an association between levels of policy 
implementation and falls in tobacco use.
A 2017 study by Gravely et al examined WHO data from 
126 countries for the first 10 years of FCTC implementation 
(2005 to 2015), to examine the relation between the 
number of POWER policies that had been implemented at 
the highest level (rated by WHO as having achieved level 
5 implementation according to a scale of 2–5, where 1=no 
data available) between 2007 and 2014 and change in 
smoking prevalence.4 The study found that each additional 
highest level policy implementation was associated 
with an average decrease in smoking prevalence of 1.57 
percentage points, or a relative decrease of 7.09%. This 
analysis extended the findings of previous studies that used 
single timepoint measures of policy implementation. In a 
study of 60 countries, Dubray et al found that those with 
a higher MPOWER implementation score (a sum of each 
of the six MPOWER measure scores) in 2008 experienced 
greater decreases in smoking prevalence between 2006 
and 2009.5 In 2016, Anderson et al found that higher 
POWER implementation scores in 2010 were associated 
with greater reductions in smoking prevalence between 
2010 and 2015.6
In 2017, Ngo et al examined the relation between smoking 
prevalence (in 63 countries) and cigarette consumption 
(in 75 countries) among adults and MPOWER composite 
scores – with a possible range between 6 (1 in each of 
the six scores) and 29 (4 in M score and 5 in POWER 
scores) – measured in 2007–8, 2010, 2012 and 2014.7 
Results indicated that greater implementation significantly 
reduced both smoking prevalence and per capita cigarette 
consumption between 2007 and 2014. With a one-unit 
increase in the MPOWER composite score, smoking 
prevalence among adults reduced by 0.2 percentage points 
and cigarette consumption by 23 sticks (approximately 
1 pack) per person per year. The study concluded that 
implementing the MPOWER package at its highest level 
from 2007 to 2014 would have generated additional 
reductions in adult smoking prevalence during this period 
of 7.3%, and in cigarette consumption per capita per year: 
13.8%.
Several studies have analysed the association between 
MPOWER policy implementation as measured by the 
Tobacco Control Scale (TCS) – a weighted average of 
the strength of implementation of six tobacco control 
FCTC/MPOWER measures8 – and smoking and quitting 
behaviour. Feliu et al analysed the relation between TCS 
scores and adult smoking prevalence across the 27 EU 
member states between 2006 and 2014.9 Those member 
states with higher TCS scores had significantly greater 
relative reductions in smoking prevalence and higher quit 
ratios, as measured by the Eurobarometer surveys, over 
that 8-year period. However, a cross-sectional study of 
27 EU countries by Bosdriesz et al found no statistically 
significant association between national TCS score 
and adult smoking cessation and smoking intensity.10  
Inconsistencies between these two studies may reflect 
differences in study design and outcome measures. 
Serrano-Alarcón et al studied longitudinal changes in older 
adults’ smoking prevalence in 10 European countries.11 
They found that a 10-point increase in TCS was associated 
with a 1.6 percentage point decrease in smoking 
prevalence among 50- to 65-year-olds, but not among 
those over 65. A cross-sectional study among adolescents in 
13 European countries found an inverse association between 
the TCS score and smoking prevalence, with 15% lower odds 
of smoking with a TCS score of 10 points higher in 2011.12
Hoffman et al assessed the impact of the FCTC on global 
cigarette consumption from 1970 to 2015 in 71 countries 
by measuring trends in consumption before and after 
the treaty was adopted in 2003.13 The analyses were 
conducted using a new open access dataset of national 
cigarette consumption estimates from verified data 
sources. Changes in cigarette consumption which are 
based on sales data can reflect changes in consumption 
among people who continue to smoke as well as changes 
in smoking prevalence but may not (accurately) capture 
consumption of illicit tobacco; however, unlike survey data, 
such data are not subject to reporting bias. The Hoffman 
study found no significant change in global cigarette 
consumption trends after 2003. However, this overall 
finding was the result of two significant, but opposing 
effects: a significant reduction in consumption after the 
FCTC in high-income countries (HICs), including the UK 
and other European countries; and a significant increase 
in consumption in low- and middle-income countries 
(LMICs) and Asian countries. The authors suggest that 
the increase in consumption in LMICs may be due to 
limited implementation of tobacco control policies in 
these countries and rapidly increasing incomes resulting 
in greater affordability and demand for cigarettes. In 
addition, the enormous shift in tobacco use from HICs to 
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LMICs had been foreseen by epidemiologists,14,15  as rapid 
economic growth in LMICs made such countries vulnerable 
to the tobacco industry seeking to regain lost sales in richer 
countries.16  
Although it is possible that FCTC policies might be less 
effective in some countries compared to others, LMICs 
which have effectively implemented and enforced FCTC 
policies have seen substantial reductions in tobacco use.17 
The research evidence thus supports the general conclusion 
that FCTC tobacco control measures reduce smoking 
prevalence. Considering the benefits of the FCTC, it is 
distressing that global implementation of these measures 
remains extremely low. The WHO reports that in 2018, 59 
countries (of which 6 have neither ratified nor signed the 
FCTC), 49 of which are LMICs, had yet to adopt a single 
MPOWER measure at the highest level of achievement,18 
despite the inclusion of FCTC implementation as an 
important means to achieving global health targets. 
Barriers to the implementation of FCTC policies in LMICs 
include: political commitment, institutional capacity and 
operational effectiveness, social climate, and tobacco 
industry interference.19 The WHO Global Action Plan for 
the Prevention and Control of Noncommunicable Diseases 
2013–2020 set a global target to cut prevalence of current 
tobacco use by 30% by 2025 relative to 2010, but only 
32 countries are currently on track to reach this target.20 
The urgent need to accelerate and strengthen the global 
implementation of the FCTC is also recognised as crucial 
to the achievement of the overall health agenda of the 
United Nations (UN) Sustainable Development Goals 
(SDGs). The SDGs were adopted in 2015 and one of 
their targets is to reduce premature mortality from non-
communicable diseases by one-third by 2030.21–23 
2.3 Effects of FCTC policies on socio-
economic inequalities 
While smoking uptake in LMICs often begins among 
the more affluent, over time smoking tends to 
become concentrated among the relatively poor and 
disadvantaged. Socio-economic inequalities in smoking 
have increased in many countries over the last few 
decades24 suggesting that tobacco control policies 
may be less effective in or are failing to reach the most 
disadvantaged groups. This may be in part because FCTC 
policies were not developed from an equity perspective; 
reducing inequalities in smoking was not specified 
as an aim.2 Many policies have taken a population-
shift approach, in which the behaviour of the general 
population is targeted, but not specifically that of the 
groups at highest risk. 
Studies of the relation between FCTC policy 
implementation in European countries, based on the 
Tobacco Control Scale,8 and smoking behaviour have 
produced mixed results. In a study of 18 European 
countries in 2008, Schaap et al. concluded that high and 
low income adult smokers benefit approximately equally 
from population-level tobacco control policies,25 while 
a more recent study of adults in 27 European countries 
concluded that associations between tobacco control 
policies and smoking cessation were detectable mostly 
among higher socio-economic groups.10 In a study 
assessing the differential policy effects in adolescent 
smokers of 13 European countries in 2003–2011, 
researchers also found no statistical difference by parental 
education level, although effects were consistently 
somewhat stronger in adolescents with highly educated 
parents.12 
A number of reviews have synthesised the evidence on 
the impact of tobacco control policies on inequalities 
in smoking. In 2008, Thomas et al concluded that 
population-level tobacco control interventions have the 
potential to benefit more disadvantaged groups.26 A 
subsequent review by Hill et al in 2014 found that evidence 
on the equity impact of interventions other than price 
– which was identified as an intervention which could 
best reduce inequalities – was inconclusive.27  Similarly, in 
reviews of the equity impact of tobacco control policies in 
both adults and young people, Brown et al found that tax 
increases had the most consistent positive equity impact, 
but that overall the evidence base was limited.28,29 However, 
Brown et al found that that most studies which identified 
a neutral equity impact found that policies benefited 
all SES groups.28 Most recently, in an update of the Hill 
review, Smith et al identified an increase in the number 
of studies assessing the equity impact of tobacco control 
interventions, but highlighted that findings are often mixed 
or unclear, due to methodological challenges.30   
Despite these uncertainties, reducing the affordability of  
tobacco has been consistently found to be most likely to 
reduce inequalities in smoking, both among adults and 
in youth27–30 and use of tax to increase tobacco price is 
generally regarded as the most effective tobacco control 
policy.31 Tobacco price increases are regressive, in that low 
income smokers spend a higher proportion of their income 
on tobacco; however, the benefits of price increases are 
progressive, with low income groups benefiting most, 
because low income smokers are more likely to reduce their 
tobacco consumption in response.32 To offset the regressive 
aspect of tobacco price increases it is argued that on 
ethical grounds, price increases should be implemented 
in combination with provision of smoking cessation 
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support targeted towards disadvantaged smokers, which 
have in turn also been found to contribute to reducing 
inequalities.30 As such, there is a need to combine national-
level strategies with activity at the local level to ensure 
that support focuses on communities where smoking 
prevalence is highest. 
Although more evidence is needed to understand the 
differential effects of tobacco control policies, overall 
it appears that multiple tobacco control interventions 
as part of a comprehensive tobacco control approach 
can reduce smoking in low income groups. Increasing 
acknowledgment of the barrier that smoking poses to 
the achievement of Sustainable Development Goals 
and human rights33–36 and the potential for tobacco 
taxation to be used to fund healthcare and other social 
programmes also supports tobacco taxation as a socially 
progressive policy. Further reducing tobacco use in 
disadvantaged groups requires sustained implementation 
of a comprehensive set of tobacco control policies, 
among which reducing access to affordable tobacco 
and enhancing cessation support for disadvantaged 
communities may have the biggest impact on inequalities.  
2.4 UK tobacco control policy and smoking 
prevalence
The implementation of a comprehensive set of tobacco 
control policies over the past 2 decades has coincided with 
consistent falls in smoking prevalence among both adults 
and young people. Nevertheless, despite these reductions 
in prevalence approximately 14% of adults continue to 
smoke in 2020, with smoking increasingly concentrated in 
disadvantaged populations such as low-income groups and 
individuals with a mental health condition (see section 2.5). 
Smoking thus remains a significant public health problem. 
Figure 2.1 demonstrates trends in smoking prevalence 
among adults and youth since the announcement of a 
comprehensive package of tobacco control policies in the 
Smoking kills white paper in 199837 and a chronology of 
the policies implemented since. In addition to those listed 
in Fig 2.1, tobacco tax increases have been consistently 
implemented since the 1990s (see chapter 7) and a range of 
tobacco control mass media campaigns delivered (see chapter 
3). However, funding for mass media campaigns has been 
reduced in recent years: in 2009–10 funding for national anti-
smoking mass media campaigns in England was just under 
£25 million, whereas in 2019–20 it was £1.78 million.38,39
Fig 2.1 Smoking prevalence in adults in Great Britain and young people in England (current and 
occasional smokers) and key dates for implementation of tobacco control policy. 
Adapted from ONS40 and NHS Digital.41
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2.5 Inequalities in smoking in the UK
Smoking is the leading preventable cause of socio-
economic inequalities in health across the UK, accounting 
for around half the difference in life expectancy between 
the richest and poorest groups.42 Smokers from more 
deprived communities in the UK disproportionately bear 
the burden of the health harms of combustible tobacco 
use.43 Furthermore, the cost of smoking exacerbates and 
perpetuates poverty for families and individuals, and 
accounts for over £2 billion per year in avoidable NHS 
expenditure.44–46 
Although smoking prevalence has declined in all socio-
economic groups in recent years (Fig 2.2), smoking remains 
more than twice as prevalent among adults in routine and 
manual occupations than among those in managerial 
and professional occupations (25% vs 10%).40 Smoking 
prevalence is also high among adults with a mental health 
condition.47 Although prevalence has declined in this group 
in recent years, more than a quarter of adults with a long 
term mental health condition are current smokers (Fig 2.3).
The UK is one of few countries worldwide to focus its 
tobacco control strategies on reducing inequalities in 
smoking. Recent action plans including the Tobacco 
Control Plan for England,42 the 2013 Scottish strategy 
and its 2018 successor,48,49 the Northern Ireland Tobacco 
Control Strategy50  and the Welsh Action Plan51 all specify 
smoking reduction among disadvantaged groups, including 
low income smokers and smokers with a mental health 
condition, among their main aims and priorities. Actions set 
out in these plans to achieve reductions include identifying 
and targeting support into areas with high levels of smokers 
and the implementation of national smoking cessation 
guidance in mental health contexts. Recent trends indicate 
that reductions in smoking prevalence have indeed 
occurred in these groups, but huge disparities in smoking 
prevalence remain. The effects of action plans focused on 
disparities will need to be closely monitored to evaluate 
whether these are sufficient to eventually close the gap. 
However, future policies may need to be further developed 
to reduce and accelerate reductions in inequalities in 
tobacco.
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Fig 2.2 Smoking prevalence in the UK,  
by occupational group. 
Adapted from ONS40
Fig 2.3 Smoking prevalence in adults with a long-term 
mental health condition, England. 
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2.6 Projecting future trends in smoking 
prevalence 
The 2019 UK government prevention green paper53 set 
the ambition for England to be smoke-free by 2030, with 
smoke-free defined in the 2017 Tobacco Control Plan 
as a smoking prevalence below 5%. The target date for 
Scotland is 2034, whereas Wales and Northern Ireland 
have not set such a date. In this section, scenarios for 
the future trends in smoking prevalence in England are 
forecast up to 2050 and the health differences between 
these trends are investigated in terms of quality-adjusted 
life years (QALYs), using the recently developed Sheffield 
Tobacco Policy Model.54 The primary data source for this 
model was the Health Surveys for England (HSE).55 The 
model simulates smoking and health in the population 
by tracking individual movements among smoking states 
(never, current and former regular cigarette smoker) in 
1-year time steps as people age, and then linking these 
states to rates of morbidity and mortality. The time 
trends in smoking prevalence are determined by initiation 
rates at young ages (<30 years), quitting, relapse, and 
mortality linked to smoking. Individuals are indexed by 
sex, age (in the range from 11 to 89 years) and socio-
economic conditions defined in terms of Index of Multiple 
Deprivation (IMD) quintiles.56 The IMD is a composite area-
level measure based on 37 indicators reflecting income, 
employment, health and disability, education and skills, 
housing, services, accessibility, crime and living/physical 
environment. It is calculated for small geographic areas in 
England of approximately 1,500 people. The model uses 
IMD scores divided into quintiles, the first quintile being the 
least deprived, and the fifth quintile the most deprived. 
Trends in smoking prevalence are linked to morbidity and 
mortality from a set of 52 tobacco-related diseases of 
adult smokers.57 This disease list is derived from recent 
reviews of tobacco-related diseases.43,58 The model also 
uses published estimates of the time-lag between quitting 
smoking and changes to the risk of disease, which can be 
immediate for some conditions but for other conditions 
such as cancers, can take decades.59,60 The rates of 
morbidity and mortality from the 52 tobacco-related 
diseases that are used in the model are stratified by age, 
sex and IMD quintiles. QALYs are calculated by summing 
the time spent in a health state (ie with one of the 52 
tobacco-related diseases) weighted by the health-state 
utility value (HSUV) associated with the health state, which 
incorporates both length of survival and quality of life 
into a single metric.61 HSUVs stratified by age and sex are 
estimated with EuroQol-5D (EQ-5D) data for each of the 
52 tobacco-related diseases. These were applied so that 
if a person within the modelled population lives a year of 
life with one of the 52 tobacco-related diseases, then that 
year of life is given a disease-specific utility score, but if a 
person lives a year of life without a tobacco-related disease, 
then that year of life is given the general population utility 
score. Following NICE guidelines, the model discounts the 
estimated gains in QALYs over time by 3.5%.62 
2.6.1. Forecast scenarios
Four scenarios for the future trends in smoking prevalence 
are investigated, which make different assumptions about 
the trends up to 2050 in the probabilities of smoking 
initiation, quitting and relapse (Table 2.1). 
Table 2.1 Scenarios summary
* The probabilities are held constant into the future at their 2020 levels.
** Forecasts are based on continuing the past trends of increase in quitting 
probabilities based on the estimated trends from 2013–2018; trends are 
forecast separately for each sex and IMD quintile subgroup of the population. 
The estimated age-specific quitting probabilities from ages 11 to 89 years are 
summarised here for a particular calendar year by calculating the weighted 
average probability of quitting, where weights are proportional to the estimated 
numbers of smokers at each age in 2018. In 2020, the average estimated 
probability of quitting is 0.12 (range across sex and IMD quintile subgroups: 0.08 to 
0.20), ie on average, 12% of current regular cigarette smokers transition to being 
former regular cigarette smokers within 1 year. There is strong age variation in the 
probabilities of quitting – the average estimated probabilities of quitting at ages 
11-20 years are 0.43, 21–50 years 0.10, 51–75 years 0.07, and 75+ years 0.14. For 
years 2025, 2030, 2035, 2040, 2045, 2050, the average forecast probabilities of 
quitting used in scenarios 2 and 4 have the following relative differences to 2020 
(scenarios 1 and 3), expressed as odds ratios: 1.20, 1.43, 1.71, 2.03, 2.42, 2.86, 
which result in the following percentages of current smokers who quit: 14%, 16%, 
18%, 21%, 24%, 27%.
*** Forecasts are based on continuing the past trends of decrease in initiation 
probabilities based on the estimated trends from 2013–2018; trends are forecast 
separately for each sex and IMD quintile subgroup of the population. The 
estimated age-specific initiation probabilities from age 11 years are summarised 
here by calculating the expected probability of ever smoking by age 25 given the 
age-specific initiation probabilities estimated for a particular calendar year. In 
2020, the average estimated probability of ever smoking by age 25 is 0.46 (range 
across sex and IMD quintile subgroups: 0.30 to 0.73), ie given the age-specific 
probabilities of initiation estimated for 2020, 46% of people would have had a 
period of current regular cigarette smoking by age 25. For years 2025, 2030, 2035, 
2040, 2045, 2050, the forecast probabilities of ever smoking by age 25 in scenarios 3 
and 4 have the following relative differences to 2020 (scenarios 1 and 2), expressed 
as odds ratios: 0.86, 0.75, 0.66, 0.59, 0.54, 0.49, which result in the following 
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2.6.2. Projected trends in smoking prevalence
The model shows that trends in smoking prevalence 
among 11–89 year olds will continue to fall, with the 
trends being more sensitive to the increasing probabilities 
of quitting smoking (scenario 2 and 4) than smoking 
initiation due to the large cohort of current smokers (Fig 
2.4). Scenario 4 forecasts the greatest declines in smoking 
prevalence with a combination of continuing decreases 
in initiation probabilities and continuing increases in 
quitting probabilities and represents a situation where 
tobacco control is progressively strengthened to levels 
greater than current policies. The model indicates that 
smoking prevalence in the English population will not reach 
the 2030 smoke-free target of 5% of smokers in any of 
the forecast scenarios, and continuing with the current 
policy environment (scenario 1) will not achieve a smoking 











































 1   2   3   4
Fig 2.4 Smoking prevalence (%) among males and females aged 11–89 years in England, by sex 2003–2050. Lines 
show model predictions for our four forecast scenarios. Points and error bars show the percentage of smokers in the 
Health Survey for England data with 95% confidence intervals.
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2.6.3. Smoking and deprivation
In Scenario 4, which reflects a progressive strengthening of 
the tobacco control environment for initiation and quitting, 
all deprivation groups for both sexes, with the exception 
of males in the most deprived IMD quintile, are projected 
to reach 5% smokers by 2050, but this would take many 
groups until beyond 2040 (Fig 2.5). Without these additional 
policy efforts, the smoking prevalence target of <5% by 
2030 for England will be missed by almost all population 
groups. Table 2.2 provides detailed forecasts of smoking 











































Fig 2.5 Smoking prevalence (%) among males and females aged 11–89 years by Index of Multiple Deprivation 
quintiles in England, 2003–2050. Results are for Scenario 4, where initiation probabilities continue to fall and quitting 
probabilities continue to rise.
Female Male
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Table 2.2 Smoking prevalence (%) among males and females aged 11–89 years by Index of Multiple Deprivation 
quintiles in England, 2003–2050 for each forecast scenario.



















6.4 9.4 3.8 6.9 3.1 5.6 2.9 4.9
1 2 10.0 12.8 6.7 10.1 5.0 8.7 3.9 7.8
1 3 11.9 15.7 7.8 12.0 5.8 10.2 4.7 9.1








6.4 9.4 3.1 5.7 1.7 3.3 1.2 2.0
2 2 10.0 12.8 5.7 8.7 3.0 5.2 1.5 3.7
2 3 11.9 15.7 6.5 10.4 3.2 6.2 1.7 3.9








6.4 9.4 3.7 6.8 2.7 5.1 2.0 4.1
3 2 10.0 12.8 6.5 9.8 4.5 7.8 3.1 6.1
3 3 11.9 15.7 7.8 11.6 5.6 8.9 4.3 6.8








6.4 9.4 3.0 5.6 1.4 2.0 0.8 1.6
4 2 10.0 12.8 5.6 8.5 2.7 4.6 1.1 2.7
4 3 11.9 15.7 6.4 10.0 3.0 5.1 1.5 2.6




20.6 23.4 15.0 17.7 9.4 12.8 5.1 8.4
Numbers show percentage of smokers aged 11 to 89 years.
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2.6.4. QALY differences between scenarios
Reductions in smoking prevalence will gradually decrease 
the rates of morbidity and mortality from tobacco-related 
diseases, and therefore differences between the four 
scenarios in the number of quality-adjusted life years 
(QALYs) lived in the population will gradually emerge. 
Taking as the comparator scenario 1 (initiation and quitting 
constant at 2020 levels), the estimated cumulative gains in 
QALYs that might be expected under scenario 4 (continued 
falls in initiation and rises in quitting) are presented. By 
2050, the difference between these scenarios amounts 
to a total cumulative gain of 153,153 QALYs: 49,885 for 
females and 103,268 for males. However, differences 
between scenarios in morbidity and mortality will continue 
to emerge beyond 2050.
Figure 2.6 shows how the cumulative QALY gains from 
scenario 4 in comparison to scenario 1 would be distributed 
among IMD quintiles. This shows substantial QALY gains 
in all IMD quintiles, and despite a complex distribution of 
QALY gains among IMD quintiles, which arises from the 
interaction between the trends in smoking prevalence 
and the existing morbidity and mortality rates in these 
population groups, a trend for greater QALY gains among 
more deprived IMD quintiles is evident.
IMD quintile 







































Fig 2.6 Potential cumulative gain in quality-adjusted life years (QALYs) for males and females aged 11–89 years in 
England, by IMD quintile. The figure presents the comparison of scenario 1 to scenario 4 and shows the expected 
gain in QALYs if the past trajectories of increase in the probabilities of quitting and the past trajectories of decrease in 
the probabilities of initiation continue to 2050. The QALY differences are discounted at a rate of 3.5% from an index 
year of 2020.
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2.6.5. Requirements to achieve a 2030 target of 
less than 5% smokers
To estimate how much progress would be needed for all 
deprivation groups for both sexes to reach 5% smokers by 
2030, additional forecasts were conducted to investigate 
by how much the probabilities of quitting in the most 
deprived IMD quintile, which has the highest smoking 
prevalence, would need to increase for this population 
subgroup to reach 5% smokers by 2030. Table 2.3 shows 
that the odds of quitting would need to increase fivefold 
in females and sixfold in males from their estimated 
2020 levels for the 5% target to be achieved by 2030. At 
the estimated 2020 levels, an average of 8% of current 
smokers in the most deprived IMD quintile would transition 
to being former smokers each year, but a sixfold increase 
in the odds of quitting would mean that this increases to 
30% of current smokers.
Table 2.3 Smoking prevalence trends (%) for females and 
males in the most deprived Index of Multiple Deprivation 
quintile.
Initiation and relapse probabilities are held constant into the future at their 2020 
levels.
The six scenarios presented are produced by adjusting the probabilities of quitting 
in 2020. The adjusted probabilities are applied and held constant in each future 
year from 2021 onwards.
A quit odds ratio of 1 corresponds to holding quitting probabilities constant into 
the future at their 2020 levels, ie this is the same as scenario 1 in Table 2.1.
The probabilities of quitting for each age, sex and IMD quintile are adjusted by 
first converting them to the odds of quitting. One of the six odds ratios shown in 
the table is applied to the 2020 odds of quitting. The adjusted odds of quitting are 
converted back to the probabilities of quitting for use in the model.
Results are shown only for the percentage of smokers at ages 11–89 years in the 
most deprived IMD quintile because this is the population subgroup with the 
highest smoking prevalence.
The weighted average probabilities of quitting in the most deprived IMD quintile 
corresponding to each of the six scenarios are: 0.08, 0.14, 0.19, 0.23, 0.27, 0.30. This 
means 8%, 14%, 19%, 23%, 27% or 30% of current regular cigarette smokers 
transitioning to being former smokers each year.
2.6.6. Implications of the trends
The UK government has set the smoke-free target of 
reaching fewer than 5% smokers in England by 2030,53 
but the model projections above indicate that this will not 
be achieved and that smoking prevalence among people 
living in the most deprived socio-economic conditions, 
particularly for males, is likely to lag far behind. There 
might also be additional factors that the model has not 
accounted for, such as smoking gradually becoming 
concentrated among people who find it hardest to quit,63 
which have the potential to further slow progress. However, 
notwithstanding that the current smoke-free target for 
England might not be met, if tobacco control policy is put in 
place that accelerates progress in decreasing initiation and 
increasing quitting until 2050 then the model projections 
indicate that there would be a total cumulative gain of 
153,153 QALYs in England by 2050, and that the largest 
gains would accrue to the more deprived in our society. Our 
additional forecasts indicate that a sixfold increase in the 
odds of quitting among males living in the most deprived 
socio-economic conditions would be needed for smoking 
prevalence in this population subgroup to reach the 5% 
target by 2030.
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Key points 
>  Tobacco control in the UK has been strengthened 
substantially over the past 70 years by a coalition of 
advocacy groups, non-governmental organisations, 
academics, clinicians and parliamentarians. 
>  Sustained activity by this coalition is required to 
hold government to account with ambitions such as 
Smokefree 2030 and national tobacco control plans, to 
ensure tobacco-related public health functions are fit for 
purpose and adequately funded, and to combat tobacco 
industry efforts to undermine tobacco control.
>  These activities are particularly important at present, 
following the abolition of Public Health England in 2020 
and progressive reductions in local authority public health 
budgets during recent years.
>  Health warnings and labelling policies play an important 
role in communicating the risks of smoking, dissuading 
young people from tobacco use and promoting smoking 
cessation among established smokers.
>  Mass media and social marketing campaigns trigger quit 
attempts, increase the prevalence of smoke-free homes 
and support reductions in smoking prevalence and 
cigarette consumption. ‘Stoptober’ is estimated to have 
initiated 2.1 million quit attempts between 2012 and 
2019, and is cost-effective.
>  In recent years national spending in England on anti-
smoking campaigns has fallen sharply from a peak of 
£23.38 million in 2008 to £1.78 million in 2019. 
>  The role of smoking in disease aetiology and 
management remains widely ignored in clinical guidelines 
for diseases strongly related to smoking and represents a 
neglect of the overriding duty of care in medical practice.
>  Training in the practical delivery of smoking cessation and 
temporary abstinence advice is poor across the NHS.
Recommendations
>  Health warnings on tobacco products are enhanced using 
larger warnings, with provision of quit-line information 
or weblinks that support cessation, and use of package 
inserts that provide information on health effects and 
quitting. 
>  The appeal of e-cigarettes to children is reduced by 
introducing standardised packaging for these products.
>  Health warnings on e-cigarette packs include a statement 
that e-cigarette vapour is likely to be substantially less 
harmful than tobacco smoke.
>  Funding of mass media campaigns is increased to at 
least 2008 levels to provide a low-cost, high-impact 
intervention to strengthen a comprehensive tobacco 
control strategy.
>  Campaigns to support the use of electronic cigarettes as 
a quitting aid or harm reduction alternative to smoking 
are carried out, and false perceptions about the safety of 
e-cigarettes compared with cigarettes are redressed.
>  Training in the practical delivery of cessation and 
temporary abstinence advice and in prescribing smoking 
cessation medications is completed by all patient-facing 
NHS and social care staff. 
3.1 Introduction
For centuries tobacco companies have promoted tobacco 
consumption, governments have become reliant on 
tobacco-related tax revenues and individual tobacco use 
has become the norm; the combination of marketing, 
money, power and addiction maintaining the status 
quo. Over the past 6 decades much has been achieved 
to change these deep-rooted behaviours, including 
influencing policymakers to implement wide-ranging 
tobacco control measures, raising public awareness of 
the harms of tobacco use and training clinicians to treat 
tobacco use as an addiction rather than a lifestyle choice. 
The use of advocacy, influence and education in further 
reducing tobacco use is reviewed in this chapter.
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3.2 The evolution of advocacy, lobbying and 
campaigning for policy change 
3.2.1 1950 to 2000
Researchers in the UK have been at the forefront of 
developing the evidence base about the harm caused by 
smoking since the 1950s.1 Initially, the conventional wisdom 
among academic researchers and professional clinical 
societies was that their role should simply be to publish 
evidence of the harms caused by smoking, believing that 
this would be sufficient to change smokers’ behaviour.2 This 
did not prove to be the case. 
In the 1950s tobacco was accepted as an essential part of 
daily life and a vital generator of tax revenues.3 Tobacco 
was included in military rations and as an economic 
supplement to old age pensions.2 Tobacco was even 
included in the Geneva Conventions, in recognition that for 
many it was ‘as essential as food’.4 The tobacco industry 
fought to keep things that way, and for many years 
succeeded. 
At that time Britain was the home of three of the top five 
global tobacco manufacturers: Imperial Tobacco, Gallaher 
and British American Tobacco. These companies were 
highly effective lobbyists, meeting regularly with policy 
makers.3 The industry argued that the evidence of the 
harm caused by smoking was inconclusive, that smokers 
knew the risks, that smoking was an adult choice entered 
into willingly, and therefore that it was not for government 
to interfere. They did this despite acknowledging privately 
in internal documents dating back to the 1960s that 
smoking was not a free choice but an addiction to the 
nicotine contained in the smoke.5 
Tobacco-related health policy began to be changed 
as a result of civil society campaigns waged over many 
decades, spearheaded by a tripartite alliance of non-
governmental organisations, clinicians and academics. 
This was not unique to Britain, with advocacy groups 
emerging at the same time in other industrialised societies, 
which successfully engaged with the World Health 
Organization (WHO) and colleagues in low- and middle-
income countries. Similar to tobacco manufacturers, civil 
society worked collaboratively to develop an effective 
global lobbying capacity that led eventually to the WHO 
Framework Convention on Tobacco Control (FCTC).6–8
In the UK the RCP played a leading role in nurturing and 
developing this alliance, recognising that it could not 
remain a passive bystander and needed to advocate 
for policy change.9 The RCP’s 1962 report, Smoking and 
health, was a turning point, the first time that evidence 
of the health harms caused by smoking was coupled 
with practical recommendations for policymakers. The 
report was widely publicised10 and had an impact on 
smokers’ behaviour and tobacco consumption in the 
years that followed, but policymakers did not adopt the 
interventionist policies recommended.11 By 1971, when the 
second RCP report on smoking was published12 there was a 
recognition that RCP reports alone would not be sufficient 
to achieve the changes that were needed in public policy; 
rather, that sustained and relentless advocacy would be 
essential. In 1971 therefore, the RCP established Action 
on Smoking and Health (ASH) as a standalone advocacy 
organisation. ASH has remained close to the medical and 
academic community, who have been active supporters 
and participants in ASH’s campaigns for concrete policy 
measures to reduce smoking attributable harm. ASH has 
been successful in engaging the media to raise awareness 
about the harms of smoking as the evidence base has 
grown. From the 1960s to the 1980s media advocacy 
played the major role in the decline of smoking prevalence, 
as government resisted active interventions, relying on an 
investment in health promotion, part of which was funding 
ASH.13 Although British governments accepted that smoking 
was harmful, they were nervous of being branded ‘the nanny 
state’ by interfering in people’s individual ‘lifestyle choices’ 
such as smoking and drinking. Governments were happy 
to fund ASH to support the provision of health education, 
but less keen to intervene themselves. Even when health 
ministers were receptive, changing government policy proved 
difficult. It was necessary that ASH was able to operate 
on the outside, funded by the leading heart and cancer 
charities to advocate for political change, and working with 
the All-Party Parliamentary Group on Smoking and Health, a 
cross-party group of backbench parliamentarians supportive 
of its aims.
The 1990s were a major turning point in tobacco control 
since the rate of decline in adult smoking prevalence 
had slowed considerably, and uptake of smoking in 
children under 16 was not falling (Fig 4.1). The industry 
was successfully fighting back by undermining health 
messaging. It was estimated that in 1992 the industry 
was spending £100 million a year on advertising.14 Most 
egregiously, the TV advertising ban had been undermined 
by an explosion in sport sponsorship which opened the 
door to far more extensive and lengthy tobacco promotion 
on public as well as commercial television. In contrast 
with the UK, during this period other countries introduced 
tobacco control measures including advertising bans in 
Norway, Canada, New Zealand and Finland as well as 
health warnings in the EU. Both of these measures were 
opposed by the UK government, which still chose to rely on 
voluntary agreements with the industry.   
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The first UK Tobacco Control Plan15 was launched in  
1998 and stated:
  ‘Smoking is now the principal avoidable cause of 
premature deaths in the UK. It hits the worst off people 
hardest of all. It harms people who do not smoke. It 
harms babies in the womb. That is why the Government 
is determined to turn things round. We want to help 
existing smokers quit the habit and help children and 
young people not to get addicted in the first place. 
These objectives can only be achieved by a concerted 
campaign to reduce smoking … a package of measures 
each of which will add to the impact of the others. A 
major part of the effort will be targeted on children.’
The 1998 Tobacco Master Settlement Agreement in the USA 
was the result of a wave of litigation brought by US states. 
It opened the door to a treasure trove of millions of industry 
documents, revealing what became known as the industry’s 
‘playbook’ and including ‘throwing sands in the gears’ of 
attempts to regulate by sowing doubt, and using deceit and 
denial of what they knew to be the overwhelming evidence 
of the harm caused by tobacco.16 The documents also 
revealed how the industry fuelled a global parallel market 
on a gigantic scale to undermine government tax policy by 
providing easy access to cheap and illicit cigarettes.17
The idea of a tobacco treaty to put in place global 
regulation of the industry was first articulated by American 
lawyers at the start of the 1990s. In 1999 the new 
Norwegian director-general of the WHO, Gro Harlem 
Brundtland, made it a key objective.18 This was the first 
treaty negotiated by the WHO, and it faced a powerful 
well-funded adversary, the transnational tobacco industry. 
ASH played a leading role in mobilising tobacco control 
civil society organisations around the world into a loose 
network, which evolved into the Framework Convention 
Alliance (FCA) by 2000.19 The FCA was influential in 
ensuring that the FCTC covered all relevant policy levers, 
including protection of public health policy from industry 
vested interests and the enshrinement of the role of civil 
society in the Treaty. Subsequent to the entering into force 
of the FCTC the FCA has continued to play a key role in 
ensuring that the framework set out in the convention 
has been strengthened by the adoption of more detailed 
guidelines and the protocol on the illicit trade in tobacco.19
3.2.2 2000 to the present
3.2.2.1 International tobacco control
The FCTC was adopted by the World Health Assembly 
in 2003 and came into force in 2005 (see section 2.2). 
The FCTC framework calls on parties to reduce demand 
and supply of tobacco products through implementation 
of a series of articles and has been strengthened by the 
development of guidelines on everything from packaging 
and labelling (Article 11), advertising (Article 13), tax policy 
(Article 6) and tobacco industry interference (Article 5.3) plus 
a protocol on illicit trade requiring the implementation of 
stringent supply chain controls by tobacco manufacturers. 
3.2.2.2 Tobacco control in the UK
Following a long campaign by ASH and others working with 
parliamentarians, the end of the 1990s saw the publication 
in the UK of the first government tobacco control strategy, 
Smoking kills.20 Among other measures, this document 
committed the government to ban advertising, raise 
tobacco taxes and set up a comprehensive NHS smoking 
cessation service. However, the government refused to 
commit to smoke-free legislation, believing that it would 
not be politically expedient and instead adopting a process 
of voluntary agreements to reduce smoking in public 
places.21 By 2003 it was clear that this approach was failing, 
so ASH set up the Smokefree Action Coalition (SFAC) 
to campaign for smoke-free laws that would prohibit 
smoking in public places, and began regular polling which 
demonstrated growing public support. The administrations 
in Scotland, Wales and Northern Ireland agreed early on 
to support implementation of comprehensive legislation 
in their jurisdictions. The UK government on the other 
hand tabled legislation for England which included 
exemptions for pubs and clubs. It was only as a result of a 
well-disciplined campaign from ASH and the SFAC which 
included charities, royal colleges, trade unions, public health 
bodies, health professionals and academics, with strong 
support from the Health Select Committee and backbench 
parliamentarians in both houses of parliament, that the 
exemptions were removed on a free vote in parliament.21 
This established an important precedent in Westminster, 
that tobacco was not a party-political issue. 
The Smokefree Action Coalition has since grown from 
around 50 to over 300 members, and has successfully 
campaigned for increasingly stringent regulation of 
tobacco, including the ban on tobacco displays in shops, 
prohibition of the sale of tobacco from vending machines, 
and, most recently, standardised ‘plain’ packaging. 
Labour, Coalition and Conservative governments have 
all accepted that ending smoking is a justifiable objective 
requiring active government intervention. Consequently, 
while it lagged behind until this century, the UK has now 
become a global leader in tobacco control.22–24 In 2019 the 
Conservative government announced that its ambition 
was for England to be smoke-free by 2030. This included an 
ultimatum for industry to make smoked tobacco obsolete 
by the same year.25
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However, the abolition of Public Health England (PHE) in 
2020 during the COVID-19 pandemic, puts the delivery 
of the government’s smoke-free ambition in question. 
Sustained advocacy by an alliance of non-governmental 
organisations (NGOs), clinicians, public health professionals 
and academics which comes together in the Smokefree 
Action Coalition will be essential to ensure the government 
lives up to its ambition and the devolved nations are able to 
live up to theirs.
3.3 Health warnings and product labelling 
3.3.1 Packaging as a way to communicate with 
consumers 
Product packaging represents an important medium 
of communication between the tobacco industry and 
consumers. For the industry, packaging is a critical 
component of marketing and represents the ‘cornerstone’ 
of brand imagery.26,27 Packaging is important given 
its frequency of exposure and the timing of exposure, 
which occurs at the point-of-purchase and immediately 
preceding use. In the case of cigarettes and other widely 
used tobacco products, packages also have broad reach 
among children and young people during the typical age 
of tobacco initiation.28
Packaging not only serves as an important promotional 
channel for industry, but is increasingly used by 
governments to communicate health information.28,29 
For most of the 20th century, health warnings were either 
absent or obscure, with vague statements about the risks 
of smoking. However, health warning policies have rapidly 
evolved over the past 2 decades. An important precedent 
was established in 2000 when Canada implemented 
the first pictorial health warnings on cigarette packs and 
required these to cover 50% of the principal display area 
of the pack. Soon after, international labelling standards 
were established in the World Health Organization’s 
FCTC, including minimum requirements for rotating text 
warnings that cover at least 30% of the package, and 
recommendations for warnings that cover 50% or more 
and pictorial warnings.30 To date, more than 100 countries 
have implemented large pictorial health warnings that 
cover 50% or more of the package.31 In the UK, pictorial 
health warnings covering approximately 50% of the 
package were adopted in 2008 and revised in 2016 as part 
of the European Tobacco Product Directive.32
A vast evidence base has established that comprehensive 
pictorial health warnings are an effective means of 
communicating the health effects of smoking and help 
reduce positive attitudes towards smoking.28,33–35 Research 
has also demonstrated that larger warnings increase the 
consumer attention given to them, are more likely to be 
recalled, and allow greater space for text and pictorial 
message components.28,36–40
The remarkable scope of disease caused by smoking 
provides regulators with the opportunity to have a large 
range of warnings which comprise anywhere from two to 
16 individual messages and can be refreshed and rotated 
over time to sustain their impact.40 Regulators have 
applied a variety of principles when selecting which health 
effects to feature in warnings, including overall disease 
burden, a mix of health effects to represent different 
disease categories (cancer, cardiovascular disease, other 
lung illnesses ), direct versus second-hand smoke effects, 
and health effects specific to a particular demographic or 
population subgroup.41 Different executional styles can 
also be used to depict health effects, including graphic 
depictions of disease, symbolic imagery, and narratives 
or personal testimonials. In general, graphic depictions 
of disease – images that feature ‘real’ images of health 
effects from ‘real’ people – are consistently identified as 
the most effective theme across diverse age groups and 
cultural contexts.28,42 Indeed, warnings featuring graphic 
images of diseased lungs and other organs are most likely 
to be recalled in post-implementation studies in Canada, 
Australia, and Europe. Graphic depictions are also most 
likely to elicit emotional arousal, which is associated with 
greater message acceptance, perceived health risk, and 
downstream behavioural outcomes.28,33,43–47 (See Fig 3.1.)
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Fig 3.1 The evolution of health warning and packaging regulations in Australia. 
© Scollo et al 2015*
The impact of health warnings can be enhanced in several 
ways. Health warnings can be linked to other public 
education efforts, such as mass media campaigns,48–52 
‘refreshed’ to maintain effectiveness over time, and 
‘rotated’ at regular intervals.53–56 The impact of health 
warnings can also be enhanced through the inclusion of 
supportive information on smoking cessation services, such 
as a telephone helpline and website, which can increase 
population-level usage of these services.57–63 In many 
countries, weblinks and helpline numbers are displayed on 
every warning along with a short, supportive statement 
designed to enhance motivation to quit smoking. Canada 
has extended this practice by requiring ‘inserts’ that 
are displayed on the interior of packages and feature 
additional information on the health benefits of quitting 
and smoking cessation64,65 (see section 5.9). 
Beyond communicating health information, labelling 
policies can also limit the promotional information on 
packaging, most notably through standardised or ‘plain’ 
packaging regulations. Standardised packaging prohibits 
the display of brand imagery and logos, and standardises 
the colour and font across all packages (see Fig 3.2). The 
first country to introduce plain packaging was Australia, in 
2012, and plain packaging has since been implemented 
in more than 15 other countries, including the UK in 2016, 
in accordance with recommendations under FCTC Article 
13.30,31 Standardised packaging can reduce brand appeal 
among young people, reduce false health beliefs about the 
relative risks of different cigarette brands, and enhance the 
impact of health.66 Many countries have also restricted other 
misleading packaging elements, including brand descriptors, 
such as ‘light’, ‘mild’, and ‘low tar’, as well as tar and nicotine 
numbers on the basis that they promote the false belief that 
some cigarettes are less harmful than others.40
*Image source: Quit Victoria pack collection 2012
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3.3.2 Novel nicotine products, including 
e-cigarettes and heated tobacco products
In contrast to well-established regulatory practices for 
conventional tobacco products, there is less evidence to 
guide labelling policies for novel nicotine products, such 
as e-cigarettes.67 In considering the broad spectrum 
of tobacco and nicotine products, there is a general 
principle that the design of health warnings should be 
commensurate with the level of harm.28,36  Accordingly, 
mandated warnings on non-combusted products are 
generally smaller than those on cigarette packs and 
feature text-only warnings. Novel products present 
additional challenges given that the long-term health 
effects are not fully known; therefore, e-cigarette warning 
messages typically focus on nicotine and addiction, rather 
than specific health outcomes which are less certain. 
For example, under the EU Tobacco Product Directive, 
e-cigarettes must display a black and white text warning 
covering 30% of the principle display area that reads, 
‘this product contains nicotine which is a highly addictive 
substance’68,69 with similar requirements in other countries 
such as the USA.70 To date, population-based studies 
suggest that relatively few consumers recall noticing 
e-cigarette warnings, particularly in countries with voluntary 
or vague warning policies.71–74 Indeed, voluntary warning 
practices are highly variable in terms of the presence of 
warnings, type of information included in the warning 
message, and the accuracy of other labelling components, 
such as nicotine levels.75–77
There is controversy over whether e-cigarette messages 
should include explicit relative risk statements to encourage 
switching among established smokers for the purposes 
of harm reduction.67 Research suggests that e-cigarette 
warnings can increase consumer perceptions of risk 
from vaping; however, their impact on perceptions of 
relative risk compared with smoking remain unclear.78–82 
In most countries, manufacturers are prohibited from 
making health claims, including statements on relative 
risks or smoking cessation unless individual products 
receive approval as a therapeutic product. In the USA, 
companies can apply to the Food and Drug Administration 
for designation as a ‘modified risk tobacco product’ and 
Fig 3.2. Example of branded versus ‘plain’ packaging in Australia.*
*Image used with permission from: Tobacco Labelling Resource Centre
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request approval to make reduced risk or reduced exposure 
claims.83 For example, Philip Morris’ IQOS device and 
Marlboro Heatsticks have been approved to make the 
following claims: ‘This significantly reduces the production 
of harmful and potentially harmful chemicals’, and 
‘Scientific studies have shown that switching completely 
from conventional cigarettes to the IQOS system 
significantly reduces your body’s exposure to harmful or 
potentially harmful chemicals.’84 Preliminary evidence 
suggests that these types of claims may reduce risk 
perceptions relative to cigarettes; however, their impact on 
product appeal among existing adult smokers and young 
people has yet to be assessed in post-market studies.85–87 
Several jurisdictions have also considered allowing 
proscribed relative risk statements, which are drafted by 
government agencies and could be used by manufacturers 
on a voluntary basis; however, these proposals have not 
been implemented to date.88,89
As is the case for health warnings, restrictions on the 
promotional elements of packaging are generally less 
comprehensive for non-combusted tobacco and nicotine 
products compared with cigarettes. Several notable 
exceptions include Norway’s standardised packaging 
requirements for snus (a tobacco powder placed under 
the lip) products and Israel’s standardised packaging 
regulations for e-cigarettes. To date, there is little evidence 
regarding the impact of these policies on patterns of 
use among young people or ‘switching’ among users of 
other tobacco products;90 it would be prudent to reduce 
the appeal of e-cigarettes to children by introducing 
standardised packaging for these products.
3.3.3 Industry opposition and legal precedents  
The evolution of health warnings and packaging 
regulations have attracted strong opposition from the 
tobacco industry. However, courts in a wide range of 
jurisdictions have upheld comprehensive packaging laws, 
including challenges to the EU tobacco warnings and 
standardised packaging in the UK.91 Notably, a recent 
ruling from the World Trade Organization (WTO) upheld 
Australia’s health warnings and standardised packaging 
laws, and ruled that such measures did not violate pre-
existing trade agreements based on their importance to 
public health.92 Nevertheless, tobacco companies continue 
to issue legal challenges to health warnings, including a 
2020 legal challenge to pictorial warnings in the USA.93,94
In summary, health warnings and labelling policies have 
played an important role in communicating the risks of 
smoking and shaping social norms around tobacco use. 
Large pictorial warnings and standardised packaging 
regulations for cigarettes are effective at dissuading 
young people from tobacco use and promoting smoking 
cessation among established smokers. Beyond their impact 
on individual consumers, these policies serve as a vivid 
illustration of a country’s commitment to tobacco control, 
commensurate for a product that causes more than 50 
diseases and kills approximately half of its long-term users. 
Labelling practices for novel, non-combusted products are 
less established and are rapidly evolving as the nicotine 
market undergoes further diversification. To date, there 
is little consensus regarding the optimal labelling policies 
for novel products, and how to ensure that consumers 
are adequately informed of potential harms, while also 
promoting accurate relative risk perceptions, particularly 
among current tobacco users seeking to reduce the risks of 
tobacco use.95
3.4 Mass media and social marketing 
campaigns
Mass media campaigns (MMCs) expose high proportions 
of large populations to messages through traditional 
media such as television, radio, billboards (Fig 3.3) and 
newspapers, in a largely passive manner, iteratively over a 
set duration at a low cost per head. Such campaigns often 
target health-risk behaviours such as tobacco and drug use, 
cancer screening and more recently infection prevention 
related to COVID-19.96–98 Social marketing campaigns 
(SMCs) integrate marketing activities to reinforce a specific 
goal through multiple media channels with the ability to 
target audiences and measure reach. Modern-day MMCs 
integrate SMCs, while SMCs may or may not include an 
MMC component. MMCs and SMCs often compete with 
well-funded industry-led product marketing and advertising 
(see chapter 5 and chapter 10), ingrained social norms, 
behaviours driven by addiction and misaligned government 
policy.99 The goals of MMCs and SMCs may be to produce 
positive changes (smoking cessation) or prevent negative 
changes (uptake of smoking).
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3.4.1 Effectiveness and cost-effectiveness 
A Cochrane review of mass media interventions for 
smoking cessation in adults concluded that tobacco control 
programmes which include MMCs can be effective in 
changing smoking behaviour in adults, and show positive 
effects whether initiated at national, regional or local levels. 
The effectiveness of these campaigns may be greater in 
relation to their intensity and duration.100 Several studies 
looking at UK MMCs have identified associations with 
triggering quit attempts,101,102 increasing the prevalence of 
smoke-free homes,103 and reductions in smoking prevalence 
and cigarette consumption.104 Little evidence was found to 
support MMCs to prevent youth uptake of smoking.105 The 
National Institute for Health and Care Excellence (NICE) 
guideline NG92 recommends campaigns to promote 
awareness of stop smoking services.106
‘Stoptober’ is a campaign delivered by PHE that 
successfully combines MMCs and SMCs to motivate 
smokers to make a quit attempt. It is estimated to have 
prompted 2.1 million quit attempts between 2012 and 
2019, with an average of 8% reporting they were not 
smoking at 4 weeks.107,108 ‘Quit for COVID’ and ‘Today is 
the Day’ SMCs to motivate people with COVID-19 related 
health concerns to quit smoking were launched in 2020109 
and await evaluation.
A systematic review of the cost-effectiveness of tobacco 
MMCs concluded that they offer value for money,110 while 
a systematic review of MMCs to communicate public 
health messages in six health topic areas that included 
tobacco also found tobacco MMCs to be cost-effective.111 
Evaluation of the ‘Stoptober’ SMC has identified it to be 
cost-effective.108,112
The argument for further substantial investment in England 
is strengthened by the sensitivity of the effectiveness of 
campaigns to budget.108,113–117 For example, a time-series 
analysis between 2008 and 2016 found higher monthly 
Fig 3.3 Billboard campaign promoting smoking cessation.
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expenditure on tobacco control mass media campaigns 
in England was associated with significantly higher quit 
success rates. 
3.4.2 Funding of MMCs
In recent years national spending in England on MMCs and 
SMCs has fallen sharply, with a more than tenfold reduction 
from a peak of £23.38 million in 2008118  to £1.78 million in 
2019.119 Over the same period there has been a significant 
fall in the proportion of smokers trying to quit. In 2007, 
44% of smokers in England had made a quit attempt over 
the preceding year, by 2018 this had fallen by a quarter to 
only 33%.120
The lack of national campaigns has in the past to some 
extent been made up for by mass media campaigns at 
regional level backed up by proactive public relations 
activity. However, cuts in public health funding to local 
authorities121,122 have led to the south-west regional MMC 
work coming to an end, with threats to funding of a similar 
initiative in the north-east of England too. 
If the overall budget in England was returned to £5.5 million 
a year, which it averaged between 2008 and 2016, we can 
extrapolate that an additional uplift of £1 million to £6.5 
million would save about 3,000 additional life years at a cost 
of just £344 per life year.117 A further increase in funding of 
MMCs to 2008 levels,118 which was associated with peak 
uptake in NHS stop smoking services in subsequent years,123 
would provide a low-cost, high-impact intervention to 
strengthen a comprehensive tobacco control strategy.
3.4.3 E-cigarette related media campaigns
E-cigarettes are substantially less harmful than smoking 
combustible tobacco and have been contributing to 
recent declines in smoking prevalence124,125 (see chapter 
9). There has however been little application of MMCs 
or SMCs to the use of electronic cigarettes as a quitting 
aid or harm reduction alternative to smoking, or to 
redress false perceptions about the safety of e-cigarettes 
compared with cigarettes. Although e-cigarettes are safer 
than cigarettes, most smokers do not believe this,126 a 
perception exacerbated by the US outbreak of vaping-
associated lung injury (VALI) that received extended 
news coverage worldwide despite subsequent clarification 
that most cases from the outbreak were associated with 
inhalation of vitamin E acetate, an additive found in some 
tetrahydrocannabinol vaping devices, typically obtained 
informally or illicitly and not nicotine e-cigarettes.127–129 
Vitamin additives are in fact explicitly banned from legal 
vaping products by the EU Tobacco Products Directive 
(TPD). These misperceptions are important because there 
is evidence at the population-level and individual-level that 
perceptions of harm are closely associated with whether 
cigarette smokers decide to use them.130–132 
3.5 Medical guidelines  
Since the burden of disease caused by smoking can be 
prevented by helping smokers to quit, smoking cessation 
support should be a routine component of all medical 
care. However, since quitting smoking also generates 
substantial improvements in disease progression for many 
of the conditions caused by smoking,123 treating smoking 
dependence should be a key component of the management 
of all diseases caused by smoking. Clinical management 
guidelines for diseases caused by smoking should in particular 
therefore include, or refer to, guidance on smoking cessation. 
In an earlier report123 we reported on the low extent to which 
the delivery of smoking cessation support is included in clinical 
guidelines for a range of diseases caused by smoking. We have 
therefore updated that review for this report. 
We used the methods described previously133 to identify 
guidelines and recommendations published between 
January 2014 and January 2019 relating to any of the 16 
diseases established in an extensive review by the Royal 
College of Physicians to be at least twice as common 
among smokers123 and produced or endorsed by a relevant 
UK national or European transnational medical specialty 
association, international professional society or government 
agency. The three outcomes of interest were inclusion in 
the guidance of (i) identification of smoking as a risk factor 
or major cause of disease; (ii) recommending smoking 
cessation intervention and (iii) provision of or reference 
to smoking cessation guidelines or recommendations of 
evidence-based treatments for smoking cessation. 
The review included 159 disease management guidelines. 
For some of the conditions of interest, guidelines were 
found where multiple conditions were included together 
in the same guidelines (pharynx/oral cavity and larynx 
cancers; ischaemic heart disease and peripheral artery 
disease; and psychosis and schizophrenia), and in such 
cases these conditions were reported together. 
Just under half (78; 49%) of the 159 guidelines mentioned 
smoking. This comprised 37 UK134–170 and 41 European 
specialty association, international professional society 
or government agency publications.171–210 Of the 81 that 
made no reference to smoking, 48% were from the UK210–
290 (Table 3.1). Smoking was mentioned as a risk factor for 
the development of the disease by 69 (43%) guidelines, a 
statement recommending smoking cessation was included 
in 50 (31%) and reference to specific treatments for 
smoking cessation or to a smoking cessation guideline in 
30 (19%). 
27© Royal College of Physicians 2021
Education: policymakers, the public and the healthcare workforce      3
Table 3.1 Summary of clinical guidelines and recommendations with reference to smoking
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6 (60) 
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(5 UK, 1 EU)
3 (30) 








(4 UK, 13 EU)
8 (47) 
(2 UK, 6 EU)
6 (35) 
(2 UK, 4 EU)
6 (35) 
(2 UK, 4 EU)
4 (24) 
(2 UK, 2 EU)
9 (53) 
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(3 UK, 4 EU)
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5 (45) 
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20 (71) 
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15 (54) 
(5 UK, 10 EU)
7 (25) 
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8 (29) 
(2 UK, 6 EU)




(11 UK, 5 EU,  
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9 (50) 
(7 UK, 2 EU)
6 (33) 
(4 UK, 2 EU)
9 (50) 
(7 UK, 2 EU)
8 (44) 
(6 UK, 2 EU)
9 (50) 
(4 UK, 3 EU,  
2 Intl.)
Respiratory
COPD 16  (5 UK, 11 EU)
13 (81) 
(5 UK, 8 EU)
13 (81) 
(5 UK, 8 EU)
6 (36) 
(2 UK, 4 EU)
5 (31) 
(2 UK, 3 EU)
3 (19) 
(3 EU)
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(1 UK, 1 EU,  
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(1 Intl.) 0 (0) 0 (0)
7 (88) 




(5 UK, 5 EU, 3 
Intl.)
7 (54)  
(3 UK, 2 EU,  
2 Intl.)
7 (54)  
(3 UK, 2 EU,  
2 Intl.)
1 (8)  
(1 UK)
2 (15)  
(2 Intl.)
6 (46)  





(10 UK, 7 EU)
5 (29)  
(3 UK, 2 EU)
4 (24)  
(3 UK, 1 EU)
4 (24)  
(2 UK, 2 EU) 0 (0)
12 (71)  
(7 UK, 5 EU)
Total
159  
(75 UK, 72 
EU, 12 Intl.)
78 (49%) 
(37 UK, 38 
EU, 3 Intl.)
69 (43%) 
(33 UK, 33 
EU, 3 Intl.)
50 (31%) 
(23 UK,  
27 EU)
30 (19%) 
(17 UK,  
13 EU)
81 (51%) 
(38 UK, 34 
EU, 9 Intl.)
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Although different smoking-related diseases were 
considered, the proportions of guidelines reporting 
smoking as a risk factor, offering cessation advice or 
referring to specific cessation guidance in this present 
review of guidelines published from 2014 to 2019 are very 
similar to those published between 2000 and 2013 in our 
previous report (50%, 40% and 19% respectively).133 Direct 
comparisons for guidelines on diseases included in both our 
earlier and current review are presented in Table 3.2.
Table 3.2 Comparison of clinical guidelines, report on smoking as a risk factor and smoking recommendations of 
conditions assessed in both the previous and current review
Conditions 
reported in both 
reviews
Number of guidelines Number providing smoking 
cessation advice
Number providing specific 
cessation treatment/guideline 
reference 
2000–13 2014–19 2000–13 2014–19 2000–13 2014–19
Pharynx/oral 
cancer 2 10 2 3 2 2
Lung cancer 26 17 14 6 4 4
Cardiovascular 
disease 21 29 16 20 13 9
Respiratory 
disease 11 32 9 7 6 6
This study demonstrates that acknowledgement of the role 
of smoking in disease aetiology and management remains 
widely ignored in clinical guidelines for diseases strongly 
related to smoking.
Since the clinical management of smoking-related 
diseases should include ascertainment of smoking status 
and delivery of effective smoking cessation support, this 
represents a significant and sustained neglect of a major 
reversible cause of disease. 
Quitting smoking reduces the progression of COPD and has 
been identified by NICE as one of the ‘five fundamentals’ 
of COPD care,291,292 it reduces the incidence of acute lung 
infections and asthma exacerbations,293 improves lung 
cancer survival,294 and reduces the risk of recurrence of 
myocardial infarction and stroke.295–299 Smoking cessation 
also improves the outcome of head and neck cancer,300 
peripheral artery disease,301 rheumatoid arthritis ,302 and 
a range of other conditions.123 Encouraging patients 
with diseases caused by smoking to quit smoking should 
therefore be a routine component of disease management, 
and systematic intervention to treat smoking is a 
fundamental component of evidence-based smoking 
cessation guidance.106,303 For nearly half of the guidelines 
on managing diseases caused by smoking included in this 
study to fail even to mention smoking cessation is clearly a 
neglect of the overriding duty of care in medical practice. 
The consequence of this omission is likely to be that 
smoking is not addressed by practitioners delivering care 
for people with these conditions. The role of smoking as 
a cause of disease, and of smoking cessation in disease 
management, remains substantially overlooked and 
neglected in clinical practice, even in relation to the 
diseases most strongly related to smoking.
3.6 The healthcare workforce
The healthcare workforce has a unique role to play in 
preventing smoking. Since smoking is associated with an 
increased risk of a wide range of diseases and disorders,123 
smokers use health services far more than non-smokers and 
every health service contact and inpatient stay represents 
an opportunity to identify individuals who smoke, and 
help them to quit.123 Systematic treatment of smokers is 
also highly cost-effective in almost all settings304,305 and 
by reducing acute events produces in-year cost savings in 
secondary care.123 It is therefore vital that the healthcare 
workforce is trained to capitalise on these opportunities 
and ensure that all smokers receive treatment aimed either 
at achieving cessation or supporting temporary abstinence 
while using healthcare services. 
The precise content of the training required differs 
according to the role of the healthcare worker and their 
level of patient contact. However, all healthcare workers 
who have face-to-face clinical contact with patients need 
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to be able to ascertain smoking status, advise quitting and 
act to ensure that smoking cessation support is delivered. 
Training in the elements of this approach, termed ‘very 
brief advice’ (VBA) is available free of charge from the 
National Institute for Smoking Cessation and Training 
(NCSCT) website306 and takes less than 20 minutes to 
complete. Although presented for use in the context of 
primary care consultations, the training can be applied in 
most clinical interactions. All patient-facing NHS and social 
care staff should therefore complete this training. 
Delivery of behavioural support and pharmacotherapy for 
smoking cessation requires more specialist skills. Training in 
these areas is also available via the NCSCT website, but as 
outlined in the 2019 NHS Long Term Plan,307 these services 
should be available and easily accessible across the NHS. 
Since provision of smoking cessation interventions on an 
opt-out rather than opt-in basis typically doubles service 
uptake, the services should be provided as an opt-out 
default. In secondary care this is achievable by following 
the principles of the Ottawa Model308 which have been 
shown to be effective in UK acute and mental health 
settings,309–311 with smoking ascertainment occurring 
on admission and delivery of pharmacotherapy and 
behavioural support automatically after establishing that 
an individual smokes. In primary care, doctors need to 
be ready to prescribe cessation medications and provide 
advice on e-cigarette use, and either provide or otherwise 
ensure the delivery of behavioural support from a local 
NHS stop smoking service if available and preferred, or else 
in-house. Training in prescribing for smoking cessation and 
delivering behavioural support are both available via the 
NCSCT website but is not currently required training. 
Ensuring that the healthcare workforce is properly trained 
and that smoking interventions become fully embedded 
in clinical practice requires all staff to be trained. The 
2018 RCP Hiding in plain sight report summarised existing 
training content of undergraduate, postgraduate and other 
higher training packages for a range of health professionals 
and found that almost across the board, these were 
inadequate. For existing staff in most settings, training 
in smoking cessation occurs at individual initiative rather 
than as a mandatory requirement. There is little evidence 
that these training deficiencies have been remedied since 
2018.312,313 Training in the practical delivery of cessation 
and temporary abstinence advice and in prescribing 
smoking cessation medications needs to become universal 
across the NHS and social care system. 
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Key points
>  Smoking among young people is twice as common in 
those from disadvantaged backgrounds, representing 
a key mechanism by which health inequalities are 
sustained over the course of successive generations.
>  Smoking forms part of a wider pattern of risk-taking 
behaviours which emerge at similar times and for 
similar reasons during adolescence.
>  Reducing exposure to smoking role models among 
household members and peer groups, and smoking 
norms in the media, will be important to continued 
progress in reducing smoking uptake (see chapter 5 for 
further detail on smoking imagery in the media). 
>  While young people’s e-cigarette use has grown rapidly 
in the USA, regular use in the UK remains rare and limited 
almost exclusively to smokers. Hence, e-cigarettes do 
not seem to be a major source of nicotine addiction for 
young people in the UK to date.
Recommendations
>  The minimum age of sale is raised from 18 to 21 years.
>  Access to tobacco vendors through tobacco vendor 
licensing schemes is limited.
>  The use of dissuasive cigarettes and health warnings on 
cigarettes is introduced.
>  Smoke-free legislation is expanded, to de-normalise 
smoking behaviour.
>  School-based interventions targeting multiple risk 
behaviours are introduced. 
>  Measures to support adult role models to quit smoking 
are continued. 
>  Long-standing survey monitoring tools are maintained: 
important for informing and evaluating action in relation 
to both smoking and e-cigarette use among youth.
4.1 Introduction
The persistent decline in use of tobacco by young people 
during the late 20th and early 21st centuries represents  
a major public health success, one that has been achieved 
through a diverse range of regulation and education.  
As in adults, smoking among young people is particularly 
concentrated in those from disadvantaged backgrounds, 
representing a key mechanism by which health inequalities are 
sustained over the course of successive generations. Globally, 
over 130 million adolescents continue to smoke daily.1
The majority of established smokers first took up smoking 
in adolescence.2 As UK nations develop their ambitions 
to become smoke-free,3 strategies are needed both to 
support smokers to quit and to prevent young people 
becoming smokers. Cessation and preventing uptake 
are complementary goals; reducing the proportion of 
adults who smoke also reduces the modelling of smoking 
behaviour to young people and hence reduces smoking 
uptake.4,5 This chapter focuses on preventing uptake, 
reflecting on what has been achieved to date through 
combining regulation and education, before discussing 
challenges and priorities for further progress. 
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4.2 Trends in young people’s smoking
Trends in smoking prevalence among young people in 
England, taken from the Smoking, Drinking and Drug 
Use (SDDU) surveys from 1982 to 2018,6 demonstrate 
that regular smoking (ie smoking weekly or more) among 
15-year-olds reached a peak of about 30% in 1996, 
shortly before the publication of the newly elected Labour 
government’s white paper Smoking kills in 19987 (Fig 4.1). 
There has since been an approximately linear decline in 
smoking prevalence among all young people, to below 3% 
of 11- to 15-year-olds in 2018. 
Fig 4.1 Trends in regular smoking in England from 1982 to 2018 among 15-year-olds, and 11- to 15-year-olds. 
Source: Smoking, Drinking and Drug Use (SDDU) survey6  
© 2019, Health and Social Care Information Centre. The Health and Social Care Information Centre is a non-departmental body created by statute, 
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While this long-term picture in England is positive, there is 
evidence that declines in young people’s smoking might 
be reaching a plateau in other UK nations. Data from the 
Scottish Schools Adolescent Lifestyle and Substance Use 
Survey (SALSUS), which samples 13 and 15-year-olds, 
indicate that following a similar linear decline in smoking 
prevalence as occurred in England until 2015, there was no 
change in smoking prevalence between 2015 and 2018.8 
In Wales, there was again no change in the prevalence 
of smoking among 11- to 16-year-olds across four School 
Health Research Network (SHRN) surveys between 2013 
and 2019.9 Differences between these survey findings are 
likely to arise at least in part from differences in response 
rate, given that response rates in SDDU (22% in 2018)6 
have declined to a greater extent over time than for 
SALSUS (52% in 2018)10 or SHRN (72% in 2019).11 The 
most recent rounds of these surveys estimate regular 
smoking among 15-year-olds at 5% in England,6 7% in 
Scotland8 and 8% in Wales.12  
Despite these differences, child smoking uptake in all of 
these surveys is at its lowest level since measurement 
began. However, smoking continues to play a role in the 
inter-generational reproduction of inequalities. Data 
from Wales in 2019 indicate that young people from 
the poorest families remain twice as likely to be regular 
smokers as those from the most affluent families (see Fig 
4.2)12. Children from poorer families are more likely to live in 
households and communities in which smoking occurs.5,13 
4      Preventing uptake of smoking by children 
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FAS 1 (low) 6
FAS 2 (med) 4
FAS 3 (high) 3
4.3 Drivers of youth smoking
4.3.1 Influence of caregivers and peers
Children who live with smokers are more likely to become 
smokers themselves.4,5,14 Data from children in the UK 
Millennium Cohort Study (MCS), collected at approximately 
14 years of age show that risk of ever having smoked 
increased if caregivers (26% vs. 10.9%) or friends (35.1% vs 
4%) smoked. There was an exposure-response association 
evident for friends’ smoking. The behaviour of more 
popular teens has greater influence on smoking uptake.15 
Peer groups disseminate beliefs about smoking. Ideas 
which increase the risk of young adult initiation, and which 
may derive from peer networks or the media, include the 
belief that smoking can calm someone down when they 
are angry or nervous.16 In marginalised young people, peers 
may influence the belief that smoking is an expression of 
‘control’ over the here and now in a multitude of ways, 
including taking control over an oppressor, controlling the 
effects of exposure to traumatic or day-to-day stress, and 
exerting control over the physical body in terms of protecting 
oneself from violence or defending one’s mental health.17
4.3.2 Smoking imagery
Most forms of advertising are banned, but tobacco 
smoking remains prevalent in television programming 
with little evidence of this having diminished over time in 
recent years.18 New media are less effectively regulated 
and the tobacco industry has made use of this by, for 
example, paying Instagram influencers to promote their 
products.19 A recent review noted that brand pages rarely 
used age-gating, did not display health warnings, generally 
posted images of a product alone and often used hashtags 
unrelated to tobacco.20 Smoking imagery in the media is 
reviewed in more detail in chapter 5.
4.3.3 Tobacco vendors
Evidence from Scotland indicates that children in more 
deprived communities are exposed to several times 
more tobacco retailing activity than peers in more 
affluent communities,21 and has identified positive 
associations between tobacco outlet density and smoking 
frequency,22,23 experimental smoking,24–26 current smoking26 
and smoking purchases.27,28 Furthermore, evidence has 
begun to emerge suggesting that, among non-smoker 
adolescents, increased tobacco outlet density is related 
to knowledge of cigarette brands,29 intention to smoke30 
and susceptibility to future smoking.28,31 Caryl et al,21 
using individual level GPS data of children, concluded 
that children in more deprived areas had seven times as 
much exposure to tobacco outlets than those in the most 
affluent areas (Fig 4.3). 
Fig 4.2 Percentage of 11- to 16-year-olds in Wales who 
are regular smokers, by score on the Family Affluence 
Scale (FAS): a high score on FAS is indicative of higher 
family affluence.12 
© School Health Research Network 2020
Fig 4.3 Frequency of exposure to tobacco retailers by income deprivation (mean +/- 95% CIs). GPS data from 1 week, from 692 adolescents (aged 
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A meta-analysis investigating the relation between tobacco 
outlet density and smoking concluded that a one-unit 
increase in tobacco outlet density around adolescents’ 
homes was associated with an 8% increase in the odds of 
adolescents having smoked in the past month.32 While the 
majority of the research to date has been cross-sectional 
and at risk of confounding from household or peer 
exposure to tobacco use, longitudinal evidence is beginning 
to emerge that allows us to draw some conclusions on 
causality. While not focused on children or adolescents, 
a recent Scottish study employing longitudinal maternity 
data was able to track mothers between pregnancies, thus 
taking account of changing geographies and changing 
exposures to tobacco retailers.33 The study identified that 
across the range of exposure to tobacco outlets, the odds 
of smoking increased by 67% over time (odds ratio 1.67, 
95% CI 1.27 to 2.20). This provides the strongest evidence 
to date of an association between the availability of 
tobacco retailers and smoking behaviours. 
4.4 How has progress to date in reducing 
smoking uptake been achieved?
4.4.1 Regulation and legislative action 
UK governments, both before and since devolution, have 
introduced increasingly restrictive regulations for tobacco. 
These have aimed in part to restrict young people’s access 
and exposure to tobacco, make cigarettes less appealing, 
and communicate new norms around smoking. Key actions 
are illustrated in Fig 2.1 (chapter 2). While this relates to 
England, and much tobacco control action is now devolved, 
UK nations have maintained substantial alignment in 
many aspects of tobacco regulation during this period, 
though with some variation in timing. Disentangling 
effects of individual policies is challenging, and the 
effects of individual policy components have most likely 
been small. However, this suite of action as a whole has 
likely contributed to the sustained downward observed 
trajectories in youth smoking observed throughout the 
beginning of the 21st century.
International literature indicates that reducing the 
affordability of tobacco via taxation can play an important 
role in reducing youth smoking uptake.34 The UK has 
historically had one of the highest international taxation 
rates for tobacco,35 but the prevalence trends discussed 
above demonstrate little correlation with changes in 
these rates over the last 30 years. Thus a tobacco duty 
escalator introduced in the early 1990s which increased 
duty above inflation by 2-5% was associated with relatively 
stable smoking rates (see above) while smoking in young 
people fell during the period from 2001 to 2010 when the 
escalator was temporarily suspended36 (see chapter 7 for 
further detail). Therefore, either there is a substantial lag 
in the effect of tax increases or, more likely, other tobacco 
control measures had a greater effect during this period. 
These included prohibition of most forms of advertising 
within the 2002 Tobacco Advertising and Promotion 
Act,37 which complemented earlier bans on television 
and broadcast advertising (introduced in 1965 and 1990 
respectively).38 Smoking in enclosed workplaces was 
prohibited in Scotland in 2006 and elsewhere in the UK in 
2007. While implemented to protect hospitality workers,39 
plans were met with arguments that this would harm 
children by displacing smoking into the home. However, 
second-hand smoke exposure, and indeed smoking in the 
home, declined following smoke-free legislation40,41 as the 
idea of smoke-free indoor spaces became accepted. Recent 
natural experimental evaluations provide some evidence 
that rates of decline in young people’s smoking accelerated 
following smoke-free legislation,42 and subsequent changes 
in age of tobacco sales from 16 to 18 years.43 
Mandatory pictorial health warnings on cigarette packs 
have been introduced in the UK, with international 
evidence suggesting warnings have important impacts 
on both cessation and uptake.44  Evidence from Ireland 
indicates a role for point-of-sale (POS) restrictions in further 
de-normalising smoking.45 POS restrictions were introduced 
in the UK for larger retailers in 2012 and smaller retailers 
from 2015, with evidence of lowered smoking susceptibility 
among young never-smokers following the introduction 
of these restrictions.46 Laws prohibiting proxy purchasing 
have sought to further restrict young people’s access to 
tobacco, recognising that while the age of sale had been 
raised to 18 years, many young people remained able 
to access tobacco via older friends and peers.47 From 
2015 bans on smoking in cars carrying children were 
introduced in England and Wales, and the following year 
in Scotland, with some evidence that young people’s 
exposure to tobacco in cars reduced as a result48 (see 
chapter 6, section 6.3.2). Plain packaging was introduced 
from 2016, alongside Tobacco Products Directive (TPD) 
regulations. Plain packaging removed a key remaining 
mechanism for tobacco companies to market their brands, 
with evidence from Australia indicating that young people 
rated packaging as less appealing, and were less aware 
of brand differences, following packaging changes.49 TPD 
regulations have banned the sale of menthol cigarettes 
since May 2020, recognising evidence that menthol 
cigarettes are appealing to young people.50
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4.4.2 Education and communication
Alongside policy action, interventions focused on educating 
young people have played some role in preventing smoking 
uptake. There is some evidence that communicating the 
harms of smoking via mass media campaigns, combined 
with school-based interventions, can make some 
contribution to reducing uptake, although this evidence 
is of low certainty.51 Systematic reviews provide evidence 
that some school-based interventions, particularly those 
combining a focus on social competence and social 
influence, can play a role in preventing smoking uptake.52 
School-based programmes such as the ‘A stop smoking in 
schools trial’ (ASSIST)53 emerged around the turn of the 
century, and focused on changing norms by identifying 
influential students and training them in having healthy 
conversations with peers about smoking. ASSIST led 
to modest but important effects on reducing uptake in 
a robust cluster randomised controlled trial (RCT), at a 
time when smoking rates were high. Data from around 
this time also indicate that pupils attending schools with 
stricter policies against smoking were less likely to take 
up smoking.54 Hence, education and communication, 
including via schools, likely played a role in shaping norms 
at a more micro-level, alongside wider policy action, 
particularly during a time when smoking uptake was 
relatively normalised.
4.5 The role of e-cigarettes
Alongside increasing restriction of tobacco, e-cigarettes 
have emerged in UK markets. While evidence is growing 
on their usefulness as a cessation aid,55 much concern 
has been expressed that their emergence might undo 
efforts to reduce smoking among young people. There 
is consistent evidence that tobacco-naïve young people 
who use an e-cigarette are more likely to go on to smoke,56 
although it remains unclear the extent to which this is a 
causal connection, reflects common risk factors, or is a 
combination of the two. Certainly the risk of becoming a 
smoker following initial e-cigarette use is much lower than 
the risk of becoming a regular smoker following a single 
cigarette: a meta-analysis found that two-thirds of people 
who tried one cigarette went on to temporarily become 
daily smokers.57 While young people’s e-cigarette use has 
grown rapidly in the US,58 regular use in the UK remains 
rare and limited almost exclusively to smokers.12,59 Hence, 
e-cigarettes do not seem to be a major source of nicotine 
addiction for young people in the UK to date. Indeed, some 
argue that while e-cigarettes might lead a small number of 
young people into smoking, for others, they may displace 
smoking.60 At the population level, there is evidence 
from UK61 and international studies60 that tobacco use 
continued to decline during the emergence of e-cigarettes. 
There is also evidence that in the UK, young people’s 
experimentation with e-cigarettes has now levelled off, 
or is falling,12 with young people describing these as a fad 
in which interest is diminishing.62 The TPD introduced a 
suite of regulations on e-cigarettes in 2016, which included 
restrictions on marketing and on the devices; the impact of 
devices on young people’s use of e-cigarettes is the subject 
of ongoing evaluation.62 
4.6 Future directions in reducing young 
people’s uptake of tobacco
4.6.1. Age of sale restrictions
Raising the minimum age of sale from 18 to 21 years to 
reduce child access to tobacco products could be expected 
to reduce smoking uptake further.63,64 In December 2019 
the United States raised the minimum legal age of sale 
(MLSA) of all tobacco products nationally to 21 years.65 
While adolescents who are of legal age are able to 
purchase tobacco products freely,66 under-age adolescents 
often obtain tobacco products either directly or indirectly 
through proxy purchase by legal-age peers.5,6 Raising the 
MLSA will effectively limit both of these mechanisms, 
first because some young people currently of legal age to 
purchase tobacco products will no longer legally be able 
to do so, and second, by increasing the age gap between 
those who can and cannot legally purchase tobacco 
products, such as through proxy purchases, and hence 
reducing those opportunities as legal purchasers will be less 
likely to be part of the adolescents’ social network. Raising 
the age of sale to 21 years would take legal purchase 
outside of school age completely.
An evaluation of raising the MLSA in England and Wales 
from age 16 to 18 in 2007 found there was a threefold 
drop in prevalence of smoking among 16- and 17-year-
olds compared to older adults.67 Evaluations of MLSA of 
21 years have focused on the implementation of laws 
within US cities and states and have found reductions in 
smoking among 18- to 20-year-olds.29,68 Modelling of the 
impact of MLSA 21 laws has predicted that raising the 
MLSA would have the largest effect among 15- to 17-year-
olds by reducing initiation by approximately 25% and the 
prevalence of smoking by approximately 12%.69
There is widespread public and political support for 
increasing the MLSA to 21 years. Most smokers and former 
smokers in England appear to support increasing age of 
sales to 21 years.70 There is growing political support for 
increasing the MLSA for tobacco products, for example 
among policymakers in Canada and Australia.71,72 
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4.6.2 Tobacco retail licensing
Licensing of tobacco retailers supports enforcement of 
tobacco control legislation through trading standards 
and the power to ban retailers from selling tobacco where 
they repeatedly break the law by selling to underage 
children or young adults. Members of the public are able 
to verify online whether their local retailer is registered. 
Spatial interventions have been enacted in Spain, where a 
minimum distance of 150 m between retailers is required.73 
In the USA some retailers have voluntarily ceased selling 
tobacco for ethical (health concerns) or for business-
related reasons (poor sales or tobacco taxes).74 Despite 
what appears to be a political reluctance to reduce the 
availability of tobacco, research has reported large-scale 
public acceptance and support for such measures with 
strong support for retail restrictions around schools.75,76 
In particular, support for retail reduction is strong among 
adolescents themselves.77 
4.6.3 Dissuasive cigarettes 
Health warnings and regulation of tobacco packaging 
have played an important role in reducing the appeal of 
cigarettes. However, supply routes for tobacco cigarettes 
have changed in recent years, with fewer young people in 
England buying tobacco from shops,6 and most obtaining 
cigarettes from peers. Where given individual cigarettes by 
peers, young people may access cigarettes without seeing 
them in their packets, removing exposure to dissuasive 
warnings. Emerging evidence indicates that cigarettes 
which are themselves unattractively coloured, or include 
health warnings (eg ‘Smoking kills’) on the actual stick may 
reduce the appeal to young non-smokers78 (see chapter 5, 
section 5.11).
4.6.4 Expansion of smoke-free legislation
This is reviewed fully in chapter 6. Expansion of smoke-free 
legislation is gaining momentum, particularly in Wales. 
Legislation will be expanded to a wider range of locations 
from March 2021, with a particular focus on places where 
children are likely to encounter smoking.79
4.6.5 Regulation of smoking imagery
Regulation of smoking imagery within the media may 
play an important role in further reducing smoking uptake. 
There is some evidence that using social media influencers 
to promote smoking cessation may be effective.80 
Regulatory action needs to adapt to these changes to limit 
young people’s exposure to pro-smoking material81 (see 
chapter 5). 
4.6.6 Taxation
Modelling studies also suggest that increasing the 
UK’s tobacco duty escalator to 5% would substantially 
accelerate the decline in adult smoking,36 and it is likely that 
this would occur both via encouraging smokers to quit and 
limiting uptake in children and young people. 
4.6.7 E-cigarettes
As described above, the UK has not to date seen substantial 
regular e-cigarette use among non-smokers but e-cigarettes 
have contributed to adults stopping smoking and helped to 
de-normalise tobacco use. Debate regarding e-cigarettes 
should not dominate discussions on preventing smoking 
uptake and draw attention from other important actions. 
Nevertheless, these trends need to be monitored, and 
the regulatory balance of ensuring e-cigarettes can play 
a role in supporting smokers to quit while limiting young 
people’s contact with them should be continuously reviewed. 
Maintaining long-standing survey monitoring tools remains 
important for informing and evaluating action in relation to 
both smoking and e-cigarette use among youth.
4.6.8 Education and communication
Multi-channel public education campaign models 
developed at a time when smoking was highly normalised 
should be tailored to a changed context, in which a 
minority of young people take up smoking, concentrated 
in more disadvantaged communities. Research on the 
aforementioned ASSIST programme in Scotland for 
example suggests that rather than universal delivery, 
targeting to areas where smoking remains more 
normalised may be more efficient.82 
4.6.9 Understanding the broader context of young 
people’s smoking uptake
Smoking forms part of a wider pattern of risk-taking 
behaviours, which emerge at similar times and for similar 
reasons during adolescence.83 Indeed, the 21st century 
decline in smoking has been mirrored in other behaviours,84 
and perhaps cannot be entirely attributed to actions 
discussed above, reflecting broader societal changes. 
Recent signals that declines in young people’s tobacco 
uptake may be beginning to plateau, at least in some parts 
of the UK, are also mirrored in other risk behaviours.9  
For cessation, where the goal is behaviour change, 
specificity of focus is important, as expecting people to 
change multiple behaviours at once is likely to be counter-
productive.85 This logic does not however necessarily hold 
for prevention, where the goal is not to change behaviours, 
but to maintain a status quo in which those behaviours 
are not occurring. There is good evidence that school-
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based interventions targeting multiple risk behaviours 
simultaneously can reduce smoking uptake.86 Interventions 
which address multiple goals are likely to be particularly 
valuable in crowded delivery contexts such as schools, 
where there is unlikely to be capacity to deliver a separate 
intervention for each health risk. Indeed, some recent 
school-based interventions which have shown promise in 
preventing uptake are not about smoking at all, but address 
issues such as social relationships in the school environment 
to reduce bullying, with secondary impacts across a wide 
range of risk behaviours including smoking, drinking, drug 
use, as well as mental health.87
Further, as described above, children’s attitudes and 
perceptions toward smoking are formed in the contexts 
in which they live their daily lives. While tobacco has been 
all but eliminated from many young people’s lives, many 
children, particularly those in poorer communities continue 
to grow up in environments in which tobacco use and 
retail is widely observed. Reducing inequalities in young 
people’s smoking uptake will likely require continued efforts 
to support adult role models in giving up smoking, and to 
address place-based drivers of these inequalities.21
References 
1  Azzopardi PS, Hearps SJC, Francis KL et al. Progress in adolescent health 
and wellbeing: tracking 12 headline indicators for 195 countries and 
territories, 1990-2016. Lancet 2019;393:1101–18.
2  Smoking (General Lifestyle Survey Overview - a report on 




onthe2011generallifestylesurvey [Accessed 12 March 2021].
3  Hopkinson NS. The path to a smoke-free England by 2030. BMJ 
2020;368:m518. www.bmj.com/content/368/bmj.m518.long [Accessed 
12 March 2021].
4  Leonardi-Bee J, Jere ML, Britton J. Exposure to parental and sibling 
smoking and the risk of smoking uptake in childhood and adolescence: 
a systematic review and meta-analysis. Thorax 2011;66:847–55.
5  Laverty AA, Filippidis FT, Taylor-Robinson D et al. Smoking uptake 
in UK children: analysis of the UK Millennium Cohort Study. Thorax 
2018;74:607–10.
6  Smoking, Drinking and Drug Use among young people in England 
2018, 2019. https://digital.nhs.uk/data-and-information/publications/
statistical/smoking-drinking-and-drug-use-among-young-people-in-
england/2018 [Accessed 12 March 2021].
7  Department of Health. Smoking kills. A white paper on tobacco. 
London: DH, 1998.
8  Scottish Schools Adolescent Lifestyle and Substance Use Survey 
(SALSUS): smoking report 2018, 2019. www.gov.scot/publications/
scottish-schools-adolescent-lifestyle-substance-use-survey-salsus-
smoking-report-2018 [Accessed 12 March 2021].
9  Page N, Hallingberg B, Brown R et al. Change over time in adolescent 
smoking, cannabis use and their association: findings from the School 
Health Research Network in Wales. J Public Health 2020;fdaa174.
10  Scottish Schools Adolescent Lifestyle and Substance Use Survey 
(SALSUS): technical report 2018, 2019. www.gov.scot/publications/
scottish-schools-adolescent-lifestyle-substance-use-survey-salsus-
technical-report-2018/pages/4 [Accesed 12 March 2021].
11  Page N, Hewitt G, Young H, Moore G, Murphy S. Student health 
and wellbeing in Wales: report of the 2019 School Health Research 
Network student health and wellbeing survey. Cardiff: Cardiff 
University, forthcoming.
12  School Health Research Network Wales. Youth smoking and vaping 
in Wales: findings from the School Health Research Network 2019 
Student Health and Wellbeing survey. Cardiff: SHRN, 2020.
13  Moore GF, Angel L, Gray L et al. Associations of socioeconomic status, 
parental smoking and parental e-cigarette use with 10–11-year-old 
children’s perceptions of tobacco cigarettes and e-Cigarettes: cross 
Sectional analysis of the CHETS Wales 3 survey. Int J Environ Res 
Public Health 2020;17:683.
14  East K, McNeill A, Thrasher JF, Hitchman SC. Social norms as a 
predictor of smoking uptake among youth: a systematic review, meta-
analysis and meta-regression of prospective cohort studies. Addiction 
2021.
15  Robalino JD, Macy M. Peer effects on adolescent smoking: are popular 
teens more influential? PloS One 2018;13:e0189360.
16  Bernat DH, Klein EG, Forster JL. Smoking initiation during young 
adulthood: a longitudinal study of a population-based cohort. J 
Adolesc Health 2012;51:497–502.
17  Antin TMJ, Hunt G, Sanders E. The “here and now” of youth: the 
meanings of smoking for sexual and gender minority youth. Harm 
Reduct J 2018;15:1–11.
18  Barker AB, Whittamore K, Britton J, Cranwell J. Content analysis of 
tobacco content in UK television. Tob Control 2019;28:381–5.
19  Campaign for tobacco-free kids: where there’s smoke, 2018. www.
takeapart.org/wheretheressmoke [Accessed 15 June 2020]. 
20  O’Brien EK, Hoffman L, Navarro MA, Ganz O. Social media use by 
leading US e-cigarette, cigarette, smokeless tobacco, cigar and 
hookah brands. Tob Control 2020;29:e87–97.
21  Caryl F, Shortt NK, Pearce J, Reid G, Mitchell R. Socioeconomic 
inequalities in children’s exposure to tobacco retailing based on 
individual-level GPS data in Scotland. Tob Control 2020;29:367–73.
22  Lipperman-Kreda S, Grube JW, Friend KB. Local tobacco policy and 
tobacco outlet density: associations with youth smoking. J Adolesc 
Health 2012;50:547–52.
23  Scully M, McCarthy M, Zacher M et al. Density of tobacco retail 
outlets near schools and smoking behaviour among secondary school 
students. Aust N Z J Public Health 2013;37:574–8.
24  McCarthy WJ, Mistry R, Lu Y et al. Density of tobacco retailers near 
schools: effects on tobacco use among students. Am J Public Health 
2009;99:2006–13.
25  Schleicher NC, Johnson TO, Fortmann SP, Henriksen L. Tobacco outlet 
density near home and school: Associations with smoking and norms 
among US teens. Prev Med 2016;91:287–93.
46© Royal College of Physicians 2021
4      Preventing uptake of smoking by children 
26  Shortt NK, Tisch C, Pearce J, Richardson EA, Mitchell R. The density of 
tobacco retailers in home and school environments and relationship 
with adolescent smoking behaviours in Scotland. Tob Control 
2016;25:75–82.
27  Leatherdale ST, Strath JM. Tobacco retailer density surrounding 
schools and cigarette access behaviors among underage smoking 
students. Ann Behav Med 2007;33:105–11.
28  Marsh L, Ajmal A, McGee R et al. Tobacco retail outlet density and risk 
of youth smoking in New Zealand. Tob Control 2016;25:e71–e4.
29  Tunstall H, Shortt NK, Niedzwiedz CL et al. Tobacco outlet density and 
tobacco knowledge, beliefs, purchasing behaviours and price among 
adolescents in Scotland. Soc Sci Med 2018;206:1–13.
30  Mennis J, Mason M. Tobacco outlet density and attitudes towards 
smoking among urban adolescent smokers. Subst Abus 2016;37:521–5.
31  Chan WC, Leatherdale ST. Tobacco retailer density surrounding 
schools and youth smoking behaviour: a multi-level analysis. Tob 
Induc Dis 2011;9:1–7.
32  Finan LJ, Lipperman-Kreda S, Abadi M et al. Tobacco outlet density 
and adolescents’ cigarette smoking: a meta-analysis. Tob Control 
2019;28:27–33.
33  Clemens T, Dibben C, Pearce J, Shortt NK. Neighbourhood tobacco 
supply and individual maternal smoking during pregnancy: a 
fixed-effects longitudinal analysis using routine data. Tob Control 
2020;29:7–14.
34  Fleischer NL, Donahoe JT, McLeod MC et al. Taxation reduces smoking 
but may not reduce smoking disparities in youth. Tob Control 2020.
35  World Health Organization. Report on Tobacco Taxation in the United 
Kingdom. WHO, 2003.
36  Knuchel-Takano A, Hunt D, Jaccard A et al. Modelling the implications 
of reducing smoking prevalence: the benefits of increasing the UK 
tobacco duty escalator to public health and economic outcomes. Tob 
Control 2018;27:e124–e9.
37  Tobacco Advertising and Promotion Act 2002, 2002. www.legislation.
gov.uk/ukpga/2002/36/contents [Accessed 22 March 2021].
38  Action on Smoking and Health. UK Tobacco Advertising and 
Promotion. ASH, 2019. www.ash.org.uk/wp-content/uploads/2019/02/
Tobacco-Advertising-and-Promotion-download.pdf [Accessed 22 
March 2021].
39  Semple S, Maccalman L, Naji AA et al. Bar workers’ exposure to 
second-hand smoke: the effect of Scottish smoke-free legislation on 
occupational exposure. Ann Occup Hyg 2007;51:571–80.
40  Mons U, Nagelhout GE, Allwright S et al. Impact of national 
smoke-free legislation on home smoking bans: findings from the 
International Tobacco Control Policy Evaluation Project Europe 
Surveys. Tob Control 2013;22:e2–e9.
41  Moore GF, Currie D, Gilmore G, Holliday JC, Moore L. Socioeconomic 
inequalities in childhood exposure to secondhand smoke before and 
after smoke-free legislation in three UK countries. J Public Health 
2012;34:599–608.
42 Katikireddi SV, Der G, Roberts C, Haw S. Has childhood smoking 
reduced following smoke-free public places legislation? A segmented 
regression analysis of cross-sectional UK school-based surveys. Nicotine 
Tob Res 2016;18:1670–4.
43 Anyanwu PE, Craig P, Katikireddi SV, Green MJ. Impact of UK tobacco 
control policies on inequalities in youth smoking uptake: a natural 
experiment study. Nicotine Tob Res 2020;22:1973–80.
44  Hammond D. Health warning messages on tobacco products: a 
review. Tob Control 2011;20:327–37.
45  McNeill A, Lewis S, Quinn C et al. Evaluation of the removal of point-of-
sale tobacco displays in Ireland. Tob Control 2011;20:137–43.
46  Ford A, MacKintosh AM, Moodie C et al. Impact of a ban on the open 
display of tobacco products in retail outlets on never smoking youth 
in the UK: findings from a repeat cross-sectional survey before, during 
and after implementation. Tob Control 2020;29:282–8.
47  Nuyts PA, Kuipers MA, Willemsen MC, Kunst AE. An increase in the 
tobacco age-of-sale to 21: for debate in Europe. Nicotine Tob Res 
2020;22:1247–9.
48  Laverty AA, Hone T, Vamos EP et al. Impact of banning smoking 
in cars with children on exposure to second-hand smoke: a natural 
experiment in England and Scotland. Thorax 2020;75:345–7.
49  White VM, Guerin N, Williams T, Wakefield MA. Long-term impact of 
plain packaging of cigarettes with larger graphic health warnings: 
findings from cross-sectional surveys of Australian adolescents 
between 2011 and 2017. Tob Control 2019;28:e77–e84.
50  Nonnemaker J, Hersey J, Homsi G et al. Initiation with menthol 
cigarettes and youth smoking uptake. Addiction 2013;108:171–8.
51  Carson-Chahhoud KV, Ameer F, Sayehmiri K et al. Mass media 
interventions for preventing smoking in young people. Cochrane 
Database Syst Rev 2017(6).
52  Thomas RE, McLellan J, Perera R. Effectiveness of school-based 
smoking prevention curricula: systematic review and meta-analysis. 
BMJ Open 2015;5(3).
53  Campbell R, Starkey F, Holliday J et al. An informal school-based peer-
led intervention for smoking prevention in adolescence (ASSIST): a 
cluster randomised trial. Lancet 2008;371:1595–602.
54  Moore L, Roberts C, Tudor-Smith C. School smoking policies and 
smoking prevalence among adolescents: multilevel analysis of cross-
sectional data from Wales. Tob Control 2001;10:117–23.
55  Hartmann-Boyce J, McRobbie H, Lindson N et al. Electronic cigarettes 
for smoking cessation. Cochrane Database Syst Rev 2020(10).
56  Khouja JN, Suddell SF, Peters SE, Taylor AE, Munafò MR. Is e-cigarette 
use in non-smoking young adults associated with later smoking? A 
systematic review and meta-analysis. Tob Control 2021;30:8–15.
57  Birge M, Duffy S, Miler JA, Hajek P. What proportion of people 
who try one cigarette become daily smokers? A meta-analysis of 
representative surveys. Nicotine Tob Res 2018;20:1427–1433.
58  Wang TW, Neff LJ, Park-Lee E et al. E-cigarette use among middle and 
high school students - United States, 2020. MMWR Morb Mortal Wkly 
Rep 2020;69:1310.
59  Bauld L, MacKintosh AM, Eastwood B et al. Young people’s use of 
e-cigarettes across the United Kingdom: findings from five surveys 
2015–2017. Int J Environ Res Public Health 2017;14:973.
60  Walker N, Parag V, Wong SF et al. Use of e-cigarettes and smoked 
tobacco in youth aged 14–15 years in New Zealand: findings from 
repeated cross-sectional studies (2014–19). Lancet Public Health 
2020;5:e204–12.
47© Royal College of Physicians 2021
Preventing uptake of smoking by children       4
61  Hallingberg B, Maynard OM, Bauld L et al. Have e-cigarettes 
renormalised or displaced youth smoking? Results of a segmented 
regression analysis of repeated cross sectional survey data in England, 
Scotland and Wales. Tob Control 2020;29:207–16.
62  Moore G, Brown R, Page N et al. Young people’s use of e-cigarettes 
in Wales, England and Scotland before and after introduction of EU 
Tobacco Products Directive regulations: a mixed-method natural 
experimental evaluation. Int J Drug Policy 2020;85:102795.
63  Schneider SK, Buka SL, Dash K, Winickoff JP, O’Donnell L. Community 
reductions in youth smoking after raising the minimum tobacco sales 
age to 21. Tob Control 2016;25:355–9.
64  Friedman AS, Wu RJ. Do local tobacco-21 laws reduce smoking among 
18 to 20 year-olds? Nicotine Tob Res 2020;22:1195–201.
65  Tobacco 21. www.fda.gov/tobacco-products/retail-sales-tobacco-
products/tobacco-21. [Accessed 19 December 2020).
66  Braak D, Cummings KM, Nahhas GJ, Reid JL, Hammond D. How 
are adolescents getting their vaping products? Findings from the 
international tobacco control (ITC) youth tobacco and vaping survey. 
Addict Behav 2020;105:106345.
67  Fidler JA, West R. Changes in smoking prevalence in 16-17-year-old 
versus older adults following a rise in legal age of sale: findings from 
an English population study. Addiction 2010;105:1984–8.
68  Nuyts PAW, Davies LEM, Kunst AE, Kuipers MAG. The association 
between tobacco outlet density and smoking among young people: a 
systematic methodological review. Nicotine Tob Res 2019;23:239–48.
69  Institute of Medicine. Public health implications of raising the minimum 
age of legal access to tobacco products. Washington, DC: National 
Academies Press, 2015.
70  Hawkins SS, Chung-Hall J, Craig L et al. Support for minimum legal 
sales age laws set to age 21 across Australia, Canada, England, and 
United States: findings from the 2018 ITC Four Country Smoking and 
Vaping Survey. Nicotine Tob Res 2020;22:2266–70.
71  Macsweeney C. Trudeau government suggests moving the 
legal smoking age to 21. City News, 2017. www.citynews1130. 
com/2017/03/01/trudeau-government-suggests-moving-
legal-smoking-age-21/ [Accessed 19 December 2020].
72  Deutrom R. Health ministers urged to lift smoking age to 21. The 
Weekend Australian, 2018. https://www.theaustralian.com.au/nation/
health/health-ministers-urged-to-lift-smoking-age-to-21/news-story/4a
d301c06efa2bd22adb68279f0531e7. [Accessed 19 December 2020].
73  Valiente R, Sureda X, Bilal U et al. Regulating the local availability of 
tobacco retailing in Madrid, Spain: a GIS study to evaluate compliance. 
Tob Control 2019;28:325–33.
74  McDaniel PA, Malone RE. “People over profits”: retailers who voluntarily 
ended tobacco sales. PLoS One 2014;9:e85751.
75  Farley SM, Coady MH, Mandel-Ricci J et al. Public opinions on tax and 
retail-based tobacco control strategies. Tob Control 2015;24:e10–13.
76  Whyte G, Gendall P, Hoek J. Advancing the retail endgame: public 
perceptions of retail policy interventions. Tob Control 2014;23:160–6.
77  Jaine R, Healey B, Edwards R, Hoek J. How adolescents view the 
tobacco endgame and tobacco control measures: Trends and 
associations in support among 14–15 year olds. Tob Control 
2015;24:449–54.
78  Moodie C, Gendall P, Hoek J et al. The response of young adult 
smokers and nonsmokers in the United Kingdom to dissuasive 
cigarettes: An online survey. Nicotine Tob Res 2019;21:227–33.
79  Welsh Government. UK first as children’s playgrounds set to be smoke-
free. 2020.  www.gov.wales/uk-first-childrens-playgrounds-set-be-
smoke-free [Accessed 22 March 2021].
80  Ling PM, Lisha NE, Neilands TB, Jordan JW. Join the commune: a 
controlled study of social branding influencers to decrease smoking 
among young adult hipsters. Am J Health Promot 2020;34:754–61.
81  Barker AB, Smith J, Hunter A, Britton J, Murray RL. Quantifying tobacco 
and alcohol imagery in Netflix and Amazon Prime instant video 
original programming accessed from the UK: a content analysis. BMJ 
Open 2019;9:e025807.
82  Dobbie F, Purves R, McKell J et al. Implementation of a peer-led school 
based smoking prevention programme: a mixed methods process 
evaluation. BMC Public Health 2019;19:742.
83  Kipping R, Campbell RM, MacArthur GJ, Gunnell DJ, Hickman M. 
Multiple risk behaviour in adolescence. J Public Health 2012;34:i1–i2.
84  Inchley J, Currie D, Vieno A et al. Adolescent alcohol-related 
behaviours: trends and inequalities in the WHO European Region, 
2002–2014. WHO Regional Office for Europe, 2018.
85  Michie S, van Stralen MM, West R. The behaviour change wheel: A 
new method for characterising and designing behaviour change 
interventions. Implement Sci 2011;6:42.
86  MacArthur G, Caldwell DM, Redmore J et al. Individual-, family-, and 
school-level interventions targeting multiple risk behaviours in young 
people. Cochrane Database Syst Rev 2018(10).
87  Bonell C, Allen E, Warren E et al. Effects of the Learning Together 
intervention on bullying and aggression in English secondary 
schools (INCLUSIVE): a cluster randomised controlled trial. Lancet 
2018;392:2452–64.
48© Royal College of Physicians 2021
Tobacco advertising and promotion 5
Key points
>  Exposure to tobacco imagery, branded or unbranded, 
is a cause of smoking uptake and is thus by definition 
harmful.
>  With limited exemptions to allow bona fide news 
reporting and use of tobacco imagery for health 
promotion purposes, it is therefore important to end the 
portrayal of tobacco imagery in any new media content 
likely to be seen by children, and where portrayal does 
occur, to take measures to ameliorate the effect through 
anti-tobacco messaging. 
Recommendations
>  Film licensing laws and television broadcasting codes require 
amendment to ensure the exclusion of all tobacco imagery 
from new productions that might be seen by children.
>  Health messaging is required on all tobacco imagery in 
existing content and when communicated in the media.
>  All new films containing tobacco imagery are classified as 
unsuitable for viewing by persons aged under 18 years.
>  Inclusion of tobacco imagery is prohibited in all new 
television programming broadcast before the 9pm 
watershed and in all programming (broadcast or on-
demand) likely to be seen by children.
>  Any film, television, video-on-demand, and other UK 
online content such as music videos and print media that 
contain tobacco imagery is required to display a health 
warning while such imagery is visible.
>  In cinemas, anti-smoking health promotion messages are 
shown immediately before films containing smoking.
>  All forms of tobacco industry sponsorship and advertising, 
including alibi marketing, are prohibited.
>  Exposure to tobacco imagery is included in the definition of 
online harm used in the forthcoming Online Safety Bill.
>  All retail tobacco gantries and cabinets are removed from 
sight.
>  Point-of-sale display legislation is extended to include 
tobacco paraphernalia such as hand rolling paper.
>  Tobacco product imagery is not shown on online sales 
websites. 
>  Pack inserts promoting cessation and providing tips and 
information to support quitting are mandated. 
>  Cigarette paper, whether manufactured or for hand 
rolling tobacco, is required to include health warnings, be 
a dissuasive colour, or both.
>  Flavour infusion products are prohibited, and flavour 
restrictions extended to filters and other tobacco 
paraphernalia. 
>  Standardised packaging legislation is extended to include 
tobacco papers and other smoking paraphernalia. 
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5.1 The evolution of tobacco promotion and 
its regulation in the UK
Tobacco advertising is a 20th century phenomenon which 
arose from mass production of branded cigarettes and 
has evolved into a strategic and sophisticated activity 
using print, film, radio, TV and most recently online media, 
complemented by indirect advertising through event 
sponsorship, brand endorsement, public relations and other 
marketing activities.1 Tobacco advertising communicates 
across the spectrum of potential and current tobacco users, 
promoting uptake of smoking by young people, sustaining 
smoking among established smokers, and promoting 
relapse to smoking among those smokers who have or are 
trying to quit,2 and thus undermines the effects of tobacco 
control policies. 
It was only after the discovery of the link between smoking 
and lung cancer that the promotion of tobacco first began 
to be challenged. The 1962 RCP report on the harms 
caused by the UK smoking epidemic3 highlighted the 
rapid increase in expenditure on UK television tobacco 
advertising after commercial television began broadcasting 
in the UK in 1955 and recommended that television 
advertising be restricted. This led to the passing of the 1964 
Television Act, which prohibited cigarette advertising on 
UK television from 1965.4 However, despite calls for more 
stringent controls on advertising in subsequent RCP reports, 
tobacco advertising remained largely self-regulated5–7 for 
the next 25 years through a series of voluntary agreements 
between the government and the tobacco industry, which 
fought a rear-guard action against effective regulation by 
voluntarily giving way over some issues while exploiting 
loopholes in existing agreements. For example, the industry 
implemented a voluntary ban on cinema advertising in 
1986, while rendering the ban on advertising of cigarettes 
on television ineffectual by vastly expanding sponsorship 
of televised sporting events.
This period of voluntary self-regulation began to reach its 
end with the 1990 Broadcasting Act,8 which prohibited all 
tobacco advertising on television and radio from 1991 (see 
Table 5.1 for legislation timeline). During the 1990s the EU 
then worked to develop a tobacco advertising directive, 
which in due course was transposed into UK law by the 
2002 Tobacco Advertising and Promotion Act.9 This UK law 
went further than the directive, which was limited to bans 
on cross-border advertising, promotion and sponsorship, 
and over a 4 year period prohibited all forms of advertising 
other than that at the point of sale, where advertisements 
were limited in size to that of an A5 sheet of paper, and 
advertising carried out within the tobacco trade. By 
prohibiting any advertising whose purpose or 
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Table 5.1 Implementation timeline of key UK advertising legislation15 
Adapted with permission from Action on Smoking and Health (ASH) 
Instrument Year Prohibited advertising 
Television Act 1965 Television cigarette 
Broadcasting Act 1990 All television and radio tobacco 
Tobacco Advertising and Promotion Act 2003 
2004
2005
Press, billboards, direct marketing, national event 
sponsorship, product placement
Point of sale other than single A5 advert
International event sponsorship, brandsharing
Audiovisual Media Services (Product 
Placement) Regulations





Vending machine (advertising and sale)
Point-of-sale advertising and displays in large shops
Point-of-sale advertising and displays in small shops
Children and Families Act 2016 Branding on packs except for product name in standard 
type (known as standardised plain packaging)
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effect was to promote a tobacco product, the 2002 Act 
also prohibited paid-for tobacco product placement in films 
or television programmes, and specific explicit regulations 
were subsequently applied to television programming in 
the 2010 Audiovisual Media Services (Product Placement) 
Regulations.10 
Branded tobacco packs are themselves advertisements 
for the brand11,12 and the 2009 Health Act prohibited all 
advertising and display of brands at point of sale in large 
retail outlets from 2012 and small retailers from 2015.13 The 
2009 Act prohibited tobacco vending machines, which also 
displayed packs and/or pack images and hence themselves 
functioned as tobacco advertisements, from 2009. 
Measures to make tobacco packs less appealing began 
with the inclusion of written health warnings on packs 
under a voluntary agreement in 1971, and subsequently 
by a series of laws increasing the size of the warning, 
mandating the text used, and from 2009 requiring pictorial 
warnings on the back of packs (see section 3.2). However, 
the use of tobacco packs to communicate brand imagery 
and other characteristics persisted until the 2015 Children 
and Families Act, which required all tobacco products sold 
in the UK after May 2017 to be packaged in standardised 
(or plain) packs; standardised packs must be ‘drab brown’, 
carry large pictorial and written warnings on the main 
display areas, and be devoid of branding except for a name 
and descriptor in standardised fonts.14 
The cumulative effect of this legislation is that the tobacco 
promotion landscape in the UK is now radically different 
from that of 50 years ago, with most manifestations of 
paid tobacco advertising and promotion prohibited and 
health warnings mandated by law. However, gaps in UK 
regulation still exist. Corporate advertising (that is, relating 
to the tobacco company rather than an individual brand or 
brands), promotion or sponsorship is still legal and is used 
to campaign against government anti-smoking policies 
and to promote tobacco industry business practices as 
‘socially responsible’. Internet sales of tobacco are still legal, 
and UK legislation does not prevent tobacco brands from 
appearing in UK media if not in the form of advertising 
or paid product placement. The inclusion of unbranded 
tobacco smoking or other tobacco imagery in the media, 
exposure to which is also a cause of smoking uptake 
among children (see section 5.2), is also unregulated. The 
explosion of social and other online media over the past 
decade or so, and the continuing 21st century shift in 
media consumption to online and on-demand sources, 
have also generated substantial new opportunities 
for tobacco product promotion, particularly to young 
people, that are as yet largely unexplored in tobacco 
control research, and represent a substantial challenge 
for regulators. This chapter reviews the evidence on the 
relation between exposure to media tobacco imagery 
and smoking behaviour; the regulatory systems that 
currently apply to different UK media and the extent to 
which tobacco imagery appears in them; known loopholes 
in or exemptions to UK legislation that have been used 
to promote tobacco products or consumption; and 
recommendations for how the UK regulatory framework 
could be further enhanced. The chapter also discusses 
measures that reduce, or could reduce, the appeal of 
generic or tobacco imagery through the use of health 
warnings and dissuasive cigarettes. 
5.2 Effect of media smoking imagery on 
smoking behaviour 
Evidence on the effect of exposure to smoking and other 
tobacco imagery in media on smoking uptake among 
children is derived almost exclusively from studies of 
children’s exposure to smoking in films. This effect was 
first declared to be causal in 2008 by the US National 
Cancer Institute, which concluded in a systematic review 
that the evidence ‘indicates a causal relationship between 
exposure to movie smoking depictions and youth smoking 
initiation’.16 The World Health Organization reached a 
similar conclusion in 2009,17 with updates in 2011 and 
2015,18,19 as did the US surgeon general in 2012.20 A 
2014 US surgeon general report clarified that the crucial 
determinant of this association was the quantity of 
tobacco imagery, not the context (for example, whether 
a character who smokes is a positive or negative role 
model).21 Since most tobacco imagery in film is unbranded, 
this effect is likely to be mediated more by social learning22 
than from exposure to specific tobacco brands.
A systematic review and meta-analysis of eight prospective 
cohort studies of the relation between exposure to smoking 
in films and smoking among young people published 
before May 2015 estimated that children in the highest 
level of exposure had a prospective risk of smoking 
initiation of 1.46 (95% confidence interval (CI) 1.23 to 1.73) 
times higher than that of children in the lowest exposure 
category.23 We have updated this systematic review for 
this report, including studies published up to January 2020, 
and from a meta-analysis of 11 longitudinal studies (eight 
of which were included in our earlier review23 and three 
of which have been published since)24–26 have estimated 
the risk of incident smoking to be increased among young 
people exposed to high levels of tobacco imagery by a ratio 
of 1.39 (95% CI 1.21 to 1.60). 
Other evidence suggests that the effect of film imagery 
exposure may be greater among children who are 
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otherwise at relatively low risk of smoking uptake on 
the grounds of having low levels of sensation-seeking, 
rebelliousness and risk-taking;27,28 and having parents who 
do not smoke.27,29 The magnitude of the effect of exposure 
appears to be related to the level of exposure,27,28 and may 
be reduced by showing anti-smoking messages before a 
film that contains smoking.30–33 
Although research to date has concentrated on studying 
the effect of exposure to depictions of smoking in films, 
which is methodologically simpler to quantify and evaluate 
exposure to than content in television programming, 
there are no grounds to suspect that the findings from this 
research do not also apply to smoking imagery in television 
programmes or other media. It has been demonstrated 
that higher levels of television viewing in general are 
associated with an increased risk of smoking uptake,34,35 but 
this association has not yet been studied in relation to the 
level of specific exposure to tobacco imagery. The evidence 
also supports the conclusion that, for adolescents, there is 
no safe level of exposure to on-screen smoking.
5.3 Smoking in films
5.3.1 The US film industry
For much of the 20th century the global film market was 
dominated by US film companies, and strong financial 
ties between the tobacco and film industries dating back 
to at least 192736 resulted in tobacco smoking being 
endemic in the films they produced. For decades the US 
film industry was dominated by a small number of studios, 
and tobacco companies made payments and provided 
supplies of cigarettes to studios and individual actors to 
generate branded product placement in films and product 
testimonials by leading actors36 (see Fig 5.1 and Fig 5.2 for 
examples). The sponsoring tobacco company also often 
paid to advertise films featuring their products, or actors 
endorsing them.36 
Fig 5.1 Examples of tobacco endorsements by film stars and producers.36 
© Lum et al 2008
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Product placement deals continued long after the 
demise of the Hollywood studio system in the mid-20th 
century,39 but for films shown to children should have 
ended in 1998 when four US tobacco companies (Philip 
Morris, RJ Reynolds, Brown & Williamson and Lorillard) 
sharing over 90% of the US market entered into a Master 
Settlement Agreement (MSA).40 The MSA specified that 
no participating manufacturer could make any payment 
to use, make reference to or use as a prop ‘any Tobacco 
Product, Tobacco Product package, advertisement for a 
Tobacco Product, or any other item bearing a Brand Name’ 
in films, television shows, theatrical production, videos or 
video games. The only permitted specified exceptions were 
if the audience or viewers were in an adult-only facility, the 
media was not intended for distribution or display to the 
public or the use was for instructional media concerning 
non-conventional cigarettes viewed only by smokers who 
are adults.40
Monitoring of tobacco content in US films since 1991 
reveals however that the MSA has had little effect on 
the frequency with which tobacco imagery appears. 
Data published by the Centers for Disease Control and 
Prevention documenting the occurrence of incidents of 
use or implied use of a tobacco product by an actor in 
all movies among the 10 top-grossing movies in every 
calendar week of each year demonstrate that while 
tobacco imagery has become rare in the minority of films 
rated suitable for viewing by children (those rated General 
or PG13, see Fig 5.3 legend for details), tobacco content 
in those rated as suitable for viewing by children aged 13 
and over, and those suitable for children aged under 17 
if accompanied by a parent or guardian, has fluctuated 
markedly from year to year but with no clear trend or step 
change before or after the 1998 Master Settlement Act 
(Fig 5.3).41 The adoption of voluntary codes of practice 
by the six major US film companies that are members 
of the Motion Picture Association of America (MPAA), 
the organisation responsible for film age rating, has had 
a mixed effect: in 2018 there was no tobacco imagery 
in films rated suitable for children aged under 13 years 
produced by two film companies (Disney and Viacom), but 
tobacco appeared in over 35% of equivalent films made by 
Comcast and Fox.41 
Fig 5.2 Correspondence confirming payment to Sylvester Stallone for tobacco product placement.37,38 
© Sylvester Stallone, James Ripslinger 1983
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Fig 5.3 Tobacco incidents in top-grossing US movies, 1991-2018.41 
G = general audience (all ages admitted); PG= parental guidance suggested (some material may not be suitable  
for children); PG-13 = parents strongly cautioned (some material may be inappropriate for children under 13 years);  
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5.3.2 UK films
The UK is home to a successful film industry which has 
produced some of the highest grossing films of all time. 
While the 20th century US studio system’s financial 
links with tobacco companies were not widely replicated 
in the UK, the UK film industry has a history of direct 
product placement deals with tobacco companies (as for 
example to include Marlboro branding in the UK-produced 
‘Superman II’, see Fig 5.4 and Fig 5.5) and indirect deals 
with third party organisations (see Fig 5.6). However, the 
dominance of the US film industry means that many of the 
most popular films in the UK are US-made, and therefore 
that the tobacco content of the most popular films in the 
UK tends to be a manifestation of US rather than UK policy 
on the inclusion of tobacco imagery. Data on tobacco 
content in films popular in the US have been collected for 
many years and are available online42 but UK data are far 
less extensively available. However, interval coding analysis 
of tobacco use, implied use, tobacco paraphernalia and 
tobacco branding in the 15 most popular films in the UK 
each year since 1989 (data from 1989 to 2008 from Lyons 
et al43 and from 2009 to 2017 by Barker et al44) reveals a 
steady decline in tobacco content in the first 3 decades of 
data, including a markedly lower level of content in 2002 
(the year of the Tobacco Advertising and Promotion Act) 
relative to 2001. There was a marked increase in tobacco 
content in the years 2011–2014, but levels have since fallen 
again (Fig 5.7).44 Between 2009 and 2017, tobacco content 
occurred in all of the four films in the sample produced 
solely in the UK, and in 37% of those produced in the US. 
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Fig 5.4 1979 agreement to place Marlboro branding in ‘Superman II’.45 
© Dovemead limited; Philip Morris Europe; Pierre Spengler
Fig 5.5 Example of Marlboro branding in ‘Superman II’. 
© Film Company Warner Bros
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Fig 5.6 Part of e-mail correspondence between Joe Keenan of Production Profiles Limited (a third-party product 
placement company) and Fran Morrison of British American Tobacco (who rejected the approach) in 2000–2001.46,47 
© Joe Keenan, Production Profiles Limited
Fig 5.7 Tobacco use, implied use, paraphernalia and branding in the most popular UK films, 1989–2017.44 
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Differences between the US and UK age-rating systems 
result in UK teenagers being more likely than their US 
counterparts to be exposed to smoking in films. Table 
5.2 compares the age rating categories applied in the 
USA by the MPAA, and in the UK by the British Board of 
Film Classification (BBFC) and demonstrates that these 
rating categories do not map directly onto each other. 
The practical consequence of this is that many films 
categorised by the US age-rating system as unsuitable for 
unaccompanied teenagers aged below age 17 are rated 
as suitable for teenagers aged 15 and over in the UK,48 
with similar outcomes also reported in other EU countries.48 
Analysis of tobacco content of popular films by age rating 
in the UK demonstrates that, in contrast to the US data 
(Fig 5.3) the majority of tobacco imagery in popular UK 
films occurs in films rated U, 12a or 15 (Fig 5.8). In the past 
decade, most tobacco imagery occurred in films rated 15. 
US (MPAA) rating Description UK (BBFC) 
rating* 
Description
G All ages admitted U Suitable for all ages
PG Some material may not be suitable for children PG Parental guidance
PG-13 Some material may be inappropriate for 
children under 13
12A Suitable for 12 years and over
R Under 17 requires accompanying parent or 
adult guardian
15 Suitable for 15 years and over
NC-17 No-one 17 and under admitted 18 Suitable only for adults
Table 5.2 US and UK film age-rating categories 
*a further category, R-18, applies to adult works shown only in specially licensed premises 
Table adapted with permission from Hanewinkel et al 2013
Fig 5.8 Tobacco content of popular UK films 1989–2017 by BBFC age-rating of film.44 
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5.3.3 Smoking in films from other countries
Although tobacco imagery in films widely seen in the UK is 
determined predominantly by the content of US and UK-
made films, this does not apply in other countries. India has 
a vibrant film industry responsible for more than one-fifth 
of global film output49 and as is the case for the UK and US, 
smoking imagery is common in these films,50–53 particularly 
in those made in local languages.54 India does however 
impose remedial measures on films containing tobacco 
imagery, which include requiring a disclaimer to be shown on 
screen when tobacco is used (see Fig 5.9 for example) and 
anti-smoking audio-visual health messages and disclaimers 
to be shown before and during the film.55 Compliance with 
these laws is, however, far from complete.53,54
China and Japan are also among the most productive 
countries in terms of global film output,49 but peer-reviewed 
data on tobacco imagery in films made in these countries 
are limited. In China however, 26 of the 30 most popular 
films in 2018 are reported by the China Association on 
Tobacco Control to include tobacco imagery,56 while over 
half of the 10 top-grossing films in Japan in the years 
2000–2006 contained smoking scenes.57 
5.3.4 Regulation of smoking content in films 
shown in the UK
Responsibility for protecting children from exposure to 
potentially harmful imagery in films shown in UK cinemas 
lies with local authorities. Cinemas are licensed (in England, 
under the 2003 Licensing Act) to show films and typically 
ensure that audiences admitted to film screenings comply 
with BBFC film ratings. BBFC ratings are however advisory; 
local authorities can override BBFC ratings if they wish and 
on rare occasions have done so. 
The BBFC (formerly the British Board of Film Censors) has 
provided age ratings for films shown in the UK for more 
than a century and is funded to do so by fees paid by film 
makers for this service. Detailed BBFC guidance refers  
to smoking only once, as follows: ‘Where smoking, alcohol 
abuse or substance misuse feature to a significant extent 
in works which appeal to children, this will normally be 
indicated in ratings info.’58 The guidance goes on to say 
that classification decisions will also take into account 
promotion or glamorisation of these activities.58 
5.4 Smoking in UK television and on-demand 
media 
5.4.1 Regulation
Unlike films, the inclusion of tobacco imagery in broadcast 
television in the UK is subject to regulation by the Office 
of Communications (Ofcom), which requires that ‘material 
that might seriously impair the physical, mental or moral 
development of people under eighteen must not be 
broadcast’.59 Ofcom further require that broadcasts are 
scheduled to protect children (defined by Ofcom to be 
persons aged under 15) from ‘material that is unsuitable 
for them’59 by ensuring that such material is broadcast 
between the hours of 9pm and 5:30am.59 Specific guidance 
on tobacco requires that tobacco imagery is not included 
in programmes ‘made primarily for children unless there 
is strong editorial justification’; ‘must generally be avoided 
and in any case must not be condoned, encouraged or 
glamorised in other programmes broadcast before the 
watershed unless there is editorial justification’; and ‘must 
not be condoned, encouraged or glamorised in other 
programmes likely to be widely seen, heard or accessed by 
under-eighteens unless there is editorial justification’.59
However, viewing patterns are changing rapidly in the UK 
with video on-demand services, which include broadcast 
‘catch-up’ services such as BBC iPlayer, ITV hub and More4, 
and subscription services such as Netflix and Amazon 
Prime Video, rapidly becoming the most popular means of 
consuming broadcast material.60 Ofcom regulation extends 
to all on-demand services based in the UK, which comprise 
the on-demand services of the BBC, ITV and other UK 
broadcasters, and Amazon Prime Video, but not to services 
based outside the UK, such as Netflix. The Ofcom code 
indicates that tobacco imagery should be avoided in on-
demand services ‘likely to be accessed by children’.59 
5.4.2 UK broadcast television
An analysis of tobacco imagery in a sample of UK 
prime time (6pm to 10pm) television broadcasts from 
2015 identified tobacco imagery in around one in three 
broadcast programmes, occurring particularly in animated 
films, comedies and drama.61 While most of this imagery 
occurred after the 9pm watershed, consistent with Ofcom 
Fig 5.9 Example of static health warning in India film 
showing tobacco use.
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guidance, and some arose from news items or other factual 
content, smoking imagery occurred in one-third or more 
of soap operas, films, chat shows, comedies, dramas and 
animated programmes shown before the watershed,61 
indicating that neither programme makers nor Ofcom 
consider smoking imagery to represent a threat to the 
‘physical, mental or moral development of people under 
eighteen’.59 These findings were not appreciably different 
from those of a similar analysis of television broadcasts 
in 2010.62 Films were a common source of imagery in 
both studies, with actual tobacco use occurring in 59% of 
prime time films in the 2010 data, and 36% in the 2015 
data. Soap operas were also found to be a significant 
source of tobacco imagery. A content analysis of soap 
operas broadcast on UK TV before the 9pm watershed 
(‘Eastenders’, ‘Coronation Street’, ‘Emmerdale’, ‘Hollyoaks’, 
‘Neighbours’, and ‘Home and Away’) in the winter of 
2018–2019 found that tobacco content (other than no-
smoking signs) occurred in 10% of episodes, generating 
substantial population exposure comprising approximately 
70 million tobacco impressions to the UK population, 
including over 4 million to children.63 
However, setting aside the fact that television programmes 
broadcast after 9pm in the interest of protecting children 
from harmful content can easily be accessed by children via 
broadcast video on-demand services, the 9pm watershed 
provides little if any real protection for children old enough 
to stay awake until after 9pm. The third series of the UK 
reality television show ‘Love Island’, which was broadcast 
at 9pm on 42 successive days in June and July 2017, 
included tobacco imagery in one in every five broadcast 
minutes, and consistently featured consumption of an 
identifiable brand of cigarette (Lucky Strike Double Click).64 
The programme maker (Independent Television, or ITV) 
described the series as a ‘massive success with young 
audiences, regularly capturing a 56% share of 16–34 
viewers’ and stated that it was ‘full of flirting, jealousy, 
rejection and romance … an emotional feast of lust and 
passion in the sun’, thus accepting that the programme 
is glamorous and seen by younger viewers64 and thus 
contravenes the Ofcom Broadcasting Code.59 The full 
programme series generated massive audience exposure 
to tobacco imagery, with a likely total of one billion tobacco 
impressions delivered to UK audiences, including over 90 
million to children aged under 16.64 These figures do not 
include on-demand viewing, or impressions delivered by the 
companion show ‘Love Island Aftersun’, a weekly review 
showing highlights from daily broadcasts. Despite the 
removal of smoking from subsequent series of Love Island, 
reality TV shows remain a concerning source of tobacco 
imagery to children and young people. A subsequent 
analysis of reality TV programmes broadcast in the UK in 
the first half of 2018 found that tobacco content occurred 
in 18% of 112 episodes across 5 programmes (‘Celebrity 
Big Brother’, ‘Made in Chelsea’, ‘The Only Way is Essex’, 
‘Geordie Shore’ and ‘Love Island’), delivering approximately 
214 million tobacco impressions to the UK population, 
including 47 million to children aged under 16.65
5.4.3 UK video on-demand services
Viewing habits are changing. All of the UK mainstream 
broadcast channels (BBC1, BBC2, ITV, Channel 4 and 
Channel 5) now offer online ‘catch-up’ or on-demand 
services that allow most programmes to be watched 
at any time during a period of typically 4 weeks, but 
sometimes longer, after broadcast. Providers such as 
Netflix and Amazon Prime Video do not broadcast to a 
set timetable but simply allow users to watch whatever 
they choose at any time of day. These video-on-demand 
services are becoming increasingly popular.66 Analysis 
of a sample of five episodes of each of the five highest 
rated original programme series on Amazon Prime Video 
and Netflix identified tobacco imagery, most of which 
was cigarette smoking, in over 70% of episodes.67 There 
was no difference between the two services in terms of 
tobacco content, but the overall content level was higher 
than that of UK broadcast television programming.67 
Higher levels of tobacco imagery in Netflix than in 
broadcast and cable television programmes have also 
been demonstrated in a study of programming in the 
USA.68 Video on-demand services have also recently 
started creating and distributing original films. A content 
analysis of 22 original movies from Netflix and Amazon 
Prime Video (11 for each service) released in 2017, carried 
out for this report, found that tobacco content occurred in 
9% of 5-minute intervals across 50% of films overall, with 
significantly higher tobacco content present in Amazon 
Prime Video original films.69 
5.4.4 Smoking in other visual media
Smoking imagery is prevalent in a range of other media 
consumed by children and young adults in the UK, 
including music videos,70 video games71 and magazines 
aimed at young women.72 These findings reflect those of 
studies outside the UK documenting a high prevalence of 
smoking (and possible product placement) in popular US 
hip-hop videos,73 and of an earlier systematic review of 
smoking in popular video games.74 The tobacco content 
in YouTube music videos reaches substantial audiences 
in the UK, particularly among adolescents.75 A brief 
(unpublished) content analysis of the UK top 40 music 
videos over a 3-month period in 2019, carried out for this 
report, found that tobacco content occurred in 36% of 
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videos, a significant increase relative to the 14% in the 
2014 analysis.70 
Music videos hosted by YouTube are not subject to BBFC 
or Ofcom oversight, and YouTube guidance on harmful or 
dangerous content does not mention tobacco or smoking.76 
Video games are regulated in the UK by the Video 
Standards Council, which provides age ratings for games in 
a system akin to BBFC age rating of films.77 Games that are 
deemed to encourage tobacco use, or include advertising 
encouraging the use of tobacco, are rated as suitable for 
age 16 and over.77 Almost all of the popular games that 
included smoking in a UK study were rated 18.71 Other 
than paid-for advertising or product placement, editorial 
references to tobacco or smoking in magazine content are 
unregulated in the UK. 
5.4.5 Smoking in social media
The media environment available for advertising and 
promotion has been transformed over the past 2 decades 
by the rise of social media sites such as Facebook 
(established in 2004), YouTube (2005), Twitter (2006), 
Tumblr (2007), a range of messenger services, and more 
recently by Instagram (2010), Pinterest (2010), Snapchat 
(2011), TikTok (2017) and others. Social media sites allow 
users to share content and communicate in online groups 
and networks, and are used widely across the entire adult 
population but particularly by younger adults.78 Social 
media use is extremely and increasingly common among 
children, with half of all 10-year olds in the UK in 2019 
owning a smartphone and 90% of 5- to 15-year-olds 
using a smartphone, tablet or computer to access online 
material.79 Ofcom estimate that almost half of 12- to 
15-year-olds and more than one-third of 8- to 11-year-olds 
watch online vloggers or influencers and hence are exposed 
to the products they promote, and that increasingly these 
are local rather than national or international figures.79 
There is evidence that exposure to tobacco content in 
social media is associated with an increased risk of smoking 
uptake80,81 and clear evidence from outside the UK that 
tobacco imagery is prevalent on some social media 
sites,82–84 including some media co-creation,85 but data on 
exposure and the effects of exposure to tobacco imagery 
in social media in the UK are sparse. 
A UK study that measured tobacco imagery in popular 
YouTube music videos found that tobacco appeared 
in 22% of all videos, with specific tobacco branding 
appearing in 4% – Marlboro being the most frequently 
appearing brand.70 A separate UK study that estimated 
exposure to tobacco content in popular YouTube music 
videos found that an estimated 203 million impressions 
of tobacco use were delivered to the British population. 
Adolescents were exposed to an average of 10.5 tobacco 
impressions per capita and adults to an average of 2.9 
tobacco impressions per capita.75
Direct and highly overt online advertising for cigarettes 
is fairly well captured under current tobacco advertising 
promotion and sponsorship regulations and online search 
engine policies. Covert depictions, promotions that cross 
international borders, exploitation of advertising definition 
loopholes, and unregulated promotion of both cigarettes 
and e-cigarettes occurs outside of easily recognisable 
online banner and video advertisements.86 For example, 
in 2018 the US based Campaign for Tobacco-Free Kids, 
found that tobacco companies were advertising cigarettes 
on social media by paying social media influencers – 
popular accounts with large online followings – to post 
images of cigarettes and smoking. The influencers were 
paid to promote cigarettes online to millions of followers 
without disclosing a connection to multi-national tobacco 
companies.87 In 2019, the UK’s Advertising Standards 
Authority (ASA) ruled that British American Tobacco (BAT) 
must stop using any public Instagram account to promote 
e-cigarettes in the UK, including advertisements for Vype, a 
BAT vaping product.88
Regulating the content accessed by all social media users 
to prevent harm is extremely challenging,89 and in February 
2020 the UK government announced plans to give Ofcom 
responsibility for regulating online content.90,91 However, 
the priority likely to be given to the regulation of tobacco 
content, in relation to a wide range of other potentially 
harmful content, is unknown. In 2018, recognising the 
global challenge of regulating online tobacco promotions, 
the WHO Framework Convention on Tobacco Control, 
Conference of the Parties (COP8) established a working 
group to develop guidelines to address cross-border 
tobacco promotions and the depiction of tobacco in the 
entertainment media.92
5.5 Alibi marketing
Alibi marketing is a technique used to circumvent 
advertising restrictions by substituting conventional 
trademarks or logos with a visual image that the consumer 
recognises and associates with the brand but is not, either 
overtly or else on closer inspection, a brand trademark 
or logo. In the early 2000s, as restrictions on tobacco 
advertising in Europe and other parts of the world became 
more stringent, alibis were widely used by tobacco 
companies sponsoring Formula 1 racing teams, but the 
practice should have ended, along with all Formula 1 team 
sponsorship, with the implementation of the EU Tobacco 
Advertising Directive in 2005.93 
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One company – Philip Morris International – has however 
maintained its sponsorship of the Scuderia Ferrari team 
for more than 20 years, at an estimated annual cost of 
75 million US dollars in 2019.94 Although conventional 
Marlboro logos were removed from Ferrari Formula 1 cars 
in 2007, the company replaced this traditional Marlboro 
branding with a barcode design which, from a distance, 
resembled but was not a Marlboro logo.95 In response to 
complaints and adverse media coverage, the alibi barcodes 
were withdrawn in 2010 but Philip Morris International 
sponsorship of the team continued. For the Japanese 
Grand Prix race in October 2018 and in partnership with 
Philip Morris International, Scuderia Ferrari launched a 
new ‘Mission Winnow’ livery, featuring the capital letters 
M and W in a design reminiscent of Marlboro branding96 
(see Fig 5.10). A version of the livery is also being used 
on Ducati racing motorcycles, again as a result of Philip 
Morris International sponsorship.97 At the time of writing 
in January 2021 the Mission Winnow logo is the highest 
placed on the array of corporate partners listed on the 
Scuderia Ferrari website, and links directly to a page 
naming Philip Morris International as a ‘title partner’ of 
the team.98 Mission Winnow is registered as a tobacco 
trademark.94 BAT has also renewed Formula 1 sponsorship 
of the McLaren team, promoting what is overtly a mission 
statement (‘A better tomorrow’), which like Mission Winnow 
is linked to the concept of technological development and 
new generation tobacco products but is not registered as a 
tobacco trademark.94
Fig 5.10 Scuderia Ferrari Mission Winnow livery announced October 2018.96
Mission Winnow is described by Philip Morris as a project 
developing and testing less harmful alternatives to 
smoking99 but the similarity of the livery to Marlboro 
branding suggests that it is another example of alibi 
marketing. Although not used in the 2019 British Grand 
Prix race, the livery has been used in races elsewhere in 
the world, with imagery from those races freely available 
on terrestrial television and online. An analysis of Formula 
One races in the 2018 series broadcast on UK television 
demonstrated that Mission Winnow imagery occurred 
frequently after being introduced late in the season when 
only five more races remained, and even having been 
present for only part of the season generated an estimated 
438 million (95% CI 395 to 481) one-second interval gross 
impressions to the UK population, including 14 million 
(95% CI 10.81 to 17.49) to children.100
5.6  Smoking and the arts  
UK law prohibiting sponsorship relates specifically to 
that intended to promote a tobacco product,9 and as 
a result the tobacco industry can continue to promote 
itself by acting as corporate sponsors. For example, the 
industry funds some arts organisations, either directly 
through sponsorship deals or indirectly through corporate 
memberships and support. These arrangements allow 
the industry to buy respectability, present themselves as 
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good corporate citizens, allow their staff to feel that they 
are part of an organisation that is giving something back 
to society, and gain access to or initiate exclusive events 
enabling contact with decision makers and opinion leaders 
in wider society. The tobacco industry also uses arts and 
related events as an opportunity to entertain politicians by 
providing complimentary tickets to events such as opera at 
Glyndebourne and the Chelsea Flower Show. Recipients of 
such hospitality have been shown to be more likely to vote 
against tobacco control legislation such as standardised 
packaging and the ban on smoking in cars with children 
present.101 
The SmokeFreeArts campaign (www.smokefreearts.
wordpress.com) was established in 2016 in response to the 
Royal Academy accepting Japan Tobacco International 
(JTI) as a premier sponsor for its exhibitions. Other 
organisations accepting sponsorship at the time included 
the Southbank Centre, the London Philharmonic Orchestra 
and the British Museum. The campaign highlighted the 
fact that tobacco money was mixing with money from 
other sponsors with strong anti-tobacco positions such as 
Bloomberg, and that the reputational risk for organisations 
from accepting tobacco industry funding might jeopardise 
support from other sources. Following the campaign, which 
included a letter signed by more than 1,000 healthcare 
professionals,102 JTI’s exhibition sponsorship arrangement 
with the Royal Academy was not renewed, though JTI 
remains a corporate member. The Southbank Centre 
decided to ‘terminate its low level corporate membership 
contract with JTI early and will not be partnering with 
tobacco companies in the future’. Other organisations that 
no longer have such arrangements include the National 
Theatre and the London Symphony Orchestra. Table 5.3 
summarises UK arts organisations with continued tobacco 
sponsorship, as of December 2019: 
Table 5.3 UK arts organisations accepting tobacco sponsorship according to online sources in December 2019.  
(Glyndebourne lists corporate sponsorships only in annual reports: most recent 2018)
Institution Sponsoring tobacco company Source  
Royal Academy 
of Arts  






JTI principal partner www.lpo.org.uk/support/thank-you.html  













5.7 Point-of-sale advertising  
Tobacco products are sold in the UK from a range of 
bricks-and-mortar and online retailers, but predominantly 
from small convenience stores and supermarkets, with 
small retailers taking over half of sales.103 Until the 2002 
Tobacco Advertising and Promotion Act9 advertising inside 
and outside these retailers was unrestricted, and tobacco 
companies frequently provided signage and other display 
materials to retailers (see Fig 5.11 for example). These 
practices ended with regulations supporting the 2002 Act 
introduced in 2004 which limited advertising at the point of 
sale to a single advertisement no larger than an A5 sheet 
of paper, of which 30% should be a health warning.104 
Exemptions were granted for advertising carried out 
within the tobacco trade and for ‘specialist’ tobacconists, 
which were defined as retailers for whom tobacco takings 
represent more than half of annual turnover. 
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The 2002 Act and associated regulations did not 
however restrict the display of packs of cigarettes for 
sale, which resulted in the use of cigarette packs, and 
their amalgamation in display gantries which were often 
provided and managed by tobacco companies, as an 
advertisement in their own right105 (Fig 5.12). Aside from 
communicating brands and prices to established smokers, 
point-of-sale displays have been shown to prompt impulse 
purchases by smokers trying to quit or who have quit, and 
also attract young people at risk of smoking initiation.105,106 
Tobacco point-of-sale displays also appeared in, and 
hence advertised, tobacco in television programmes such 
as the soap opera ‘Coronation Street’ (Fig 5.13). Point-of-
sale displays also enable marketing by price. A study of 
small retailers in Nottingham in 2010 found that 40% of 
cigarette and hand rolling tobacco products on display 
carried a promotional price mark.107 
Fig 5.11 Benson and Hedges retail signage and Embassy window advertising in small retailer, c. 1990.
Fig 5.12 Examples of point-of-sale displays in small and large retailers.  
(left image Nottingham 2010,107 right image c. 2008)108 
Left image © Spanopoulos et al 2012. Right image used with permission from Action on Smoking and Health (ASH)
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Fig 5.13 Tobacco point-of-sale displays in the prime time television soap opera ‘Coronation Street’  
(broadcast in 2010).62  
© Lyons et al 2014
Fig 5.14 Examples of tobacco retail gantries in large (left) and small (right) retailers after implementation  
of point-of-sale legislation in 2012 and 2015, respectively.
This new prominence of point-of-sale displays as a means 
of tobacco advertising and promotion ended with the 
2009 Health Act, which required tobacco products to be 
hidden from view in large retailers (defined as stores with 
a floor area greater than 280 m2) from 2012, and in all 
other retailers from 2015 (Fig 5.14).13 The new legislation 
also ended the allowance of a single A5 advertisement at 
point of sale, restricted any permanent display of prices 
Advertising and promotion of tobacco at the point of sale is 
thus now significantly restricted in the UK. Compliance with 
the new legislation has been high from the outset,109 and 
appears to have resulted in a reduction in brand recognition 
and susceptibility to smoking among young people in the 
UK,110,111 as has been reported elsewhere in the world.111–113 
However, tobacco promotion at the point of sale through 
other means, such as verbal recommendations by 
shopkeepers, probably continues.114 Tobacco products 
continue to be freely displayed, without age verification, 
to an A3 sheet carrying only brand names and prices in 
standard Helvetica font, and removed the exemption 
allowing specialist tobacconists to display cigarette or hand 
rolling tobacco advertising.13 Under this legislation, tobacco 
products and their prices, or price lists carrying pictures 
of tobacco products, can only be shown to customers 
requesting to purchase tobacco and after age verification.13 
by online retailers including leading UK supermarkets (Fig 
5.15). There is also a concern that the salience of tobacco 
product cabinets in stores means that the availability of 
tobacco remains highly visible, particularly in areas of 
deprivation where tobacco retailers are more prevalent.115 
Point-of-sale legislation also continues to exclude tobacco-
related products such as cigarette lighters and paper for 
hand rolling tobacco, creating an opportunity to promote 
smoking by displaying these products. 
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5.8 Standardised tobacco packaging 
Tobacco packaging has been used by the tobacco industry 
for decades to promote brand names and imagery, appeal 
to young people through novelty designs and flavours, 
distract attention from health warnings, and to build and 
sustain brand equities that help recruit new and sustain 
brand loyalty among established customers.11,116–120 
Through these mechanisms, cigarette pack branding 
and design also advertise the product wherever packs 
are visible, for example in film, television and other media 
(see sections 5.3 and 5.4). Branding is also crucial to the 
market segmentation and pricing models used by the 
tobacco industry to maximise profits,121 and in particular 
the use of higher profit margins on premium products to 
absorb and hence reduce the effect of tax increases on the 
affordability of brands in the lower end of the tobacco price 
spectrum, which tend to be favoured by the most price-
sensitive smokers122 (see chapter 7). 
In 2015 the UK parliament passed new packaging 
regulations which introduced standardised (‘plain’) 
tobacco packaging in the UK.123 The main objectives of 
the legislation were to reduce smoking appeal and uptake 
among young people, encourage cessation and reduce the 
risk of relapse after quitting. Alongside a range of measures 
including minimum pack sizes for cigarettes and hand 
rolling tobacco (20 cigarettes and 30 g, respectively) and 
larger, updated pictorial health warnings required by the 
2014 EU Tobacco Products Directive,124 the legislation also 
included a requirement that all tobacco products released 
by manufacturers for sale in the UK after 20 May 2016, and 
all tobacco products sold in the UK after 20 May 2017, were 
packaged in dull green standardised packs with the brand 
name and up to one descriptor presented in a standard 
font and no superimposed imagery (such as price marks) 
on the wrappers.123 During this 1-year implementation 
period both conventional and standardised packs were 
thus allowed to be sold in the UK, and the first standardised 
packs did not appear on the market for several months.125 
However, by the end of May 2017 almost all licit UK 
tobacco products were sold in plain packs.125
Australia was the first country in the world to introduce 
standardised packaging, doing so in December 2012, 
and followed in 2017 by the UK and France, in 2018 by 
New Zealand, Ireland and Norway, and subsequently by 
many more countries.126,127 In Australia, the introduction 
of standardised packaging was associated with: an 
increase among smokers in the perception of packs as less 
appealing and the products as less satisfying and of lower 
quality;128 increased quitting;129 an increase in prices paid 
for tobacco products;130 and increased use of ‘value’ (low 
price) brands.130 
During the period preceding the introduction of 
standardised packs in the UK, the tobacco industry 
introduced several new low price products and product 
variants, often in packs of less than 20 cigarettes which 
enabled sale at prices just below perceptual price points, 
for example £5.99 for 19 instead of £6.30 for 20.125 The 
transition over the year from May 2016 to May 2017 to 
plain packs of at least 20 cigarettes, in conjunction with 
the introduction of a minimum excise duty in May 2017, 
was associated with a significant increase in cigarette 
prices across the spectrum of cigarette brands; a sustained 
secular decline in cigarette sales;125,131,12 and switching 
Fig 5.15 Example of online purchase platform of a major UK supermarket (as of 30 April 2021).
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by smokers from more to less expensive brands of 
cigarette.133 There was an increase in sales of hand rolling 
tobacco during the transition period, the price of which 
rose proportionately more than that of manufactured 
cigarettes but remained less expensive per cigarette than 
manufactured cigarettes.134 There was also evidence of 
switching from tobacco to e-cigarettes.133 The introduction 
of plain packaging in the UK has resulted in a marked 
increase in the proportion of smokers who notice the 
health warning, and a decrease in the appeal of packs 
to smokers,135,136 with similar results reported from New 
Zealand.137 In France, plain packaging and larger health 
warnings have resulted in an increasing perception that 
smoking is harmful, but without evidence of switching to 
e-cigarettes.138 
The tobacco industry responded to legislative requirements 
by changing brand names and using innovative packaging 
designs139 and although young people generally reported 
that they found standardised packs unappealing, some 
innovative designs and brand names were perceived 
positively.140 This suggests that continued vigilance and 
further legislative or regulatory measures may be required 
to combat efforts by the industry to undermine the impact 
of standardised packs legislation. 
Since standardised packaging has been introduced only 
recently in other countries, evidence on the effects of 
this remains sparse. There are, however, some marked 
differences in the standardised packaging regulations 
between countries141 and future research may be able 
to discern the relative importance of allowing residual 
freedoms in pack structure, the use of brand descriptors, 
and other aspects of pack design.141 The effect of the 
exemption for cigarette papers, which allows products 
such as Rizla to be advertised on point-of-sale gantries 
and to act as a possible alibi for smoking (leading the UK 
Advertising Standards Authority to recently withdraw a 
Rizla advert)142 also needs to be explored. 
5.9 Pack inserts 
Tobacco companies have used cigarette cards, coupons 
and inserts to promote their brands since the late 19th 
century.143 In the UK, cigarette cards were common in the 
early 20th century and continued to be used sporadically 
until 2003 when they, and coupons, were banned under the 
2002 Tobacco Advertising and Promotion Act. Advertising 
inserts were used in packs until 2016144 when they were 
prohibited alongside the introduction of plain packaging. 
In January 2019, Philip Morris International ran adverts 
in newspapers in the UK explaining that their new year’s 
resolution was ‘to stop selling cigarettes in the UK’,145 and 
that to help meet this goal they would seek approval from 
the UK government to include inserts with information on 
quitting and alternatives to smoking inside their packs. One 
of their objectives was to use these inserts to promote their 
heated tobacco product IQOS, as they have been doing 
in European countries which still permit the inclusion of 
promotional inserts in packs (see Fig 5.16).
While pack inserts are an inexpensive tool for tobacco 
companies to promote their products, they also offer policy 
makers the opportunity to promote healthier choices. From 
2000, tobacco companies in Canada have been required 
to include messages encouraging cessation or providing 
information about the harms of smoking, either via inserts 
or on the pack interior, to complement the on-pack health 
warnings.146 In 2012 these messages were updated, with 
eight new messages aimed at promoting self-efficacy 
or response-efficacy, and the inserts featuring coloured 
graphics rather than just text (Fig 5.17).
A longitudinal evaluation of the 2012 inserts indicates that 
they were read by over one in four smokers, particularly 
those intending to quit or having recently tried to quit, and 
that smokers who read the inserts relatively frequently 
were more likely to make a quit attempt.147 Reading inserts 
significantly increased across waves of the study, with more 
frequent reading of inserts associated with quit attempts 
and sustained quitting at follow-up.148 In a focus group 
study with smokers in Scotland, the Canadian inserts were 
viewed favourably, with the positive messaging considered 
encouraging and informative, and a supplement to the 
on-pack warnings. The inserts were thought to help 
smokers think about or question their smoking behaviour 
or encourage them to stop.149 In an online survey of young 
UK adult smokers asked about pack inserts (with an image 
of an insert used in Canada shown for each question), a 
majority indicated that they supported the inclusion of 
Fig 5.16 Examples of 
European pack inserts 
promoting IQOS.
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inserts and considered them to be a good way to provide 
information about quitting, encourage quitting, and help 
if they decided to quit.143 The evidence indicates that pack 
inserts could be used more extensively to encourage cessation. 
5.10 Flavours and flavour capsules
Cigarettes and other tobacco products can also be promoted 
through product innovations. An example is the introduction 
of capsules in the cigarette filter that can be burst, by firmly 
pressing the filter, to change the flavour. Capsule cigarettes 
were introduced in the UK in 2011 using a range of appealing 
descriptors, such as ‘Crushball’, ‘Choice’, ‘Click & Roll’, ‘Click 
on’ and ‘Fresh Burst’. There can be as many as three different 
flavour capsules in the filter, and up to five different flavours 
in packs of capsule cigarettes, with mint, fruit and beverage 
flavours the most commonly used.150 Capsule cigarettes 
have experienced remarkable global growth and by 2017 
had captured one-third of the entire tobacco market in 
several Latin American countries.150 The products are highly 
appealing to young people,151,152 with key drivers of use being 
taste, flavour choice, interactivity, pack design, and perceived 
reduced harm.152–155 The sale of flavoured cigarettes (including 
capsules) and hand rolling tobacco has been prohibited in 
the UK since May 2020.156 The legislation does not however 
include other tobacco products such as cigars or cigarillos. 
Neither does it extend to innovations that can be used to 
flavour cigarettes, such as flavour sprays or flavour cards (for 
example, Rizla Flavour Infusions) which are inserted into the 
pack to flavour the tobacco product. 
Fig 5.17 Examples of text inserts of the type required in Canada from 2000 (left)  
and of graphic inserts required from 2012 (right).
5.11 Dissuasive cigarettes
Individual cigarettes have been used as a marketing 
medium for many years.157,158 With a growing number of 
countries having implemented standardised packaging 
(15 as of January 2021) and most countries requiring large 
pictorial warnings on packs, thus diminishing the ability of 
the pack to create appeal, the cigarette stick has become 
a key promotional tool for tobacco companies. However, 
the cigarette stick also offers governments opportunities 
to discourage smoking. Several concepts of what are 
often referred to as ‘dissuasive cigarettes’ have emerged, 
including cigarettes with a text warning159–162 or a text 
warning and symbol (such as a skull and crossbones) on 
the cigarette paper,163,164 cigarettes with the minutes of 
life lost due to smoking down the length of the cigarette 
paper,165,166 and unattractively coloured cigarettes.116,167,168 
A warning on each cigarette stick, for instance ‘Smoking 
kills’ (see Fig 5.18), has been found to reduce appeal, 
increase perceptions of harm, and is thought to help 
deter smoking.160,169 Similarly, cigarette colour can be 
manipulated to reduce appeal, with certain colours (dark 
green, brown, grey) viewed particularly unfavourably, and 
thought to reduce social acceptability and make smoking 
appear dirty.168 Dissuasive cigarettes would also make the 
image of single cigarettes in the media less attractive. 
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While no country has implemented dissuasive cigarettes, 
the measure is being considered by the Canadian, Scottish 
and UK governments.
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Key points
>  Smoke-free policies reduce exposure to tobacco smoke, 
generate significant health benefits and are supported by 
the general public.
>  There is increasing interest in extending smoke-free 
policies to unenclosed outdoor areas used by children, 
such as playgrounds and parks, to reduce exposure to 
smoking role models.
>  Extensions to smoke-free policy generally enjoy strong 
public support.
>  NHS policy and NICE guidance requires outdoor areas of 
health facilities, particularly hospitals, to be smoke-free 
but implementation is poor.
>  Failure to deliver smoke-free NHS grounds reflects 
failure to remove smoking shelters and failure to provide 
adequate cessation services for patients who smoke. This 
is especially true in mental health settings.
>  This has led the Welsh government to introduce, and the 
Scottish government to consult on, legislation prohibiting 
smoking in hospital grounds. 
>  Smoking in the home remains a major source of 
involuntary exposure to tobacco smoke, particularly in 
disadvantaged households. 
>  Electronic cigarettes do not emit smoke and their use in 
public places does not fall within the remit of smoke-free 
legislation. 
Recommendations
>  Legislation prohibiting smoking in hospital grounds is 
adopted in England, thus aligning with laws adopted by 
the devolved nations. 
>  Hospital tobacco dependence services and smoke-free 
grounds are monitored by commissioners and regulators 
to ensure compliance with national policy. 
>  Smoking in the home is reduced by interventions which 
target home smoking behaviour, encouraging quitting 
and/or smoking only outdoors. 
>  Policies on vaping in indoor and outdoor areas are used 
to facilitate smoke-free policies, acknowledging that 
permitting vaping where smoking is prohibited may help 
indoor and outdoor smoke-free measures to succeed. 
6.1 Introduction
Comprehensive legislation prohibiting smoking in 
workplaces and enclosed public places has been in place 
across the UK for over 13 years, and it is important to 
remember that before 2007 in the UK, smoking was 
commonplace in many enclosed public places where we 
now take clean air for granted. This chapter summarises 
the history of smoke-free policy in the UK and considers 
the case for extending rules to prohibit smoking in other 
environments such as the grounds of healthcare facilities, 
parks and playgrounds. 
6.2 The evolution of public and workplace 
restrictions on smoking in the UK
For much of the second half of the 20th century, smoking 
in workplaces and in enclosed public places was widespread 
in the UK. Although the 1974 Health and Safety at Work 
Act required employers to provide and maintain a safe 
working environment, protection from tobacco smoke was 
not generally considered to fall within the remit of the Act. 
Restrictions on smoking in cinemas, theatres and transport 
were introduced during the later decades of the 20th 
century but largely on the grounds of preventing nuisance 
or fires rather than to protect customers or employees 
74© Royal College of Physicians 2021
6      Public space smoking restrictions
from the adverse effects of passive smoke exposure on 
health. Within the UK NHS, smoking indoors continued 
to be allowed in some general medical inpatient areas 
at least until the 1980s and in mental health settings for 
considerably longer, while designated smoking rooms for 
patients and/or staff continued to be provided in some 
hospitals well past the turn of the 21st century.1 
6.2.1 General smoke-free legislation
Legislation specifically prohibiting smoking in enclosed 
public and workplaces was implemented in Scotland in 
March 2006,2 in Wales and Northern Ireland in March 
2007,3,4 and in England in July 2007.5  The primary objective 
of the legislation was to protect employees and the public 
from harm arising from involuntary exposure to tobacco 
smoke, so the legislation did not extend into private homes 
or vehicles. Each of the UK jurisdictions allowed a limited 
range of exemptions, primarily for workplaces that were 
also people’s homes or where people were living, such 
as designated bedrooms in hotels, or in private clubs or 
prisons. An exemption for performance artists was made 
in England but not Wales or Scotland. In recognition of 
the continued widespread practice of smoking indoors 
in mental health settings, mental health facilities were 
provided with a further year in which to prepare for and 
implement the measures. 
At the time and since the legislation was introduced, 
smoking has also been prohibited by local rules or by-laws 
in areas such as sports stadia and railway stations that are 
unenclosed, or enclosed to an extent that falls below the 
threshold for the legislation to apply. 
6.2.2 Smoking in private vehicles 
The UK smoke-free legislation applied to vehicles used in 
the course of paid or voluntary work to carry members of 
the public or which were used by more than one person, but 
did not extend to private vehicles in private use. However, 
legislation prohibiting smoking in private vehicles carrying 
children has since been introduced in England and Wales 
in 2015 and in Scotland in 2016. A consultation on similar 
legislation was carried out in Northern Ireland in 2017 but 
at the time of writing no legislation has been implemented. 
6.2.3 Smoking in prisons
The 2006–7 UK smoke-free legislation2–5 included 
exemptions that permitted prisoners to smoke in their 
cells if occupied singly or with another smoker. Since 2015 
however this exemption has progressively been closed in 
prisons in England, Scotland and Wales, and at the time 
of writing is in the process of being closed in prisons in 
Northern Ireland. 
6.3 Effects of smoke-free policies 
6.3.1 Public places and workplace policies
The implementation of smoke-free legislation in the 
UK in 2006–7 proved to be popular and achieved high 
levels of compliance.6,7 A 2016 Cochrane review of the 
effects of public and workplace policies including data 
published up to February 2015 and involving 77 studies 
from 21 countries concluded that introducing smoke-free 
policies reduces exposure to tobacco smoke and generates 
significant health benefits, particularly by reducing 
the incidence of acute coronary syndrome and other 
cardiovascular disease.8 The review found that evidence 
of an effect on respiratory and perinatal health was less 
consistent, and on smoking prevalence and tobacco 
consumption inconsistent.8 Evidence from substantive 
studies and reviews published since the 2016 Cochrane 
review has further confirmed beneficial effects on 
cardiovascular disease9 and identified significant benefits 
in child health (reductions in preterm births, asthma 
exacerbations and respiratory infections).10 
The 2016 Cochrane review also concluded that evidence of 
an effect of smoke-free legislation on smoking prevalence 
or tobacco consumption was inconsistent, a finding which 
contrasts with earlier evidence suggesting that smoke-
free policies reduce smoking prevalence (as, for example, 
reviewed by Hopkins et al in 201011). A possible explanation 
for this discrepancy lies in differences in the context in 
which smoke-free policies are introduced. For example, 
when a workplace that has always allowed smoking 
introduces a smoke-free policy for the first time, this marked 
change in the working environment stimulates employees 
who smoke to try to quit.11 However, by the time smoke-
free policies are introduced at national level within the UK 
and elsewhere, many workplaces and public places have 
typically already introduced their own smoke-free policies 
and generated quit attempts, thus reducing the impact of 
the introduction of national legislation on quit attempts. It 
is clear however that smoke-free policies reduce harm from 
tobacco and generate strong public support, and these 
effects alone are sufficient to justify their use. 
6.3.2 In private vehicles
A recent evaluation of the 2015 English legislation 
prohibiting smoking in cars carrying children, using data 
from nationally representative samples of children aged 
under 15 collected between 2008 and 2017 reported 
a secular downward trend in tobacco smoke exposure 
among children but no evidence of a significant additional 
effect from the legislation on either children’s self-reported 
tobacco smoke exposure or respiratory health.12 However, 
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a more recent study comparing trends in tobacco smoke 
exposure among children in England and Scotland 
between 2014 and 2016 also demonstrated downward 
trends in both countries but with a marked and significant 
additional fall in exposure among children in England, 
where legislation was introduced in 2015, that did not occur 
during the same period in Scotland, where legislation was 
introduced the following year.13 
6.3.3 In prisons
The introduction of smoke-free policies in prisons in 
England and Scotland has been shown to have resulted 
in marked reductions in levels of tobacco smoke in indoor 
prison environments.14,15 
Anecdotal reports indicate that when smoking in prison 
cells was first prohibited and sale of tobacco to prisoners 
ended, attempts to smuggle tobacco into prisons increased 
and prisoners without tobacco improvised by making 
cigarettes from the dried content of used teabags mixed 
with nicotine paste from Nicotine Replacement Therapy 
(NRT) patches (‘teabacco’) hand rolled in paper. However, 
the subsequent decision to make e-cigarettes available in 
prisons has helped to reduce these problems. 
6.4. Smoke-free policies in hospital settings 
6.4.1 Rationale and policy frameworks
To protect the health of and promote healthy behaviours 
among people who use or work within their services, 
hospitals around the world have increasingly implemented, 
or are implementing, smoke-free policies. Hospitalisation 
has been described as a ‘teachable moment’, with 
systematic reviews16,17 indicating that offering evidence-
based smoking cessation treatment to smokers during 
a hospital stay can be effective in increasing smoking 
cessation rates in acute hospitals,16 more effective as a 
default or opt-out service18-19 and may lead to positive 
smoking-related behaviour change that includes 
motivation to quit and beliefs about quitting ability in the 
context of mental health inpatient stays.17 Acute hospitals 
in England went smoke-free indoors by law in 2007, while 
mental health settings were granted an additional year to 
comply with the new legislation. 
The National Institute for Health and Care Excellence 
(NICE) published guidelines (PH48) for smoke-free 
secondary care settings including acute, mental health 
and maternity services20 in 2013, recommending that 
these settings be completely smoke-free indoors and 
outdoors, with no exemptions granted for patients, visitors 
or staff to smoke anywhere on the premises; and prompt, 
comprehensive evidence-based treatment to support 
smoking cessation or temporary abstinence provided 
to all patients on and throughout their admission. The 
2017 Tobacco Control Plan for England,21 the 2018 Royal 
College of Physicians report,22 and the 2019 NHS Long 
Term Plan23 reinforced the content of this guidance. The 
latter two recommended that comprehensive specialist 
smoking cessation treatment should be routinely provided 
on an opt-out basis in all NHS treatment settings to ensure 
appropriate support of patients who smoke and help 
address tobacco-related inequalities. However, despite 
existing legal and policy frameworks, challenges of 
smoke-free policy implementation and persistent limited 
compliance with relevant guidelines have been recognised. 
6.4.2 Smoke-free policies in NHS settings: progress 
in small steps
A mixed-methods study of all NHS trusts (acute and mental 
health) undertaken briefly before new indoor smoke-free 
legislation for acute trusts came into force in 2007 and in 
advance of ratification in mental health settings, found that 
virtually all trusts reported having a smoke-free policy at this 
time, often including outdoor premises. However, despite the 
existence of formal policies, smoking was found to be highly 
prevalent, both among patients, visitors and staff.24  
Almost 10 years later, in 2016, a major audit25 of smoking 
cessation policy and practice based on the 2013 NICE 
guidance for secondary care settings was conducted by 
the British Thoracic Society (BTS), including 120 acute NHS 
trusts (146 individual hospital sites) and 14,750 patient 
records in the UK. It found that approximately 40% of NHS 
hospital sites still provided designated smoking areas in 
the grounds, and only 11% of hospitals fully implemented 
smoke-free grounds. While smoking status was recorded 
in 73% of patient records, only 28% of patients were 
asked if they would like to quit, and of those who did, only 
20% were referred to an in-house specialist stop smoking 
advisor. Provision of evidence-based smoking cessation 
pharmacotherapy (bupropion, varenicline and NRT) was 
overall judged as poor, and it was highlighted that half of 
hospital staff were not offered regular smoking cessation 
training. The audit concluded that ‘current adherence to 
national standards in smoking cessation is woefully lacking’ 
and committed to further work and assessment in this 
area, which ensued in the second audit, completed in 2019. 
A similar number of hospital settings (n=123) and patient 
records (n=13,647) were included, and although results 
indicated that concerns comparable to those that emerged 
in the previous audit still existed, some clear progress was 
identified. For example, fewer trusts (~25%) had designated 
outdoor smoking areas; more smokers (~50%) were asked 
if they wanted to quit; availability of pharmacotherapy 
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was improved (100% of hospitals had NRT on formulary, 
50% also offered varenicline on formulary), and more 
patients (~12%) were referred to a specialist stop smoking 
advisor in-house. The 2019 audit concluded that, despite 
signs of improvement, the treatment of smokers in NHS 
acute settings remains poor with ‘considerable work to be 
done’ to improve the situation. This mirrors insights from 
two surveys conducted by Public Health England (PHE) 
between 2018 and 2020 in NHS acute trusts, both of which 
found that, although almost all participating trusts (n=143) 
reported increasing levels of compliance with NICE PH48 
guidelines in their self-reports, nearly one-third (31%) did 
not enforce complete smoking bans on their sites.26
In NHS mental health trusts, the implementation of smoke-
free policies had originally been a matter of considerable 
debate,27,28 largely due to misconceptions relating to the 
link between smoking and mental health (see chapter 9). 
Some types of mental health treatment settings, especially 
highly secure forensic institutions such as Rampton hospital, 
achieved completely smoke-free status successfully29 
(despite initial legal challenges30) – probably aided by 
highly secure environments that render regular breaches of 
smoke-free policy generally difficult. For the vast majority 
of NHS mental health inpatient settings, the situation is 
however much more complex than this. Most settings 
provide treatment to a mix of voluntarily admitted and 
formally detained patients, with varying degrees of ‘leave’ 
from the ward granted as recovery progresses, during which 
time patients can access cigarettes to bring back on site. 
Over the last decade, a number of small UK-based 
mixed-methods studies in acute adult mental health 
inpatient settings have indicated that smoke-free policy 
implementation is progressing slowly, with some clear 
challenges identified – mostly related to problems with 
adherence to guidelines.31–35 A 2019 national survey36 
assessing compliance with NICE guidance PH4820 in 45 
mental health trusts (representing 83% of the 54 mental 
health trusts with inpatient services in England) highlighted 
that non-adherence to smoke-free policies was still 
‘universal’, with patients reportedly smoking frequently in 
bedrooms, ward courtyards or hospital grounds. Over half 
of trusts reported that staff still accompanied patients 
on smoking breaks every day (in direct breach of NICE 
guidelines), and over 80% of trusts indicated that Section 
17 of the Mental Health Act 1983 (MHA) (that makes 
provision for patients detained under the MHA to have 
authorised leave of absence from hospital) was used to 
facilitate smoking breaks, contrary to the intended use of 
this provision in the Mental Health Act. All surveyed trusts 
reported offering smoking cessation treatment to patients 
who smoked, with 82% offering two or more NRT varieties 
but only 49% stocking varenicline on the formulary. 
Notably, almost all trusts (91%) permitted patients to use 
e-cigarettes during their stay, although individual policies 
on location and products of use varied. The survey report 
concluded that, despite developing complete smoke-free 
policies, ‘in practice, no mental health trust in England 
is entirely smokefree’,36 and that delivering smoke-free 
environments remains a challenge.  
Opportunities to promote and support a smoke-free life 
among a highly disadvantaged group of smokers keep 
being missed,37 valuable resource keeps being invested in 
facilitating smoking,38 and nicotine withdrawal is likely to be 
systematically under-recognised and under-treated.37 
6.4.3 Accelerating progress
More than 7 years after NICE published guidance on 
smoke-free secondary care settings, NHS acute and mental 
health trusts are still grappling substantially with smoke-
free policy implementation, including the provision of 
adequate support to smokers admitted to hospital. Under 
the original general smoke-free UK legislation, smoking in 
outdoor areas on or around NHS facilities has remained 
legal. In 2020, however, the Welsh government announced 
new regulations that will prohibit smoking in hospital 
grounds (and in school grounds and public playgrounds) 
from March 2021,39 the Scottish government has reported 
the results of a consultation on proposals to extend 
smoke-free laws to NHS grounds,40 though at the time of 
writing no legislation has been passed. Northern Ireland 
has legislation in place requiring smoke-free hospital 
grounds,41 although the effectiveness of these laws requires 
evaluation. 
Commonly identified36,42 ‘enablers’ of policy 
implementation include leadership, including senior 
executive support; buy-in from frontline staff (including 
‘champions’); adequate staff training and preparation to 
go smoke-free; a clear, consistent approach to supporting 
policy adherence; and (more recently) access to electronic 
cigarettes.35,36,43 Intervention studies that incorporate these 
aspects to address implementation problems are emerging, 
for example in the recent CURE study,19 which assessed 
the feasibility, uptake and impact of a hospital-wide 
opt-out tobacco addiction treatment pathway including 
post-discharge support. The study found that 22% of the 
2,393 patients admitted to the hospital were smoke-free 
(biochemically verified) at 3 months, a quit success rate 
that is comparable with national stop smoking services, at 
a cost of £183 per quitter in line with previous estimates.22 
Effective treatment of tobacco dependency for inpatients, 
maternity and NHS staff set out in the NHS Long Term 
Plan, reduces the likelihood of nicotine withdrawal and 
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supports hospital smoke-free grounds policy. In light of the 
major gaps that have been identified in national audits 
and surveys, it would seem prudent to promote evidence-
based interventions nationwide with support from NHS 
commissioners, and ongoing monitoring and evaluation. In 
addition, gaining further insight into barriers and enablers 
to smoke-free policy implementation in a variety of health 
settings, while acknowledging heterogeneities, should be 
encouraged, and practice-based action plans to address 
them be developed. 
6.5 Effectiveness of further restrictions – 
outdoor public and commercial places and 
social housing 
6.5.1 Exposure to ambient tobacco smoke
Article 8 of the Framework Convention on Tobacco Control 
(FCTC) sets out the need for parties to adopt policies which 
protect the population from ambient tobacco smoke in 
indoor environments. Guidelines for implementing Article 8 
advise that:
  ‘The language of the treaty requires protective measures 
not only in all “indoor” public places, but also in those 
“other” (that is, outdoor or quasi-outdoor) public places 
where “appropriate”. In identifying those outdoor 
and quasi-outdoor public places where legislation is 
appropriate, Parties should consider the evidence as to the 
possible health hazards in various settings and should act 
to adopt the most effective protection against exposure 
wherever the evidence shows that a hazard exists.’44
Evidence on levels of exposure to ambient tobacco smoke 
in outdoor areas is far more limited than exposure indoors. 
There is evidence from systematic reviews that in certain 
circumstances exposure outdoors can reach levels of 
indoor exposure.45 One systematic review of studies using 
particulate matter levels to measure exposure found that 
mean PM
2.5
 concentrations reported for outdoor smoking 
areas when smokers were present ranged from 8.32 to 124 
µg/m3 at hospitality venues, and 4.60 to 17.80 µg/m3 at other 
locations. Mean PM
2.5
 concentrations in smoke-free indoor 
settings near outdoor smoking areas ranged from 4 to 
120.51 µg/m3. The World Health Organization guideline limit 
for maximum level of exposure to PM
2.5
  in 24 hours is 25 µg/
m3., a value mirrored by the EU and transposed in UK law.46,47 
Factors that increase levels of exposure to PM
2.5
  include the 
density of smokers, proximity to smokers and enclosure of 
outdoor areas.48
6.5.2 Support for smoke-free outdoor policies
Levels of support for smoke-free outdoor policies can 
be dependent on the location under consideration and 
who is likely to be exposed. For example, questions asked 
on attitudes towards outdoor smoking in the Action on 
Smoking and Health (ASH)/YouGov GB Smokefree Survey 
2017 found greater support for banning smoking in 
outdoor children’s play areas (82% agreement) than in 
outdoor public spaces such as parks (56% agreement).49 
Similarly, in Greater Manchester, while 51% of the public 
who responded to a survey supported making general 
outdoor events smoke-free, this level of support increased 
to 83% for outdoor events specifically for children and 
families. The level of support for smoke-free town centres 
was lower at 39%.50 
However, even in locations with higher levels of support, 
compliance with outdoor smoke-free areas can be limited. 
A study of a smoke-free park in New Zealand (in which the 
smoke-free policy was voluntary, not mandatory) found 
cigarette butts throughout the park.51 Mandatory smoke-
free parks and beaches in Canada have also had evidence 
through litter collections of continued smoking, although 
the litter was considerably reduced.52 This suggests 
that successfully enforcing any restrictions will involve 
considerable resource, including training people, such as 
park staff, in enforcing new policies.
6.5.3 Changing behaviour and attitudes
An evidence synthesis by PHE49 found mixed evidence 
on whether outdoor smoking bans change smokers’ 
behaviour. One good quality study found evidence of a 
reduction in smoking prevalence on university campuses 
following a ban on smoking outdoors, although the ban 
was part of a wider set of tobacco control measures.53 A 
quasi-experimental study found similar prevalence levels 
pre- and 12 months post the introduction of a smoke-free 
campus.54 The same study found no significant change in 
the proportion of smokers who planned to quit. However, 
longitudinal data from Korea found outdoor smoking 
bans increased the probability of a smoker making a quit 
attempt by 16%.55
Local areas that want to introduce smoke-free outdoor 
policies should clearly identify the goal of the policy, for 
example protecting children and adults from exposure 
to ambient tobacco smoke. Evaluation of such policies 
could include standardised, controlled studies on levels of 
exposure to ambient tobacco smoke; changes in attitudes 
for adult smokers, non-smokers and children; and assessing 
whether these policies have a positive effect. Investment in 
these policies by local areas should be considered as part of 
a comprehensive tobacco control strategy. 
6.5.4 Social housing
Smoking prevalence is strongly related to housing tenure in 
the UK, being highest (29.8%) among those who rent from 
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a local authority or housing association, 22.2% among 
private renters, and 7.9% among those who own their 
houses outright (mortgage free).56
Adult smoking in the home exposes children to ambient 
tobacco smoke, and this exposure is greater in young 
people in lower socio-economic groups. Children exposed 
to smoke at home are also themselves more likely to take 
up smoking.57 The ASH/YouGov Youth Smokefree Survey 
in 2019, found that 6% of 11- to 18-year-olds in ABC1 
(non-manual occupation) socio-economic grade lived in a 
home where people were allowed to smoke. This increased 
to 11% for young people from C2DE (manual occupation) 
families.58 Additional harms from smoking in the home 
include fires: while smoking related materials caused 
8.5% of accidental fires, they caused 36% of accidental 
fire-related deaths.59 Working with fire services represents 
an opportunity to reduce entirely preventable smoking-
related deaths. Sustained collaboration with local housing 
providers offers the prospect of engaging with smokers 
about their behaviour, protecting children from ambient 
tobacco smoke and supporting quit attempts:
a. Smoking cessation
There have been smoking cessation projects targeted at 
people in social housing. Salford’s ‘Swap to Stop’ offered 
free e-cigarettes and liquids for 4 weeks to smokers through 
social housing providers, on the condition of receiving 
behavioural smoking cessation support. The project 
achieved a 62% 4-week quit success rate, with 69% of 
service users at the start of the programme coming from 
the most deprived decile.60 In a UK randomised controlled 
trial among deprived communities in Nottingham and 
Nottinghamshire, NRT with behavioural support was 
provided by a smoke-free homes advisor together with 
feedback on home air quality; in comparison to the 
control group, the intervention group had an increase 
in quit attempts, reduced adult cigarette consumption, 
reduced indoor PM
2.5
 levels above 25 µg/m3 and reduced 
child salivary cotinine concentrations.61 A study from the 
USA which offered intensive cessation support with social 
housing residents trained as smoking cessation advisors 
was found to be effective, with an intervention comprising 
multiple visits and motivational interviewing achieving 
double the quit rate of a control intervention involving 
printed literature and a single visit from a trained peer 
health advocate.62
b. Communications campaigns
Communications campaigns can encourage smokers who 
do not want to stop smoking to smoke outside instead of 
inside their home. Campaigns such as ‘Secondhand smoke 
is poison’ run by Fresh in north-east England,63 or ‘Take it 
right outside’ by the NHS in Scotland,64 focus on the harms 
of ambient tobacco smoke to children and encourage 
adults to smoke outside the home. There are indications 
of health benefits from these campaigns. An analysis of 
children’s admissions to hospital for asthma found an 
association between the ‘Take it right outside’ campaign 
and lower levels of admission in under 5-year-olds.65
Interventions targeting either smoking in the home or 
social housing using community-based approaches have 
some evidence of effectiveness. These approaches could 
be used to address health inequalities caused by smoking 
and exposure to ambient tobacco smoke.
6.6 Use of vaping in public places to facilitate 
smoking bans
Allowing vaping in areas where smoking is prohibited 
may prevent former smokers who vape from relapsing 
to smoking and current smokers unable or unwilling to 
quit smoking to abstain from smoking. The health risk to 
bystanders from such policies is likely to be low, e-cigarette 
aerosol generates levels of particulate matter, carbon 
monoxide and black carbon orders of magnitude lower 
than for cigarette smoke.66–69
6.6.1 Vaping in indoor public places
Authors have sought to clarify the policy objectives relating 
to vaping bans.70,71 Most commonly, the objective of 
indoor vaping bans is expressed as ancillary to smoke-free 
places but in some cases, reducing vaping appears to be 
considered a goal in itself, possibly due to confusion on 
the role of nicotine, vaping and its effectiveness in treating 
tobacco dependency (see section 9.5). 
While vaping may cause nuisance or offence to others, 
these issues may be more appropriately dealt with by 
non-statutory measures.72 Vapers who have switched from 
smoking completely might be at greater risk of relapse 
to smoking if they are required to join smokers outdoors 
whenever they want to vape.71
6.6.2 Vaping in outdoor public places
Outdoor vaping bans can conflate smoking and vaping 
and in doing so risk public confusion.70 Harms from 
outdoor exposure to e-cigarette vapour have yet to 
be demonstrated and it seems unlikely that the use of 
e-cigarettes would have a measurable impact on outdoor 
air quality. 
Maintaining the distinction between smoking and vaping 
offers several public health opportunities. Where customers 
and employees can vape in the grounds (but must leave 
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the grounds to smoke) switching to reduced risk alternatives 
is encouraged. Conversely, because e-cigarettes generally 
deliver lower and slower doses of nicotine,73 where smokers 
and vapers alike must leave the building and its grounds, 
the balance may advantage smoking. At the very least, 
treating smokers and vapers alike seems unlikely to 
reinforce a vaper’s identity as distinct from any previous 
identity as a smoker.
Permitting vaping in outdoor areas where smoking is 
prohibited makes a clear distinction between these two 
activities each with very different health implications 
for both the user and the bystander. At the same time, 
it creates a situation where smokers are ‘nudged’ into 
replacing smoking with a far less harmful activity and it 
protects ex-smokers who have quit smoking from the risks 
of exposure to smoke and relapse to smoking. 
References
1  McKee M, Gilmore A, Novotny TE. Smoke free hospitals. BMJ 
2003;326:941-2.
2  Smoking, Health and Social Care (Scotland) Act 2005. www.legislation.
gov.uk/asp/2005/13/contents [Accessed 23 November 2020].
3  The Smoking (Northern Ireland) Order 2006. www.legislation.gov.uk/
nisi/2006/2957/contents [Accessed 23 November 2020].
4  The Smoke-free Premises etc. (Wales) Regulations 2007. www.
legislation.gov.uk/wsi/2007/787/contents/made [Accessed 23 
November 2020].
5  Health Act 2006. www.legislation.gov.uk/ukpga/2006/28/contents 
[Accessed 26 March 2021].
6  Department of Health. Smokefree England – one year on. London: 
DH, 2008 www.smokefreeengland.co.uk/files/dhs01_01-one-year-on-
report-final.pdf. [Accessed  
24 November 2020]
7  NHS Health Scotland. Evaluation of smoke-free legislation: publications. 
2014. http://www.healthscotland.com/scotlands-health/evidence/
smokefreelegislation/publications.aspx [Accessed 24 November 2020].
8  Frazer K, Callinan JE, McHugh J et al. Legislative smoking bans for 
reducing harms from secondhand smoke exposure, smoking prevalence 
and tobacco consumption. Cochrane Database Syst Rev 2016(2).
9  Mayne SL, Widome R, Carroll AJ et al. Longitudinal associations of 
smoke-free policies and incident cardiovascular disease. Circulation 
2018;138:557–66.
10  Faber T, Kumar A, Mackenbach JP et al. Effect of tobacco control 
policies on perinatal and child health: a systematic review and meta-
analysis. Lancet Public Health 2017;2(9):e420–e37.
11  Hopkins DP, Razi S, Leeks KD et al. Smokefree policies to reduce 
tobacco use. A systematic review. Am J Prev Med 2010;38:S275-89.
12  Faber T, Mizani MA, Sheikh A et al. Investigating the effect of 
England’s smoke-free private vehicle regulation on changes in 
tobacco smoke exposure and respiratory disease in children: a quasi-
experimental study. Lancet Public Health 2019;4:e607–e17.
13  Laverty AA, Hone T, Vamos EP et al. Impact of banning smoking 
in cars with children on exposure to second-hand smoke: a natural 
experiment in England and Scotland. Thorax 2020;75:345–7.
14  Jayes LR, Murray RL, Opazo Breton M et al. Smoke-free prisons in 
England: indoor air quality before and after implementation of a 
comprehensive smoke-free policy. BMJ Open 2019;9:e025782.
15  Semple S, Dobson R, Sweeting H, Brown A, Hunt K. The impact of 
implementation of a national smoke-free prisons policy on indoor 
air quality: results from the Tobacco in Prisons study. Tob Control 
2020;29:234–6.
16  Rigotti NA, Munafo MR, Stead LF. Smoking cessation interventions 
for hospitalized smokers: a systematic review. Arch Intern Med 
2008;168:1950–60.
17  Stockings EA, Bowman JA, Prochaska JJ et al. The impact of a smoke-
free psychiatric hospitalization on patient smoking outcomes: a 
systematic review. Aust N Z J Psychiatry 2014;48:617–33.
18  Mullen KA, Manuel DG, Hawken SJ et al. Effectiveness of a hospital-
initiated smoking cessation programme: 2-year health and healthcare 
outcomes. Tob Control 2017;26:293–9.
19  Evison M, Pearse C, Howle F et al. Feasibility, uptake and impact of a 
hospital-wide tobacco addiction treatment pathway: Results from the 
CURE project pilot. Clin Med 2020;20:196–202.
20  National Institute for Health and Care Excellence. Smoking Cessation 
in secondary care: acute, maternity and mental health services. PH48. 
NICE, 2013. www.nice.org.uk/guidance/ph48 [Accessed 20 April 2021].
21  Department of Health. Towards a smokefree generation: tobacco 
control plan for England. https://www.gov.uk/government/publications/
towards-a-smoke-free-generation-tobacco-control-plan-for-england. 
London: DH, 2017.
22  Royal College of Physicians. Hiding in plain sight: treating tobacco 
dependency in the NHS. London: RCP, 2018. www.rcplondon.ac.uk/
projects/outputs/hiding-plain-sight-treating-tobacco-dependency-
nhs [Accessed 20 April 2021].
23  National Health Service. NHS Long Term Plan. NHS, 2018. www.
longtermplan.nhs.uk [Accessed 20 April 2021].
24  Ratschen E, Britton J, McNeill A. Smoke-free hospitals – the English 
experience: results from a survey, interviews, and site visits. BMC 
Health Serv Res 2008;8:41.
25  British Thoracic Society. Smoking cessation policy and practice 
in NHS hospitals. London: BTS, 2016. www.brit-thoracic.org.uk/
media/454755/bts-smoking-cessation-audit-report-7-december-2016-
final.pdf [Accessed 20 April 2021]. 
26  PHE calls on all NHS Trusts to ban smoking on hospital grounds, 2019. 
www.gov.uk/government/news/phe-calls-on-all-nhs-trusts-to-ban-
smoking-on-hospital-grounds [Accessed 20 April 2021]. 
27  Campion J, McNeill A, Checinski K. Exempting mental health units from 
smoke-free laws. BMJ 2006;333:407–8.
28  Ratschen E. Smokefree mental health inpatient settings – a matter of 
debate? Sucht 2019;65:42–7.
29  Hempel AG, Kownacki R, Malin DH et al. Effect of a total smoking 
ban in a maximum security psychiatric hospital. Behav Sci Law 
2002;20:507–22.
30  Ratschen E, McNeill A, Doody GA, Britton J. Smoking, mental health, 
and human rights: a UK judgment. Lancet 2008;371:2067–8.
80© Royal College of Physicians 2021
6      Public space smoking restrictions
31  Ratschen E, Britton J, Doody G, McNeill A. Smoking attitudes, 
behaviour and nicotine dependence among mental health acute 
inpatients: an exploratory study. Int J Soc Psychiatry 2010;56:107–18.
32  Ratschen E, Britton J, Doody GA, Leonardi-Bee J, McNeill A. Tobacco 
dependence, treatment and smoke-free policies: a survey of mental 
health professionals’ knowledge and attitudes. Gen Hosp Psychiatry 
2009;31:576–82.
33  Ratschen E, Britton J, Doody GA, McNeill A. Smoke-free policy in 
acute mental health wards: avoiding the pitfalls. Gen Hosp Psychiatry 
2009;31:131–6.
34  Ratschen E, Britton J, McNeill A. Implementation of smoke-free 
policies in mental health in-patient settings in England. Br J Psychiatry 
2009;194:547–51.
35  Huddlestone LS, Sohal H, Paul C, Ratschen E. Complete smokefree 
policies in mental health inpatient settings: Results from a mixed-
methods evaluation before and after implementing national 
guidance. BMC Health Serv Res 2018;18:1–12.
36  Action on Smoking and Health. Progress towards smokefree mental 
health services. Findings from a survey of mental health Trusts in 
England. London: ASH, 2019. www.ash.org.uk/information-and-
resources/reports-submissions/reports/progress-towards-smokefree-
mental-health-services [Accessed 20 April 2021]. 
37  Ainscough TS, Mitchell A, Hewitt C et al. Investigating changes in 
patients’ smoking behaviour, tobacco dependence and motivation to 
stop smoking following a ‘smoke-free’ mental health inpatient stay: 
results from a longitudinal survey in England (in press). Nicotine Tob 
Res (forthcoming).
38  Sohal H, Huddlestone L, Ratschen E. Preparing for completely smoke-
Free mental health settings: findings on patient smoking, resources 
spent facilitating smoking breaks, and the role of smoking in reported 
incidents from a large mental health trust in England. Int J Environ Res 
Public Health 2016;13:256.
39  Welsh Parliament. SL(5)625 – The Smoke-free Premises and Vehicles 
(Wales) Regulations 2020. 2020 www.senedd.wales/laid%20
documents/cr-ld13577/cr-ld13577-e.pdf [Accessed 23 November 2020].
40  Scottish Government. Prohibiting smoking outside hospital buildings: 
consultation analysis. 2020  www.gov.scot/publications/consultation-
analysis-prohibiting-smoking-outside-hospital-building [Accessed 23 
November 2020].
41  Government NI. Smoking regulations in Northern Ireland. 
www.nidirect.gov.uk/articles/smoking-regulations-northern-
ireland [Accessed 11 November 2020].
42  Lawn S, Campion J. Achieving smoke-free mental health services: 
lessons from the past decade of implementation research. Int J 
Environ Res Public Health 2013;10:4224–44.
43  Ratschen EL, Stewart, P, Horspool M, Leahy M. Smokefree acute adult 
mental health inpatient wards: the service user experience. BJPsych 
Bull 2018;April 26.
44  World Health Organization. Guidelines on the protection from 
exposure to tobacco smoke. WHO. www.who.int/fctc/cop/art%20
8%20guidelines_english.pdf?ua=1 [Accessed 4 September 2020].
45  Sureda X, Fernández E, López MJ, Nebot M. Secondhand tobacco 
smoke exposure in open and semi-open settings: a systematic review. 
Environ Health Perspect 2013;121:766–73.
46  World Health Organization. WHO Air quality guidelines – global 
update 2005. WHO, 2006. www.who.int/airpollution/publications/
aqg2005/en [Accessed 12 December 2020].
47  European Commission. Air quality standards. www.ec.europa.eu/
environment/air/quality/standards.htm [Accessed 12 December 2020].
48  Licht AS, Hyland A, Travers MJ, Chapman S. Secondhand smoke 
exposure levels in outdoor hospitality venues: a qualitative 
and quantitative review of the research literature. Tob Control 
2013;22:172–9.
49  Public Health England. Smokefree outdoor public places and 
outdoor commercial places: An Evidence Synthesis Review. PHE, 
2018. https://phe.koha-ptfs.co.uk/cgi-bin/koha/opac-retrieve-
file.pl?id=e2122fadd0869947cf40809c907aaa0f [Accessed 4 
September 2020].
50  Greater Manchester Health and Social Care Partnership. Making 
Smoking History – A tobacco free Greater Manchester 2017-2021. www.
gmhsc.org.uk/wp-content/uploads/2018/05/A-Tobacco-Free-Greater-
Manchester-2017-–-2021.pdf [Accessed 4 October 2020].
51  Wilson N, Thomson G. Evaluating compliance in a large smoke free 
park: methods, issues and results. University of Otago, 2016. https://
aspire2025.files.wordpress.com/2016/06/wellington-smokefree-park-
methods-6-2016.pdf [Accessed 4 October 2020].
52  Pederson A, Okoli CT, Hemsing N et al. Smoking on the margins: a 
comprehensive analysis of a municipal outdoor smoke-free policy. 
BMC Public Health 2016;16:852.
53  Lupton JR, Townsend JL. A systematic review and meta-analysis of the 
acceptability and effectiveness of university smoke-free policies. J Am 
Coll Health 2015;63:238–47.
54  Burns S, Hart E, Jancey J et al. A cross sectional evaluation of a 
total smoking ban at a large Australian university. BMC Res Notes 
2016;9:288.
55  Ko H. The effect of outdoor smoking ban: Evidence from Korea. Health 
Econ 2020;29:278–93.
56  Smoking habits in the UK and its constituent countries, 
2020. www.ons.gov.uk/peoplepopulationandcommunity/
healthandsocialcare/healthandlifeexpectancies/datasets/
smokinghabitsintheukanditsconstituentcountries [Accessed 4 
October 2020].
57  Laverty AA, Filippidis FT, Taylor-Robinson D et al. Smoking uptake 
in UK children: analysis of the UK Millennium Cohort Study. Thorax 
2019;74:607–10.
58  Action on Smoking and Health/YouGov. Youth Smokefree Survey 
2019. ASH/YouGov, 2019. www.drugsandalcohol.ie/30694/1/ASH-
Factsheet-Youth-E-cigarette-Use-2019.pdf [Accessed 21 April 2021].
59  Public Health England. Local tobacco control profiles. PHE. https://
fingertips.phe.org.uk/search/fires#page/0/gid/1/pat/159/par/
K02000001/ati/15/are/E92000001/iid/91185/age/-1/sex/-1/cid/4/
tbm/1/page-options/ovw-do-2 [Accessed 21 April 2021].
60  Coffey M, Cooper-Ryan AM, Houston L et al. Using e-cigarettes for 
smoking cessation: evaluation of a pilot project in the North West of 
England. Perspect Public Health 2020;140:351–61.
61  Ratschen E, Thorley R, Jones L et al. A randomised controlled trial of 
a complex intervention to reduce children’s exposure to secondhand 
smoke in the home. Tob Control 2018;27:155–62.
81© Royal College of Physicians 2021
Public space smoking restrictions      6
62  Brooks DR, Burtner JL, Borrelli B et al. Twelve-Month Outcomes of 
a Group-Randomized Community Health Advocate-Led Smoking 
Cessation Intervention in Public Housing. Nicotine Tob Res 
2018;20:1434–41.
63  Fresh North East. Second hand smoke is poison. www.freshne.com/
what-we-do/our-campaigns/take-7-steps-out/overview [Accessed 4 
October 2020].
64  Scottish Government. Smoking in cars TV ad. 2016. www.nhsinform.
scot/campaigns/take-it-right-outside [Accessed 4 October 2020].
65  Turner S, Mackay D, Dick S, Semple S, Pell JP. Associations between a 
smoke-free homes intervention and childhood admissions to hospital 
in Scotland: an interrupted time-series analysis of whole-population 
data. Lancet Public Health 2020;5:e493–e500.
66  Fernández E, Ballbè M, Sureda X et al. Particulate matter from 
electronic cigarettes and conventional cigarettes: a systematic review 
and observational study. Curr Environ Health Rep 2015;2:423–9.
67  Avino P, Scungio M, Stabile L et al. Second-hand aerosol from tobacco 
and electronic cigarettes: Evaluation of the smoker emission rates and 
doses and lung cancer risk of passive smokers and vapers. Sci Total 
Environ 2018;642:137–47.
68  Protano C, Manigrasso M, Avino P, Sernia S, Vitali M. Second-hand 
smoke exposure generated by new electronic devices (IQOS® and 
e-cigs) and traditional cigarettes: submicron particle behaviour in 
human respiratory system. Ann Ig 2016;28:109–12.
69  Committee on toxicity of chemicals in food, consumer products and 
the environment. Potential toxicological risks from electronic nicotine 
(and non-nicotine) delivery systems (E(N)NDS – e-cigarettes).  https://
cot.food.gov.uk/sites/default/files/2020-09/COT%20E(N)NDS%20
statement%202020-04.pdf [Accessed 21 April 2021].
70  Bauld L, McNeill A, Hajek P, Britton J, Dockrell M. E-cigarette use in 
public places: striking the right balance. Tob Control 2017;26:e5–e6.
71  Wilson N, Hoek J, Edwards R. Should e-cigarette use be included in 
indoor smoking bans? Bull World Health Org Suppl 2017 Jul 1;95:540.
72  Royal College of Physicians. Going smoke-free: the medical case for 
clean air in the home, at work and in public places. A report on passive 
smoking by the Tobacco Advisory Group of the Royal College of 
Physicians. London: RCP, 2005.
73  Hajek P, Przulj D, Phillips A, Anderson R, McRobbie H. Nicotine delivery 
to users from cigarettes and from different types of e-cigarettes. 
Psychopharmacology (Berl) 2017;234:773–9.
82© Royal College of Physicians 2021
Economics of tobacco  7
Key points
>  Tobacco’s addictive properties mean that established 
smokers are dependent on tobacco, which influences 
their response to tobacco price increases. 
>  The price elasticity of demand describes the percentage 
change in quantity demanded for a given percentage 
change in price.
>  Demand for tobacco products is inelastic, so tobacco 
tax increases tend to reduce consumption while also 
increasing tobacco tax revenue.
>  Prevalence elasticity, which describes the change in 
prevalence in response to a price change, is estimated to 
be around half of the overall price elasticity.
>  A sustained policy of reducing affordability of tobacco 
by increasing taxes above inflation was implemented by 
the UK government in 1990 and enhanced through the 
introduction of an annual tobacco tax escalator in 1993.
>  The tobacco industry uses a wide range of actions to 
mitigate the effectiveness of government tax policies in 
order to protect its profitable market position.
>  When the price of factory-made cigarettes increases, 
many smokers downtrade either to budget cigarettes 
or to hand rolling tobacco, demonstrating that these 
products are substitutes.
>  Increasing specific tobacco taxes reduces the differentials 
that encourage downtrading, whereas increasing ad 
valorem taxes tends to amplify them. 
>  The level of taxation on smoking-related products should 
directly correspond to the health risks associated with use 
of that product. 
>  Smoking rates are highest among the populations that 
can least afford it, substantially exacerbating poverty.
>  Making smoking obsolete would release a substantial 
proportion of the budget in households in the most 
disadvantaged communities, representing a highly 
targeted tax cut for some of the most deprived families. 
Recommendations
>  Ad valorem taxes on tobacco are abandoned. 
>  Taxation of factory-made cigarettes is changed to be 
100% specific to minimise price differences between 
different market segments.
>  The minimum excise tax is regularly increased to raise the 
cost of the cheapest factory-made cigarettes.
>  Tobacco product affordability is reduced by large, annual, 
above-inflation tax increases on all tobacco products 
that are translated immediately into retail prices with 
consideration given to applying more radical increases 
aiming, for example, to double the price of cigarettes over 
a 5-year period.
>  Tax on hand rolling tobacco is increased to ensure that 
within 5 years, the tax paid per cigarette containing the 
typical weight of tobacco used is equivalent to that on 
factory-made cigarettes.
>  Tax loopholes are closed to ensure cigarillos are taxed in 
the same way as factory-made cigarettes. 
>  Measures to reduce tobacco companies’ ability to 
undermine tobacco tax policy are adopted, including 
limiting the number of times per year the industry can 
change its prices to once or twice; restricting the quantity 
of new brands and brand variants into the market; and 
maintaining and reinforcing existing measures to reduce 
the size of the illicit tobacco market. 
>  VAT on electronic cigarettes is reduced to 5%. 
>  VAT on nicotine replacement therapy is reduced to zero.
7.1 Introduction 
In addition to harms to the health and wellbeing of 
smokers and their families, smoking generates a significant 
financial burden on wider society through health and social 
care costs, and through reductions in productivity. In 2018 
alone, smoking in England was estimated to have cost 
society at least £12.5 billion, comprising £2.4 billion in NHS 
treatment costs; £8.9 billion in lost productivity caused by 
early deaths, absenteeism and smoking breaks at work; 
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£880 million in social care costs arising from additional 
social care needs due to disease and disability caused by 
smoking; and £325 million arising from the cost of fires 
caused by smoking.1 
These wider societal financial burdens are reduced when 
smoking prevalence falls. Decreasing the affordability of 
tobacco through above-inflation tax rises has been shown 
to be highly effective in reducing smoking prevalence2 and 
has the further benefit of increasing government revenues.3 
Since young people may be even more sensitive to tobacco 
price increases than adults, price increases are an effective 
means of reducing smoking uptake as well as increasing 
quitting among established smokers.2 
Tobacco tax increases can also reduce socio-economic 
inequalities in tobacco use because poorer smokers are 
more sensitive to price rises than the general population.2,4,5 
However, disadvantaged smokers who do not quit in 
response to tax increases bear a disproportionate share of 
the tobacco tax burden, due to the greater concentration 
of smoking among these groups.6 The positive health 
impact of tobacco taxes is greater when supported by 
comprehensive tobacco control strategies,3 and for ethical 
reasons it is essential that tax increases are introduced in 
conjunction with support to help people quit smoking.
7.2 The price elasticity of demand for  
tobacco products
7.2.1 An overview
It is a well-known economic concept that, for most goods, if 
the price of the product increases, demand for that product 
will decrease. This process is quantifed as the price elasticity 
of demand, which is the percentage change in quantity 
demanded in relation to a given percentage change in 
price. For example, if a 10% increase in price results in a 5% 
fall in the quantity demanded, then the price elasticity of 
demand is -0.5. Demand for a product is said to be ‘elastic’ 
if the absolute value of the price elasticity of demand is 
greater than 1, ‘unit elastic’ if it is equal to 1, and ‘inelastic’ 
if it is less than 1. Price elasticity has important implications 
for consumer behaviour, spending and tax revenue. 
Tobacco’s addictive properties mean that established 
smokers are typically dependent on tobacco and therefore 
relatively likely to continue purchasing the product even 
when prices rise. Price elasticity of demand for factory-
made cigarettes is generally estimated to be around -0.5.7 
Price elasticity of demand for other tobacco products, such 
as hand rolling tobacco, has been much less extensively 
studied, but has been estimated to be similar to that for 
factory-made cigarettes.7 Because demand for tobacco 
products is inelastic, tobacco tax increases tend to reduce 
consumption while also increasing tobacco tax revenue. 
To be effective, tobacco tax increases must decrease the 
affordability of tobacco, such that prices increase relative to 
consumer income.
The price elasticity of demand for tobacco captures the 
combined effect of lower levels of consumption among 
individuals who continue to use tobacco, and that of lower 
prevalence arising from reduced uptake and increased 
quitting. The prevalence elasticity (also referred to as the 
participation elasticity), which estimates the change in 
prevalence in response to a price change, is important for 
tobacco because reducing consumption alone is not an 
effective way to improve public health; improving public 
health requires people to quit or not take up smoking. 
Prevalence elasticity is estimated to be around half of the 
overall price elasticity.8
Price elasticities can be calculated as either ‘own-price’ or 
‘cross-price’ elasticities of demand. Own-price elasticities 
show the percentage change in quantity of a product 
(product X) demanded for a percentage change in the 
price of product X, as in the examples above. Cross-price 
elasticities show the percentage change in quantity of 
product X demanded for a percentage change in the price 
of product Y. For most goods, including tobacco, own-price 
elasticities are negative, whereas cross-price elasticities can 
either be positive or negative. If a cross-price elasticity of 
demand is negative, meaning that an increase in the price 
of product X results in a decrease in demand for product 
Y, then the products are ‘complements’. Conversely, if 
a cross-price elasticity of demand is positive, meaning 
that an increase in the price of product X results in an 
increase in demand for product Y, then the products are 
‘substitutes’. In the case of tobacco, studies may assess the 
own-price elasticity for tobacco products as a whole or a 
particular type of tobacco product (such as manufactured 
cigarettes), and/or the cross-price elasticity of demand 
between different tobacco products, such as factory-made 
cigarettes and hand rolling tobacco.
Products can have different price elasticities depending 
on whether the elasticity is calculated for the short run 
(generally the first 1–2 years following a tax increase) or 
the long run (the period after which consumers fully adjust 
to the changes).7 This is because some factors might be 
fixed in the short run but more variable in the long run. In 
the case of tobacco, addiction means that in the short run, 
smokers are likely to be less responsive to price. In the long 
run, smokers are expected to reduce their consumption 
further, and price increases make it less likely that non-
smokers will take up smoking, hence the long-run price 
elasticity is roughly double the short-run price elasticity.7
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7.2.2 International and UK estimates of the price 
elasticity of demand for tobacco products
A significant body of evidence on the price elasticity of 
demand for cigarettes is available across both high- and 
low-income countries. Reviews of these studies typically 
find that smoking is responsive to tobacco price but 
inelastic (a change in price causes a smaller percentage 
change in demand), with estimates of own-price elasticities 
of demand falling between -0.2 and -0.6 for adults in high-
income7 and -0.2 to -0.8 in low-income countries, with most 
estimates in the region of -0.5.7
There are few recent peer-reviewed studies of price 
elasticity of demand for tobacco in the UK. A study by 
Duffy in 2003 estimated a long-run price elasticity of 
demand for tobacco of -0.4 for the period 1963–96, which 
is consistent with commonly reported estimates.7,9 In a 
separate study, Duffy compared elasticity estimates using 
data adjusted and non-adjusted for smuggling in the UK 
and found the elasticity was reduced when smuggling 
was taken into account.10 This distinction is important, 
because studies which do not account for illicit tobacco 
consumption do not capture the full effect of price changes 
on tobacco consumption, as they do not reflect the fact 
that some smokers respond to price increases by switching 
to illicit tobacco. In the same study, the estimated price 
elasticity of total demand for tobacco – including illicit 
tobacco – changed from -0.4 in 1963 to -0.8 in the 1990s. 
By contrast, Mazzocchi, in a study covering 1963–2003, 
found that tobacco consumption in the UK became less 
price elastic over time, although the nature of the data 
used in the study was not clear.11 
In addition to these peer-reviewed studies, the UK 
government has produced estimates of the price elasticity 
of demand for tobacco based on duty-paid tobacco. A 
model covering the years 1963 to 1998 found an own-price 
elasticity for tobacco in the region of -0.25.12 A subsequent 
study estimated the own-price elasticity for duty-paid 
cigarettes at -1.26, while the own-price elasticity for 
tobacco products as a whole (including the illicit and cross-
border market, and including cigarettes and hand rolling 
tobacco) was -0.72.13 The higher elasticity for cigarettes 
alone most likely reflects the fact that when the price of 
factory-made cigarettes increases, many smokers switch to 
cheaper tobacco products such as hand rolling tobacco. 
In 2010, the UK government combined national household 
expenditure data with cigarette prices provided by tobacco 
manufacturers, quarterly from 1982 to 2009, to estimate 
the long-run price elasticity of demand of duty-paid 
cigarettes at -1.05.14 A recent update using the same 
methodology estimated price elasticity of demand at 
-1.19 (confidence interval -1.07 to -1.30). A study published 
by Deloitte in 2019, using data from the Living Costs and 
Food Survey, found a price elasticity of demand of -1.32 
for factory-made cigarettes and -0.57 for hand rolling 
tobacco.15 Younger adults and people with lower incomes 
are generally more responsive to price, indicating that 
tax increases may be particularly effective for reducing 
smoking in these populations,8 though these effects are 
undermined by the opportunity to downtrade to hand 
rolling tobacco, substitute with illicit tobacco, and by 
tobacco industry pricing strategies which undermine the 
effect of tax rises (see sections 7.3 and 7.4).16 
There is evidence that large unexpected tax increases allow 
less opportunity for the tobacco industry to manipulate 
prices to minimise the effects of price increases on 
consumption, and hence lead to a larger reduction in 
tobacco use than an equivalent rise applied via a series 
of expected smaller increases.17 Evidence from Australia, 
which implemented a sudden 25% tobacco tax increase 
in 2010 and a pre-announced series of four 12.5% 
annual tobacco tax increases (well above the magnitude 
of typical tobacco tax increases in the UK – see Table 
7.1) demonstrates that large tax increases can have an 
immediate discernible impact on prevalence, and that this 
effect may be higher in low socio-economic status (SES) 
groups.18 This study, although unable to provide a definitive 
head-to-head comparison, also found that substantial 
staged increases may be more effective than one-off large 
increases in achieving sustained reductions in prevalence. 
However, the immediate regressive financial effects of 
large unexpected prices on low SES smokers who cannot 
quit are inevitably more severe. There is also evidence from 
Australia that smoking rates in low SES groups can rebound 
following initial reductions in response to large price 
increases, demonstrating the need to assess the longer 
term effects of such price rises and the importance of 
interventions to minimise relapse among low SES smokers.19 
Overall therefore, the optimal size and frequency for 
tobacco tax increases is unclear, and is likely to vary across 
different contexts; however, implementing tax increases of 
a magnitude which reduce the affordability of tobacco has 
been consistently shown to be effective.
7.2.3 Tobacco price and substitution effects
Understanding the cross-price elasticity of demand for 
tobacco products is key to the effective implementation 
of tobacco tax increases, due to the potential for tobacco 
users to switch to cheaper products, rather than quit, if 
cheaper products are available. Relatively few studies have 
assessed the cross-price elasticity of demand for tobacco 
products; however, existing evidence indicates that in 
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high-income countries tobacco products are generally 
substitutes for each other.8 Tobacco taxes should therefore 
be structured to minimise the price differential between 
manufactured cigarettes and hand rolling tobacco and 
hence minimise downtrading to cheaper hand rolling 
tobacco. In the UK, the price of hand rolling tobacco, when 
measured in terms of price per cigarette, has tended to 
be much lower than the price of manufactured cigarettes, 
and may explain the increase in hand rolling tobacco use 
as a proportion of tobacco use over time.16,20 As described 
in section 7.3, the UK government has taken steps in 
recent years to reduce the price differentials between 
cigarettes and hand rolling tobacco, by implementing tax 
increases for hand rolling tobacco over and above those for 
manufactured cigarettes, but significant price differences 
remain and need to be eradicated.
7.3 Historic overview of tobacco prices and 
affordability in the UK 
Immediately after the Second World War, a majority 
of tobacco consumed in the UK was imported from the 
USA. In 1947, when a balance of trade crisis created a risk 
that the UK would run out of dollars, the UK chancellor 
increased tobacco tax by 50% in the March Budget to 
reduce consumption and hence the need for US tobacco 
imports. Tobacco consumption fell by a half in the month 
immediately after the Budget, compared with the monthly 
average in the previous financial year. Although there 
was a rebound in consumption, consumption was still 
20% below pre-April levels in August, and a significant 
reduction was sustained; between 1945–6 and 1949–50, 
tobacco consumption fell by 18.5%.21 Despite this fall in 
consumption, tax receipts from tobacco increased by 27% 
in the year following the tax increase.21 Despite the success 
of this tax increase in both reducing consumption and 
increasing tax revenue, tobacco taxes were not increased 
significantly again until the 1970s. As a result, as incomes 
rose, tobacco became more affordable, reaching a peak in 









































Fig 7.1 Affordability of tobacco index*, UK, 1987–2018 
(base = 1987).22
*The affordability of tobacco index shows the relative affordability 
of tobacco by comparing the relative changes in the price of tobacco 
with changes in disposable income per capita over the same period. 
If the affordability index is above 100, then tobacco is relatively more 
affordable than in January 1987.22
Contains information from NHS Digital, licensed under the current 
version of the Open Government Licence
In the 1990s the UK government implemented a sustained 
policy of reducing the affordability of tobacco by increasing 
taxes above inflation with the intention of both increasing 
government revenues and reducing tobacco consumption 
and smoking prevalence.23 This was done through the 
introduction of an annual tobacco tax escalator, initially set 
at 3% above inflation in 1993,24 and increased to 5% in 
199725 (see Table 7.1).
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Years Tobacco tax increases
1989 Spring: No increase (RPI increased by 7.8%)
1990 Spring: 10% (RPI=9.5%)
1991 Spring: 15% (RPI=5.9%)
1992 Spring: 10% (RPI=3.7%
1993
Spring: 6% (RPI=1.6%)
Autumn: 7.3%. Plus committed to introduce an annual tobacco tax escalator of a minimum of 3%  
above projected RPI
1994 Autumn: 7.3% (RPI=2.4%)
1995 Autumn: 3% above projected RPI for cigarettes, tax on HRT frozen (RPI=3.5%)
1996 Autumn: 3% above projected RPI for cigarettes, increase at projected RPI for HRT
1997–98
Commitment to annual tobacco tax escalator 5% above projected RPI. Took effect in December 1997  
and December 1998.
1999 Spring: 5% above projected RPI for cigarettes, no increase for HRT (RPI=1.5%)
2000 Spring: Escalator abolished. Tobacco tax increased by 5% above projected RPI
2001–08 Spring: annual increases in line with projected RPI
2009 Spring: 2% increase (NB RPI=-0.5% so effective increase of 2.5%)
2010
Spring: 1% above projected RPI with commitment to escalator of 2% above RPI for all tobacco products 
for remainder of the parliament (2011–15)
2011 Spring: 2% above projected RPI plus additional 10% increase on HRT
2012–13 Spring: 2% above projected RPI
2014
Spring: 2% above projected RPI with commitment to continue tax escalator for the subsequent parliament 
from 2015–20
2015 Spring: 2% above projected RPI 
2016 Spring: 2% above projected RPI with additional 3% for HRT
2017
Spring: 2% above projected RPI
20 May 2017: Introduction of MET of £268.63 per 1,000 cigarettes, setting a floor below which taxes 
cannot fall (see section 1.2.1). 
Autumn: one-off additional 1% for HRT. MET set at £280 per 1,000 cigarettes
A commitment to a 2% above projected RPI annual escalator for all tobacco products for remainder  
of current parliament (up until 2022) 
2018 Autumn: 2% above projected RPI with an additional 1% for HRT
2019 No Budget
2020
Spring: 2% above projected RPI for all tobacco products until the end of this Parliament (2019–23).  
The rate on HRT increased by an additional 4% 
Autumn: 2% above projected RPI for all tobacco products plus an additional 4% for HRT
Table 7.1 Timeline of tobacco tax increases for manufactured cigarettes and hand rolling 
tobacco (HRT) in the UK
HRT = hand rolling tobacco; RPI = Retail Prices Index; MET = minimum excise tax 
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additional hand rolling tobacco tax increases to reduce 
the price differential between hand rolling tobacco and 
manufactured cigarettes; and the introduction of minimum 
pack sizes to increase the minimum purchase price of 
tobacco products, particularly for hand rolling tobacco. 
Furthermore, Brexit has ended the import of cheap EU duty 
paid tobacco.34
7.4 Tobacco industry tactics to mitigate tax rises 
7.4.1 Summary of industry tactics
The tobacco industry has been shown to take a range 
of actions to protect its profitable market position by 
mitigating the effectiveness of government tax policies.35 
A number of these are now prevented or minimised in the 
UK as a result of standardised packaging legislation and 
the introduction of the minimum excise tax, but the wider 
strategies comprise: 
>  Raising concerns that illicit tobacco use will rise if 
taxes increase:36 Evidence suggests that with robust 
customs and excise systems, higher taxes are not linked 
to illicit (non duty paid) tobacco.37
>  Facilitating the illicit tobacco market: A variety of 
data sources have demonstrated that the single largest 
component of the illicit tobacco market in the UK and 
globally is tobacco industry illicit, comprising smuggled 
non-UK duty-paid products from lower-taxation markets 
and UK brands on which duty has not been paid.38 Weak 
tobacco industry-created ‘track-and-trace’ tobacco 
supply chain monitoring systems are promoted to 
undermine efforts to curb the illicit market.39,40
>  Stockpiling/forestalling products prior to a tax rise so 
retailers can use existing lower taxed stocks to sell at 
lower prices, potentially for many months.35,41
>  Lobbying for predictable tax changes: Predictability 
in a tax regime is viewed as being ‘good for business’42 
providing the opportunity for the maximium utilisation 
of tax-undermining measures. The tobacco industry 
therefore lobbies for small regular tax increases rather 
than large and unexpected increases, and then looks to 
deploy the tactics outlined in this chaper.
>  Price smoothing: Instead of passing higher tobacco 
tax to consumers in the form of a single price change 
when the tax increase is implemented, price changes are 
introduced gradually, with several smaller increases giving 
smokers time to get used to changes.20,35 For example, 
after the March 2012 duty increase, one Pall Mall variant 
from British American Tobacco (BAT) increased by 7p in 
April, 6p in May, 12p in August, and 14p in September 
(Nielsen data, authors’ own analysis). Furthermore, when 
The tobacco industry response to this policy was to 
facilitate a rapid increase in the illicit tobacco trade26–28 
developing a parallel market which sustained its profits 
while at the same time arguing that tax increases had 
caused the increase in illicit trade. This strategy had been 
successfully used in other countries where taxes were 
increased significantly above inflation, such as Canada and 
Sweden, to persuade governments to cut tobacco taxes.29 
However, such reductions were shown to be followed by an 
increase in smoking, while the illicit trade did not decline.29 
The UK government instead commissioned an 
independent review of illicit trade in the UK,30 which 
was estimated in 2000 to have a market share of 20% 
for manufactured cigarettes, over 60% for hand rolling 
tobacco, and to be rising.31 Concluding that illicit trade 
arose from insufficient enforcement rather than high 
taxes, the government launched a far-reaching anti-illicit 
strategy, stating that ‘The Government is determined that 
criminal activity will not undermine its policies to improve 
the nation’s health.’ The government’s tax gap estimates 
indicate that during the first 10 years of the illicit tobacco 
strategy, from 2000–01 to 2009–10, the illicit market share 
for cigarettes nearly halved. The illicit market share for 
hand rolling tobacco fell less consistently, but dropped from 
61% to 44% (central estimates) during the same period.32
Between 2001 and 2008 the escalator was discontinued, 
so that tobacco taxes increased only in line with inflation 
during this period. Tobacco taxes were increased above 
inflation in 2009 and an escalator of 2% above inflation 
was reintroduced for factory-made cigarettes, and greater 
ad hoc increases for hand rolling tobacco, from 2010 (see 
Table 7.1). This measure came with a commitment for 
this to be sustained for the parliament, which has been 
renewed for the current parliament (2019–23). 
Government tax policy has not been completely successful 
in reducing the affordability of tobacco, due to loopholes 
in tax structures described in section 7.4 below which 
have allowed the industry to take advantage of the tax 
system and given smokers the opportunity to downtrade to 
cheaper manufactured and hand rolling tobacco products 
instead of quitting. Furthermore, although the illicit market 
share for both cigarettes and hand rolling tobacco has 
reduced in recent years, illicit tobacco continues to account 
for a significant proportion of the markets, especially for 
hand rolling tobacco (33% in 2018/19; 8% for factory-
made cigarettes).33 Additional measures have been taken 
in recent years to reduce access to cheaper tobacco. These 
include a minimum excise tax for cigarettes introduced 
in 2017 which reduced the differential price advantage 
of low-cost economy brand cigarettes (see section 7.4); 
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tax changes are expected, prices can be increased in 
anticipation of, as well as following, a tax rise.20 This was 
illustrated when the minimum excise tax, which was 
designed to prevent the tobacco industry from selling 
very cheap cigarettes, was announced in March 2017, 
and the prices of the cheapest packs rose gradually from 
the announcement rather than occurring at the time of 
the implementation in May. A typical cheap [anonymous] 
brand variant’s prices increased from £7.05 in February 
2017 by 14p in both March and April, and by 8p in both 
May and June, to £7.49, rather than suddenly increasing 
by 44p in May. (Nielsen data, authors’ own analysis).  
>  Over- and under-shifting tax increases: Instead of 
passing on tobacco tax increases uniformly, the tobacco 
industry varies price increases by brand segment. 
Accordingly, the most expensive (‘premium’) brands face 
larger and quicker price increases that soon exceed the 
tax increase, while economy brands face slower and more 
gradual price increases. This approach leads to larger 
profits from consumers who are relatively insensitive to 
price, but cushions the impact on those that are more 
sensitive to reduce the likelihood that they will quit.20 In 
April 2013, after tax changes, Imperial Brands’ premium 
Embassy Number 1 brand increased in price by 27p, more 
than double the increase in any other month, whereas 
one of their cheapest brands, Carlton Superkings, did not 
increase in price until July and then only by 5p (Nielsen 
data, authors’ own analysis).  
>  Increasing market segmentation through brand/
brand variant proliferation: Cheaper brands of 
manufactured cigarettes and hand rolling tobacco, and 
hand rolling tobacco versions of existing factory-made 
cigarette brands, have also been introduced to offer 
smokers cheaper options without the need to leave 
familiar brands.43 For example, Benson and Hedges 
(from Japan Tobacco) not only offer the traditional Gold 
premium variant, but also newer mid-priced (Silver) and 
cheap (Blue) factory-made variants, and Benson and 
Hedges Silver hand rolling tobacco. This creates a growing 
range of different variants of the same brand positioned 
at different price points in the market, helping to retain 
price-sensitive existing smokers and attract new ones.  
>  Introduction of increased value hand rolling tobacco 
‘combipacks’: Bundled products that include filters and 
papers as well as tobacco are sold at a cheaper price 
than if each was bought separately. For example, in 
November 2019 a 30 g pack of Amber Leaf (from Japan 
Tobacco) was retailing at £13.89, while the combipack 
version with the same amount of tobacco and 50 papers 
was only 10p more expensive when a pack of 50 papers 
alone cost 28p. A large number of papers/filters are 
generally included in combipacks, which provides smokers 
with the ability to roll slimmer cigarettes so that each is 
even cheaper.44 For example, the 30 g combipacks of 
Riverstone were launched in 2019 with 60 papers and 
filters.43  
>  ‘Premiumisation’: Premiumisation involves the 
introduction of new brand variants and gimmicks such 
as a ‘crushball’ (the ability to crush the filter to release a 
menthol flavour), filter changes, packaging innovations 
such as bevelled edges, and other features designed to 
suggest a more premium product appearance.45 The 
majority of these variants are no longer legal in the 
UK, due to standardised packaging regulations and 
the Tobacco and Related Products Regulations which 
implemented the EU Tobacco Products Directive.46,47 
Sometimes these have been introduced in order to 
minimise the impact on smoker behaviour of increasingly 
higher prices arising from both taxes and industry 
profit-seeking.20 For example, Imperial Brands stated 
that premium-like features were being introduced into 
a cheaper brand (John Player and Sons) 2 months after 
the November 2017 tax rise so that smokers would feel 
they gained something for the higher retail price; these 
features included ‘filters designed to be more durable, 
deliver a smoother taste and create less smoke’, while also 
retaining the post-tax rise selling price of £8.30 per pack.48 
>  Shrinkflation: Higher tobacco prices are disguised 
by shrinking pack sizes rather than changing the pack 
purchase price. Reducing pack sizes from 20 cigarettes, 
to 19, 18, and even 17,49 means the pack purchase price 
does not need to increase despite higher taxes, as the 
higher price per cigarette is disguised by smokers not being 
required to pay a higher price for their usual packet of 
cigarettes. When, for example, 19-stick packs of Benson 
and Hedges Blue arrived on the market in July 2014 
they were priced at £6.47, which was the same as the 
20-stick pack. Minimum pack size legislation in the UK 
implemented in 2017 means that this strategy is no longer 
legal in the UK.
>  Identify weaknesses and inconsistencies: To keep 
tobacco products more affordable and appealing, 
weaknesses in the taxation system and other regulations 
are identified and exploited. Examples of this behaviour 
include selling tobacco for hand-rolled cigarettes as lower 
taxed pipe tobacco,50 and launching a cigarillo version of 
Sterling Cigarettes, as cigarillos are subject to lower taxes 
per stick (and can also be sold in colourfully branded 
packs of 10 with menthol flavour, all of which are now 
banned for cigarettes).51 Most recently, new forms of 
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measures to reduce the use of these strategies. These have 
included the UK anti-smuggling strategy;58 increases in 
minimum tax rates on tobacco products and reductions 
in the differential between manufactured cigarettes and 
hand rolling tobacco in the EU; and the development 
of the WHO Illicit Trade Protocol which sets out a range 
of measures to combat the illicit tobacco trade. Other 
measures that have countered industry pricing tactics 
in the UK include the implementation of the minimum 
excise tax, the introduction of standardised packaging and 
minimum pack sizes. While the UK has now left the EU, the 
relevant EU directives have been transposed into UK law, 
often with additional restrictions (such as standardised 
packaging) included. These rules are required to undergo 
post-implementation reviews, and so there is the potential 
for taking regulations further in the future. 
7.5 Future directions for tobacco price and 
taxation policy
Despite the implementation of a range of measures to 
reduce the tobacco industry’s use of pricing strategies 
in the UK, the industry is generally still free to price its 
products as it sees fit and to introduce as many brands/
brand variants as it wishes. Further measures are therefore 
needed to address such behaviour and hence ensure the 
full benefits of tobacco taxation are realised. Limiting the 
frequency with which the industry can change its prices 
to once or twice per year would make it difficult for the 
industry to introduce tax-induced price increases gradually, 
or to differentially over- and under-shift tax increases 
between market segments.20 This could be implemented 
as part of the product notifications under the Tobacco 
and Related Products Regulations (TRPR), which currently 
require tobacco manufacturers to report to Public Health 
England, annually and for every product and product 
variant they sell, an extensive range of data (see chapter 
8).47 Furthermore, restricting the introduction of new brands 
and limiting existing brands to a small number of variants 
would also be a useful addition, as it would make it more 
difficult for the industry to support smokers downtrading to 
cheaper products instead of quitting.21  
The structure of tobacco taxes could also be revised to 
maximise their effectiveness, especially in light of the UK 
leaving the EU and the opportunities this presents for 
policy changes.34 At present, the factory-made cigarette tax 
excise comprises a mix of specific taxes – which are applied 
as a fixed amount of tax payable on each unit sold – and 
ad valorem taxes – where tax is paid as a percentage of the 
pack price. Changing taxation of factory-made cigarettes 
to be 100% specific would minimise price differences 
between different market segments.59 In addition, regular 
filters, papers and packaging were introduced to blunt the 
impact of the May 2020 menthol ban.52,53
Since tobacco taxation is essentially a price-based strategy, 
the tobacco industry response to taxation forms part of its 
wider pricing strategy in the marketplace (which will also 
be affected by a number of things beyond taxation). The 
tactics mentioned above are therefore utilised holistically 
rather than just for taxation in isolation, and in conjunction 
with wider price related tactics including:
>  Increasing retail prices in line with affordability: 
When household income levels are increasing, tobacco 
can become more affordable even as tobacco taxation 
increases. The industry has been found to consider 
tobacco affordability when setting its retail prices in the 
absence of tax changes, both overall and in regards to 
different brands/brand variants.54  
>  Price-marked packaging: To make sure that 
manufacturers rather than retailers set the price of 
tobacco products, a recommended retail price is printed 
on tobacco packaging, thereby making it difficult for 
retailers to increase their prices and profit margins. This 
practice retains price sensitive smokers in the market.35 
However, standardised tobacco packaging legislation 
now prevents this in the UK.
>  Streamlining the supply chain to increase profit 
in an environment of taxes taking up more of the 
stick price: Reducing the number of parent brands and 
creating global brands with huge sales (for example, 
the Rothmans brand, which grew from 12 to 58 billion 
sticks between 2012 and 2017) enables manufacturers 
to depress costs, amplify pricing power, and create 
resilience to regulation.55 Moreover, tobacco farming 
and manufacturing has moved to countries where costs 
and taxes are lower,56,57 allowing tobacco companies 
to lower their costs of product, thereby removing some 
of the corporate need for industry-created price rises. 
Furthermore, production in foreign locations allows the 
industry to more easily facilitate the illicit market.40
7.4.2 Measures which have addressed the actions 
of the tobacco industry
The collective impact of all of these industry pricing 
strategies has been to significantly broaden the price 
range of tobacco products in the marketplace, which 
helps the industry both to maximise profits and keep 
tobacco within the reach of price-conscious smokers. To 
address the actions of the tobacco industry, academics 
and advocacy organisations have worked to provide 
evidence on industry actions to governments at the UK, 
EU, and global level to encourage the implementation of 
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updates to the minimum excise tax introduced in 2017 
should help to raise the cost of the cheapest factory-made 
cigarettes. Furthermore, the yearly tax escalator that 
commits to increasing tobacco taxes by 2% above inflation 
should be revised to allow more substantial annual above-
inflation specific tax increases to reduce the affordability of 
all tobacco products. 
Hand rolling tobacco presents a cheap route for tobacco 
consumption,60 in part because it is significantly under-
taxed relative to factory-made cigarettes.44 Significant 
increases in hand rolling tobacco taxation, over and above 
those implemented for factory-made cigarettes, would 
close this price gap, thereby encouraging quitting in place 
of downtrading. This strategy may be more effective if 
rolling papers and filters were also to be subject to new 
tobacco-related taxation (and indeed wider tobacco-
related regulation), as that would further increase the cost 
of each hand-rolled cigarette. Indeed, since such products 
have recently been used to help the industry bypass the 
ban on menthol characterising flavour, all such tobacco 
accessories should be classed as tobacco products so that 
they are subject to all tobacco regulations. 
Finally, since the industry uses the illicit trade to argue 
against tobacco taxes, it is important that firm policy 
action is taken to continue to reduce the illicit share of 
the market. The introduction of duty-free sales in place 
of unlimited imports of cheap duty-paid products from 
the EU as a result of the UK leaving the EU is likely to help, 
but more needs to be done. Illicit tobacco continues to 
undermine the effectiveness of tobacco tax policies in the 
UK, and is associated with significant revenue losses. In 
addition to maintaining and reinforcing existing measures, 
a key priority is to improve control of the illicit supply chain, 
as stipulated by the WHO Illicit Trade Protocol.38
7.6 Taxation and price elasticity of smoking 
cessation medication, non-tobacco nicotine 
consumer products and heated tobacco 
products
It has been argued that to minimise harm to health from 
the use of nicotine, the level of taxation on nicotine-
containing products should directly correspond to the 
health risks associated with use of that product.61 At 
present, nicotine products in the UK are subjected to a 
range of tax systems, as described below.
7.6.1 Taxation and the price of smoking cessation 
medication in the UK
In the UK, the NHS provides smokers who are trying to 
quit smoking with nicotine replacement therapy (NRT), 
bupropion or varenicline by prescription. In England, 
smokers are usually required to pay a fixed charge for each 
prescription item unless exempted on the basis of age or 
low income. In Scotland, Wales and Northern Ireland all 
stop smoking medication prescriptions are free. NRT can 
also be purchased over the counter (OTC). OTC NRT is 
subject to a reduced rate of value added tax (VAT) of 5%. 
The price elasticity of demand for NRT has not been 
investigated in detail, and no UK estimates are available. 
Based on US data, the own-price elasticity of demand for 
NRT has been estimated to be in the region of -2.3 to -2.5, 
suggesting that decreases in the price of NRT would lead to 
substantial increases in per capita sales of NRT products.62 
A more recent study has estimated a more conservative 
own-price elasticity of -1.4 for NRT gum and lozenges, and 
-1 for patches; however, this still reflects that NRT demand 
is highly sensitive to price.63 A study from the USA estimates 
that the price elasticity of demand for NRT with respect 
to the price of cigarettes is in the region of 0.8, suggesting 
that increases in the price of cigarettes would lead to 
substantial increases in per capita sales of NRT products.62
Given that only a small proportion of smokers who make 
a quit attempt access stop smoking services or receive 
cessation support in primary or secondary care, most 
people who use smoking cessation medication will pay 
for over-the-counter NRT.64 Recent estimates suggest that 
exclusive NRT users in England spend less than half as 
much money on these products than exclusive smokers 
spend on tobacco.65 NRT use in Britain has been overtaken 
by e-cigarette use in recent years, and e-cigarette prices 
may be more significant in influencing tobacco use than 
that of pharmacotherapies.66 
7.6.2 Taxation and price of non-tobacco nicotine 
consumer products in the UK
E-cigarettes and e-liquids are not tobacco products and so are 
exempt from tobacco excise duties in the UK, but are subject 
to the standard 20% rate of VAT. This means that e-cigarette 
use is less costly than smoking, although this depends on the 
type of product purchased and patterns of use.65,67 
There have been limited studies to date of the price 
elasticity of demand for e-cigarettes. A particular challenge 
to such studies is the capture of data on the full e-cigarette 
market for a particular jurisdiction, given that e-cigarettes 
are sold in a wide range of outlets including specialist vape 
shops, which are not typically captured in commercial 
sales data. A systematic review of studies up to 2017 
identified four studies reporting own-price elasticity of 
demand, with a median of -1.8.68 This suggests that price 
rises of e-cigarettes have a larger impact on e-cigarette 
consumption than price rises of cigarettes do for cigarette 
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average weekly expenditure per smoker in England was 
over £23.64 Extrapolating this to the total population of 
adult smokers in England in 2018 (6.4 million, estimated 
using smoking prevalence calculated from the Annual 
Population Survey applied to ONS mid-year population 
estimates)74 would suggest a total annual tobacco spend 
in England of close to £8 billion, and hence a smoke-free 
dividend of over £7 billion. However, these self-reported 
spending data are a significant underestimate since the 
total collected by the government in tobacco duty alone 
in 2018/19 was £9.29 billion.75 This indicates that smokers 
significantly underestimate the proportion of income that 
they spend on tobacco products and therefore that these 
figures underestimate the extent to which smoking reduces 
the resources they have left to spend on other goods.
The harms of tobacco use are typically framed in 
terms of its health consequences and economic costs 
both in healthcare and wider productivity. There is, 
however, another dimension to this, which arises from 
the concentration of smoking among the country’s 
poorest communities. Ending smoking is not only a 
powerful measure to reduce health inequalities but, 
because smoking is so concentrated among the most 
disadvantaged in society, would also represent a highly 
targeted tax cut which directly benefits the country’s most 
deprived families and depressed economies. Although 
it is not known how funds diverted away from tobacco 
spending would be reallocated, reducing tobacco use 
would free up a substantial proportion of the budget in 
the most disadvantaged communities, leaving those 
families in greater charge of how they spend their share 
of the smoke-free dividend. Although there are ethical 
challenges associated with viewing expenditure on tobacco 
as an unnecessary exacerbation of poverty which could be 
mitigated by alternative spending decisions, there is no safe 
level of smoking,76 and most smokers state that they would 
prefer not to continue smoking. Furthermore, because 
almost all the money spent on tobacco flows directly 
out of the local economy, it places an additional burden 
on the community. This supports the argument that 
the government should do more to protect people from 
tobacco addiction, particularly in low-income communities. 
Highlighting the financial burden of tobacco use on 
households and communities may appear to be at odds 
with recommendations to reduce affordability as a means 
of reducing tobacco consumption. However, as described 
above, low socio-economic groups are most responsive to 
tobacco price increases. As highlighted in chapter 2, for 
smokers who continue to smoke following tax increases, 
however, it is essential that additional support to quit 
tobacco use is provided. Making smoking obsolete would 
consumption (-0.4). Across the same four studies the cross-
price elasticity of demand for e-cigarettes with respect to 
combustible cigarettes was 1.2, implying that e-cigarettes 
and cigarettes are substitutes. One of the included studies 
included data for the UK, but these were pooled with data 
from other countries.69 There is a need for UK-specific 
evidence on this issue; however, overall, existing studies 
suggest that continued tobacco price increases will support 
switching to e-cigarettes, and that lower e-cigarette prices 
will encourage e-cigarette use. A reduction in level of VAT 
on e-cigarettes could be used to reduce e-cigarette prices. 
7.6.3 Taxation of heated tobacco products 
Unlike e-cigarettes, heated tobacco products (HTPs, also 
known as ‘heat-not-burn’ products) contain tobacco which 
when used is ‘heated without reaching ignition to produce 
an emission containing nicotine and other chemicals’.70 The 
tobacco industry claims that such products are less harmful 
than combustible tobacco products, though these claims 
are as yet not fully supported by independent evidence. 
In the UK, where few HTPs are currently available and the 
prevalence of HTP use is low, HTPs are currently in their own 
excise tax bracket, taxed by weight at the same level as 
hand rolling tobacco. When the relative harms of HTPs are 
more clearly understood, tax structures for HTPs should be 
reviewed and revised accordingly.
7.7 A smoke-free dividend
In the prevention green paper Advancing our health: 
prevention in the 2020s the government set out the 
ambition of making smoked tobacco obsolete by 2030.71 
This presents a major opportunity, not only to improve 
health and to reduce health inequalities but also to improve 
the finances of the UK’s most disadvantaged families and 
its most deprived communities. 
Smoking rates are highest among the population groups 
that can least afford to smoke (see chapter 2) and it is 
estimated that over 1 million people, including over a quarter 
of a million children, live in poverty as a result of the cost of 
smoking to the family budget.72 Furthermore, this spending 
is not useful to the local economy as almost all of the money 
spent on tobacco is transferred to the Treasury in the form 
of duties, to manufacturers as profits, or to criminals through 
the illicit trade in tobacco products. It has been estimated 
that typically only around 7% of the revenue from the sale 
from licit tobacco products is retained by retailers.73 This 
suggests that if smoking were to become obsolete, at least 
93% of current spending on tobacco would be redistributed 
back into local communities. We refer to this redistribution as 
the ‘smoke-free dividend’.
The Smoking Toolkit Study (STS) estimates that in 2018 
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act as a highly targeted tax cut reaching precisely our most 
deprived families and communities making a material 
difference to household finances and local economies. 
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Key points
>  The range of tobacco and nicotine products available 
to consumers has expanded substantially over the 
past 60 years. 
>  The lethal nature of combusted tobacco products 
has not changed, with alterations in cigarette design 
and tar content to date predominantly representing a 
misleading distraction. 
>  There is no safe level of combusted tobacco use.
>  The use of filter vents generates misleadingly low tar 
and nicotine emissions when cigarettes are machine-
smoked, and should be prohibited.
>  Mandating lower maximum standard tar, nicotine, 
and carbon monoxide yields may make cigarettes 
less desirable and encourage smoking cessation or 
the use of less hazardous nicotine delivery systems.
>  The relative harms or benefits of heated tobacco 
products in relation to combusted tobacco are yet to 
be determined.
>  There remain approximately twice as many smokers 
as vapers in the UK and fewer than half of all smokers 
believe, correctly, that vaping is less harmful than 
smoking.
>  Oral tobacco products that are not intended to be 
chewed are prohibited in the UK and all EU countries 
except for Sweden, where snus remains legal, is widely 
used, and has contributed to the low prevalence of 
tobacco smoking there. 
>  Reduced ignition propensity cigarettes have had 
little measured impact on cigarette-related fires 
and fatalities and more effective design and testing 
requirements should be evaluated and introduced.
Recommendations
>  The toxicology of novel tobacco products is 
independently verified.
>  A review of the regulation of e-cigarettes in the UK is 
undertaken to assess the extent to which the regulations 
support switching from smoking, while limiting appeal 
to and use by youth, and the extent to which the current 
regulations ensure products on the market are safe.
8.1 Introduction 
Combustible tobacco products have been meticulously 
designed and promoted by the tobacco industry to 
encourage uptake and maximise addiction while 
minimising the impact of regulatory requirements. In 
this chapter we review the constituent components of 
combustible tobacco and other nicotine products, and their 
regulation.
8.2 Components, design, and use of  
tobacco products 
8.2.1 Cigarettes
The modern mass-manufactured cigarette is engineered 
to optimise delivery of nicotine to the smoker by tobacco 
combustion.1–4 The burning cone of a cigarette generates 
temperatures of up to 900°C, creating conditions for 
complex combustion and pyrolysis reactions that generate 
an inhalable aerosol (smoke) containing nicotine.3,5 
Cigarette emissions are typically measured using a smoking 
machine which captures these aerosol components on 
a filter pad. The total mass captured is termed the total 
particulate matter, and when nicotine and water are 
removed from this, the residual is termed ‘tar’. The gaseous 
phase of smoke that passes through the pad can also be 
collected and analysed for additional components such 
as carbon monoxide. To date, analysis of tar and gaseous 
components of tobacco smoke has identified over 7,000 
constituents5 which can be divided into three classes: 1) 
constituents of the tobacco itself; 2) compounds that are 
added to the product during manufacture; 3) constituents 
created by combustion and/or pyrolysis of the cigarette.6 
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Prominent examples of compounds in these three 
categories are listed in Table 8.1. 
Researchers have identified components of cigarette 
smoke thought to represent a risk to health, often relying 
on carcinogenic potency indices and relative concentrations 
in smoke.7,8 In these analyses N-nitrosamines, benzene, 
1,3-Butadiene and cadmium often rank highly. However, 
it is also important to measure the exposure of smokers 
to these components9–11 and the development of 
modern mass spectrometry methods has allowed for the 
measurement of multiple metabolites of tobacco smoke 
compounds in human biospecimens.12–14 
A contemporary manufactured cigarette typically comprises 
a tobacco filler, paper wrapper and (usually) a filter attached 
to the tobacco rod using tipping paper (Fig 8.1).2,4 The 
tobacco filler, typically 0.5 to 1 g per cigarette, can be made 
from a number of tobacco types. In the UK, Canada and 
Australia cigarette tobacco is primarily flue-cured (Virginia, 
or golden) tobacco while in the USA and many other 
markets it is typically a blend of flue-cured, burley, and 
oriental tobaccos. Blends may also include reconstituted 
sheet tobacco, which is made from leftover tobacco pieces, 
or expanded (‘puffed’) tobacco that contributes to lower 
rod density. The wrapping paper is typically engineered 
to a certain porosity (amount of airflow) to maintain a 
consistent burn rate. The filter is most commonly cellulose 
acetate fibres arranged to balance trapping ability with 
airflow to maintain an acceptable resistance to draw across 
the whole cigarette. Many filters employ tip ventilation to 
dilute the smoke (explained in greater detail in section 8.3 
below), and in some markets (such as Japan), the filter may 
also contain activated charcoal.  
Table 8.1 Classes of compounds in cigarettes and prominent examples in each class
Constituent  
of tobacco




Minor tobacco alkaloids (nornicotine, 
anatabine, anabasine)
Tobacco-specific nitrosamines (nicotine-
derived nitrosamine ketone (NNK),  
N-Nitrosonornicotine (NNN)) 
Arsenic
Heavy metals (lead, cadmium, nickel)
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Roll-your-own (RYO) and make-your-own (MYO) cigarettes 
require the smoker to assemble the cigarette components 
bought either separately, typically as loose tobacco and 
cigarette paper (RYO) or as part of a packaged kit including 
pre-fabricated filter tubes which, when assembled, more 
closely resemble manufactured cigarettes (MYO). In both 
cases the constituent products typically attract lower tax 
rates than manufactured cigarettes, and hence reduce 
the cost of smoking (see chapter 7). However, in relation 
to the range of toxins to which smokers are exposed there 
are few substantive differences between manufactured 
and RYO/MYO products, and little evidence of differences 
in health risk.15 Table 8.2 describes mean values and 
standard deviation observed for key design characteristics 
for leading brands in the USA, UK, Canada, and Australia in 
200816 and demonstrates that for comparable bands of tar 
cigarette designs are fairly consistent across countries, and 
that ventilation tends to increase with decreasing tar band, 
whereas other features tend to be more stable.
Table 8.2 Key design characteristics for leading brands in the USA, UK, Canada, and Australia in 200816
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8.2.2 Other tobacco products
Filtered cigars (sometimes called small or little cigars) 
resemble and include similar design elements to 
manufactured cigarettes, including filter ventilation in some 
cases.17–19 The main distinguishing feature is a wrapper 
that contains tobacco elements, which in most jurisdictions 
allows them to be classified as cigars. Cigarillos are smaller-
sized cigars, often flavoured, and some include wooden 
or plastic mouthpieces. Cigar smoke emissions are similar 
to those of cigarettes, and cigar smokers share many 
biomarkers of exposure with cigarette smokers.20–22  
Hookah, also known as shisha, narghile or waterpipe, is a 
form of tobacco smoking common in North Africa and 
the Eastern Mediterranean that has become increasingly 
popular in Europe and North America, particularly 
among young people.23–25 Hookah smoking typically 
involves heating a moist tobacco mixture with charcoal, 
and drawing the smoke through a hose connected to a 
vessel containing water. The smoke bubbles through the 
water chamber before reaching the user. The tobacco 
mixtures employed for hookah are often highly flavoured 
and contain high levels of humectants (eg glycerine).26,27 
Toxicant levels in hookah smoke are broadly similar to those 
from cigarettes28–31 with the exception of higher levels of 
carbon monoxide arising from the charcoal used to heat 
the tobacco.26,32  
Over the past 40 years tobacco manufacturers have 
proffered many technological innovations purported 
to reduce exposure to toxicants and/or the health risks 
arising from smoking. The first of these was the filter 
itself, though long-term evidence suggests that there 
has not been a reduction in smoking-attributable cancer 
risk commensurate with the scale of filter adoption in 
the market.33–36 A second was the attempt to develop 
less hazardous substitutes for neat tobacco, with the 
development of ‘new smoking material’ (trademarked 
Cytrel) in the UK, and in the USA, a National Cancer 
Institute programme to develop a less hazardous cigarette. 
More radical design changes emerged in the USA in the 
1980s and 1990s, including products such as Premier, 
Eclipse and Accord which heated rather than burnt tobacco, 
and products with selective reductions in contents/
emissions (Advance, Omni, Quest). The 2001 and 2011 
US Institute of Medicine monographs offer more detailed 
history of these products.37,38 The heated tobacco concept 
has recently evolved into currently available products 
such as IQOS, glo, TEEPS and PloomTech. A core idea of 
heated tobacco products is to aerosolise nicotine without 
combustion, thus reducing the toxicant load.39 Like Eclipse, 
TEEPS uses an integrated carbon rod heating element 
to heat the tobacco, while IQOS and glo use an external 
electrical heating device into which specially designed 
cigarettes are inserted.40 Examples of these two basic 
heated tobacco product (HTP) designs are shown in Fig 8.2.
1. Eclipse nicotine delivery system41
System of papers and 
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2. IQOS 
(A) IQOS charger, holder and HeetStick (tobacco stick)  
(B) Schematic drawing of holder  


















Fig 8.2 Examples of heated tobacco products. 
© Slade et al 2002 (1) and © Glantz 2018 (2)
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8.3 Filter ventilation on tobacco cigarettes
Filter ventilation, which dilutes the smoke drawn through 
the filter with air drawn in through pores in the filter paper, 
was first used in US cigarette brands in the 1960s.1,2 Filter 
ventilation reduces tar emissions measured by machine-
smoking, and became a critical design feature of filter 
cigarettes in the later decades of the 20th century when 
governments began to encourage the use of cigarettes 
which delivered lower levels of tar measured by this 
method.1–4 Although there are other design features that 
can reduce smoke emissions, filter ventilation has arguably 
the most important effect,1–3,5,6 and has become by far the 
most dominant design feature for reducing mainstream 
smoke emissions in cigarettes.3,4 
Filter ventilation reduces emissions primarily by dilution but 
also slows the passage of smoke as it passes through the 
filter thereby increasing filter effectiveness and reducing 
the temperature at which smoke is produced.3,26 Discrete 
ventilation holes or porosity along the length of a cigarette 
also make the first puffs of a cigarette taste milder and 
weaker, and the smoke from ventilated filter cigarettes is 
often also perceived by smokers to be milder, and hence 
inferred to be less harmful.1,3,14–16 However, as the cigarette 
burns down, these ventilation effects are diminished. 
Researchers at British American Tobacco also documented 
that stronger puffing by the smoker would decrease the air-
dilution effect from filter vents but increase the air-dilution 
effect from paper porosity,8 noting that ‘cigarettes in which 
the degree of ventilation decreases with increasing flow 
rate (filter tip ventilation) would be preferred to cigarettes 
in which the degree of ventilation increases’.8 Hence, during 
the late 20th century, average machine-smoked ‘tar’ levels 
of cigarettes dropped substantially,43 but it also became 
clear that in practice, the ability of smokers to reduce these 
ventilation effects negated any potential or expected 
reduction in harm.1,44–46 
8.4 Labelling – tar, nicotine and carbon 
monoxide (TNCO) levels 
Comparisons of brands in relation to their ‘tar’ levels 
became a marketing strategy through the 1940s and 
1950s, and were used to imply higher or lower health 
risks. By the 1960s, smoking machine testing became 
standardised with the implementation of the US Federal 
Trade Commission (FTC) method (later adopted by 
other governments and eventually the International 
Standardisation Organisation), which prescribed a specific 
puffing regimen (35 mL puff, 2-second duration, 60-second 
interval) and stopping point (overwrap + 3 mm).47 This 
approach incentivised manufacturers to design cigarettes 
to perform well in machine-smoking tests while allowing for 
‘elastic’ delivery for the user. This began the era of so-called 
‘light/mild’ cigarettes, which held particular appeal for 
women and health-concerned smokers. From the 1980s 
it became recognised in the scientific community that 
filter ventilation could be problematic48,49 and later work 
showed that smokers could compensate for the machine-
measured reductions in ‘tar’ and nicotine in ventilated 
cigarette smoke by taking larger puffs, smoking more 
of the cigarette, smoking more cigarettes, or blocking 
filter vents with lips or fingers.50 By the early 2000s it was 
clear that ‘light’ and similar descriptors were inherently 
misleading,1,51 and these have since been widely prohibited 
through the Framework Convention on Tobacco Control 
(FCTC) (Article 11), lawsuits, and country regulators. In 
2008, the FTC disavowed its testing method as inherently 
misleading. However, vestiges of the prior thinking remain 
in the European Union Tobacco Products Directive (EU 
TPD) ‘10-1-10’ ratio (maximum level of 10 mg tar, 1 mg 
nicotine, and 10 mg CO) requirements,52 and similar ‘tar’ 
caps in other countries. Misleading descriptors such as 
‘light’ have been replaced in many instances with other 
terms and/or colour coding, but even after removal of 
misleading product descriptors, misconceptions that low tar 
cigarettes represent a lower health hazard persist, possibly 
because filter ventilation still distinguishes brands.53–55 
Plain or standardised packaging has been introduced in 
many countries in part to address these lingering problems, 
though others have suggested more radical options such 
as design standards for cigarettes which prohibit filter 
ventilation.50,56 It has also been proposed that a lower 
standard maximum-yield threshold of 5 mg tar, 0.5 mg 
nicotine, and 5 mg CO should be established, so that 
such lower-yield cigarettes would be less susceptible to 
compensatory smoking behaviors.2 The banning of filter 
vents, along with lower maximum standard tar, nicotine, 
and carbon monoxide yields, would likely make cigarettes 
less desirable, and might encourage smoking cessation 
or the use of less-hazardous nicotine delivery systems.33 
Banning filter vents could also increase the use of other 
design features such as decreased tobacco weight or higher 
filter efficiency that may be less consumer acceptable and/
or less prone to compensatory smoking. 
8.5 Reporting requirements on the tobacco 
industry  
Access to tobacco company data on product ingredients, 
emissions and toxicity are required to facilitate monitoring and 
research. This is a particular priority for novel tobacco products, 
which are receiving significant tobacco industry investment,57 
but the health harms of which are relatively unclear.58,59
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Since May 2016 tobacco companies have been required to 
notify Public Health England (PHE) of all tobacco products 
to be sold in the UK. Notification was a requirement of the 
EU Tobacco Products Directive (2014/40/EU) (TPD),52,60 
and this requirement has been maintained following the 
Brexit transition period. The notification process requires 
companies to report annually to PHE an extensive range 
of data for each product they sell. This requirement 
includes the physical characteristics of tobacco products 
and their filters; ingredients, flavours and other additives 
used; nicotine, tar, carbon monoxide and other emissions; 
emission toxicity data; sales volumes and other marketing 
data.61 In May 2020 a ban on characterising flavours, such 
as menthol, in cigarettes and hand rolling tobacco came 
into effect in the UK. In addition, every brand of cigarette 
is tested for tar, nicotine and carbon monoxide (TNCO) 
six times per year at an independent lab contracted by 
PHE and paid for by the industry. Prior to January 2021 all 
notifications were made via the EU’s notification portal; 
since January 2021 notifications for products intended 
for sale in Great Britain are made via a domestic tobacco 
notification system. Products intended for sale in Northern 
Ireland continue to be notified to the EU system.
Manufacturers of e-cigarettes and e-liquids are also 
required to report data including ingredients, emissions, 
toxicology, nicotine dose and uptake and sales volumes 
to the Medicines and Healthcare products Regulatory 
Agency (MHRA),61 and as for tobacco products, notification 
of products intended for sale in Great Britain is now via 
a domestic system. These data provide a potentially 
powerful resource from which to monitor the characteristics 
of the many thousands of tobacco products and electronic 
nicotine delivery systems on the market. However, recent 
research using the submissions data on vaping products 
up to October 201762 indicates that the reporting of these 
data is unstandardised and that the data require extensive 
cleaning and anonymisation before they can be used, 
thus reducing their utility. Standardising data collection 
and making data made available for research in a format 
which reduces the time needed for data management 
will facilitate and increase confidence in future analysis. 
Given that data on the ingredients and emissions of vaping 
products and toxicological information are not available 
from other sources, these should be a priority. Providing 
data such as sales volumes, prices and other marketing 
data would facilitate policy evaluation and market analysis. 
In addition, there is a need for independent verification of 
the toxicology of novel tobacco products. As mentioned 
above, many tobacco companies are currently investing 
significantly in these products, and they are consistently 
marketed as a less harmful alternative to combustible 
tobacco. However, relatively little is known about the health 
consequences of novel tobacco products, and much of the 
current evidence is based on tobacco company-funded 
research.63 In contrast to cigarettes, however, there is 
currently no independent testing or verification of novel 
tobacco products. One approach to rectifying this problem 
would be to amend Statutory Instrument 507, which sets 
out the UK regulations for the implementation of the TPD, 
to require the notification fee for novel tobacco products 
paid by manufacturers be set at a level sufficient to meet 
the full cost of the development of standardised methods 
and the independent verification of the manufacturers’ 
toxicological claims.39,64
8.6 Nicotine product regulation
Nicotine-containing products range in purity and health 
risk, with cigarettes and other smoked tobacco products 
at one extreme and medicinal nicotine at the other. 
Within this spectrum of risk lie a host of other products 
including smokeless tobacco (such as snuff and chewing 
tobacco), heated tobacco products and electronic 
cigarettes. Nicotine products continue to be regulated 
inconsistently and disproportionately in relation to their 
risk in the UK, under a number of consumer and medicines 
laws, including: the European Union Tobacco and Related 
Products Regulation (EU TRPR)61 which sets out product 
regulations that apply to sale and promotion, product 
content reporting, packaging, tracking and tracing, and 
safety and quality requirements of cigarettes, hand 
rolling tobacco, pipe tobacco, cigars, smokeless tobacco, 
electronic cigarettes and herbal products for smoking; the 
General Product Safety Regulations 200565 that regulate 
non-nicotine containing electronic cigarettes; and the 
regulations of the MHRA, that regulate nicotine containing 
medicinal products.66 
A rational approach to regulating nicotine products would 
aim to minimise the uptake of nicotine use among non-
users, particularly children; promote complete cessation 
of nicotine use among current users wherever possible; 
and encourage as many current smokers as possible who 
choose or otherwise fail to stop using nicotine to reduce 
harm by switching from smoked tobacco to less hazardous 
products.67–69 The RCP has long argued that achieving 
this would be enabled by integrating the regulation of 
all nicotine products into a comprehensive regulatory 
framework which applies market controls on these products 
in proportion to their hazard to consumers. The following 
discussion of approaches to regulating different nicotine 
product types relates primarily to the UK but applies in 
principle to most rich countries. 
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8.6.1. Smoked tobacco 
Use of tobacco products originated in the Americas 
and predates historical records, but the global uptake 
of tobacco use dates back to the 16th century, and of 
manufactured cigarettes to the late 19th century.70 While 
there can be little doubt that if smoked tobacco products 
were to be introduced as a new product in any country 
with functional consumer protection laws today they 
would be immediately prohibited, consumer laws have 
in practice been applied retroactively to conventional 
tobacco products and, with the exception of Bhutan, where 
production and sale of tobacco were banned in 2010,71 
have stopped short of prohibition. Most countries do now 
have at least some regulatory controls on the promotion, 
sale or consumption of tobacco,72 but continue to allow this 
highly hazardous product to be sold and consumed. 
In the UK, current regulations have a number of gaps 
allowing manufacturers to adapt products to encourage 
consumption, including: the use of colour descriptors 
to convey misleading risk messages and product 
characteristics; flavoured filters and card inserts marketed 
to circumvent flavour bans;73,74 and exemptions for cigarillos 
from regulations requiring standardised packaging, 
minimum pack sizes and the ban on characterising 
flavours.75,76 Regulations to close these loopholes should be 
implemented following the example of countries outside of 
the EU.77 Additional regulation where there is evidence of 
benefit78 include a larger size of graphic health warnings to 
cover 85% of the front and back of packs,79 maximum and 
minimum pack sizes,80 use of ‘dissuasive’ cigarettes that 
carry health warnings on individual cigarettes 81,82 and the 
use of government-mandated information and advice on 
quitting and switching to less harmful nicotine products.83 
8.6.2 Medicinal nicotine
At the other end of the nicotine product regulatory 
spectrum, medicinal nicotine products (typically termed 
nicotine replacement therapy, or NRT) such as transdermal 
patches, gum, sprays and others are, in most countries, 
regulated as medicines. Although also derived from 
tobacco, the nicotine in these products has been distilled to 
achieve high levels of purity and pose little by way of health 
hazard.84 Although initially available only on prescription, 
regulation of these products has relaxed significantly in 
the UK and elsewhere, such that in the UK they can now 
be bought over the counter (though not by children under 
12 years of age) and used without medical supervision. 
Advertising medicinal nicotine products is permitted within 
limits,85,86 and advertisements are allowed to include claims 
of efficacy in helping smokers to quit.86 Medicinal nicotine 
is subject to a reduced level of UK sales tax (5%, rather 
than the standard 20%), but the costs arising from meeting 
medicines manufacturing and supply standards, and perhaps 
also the pricing structures adopted by the pharmaceutical 
industry, result in medicinal nicotine retail prices that are high 
in relation to tobacco or unlicensed products. 
8.6.3 Smokeless tobacco
Smokeless tobacco products such as nasal snuff, chewing 
tobacco and Swedish snus provide nicotine by absorption 
through the oral or nasal mucosa and are typically 
much less hazardous than smoked tobacco, but are also 
appreciably more hazardous than medicinal nicotine.87 In 
the UK and most EU countries, nasal snuff and chewing 
tobacco are little used and are allowed to be sold under 
similar regulations to smoked tobacco,61 though in the UK 
these products are not subject to standardised packaging 
regulations.88 Oral tobacco products that are not intended 
to be chewed are, however, prohibited in the UK89 and 
indeed in all EU countries except for Sweden, where snus 
remains legal, is widely used, and has contributed to the 
low prevalence of tobacco smoking there.68,69,87 
8.6.4 Heated tobacco products
Although the heated tobacco products (HTP) launched 
in the later part of the 20th century and described above 
were not commercially successful,63 the new generation 
of HTP which include IQOS (made by Philip Morris), Ploom 
(Japan Tobacco), iFUSE (British American Tobacco) and 
Pulze (Imperial Brands) have to varying degrees proved 
more commercially viable, with IQOS in particular achieving 
significant market penetration in Japan.90 Although much 
of the available data on HTP emissions and exposure 
arises from tobacco industry sources and are therefore of 
questionable reliability, these products appear to generate 
lower levels of exposure than conventional smoked 
tobacco products to the extent that their use is likely to 
be appreciably less hazardous than smoking, though the 
magnitude of this risk reduction remains uncertain and 
they are designed to be as addictive as smoking.63,91,92 HTP 
products are regulated in much the same way as smoked 
tobacco products in the UK, although they are exempt 
from standardised packaging regulations. 
8.6.5 E-cigarettes
E-cigarettes generate nicotine for inhalation by vaporising 
nicotine solutions rather than by burning tobacco. Although 
the vapour they produce typically contains propylene 
glycol, flavours and the pyrolysis products generated when 
these components are heated, e-cigarettes are widely 
(though far from universally) accepted to offer a means 
to consume inhaled nicotine at substantially reduced risk 
relative to tobacco smoking.69,93–95 E-cigarettes are the most 
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widely used source of nicotine other than smoked tobacco 
in the UK,96 have been demonstrated to be effective 
quitting aids97,98 and therefore offer significant potential 
as a tobacco harm reduction product,69,93 and their use 
for tobacco harm reduction has been endorsed by a wide 
range of medical organisations.99 Although a successful 
application for a medicines authorisation has been made 
for at least one e-cigarette product,100 no medically licensed 
e-cigarette has yet come to market. Without a medicines 
licence, e-cigarettes cannot be advertised as a means to 
quit smoking. 
Regulatory approaches to e-cigarettes vary substantially 
between countries, but in the UK they are regulated 
differently from tobacco in several ways, including 
exemption from smoke-free laws (though informal 
restrictions on use indoors are commonplace) and from 
standardised packaging, point-of-sale display restrictions 
and others.62 Advertising is, however, tightly restricted, 
in particular prohibiting any claim of efficacy in helping 
smokers to quit smoking.101 Regulations of e-cigarettes also 
include the size of tank or refill containers, limits on nicotine 
content to no more than 20 mg/ml and warnings on packs.
8.6.6 Other non-tobacco nicotine consumer 
products
In addition to electronic cigarettes, other unlicensed 
non-tobacco products, such as oral pouches containing 
flavoured nicotine, have been or remain available through 
bricks-and-mortar or online suppliers as consumer products 
in the UK. None has to date proved as commercially 
successful as e-cigarettes. 
8.6.7 Rationalising nicotine regulation in the UK
Nicotine regulation in the UK has evolved piecemeal as the 
range of nicotine products has grown, and it is overseen 
by a range of different laws and regulators with inevitable 
anomalies. However, over recent years regulations on 
the highest risk product, smoked tobacco, have become 
more stringent, and those on the lowest risk product, NRT, 
have been relaxed to allow wider sale and access. Having 
initially considered imposing medicines regulation on 
e-cigarettes,102 UK regulators have succeeded in creating 
a regulatory niche for e-cigarettes that has allowed 
widespread access and affordability, and indeed product 
innovation and widespread use. However, there remain 
approximately twice as many smokers as vapers in the 
UK103–105 indicating that more could be done to encourage 
smokers to shift to less harmful products, and the finding 
that fewer than half of all smokers believe that vaping 
is less harmful than smoking105 identifies one key area in 
which regulation could change for the better. 
Current regulations permit health claims to be made only 
for products with a medicines licence. While necessary 
to protect the public from unsubstantiated health claims 
across a wide potential range of non-medicinal products, 
in a context in which the default for smokers is to continue 
to use a far more hazardous combustible tobacco 
product, this restriction is probably counter-productive to 
public health. The continued absence of a commercially 
available licensed e-cigarette in the UK some 13 years 
after the products first appeared on the UK market 
is evidence in itself that the licensing process has not 
been a commercially attractive prospect for e-cigarette 
manufacturers. There remains a case, therefore, to make 
nicotine products an exception and allow health-based 
promotion of products for which a rational basis for 
reduced harm can be established. 
A review of the regulation of e-cigarettes in the UK should 
be undertaken to assess the extent to which the regulations 
support switching from smoking including nicotine 
concentrations and the use of flavourings, while limiting 
appeal to, and use by youth through improved regulations 
on packaging, labelling and promotions,101,106,107 and review 
the extent to which the current regulations ensure products 
on the market are safe.
The ‘e-cigarette or vaping product use-associated lung 
injury’ (EVALI) outbreak in the USA108 caused by the use 
of a toxic additive, vitamin E acetate, which is prohibited 
by the EU TPD, supports the need to maintain monitoring 
and regulations for non-nicotine containing e-cigarette 
products to prevent such occurrences in the UK. 
8.6.8 Denicotinised cigarettes
In March 2018 the US Food and Drug Agency (FDA) issued 
an advanced notice proposing a new approach to tobacco 
product regulation based on reducing the nicotine content 
of combustible cigarettes to minimally or non-addictive 
levels.109,110 The logic of the measure is to make cigarettes 
non-addictive to new users, and unsatisfying to existing 
users, thus discouraging smoking uptake and promoting 
cessation or a switch to less harmful sources of nicotine 
among existing smokers.109 
While it is plausible that young people who experiment 
with a non-addictive product are unlikely to become 
long-term users, the argument that reducing nicotine will 
cause smokers to quit is less compelling. In clinical trials of 
smokers who consent to use denicotinised cigarettes there 
is indeed evidence that reducing nicotine levels below 95% 
promotes quitting,111 but whether this would apply to the 
general population of smokers if such very low nicotine 
levels were imposed across the board, is far less clear. While 
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likely to help some smokers to quit smoking completely, the 
withdrawal of conventional cigarettes may also generate a 
substantial illicit market in these products. Even if this can 
be managed successfully in the USA, it is also questionable 
whether denicotinisation would succeed in countries with 
more porous borders. Whether denicotinisation will work 
therefore remains to be seen. 
8.7 ‘Fire safer’ cigarettes 
One of the less widely publicised means by which cigarettes 
harm health is through their inherent fire risk.112,113 
Cigarettes have historically been a leading cause of fires, 
and in particular fatal fires, in residential or commercial 
buildings. Gunja et al showed that product liability fears 
appeared to suppress the introduction of technology to 
reduce fire ignition risk that had existed for decades.114 
To reduce the risk of fires started by cigarettes, various 
bodies have investigated and proposed cigarette ‘fire 
safety’ standards. The principle is consistent with the harm 
reduction paradigm – reducing morbidity and mortality 
associated with smoking by changing the product even 
as smokers continue smoking.38 New York (NY) State in 
2004 became the first locality in the world to mandate fire 
safety standards for cigarettes. In 2011 the UK introduced 
a similar standard for reduced ignition propensity (RIP) 
cigarettes as part of EU-wide regulations.115 The EU 
standard for RIP cigarettes116 allows for a fail rate of up 
to 25% over 40 tests. Analysis of Swedish data pre- and 
post-implementation of the standard in 2011 found no 
statistically significant intervention effects on residential 
fires, fatal residential fires, residential fires where smoking 
was a known cause, or fatal residential fires where smoking 
was a known cause.117 In the UK too it does not appear to 
have had a significant impact,118 since fire safer cigarettes 
continue to be involved in fire deaths.119 The test to meet 
the EU standard is an ISO standard120 but the pass rate was 
set by the EU. Reducing the fail rate to no more than 5% 
over 40 tests has been suggested by fire authorities119 to 
improve the likelihood of preventing cigarette-related fires.
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Key points
>  It is essential that smokers who contemplate or make a 
quit attempt are able easily to access the best evidence-
based support and treatment to quit.
>  Opt-out treatment of tobacco dependency more than 
doubles quit rates in hospitals.
>  Financial incentives improve quit rates in pregnancy.
>  Patients with serious mental health disorders are more 
likely to quit with tailored treatment. 
>  LGBT people are more likely than heterosexual people to 
smoke and face multiple barriers to smoking cessation.
>  Treatment of tobacco dependency in primary care is poor 
and represents a significant opportunity for intervention 
to improve health and reduce demand on NHS services.
>  E-cigarettes are an effective treatment for tobacco 
dependency. 
Recommendations
>  The NHS provides opt-out tobacco dependency treatment 
to all smokers at any point of contact with the NHS.
>  Financial incentives are provided in maternal smoking 
cessation pathways.
>  Patients with serious mental illness are offered tailored 
treatment for tobacco dependency.
>  Better access and services are provided for the LGBT 
community who are tobacco dependent.
>  Primary care practitioners treat tobacco dependency, 
supported by a reform to the system that rewards 
treatment and enhanced training in primary care.
>  E-cigarettes are included in standard protocols to treat 
tobacco dependency.
9.1 Introduction
Treatment of tobacco dependency is recognised as one 
of the pillars of tobacco control.1 However, despite tobacco 
use being prevalent in the UK for hundreds of years, 
effective treatments being available for over 30 years and 
government funding of stop smoking services for the past 
20 years, uptake and provision of these treatments across 
the NHS remains poor. In this chapter we will review the core 
elements of tobacco addiction and treatment, and consider 
the opportunities to treat tobacco dependency in the NHS.
9.2 The cycle of addiction in a smoker 
Addictive behaviours such as cigarette smoking are 
best understood as a chronic relapsing brain disease – a 
brain disease because drugs such as nicotine change 
brain structure and function; chronic, because they are 
characterised by compulsive drug-seeking that persists over 
time despite harmful consequences; and relapsing because 
the majority of those who attempt to quit revert to drug 
use within 12 months.2
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There are numerous non-biological factors that contribute 
to whether people start to smoke, whether they progress to 
daily smoking, how heavily they smoke, and how difficult 
they find it to stop smoking. It is no longer contentious that 
cigarette smoking is addictive, but the drivers of cigarette 
smoking are complex and may have changed considerably 
over the past century and since the harms of smoking 
became known in the 1950s.
Young people typically experiment with their first cigarette 
in adolescence, and few first try a cigarette after the age of 
20.2 Therefore, most smokers begin smoking in adolescence 
or early adulthood. However, smoking initiation among 
young people has been declining over time. The data 
shown in Fig 9.1 clearly demonstrate that the majority 
(although not all) of the reduction in smoking prevalence 
in the UK over the past 50 years is attributable to fewer 
people starting over time.3 
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Figure 9.1, taken from an earlier RCP report,3 shows 
that rates of smoking uptake among young people 
has gradually decreased over time, with people born 
before the 1970s being more likely to be smokers in late 
adolescence and early adulthood than those born after 
the 1970s. In Fig 9.1, the proportion of current smokers at 
age 18 is approximately 35% among those born between 
1961 and 1965, but only around 20% among those 
born between 1991 and 1995. In contrast, the decline 
in smoking prevalence with age is similar across all birth 
cohorts, suggesting little improvement in rates of quitting 
over time.3 (These data only extend to 2011, and therefore 
do not capture recent changes, such as the growth in 
popularity of e-cigarettes.) 
Nicotine has been widely acknowledged to be the primary 
addictive constituent of tobacco since the first evidence 
that rodents would preferentially self-administer nicotine 
emerged in the 1970s.4 The addictive properties of 
nicotine are enhanced by the presence of other tobacco 
constituents (principally monoamine oxidase inhibitors), 
and by delivery through inhalation which results in delivery 
of nicotine to the brain within 10 to 15 seconds – faster 
than the delivery of intravenously injected heroin.3,4
Nicotine is metabolised very rapidly, meaning that after 
even a short period of abstinence from smoking, for 
example on waking after sleep, a regular smoker will have 
very low levels of circulating nicotine, and therefore be 
nicotine deprived and in withdrawal. The time between 
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waking up and smoking the first cigarette of the day 
therefore provides information as to the degree of 
dependence of an individual, as it captures the degree of 
urgency with which a nicotine-deprived smoker needs to 
smoke (in other words, the severity of withdrawal). 
The first cigarette is therefore typically viewed by a 
dependent smoker as the 'best' cigarette of the day, as it 
leads to the release of the neurotransmitter dopamine to a 
greater degree than subsequent cigarettes.5 Over the course 
of the day, nicotine continues to be cleared rapidly, so the 
smoker needs to smoke frequently to maintain background 
levels of circulating nicotine and to stave off withdrawal 
symptoms. On sleeping, nicotine clears almost entirely from 
the body, as described above, and the cycle repeats. This 
illustrates the close degree of biological control that nicotine 
exerts over behaviour in regular smokers – in other words, 
dependent smokers smoke (largely) for the nicotine.5
The rapid delivery of nicotine to the brain when smoking a 
cigarette results in an acute spike in nicotine levels, which 
leads to strong associations being formed between the 
psychoactive effects of the drug and other cues present 
at the time, such as the sight of others smoking or other 
sensory aspects of smoking. These cues, over time, become 
triggers of drug-seeking behaviour themselves, and can 
precipitate relapse among abstinent smokers even after 
several months or years of abstinence.5
Smoking therefore follows a second order schedule of 
reinforcement.6 Initially, smoking a cigarette is reinforced 
by dopamine release, particularly in regions of the brain 
(eg the nucleus accumbens and ventral tegmental area) 
related to reward. Release of dopamine in these regions 
facilitates the establishment of associations with other cues 
present at the time, such as the smell and taste of smoke. 
These cues become conditioned reinforcers. Over time, 
only the first cigarette of the day (when circulating levels 
of nicotine are low) leads to the release of dopamine, while 
subsequent cigarettes do not (due to higher circulating levels 
of nicotine). However, smoking-related cues, as conditioned 
reinforcers, continue to drive behaviour even when smoking a 
cigarette does not lead to dopamine release (eg subsequent 
cigarettes over the course of a day).5
This is important for two reasons. First, the release 
of dopamine in the nucleus accumbens and ventral 
tegmental area is a common feature of many addictive 
drugs, including heroin, cocaine, alcohol, opiates and 
amphetamine, as well as nicotine. Second, second-order 
schedules of reinforcement (illustrated in the case of 
smoking in Fig 9.2) result in a very high rate of responding 
for the drug when conditioned stimuli such as smoking cues 
are presented.5
Fig 9.2 Smoking as a second order schedule of reinforcement.
Second order schedule of reinforcement
Raised blood nicotine
Low blood nicotine Increased  
dopamine release
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This understanding of the mechanism of addiction informs its 
assessment. Tobacco dependence and associated constructs 
such as craving are typically measured via self-reported 
behaviour. For example, the widely-used Fagerström Test of 
Nicotine Dependence (FTND) contains a number of items 
that are scored and summed to give a total score, with higher 
scores reflecting higher levels of dependence.7 The single item 
on the FTND that captures the most variance in total score 
is the first – how soon after waking the respondent smokes 
their first cigarette of the day.8 In other words, the sooner after 
waking the respondent smokes their first cigarette, the more 
likely they are to be dependent. 
This understanding of the mechanisms of nicotine 
dependence also explains, in part, the popularity of 
e-cigarettes. Unlike pharmaceutical nicotine replacement 
products, e-cigarettes, particularly later-generation devices 
deliver nicotine rapidly in a manner more similar to a 
cigarette.9 They also come closer to mimicking some of the 
conditioned stimuli associated with smoking, for example 
the hand-to-mouth motion and the sensation of inhalation.
Relapse to smoking following abstinence is high, again 
in common with other addictive drugs (relapse rates for 
smoking, alcohol and heroin are shown in Fig 9.3).6 This 
is partly due to the intensity of the withdrawal syndrome 
associated with abstinence, and partly to the ability of 
conditioned stimuli, such as being in a place where the 
individual previously smoked, or seeing someone else smoke 
a cigarette, to continue to elicit drug-seeking behaviour even 
after several months or even years of abstinence.5
There is therefore a complex interplay of biological and 
non-biological factors that influence smoking behaviour. 
In the short-term, behavioural support can enhance 
motivation to stop smoking, minimise motivation to return 
to smoking once an attempt to stop has been made, and 
help prevent any motivation to smoke translating into 
action.10 This is most effective when combined with one or 
more pharmacotherapies. 
However, while many effective treatments for smoking 
cessation exist (including pharmacological treatments 
and behavioural support), the persistence of conditioned 
associations means that cues to smoking can trigger 
cravings and relapse many years after stopping smoking. 
Relapse prevention over the longer-term is therefore 
challenging, and this contributes to declining rates of 
sustained abstinence over time. For this reason, many 
tobacco control policies focus on reducing the availability 
and visibility of smoking, to reduce these cues and de-
normalise smoking.
9.3 Triggering quit attempts 
For most people who smoke, quitting involves i) making 
a serious attempt to avoid smoking permanently and ii) 
successfully overcoming powerful urges to smoke over the 
subsequent days, weeks and even years that follow. The 
initiation of the attempt and the success once initiated are 
distinct processes, and are associated with different smoker 
and sociodemographic characteristics, and subject to 
policy and environmental influences. The following section 
focuses on quit attempts.
9.3.1 Trends in quit attempts in England
At a population level, the rate at which the 6.9 million 
people in the UK who smoke11 quit smoking is a key 
influence on smoking prevalence. The proportion of those 
who have smoked and made a quit attempt in the past 
year in England has declined from 42.5% in 2007 to less 
than 30% during 2018 and 2019 (Fig 9.4). The decline has 
been non-linear, with variation during this period at the 
annual and especially monthly level, although a marked 
rise of around 20% has been observed in quit attempts in 
2020, most likely influenced by health concerns related to 
the COVID-19 pandemic.12
Fig 9.3 Relapse rates over time for heroin, smoking and 
alcohol. Source: Hunt et al (1971), cited in Schindler6
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Fig 9.4 Proportion of quit attempts (and 95CIs) among past-year smokers in England between January 2007 and 
December 2019. 





























































































9.3.2 Influences on quit attempts at the 
population level
A recent time-series analysis attempted to quantify 
population-level associations between changes in the rate 
of monthly quit attempts and both smoker characteristics 
and a variety of tobacco control interventions between 
2007 and 2017 in England, using aggregated data from 
more than 50,000 past-year smokers.13 Increases in the 
prevalence of high motivation to quit (smokers reporting 
wanting to stop smoking and intending to in the next 
3 months) were associated with higher prevalence of 
attempts to quit smoking, while an increase in the mean 
age of smokers was associated with lower prevalence of 
quit attempts. The introduction of the partial point-of-sale 
tobacco display ban in 2012 appeared to have a temporary 
positive impact (a higher prevalence of quit attempts). 
A key implication is the need for intervention or policy to 
stimulate quit attempts in older smokers. 
In other analyses and evaluations, exposure to mass media 
campaigns and social marketing campaigns (see section 
3.3) have been consistently associated with population quit 
attempts.14–18 For example, since 2012, there has been an 
annual ‘Stoptober’ mass media campaign for collective 
smoking cessation in England during the month of October. 
Between 2012 and 2017 there was an increase in past-
month quit attempts during October compared with 
other months, which was not evident during the preceding 
2007-2011 period. The increase varied from year to year, 
and importantly appears to have been greater when the 
campaign budget was higher, increasing the ‘dose’ of 
marketing to which individual smokers were likely to have 
been exposed.19 
The rise in the use of e-cigarettes in England has been cited 
as a possible explanation for the national decline in quit 
attempts, with the suggestion that the wide availability 
of e-cigarettes has re-normalised smoking and depressed 
cessation.20,21 However, a closer inspection reveals that 
trajectories for quit attempts and the use of e-cigarettes 
are quite different, with e-cigarettes becoming especially 
popular around 2013 when quit attempts appeared to 
rebound temporarily (see Fig 9.4). Formal time-series 
analysis has found no evidence of a clear association 
between e-cigarette use and prevalence of quit attempts, 
suggesting their rise in popularity has not undermined 
attempts to stop.22
More recently, there has been urgent attention given 
to the possible impact of the COVID-19 pandemic on 
smoking. COVID-19 is a respiratory disease that has 
caused a significant global socio-economic shock. It may 
have stimulated quit attempts by providing a teachable 
moment that increases the salience of smoking-associated 
health risks. Early evidence from England suggests that the 
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onset of the first COVID-19 lockdown in March 2020 was 
associated with increases in the rate of quit attempts and 
cessation among past-year smokers.23
9.3.3 Influences on quit attempts at the  
individual level
In England, the five most commonly cited triggers among 
people who have smoked in the past year and attempted 
to stop are advice from a health professional, concern 
about future health problems, a decision that smoking 
was too expensive, comment by a close social connection 
and current health problems.24 Quit attempts prompted 
by health professional advice appear to be more likely to 
involve gradual reduction and use of treatments. Those 
prompted by health concerns and cost appear more likely 
to succeed.24 
Brief advice from a GP increases quit attempts compared 
with minimal or no intervention.25 The nature of the 
advice affects the likelihood of triggering a quit attempt: 
GPs are more effective in promoting quit attempts by 
opportunistically offering support to all smokers, rather 
than raising the topic but only offering advice and 
assistance to those who express an interest.26 There is 
evidence that advice without offer of support appears 
only to be associated with increased odds of making a 
quit attempt in smokers with greater socio-economic 
disadvantage.27
9.3.4 Policy priorities to increase quit attempts
Increasingly, there is welcome recognition that public 
health strategies need more focus on the population-level, 
or an upstream approach.28 However, an oversimplified 
argument which pitches upstream approaches against 
so-called individual-level or downstream approaches, or 
systems science against behavioural science should be 
avoided,29,30 as to do so may undermine individual agency 
and be interpreted as a reason for cutting funding from 
highly successful individual-level support services. Instead, 
an ambitious agenda is required that aims to influence 
multiple levels of the system. 
It is well understood that smoking prevalence is influenced 
by a large combination of general and specific biological, 
social and psychological factors interacting with current 
opportunities afforded by the social and physical 
environment. Figure 9.5 describes state transitions 
between never smoking, trying smoking, regular smoking, 
attempting to quit and ultimately successful quitting.31 
It is not a systems map but illustrates the wide range of 
influences on these transitions, and, in red, how different 
interventions simultaneously impact on several parts of the 
model. For example, increases in the cost of smoking create 
barriers to both experimentation and progression to regular 
smoking, and trigger quit attempts for a large proportion of 
people and remain a widely cited motive during the course 
of a quit attempt for maintaining resolve. 
Fig 9.5 Factors associated with transitions between smoking status (parentheses indicate negative associations). The red 
boxes and red arrows illustrate how different interventions have simultaneously impacted on several different transitions.31   
Based on an original figure © West 2017. Published by Informa UK Limited, trading as Taylor & Francis Group. Adapted with additional material. 
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Influencing the transitions between smoking status makes 
the case for policy to prioritise a comprehensive and 
dynamic approach which explicitly aims to simultaneously 
i) motivate quit attempts, ii) improve quit success and iii) 
reduce uptake. A comprehensive approach is evidence-
based, appreciates contributions from both behavioural 
and systems science, and is likely to go beyond additive 
effects, and to benefit instead from complex and 
unexpected synergies and feedback.32 We know that for 
many existing policies, such as mass media campaigns, 
provision of smoking cessation support and age restrictions, 
that greater evidence-based implementation produces 
larger effects.33 
9.4 Treatment of tobacco dependency in 
healthcare  
NHS healthcare in England is split into acute care, primary 
care, mental health and maternity services, while public 
health functions are led by local government. The 
responsibility for some public health functions may alter 
with the abolition of Public Health England in 2021. Each 
of these services represents a unique opportunity to treat 
a tobacco dependency that needs to be aligned with the 
needs of service users. In January 2019, the NHS Long 
Term Plan (NHS LTP) announced an ambition to treat 
tobacco dependency in acute care and mental health 
inpatients and maternity services on an opt-out basis by 
2023–24, the treatment of ‘high risk groups’ with mental 
health disorder in outpatient settings; and treatment for 
NHS staff who smoke. The investment in treating NHS 
patients for tobacco dependency is in addition to ongoing 
local government funding of tobacco control and smoking 
cessation services.34
9.4.1 Treatment in hospitals
Acute care hospital trusts provide a highly concentrated 
population of smokers due to smoking related illnesses, 
with people who smoke over 30% more likely to be 
admitted than non-smokers.35 Despite the declining 
smoking prevalence in the general population, sequential 
national audits of smoking in hospital admissions in 2016 
and 2019 show a persistently high prevalence of smokers 
in acute hospital admissions in the UK at 25% and 24% 
respectively.36,37
There is growing evidence that hospital-based interventions 
provide highly cost-effective outcomes. The Ottawa 
Model of Smoking Cessation (OMSC) provides an 
exemplar of hospital-based tobacco addiction treatment 
demonstrating immediate benefits for smokers that stop 
smoking at the point of a hospital admission.38 The OMSC 
consists of systematic screening of hospital admissions to 
identify current smokers, and an opt-out bedside review 
with a trained practitioner who completes a standardised 
assessment form, recommends pharmacotherapy for the 
inpatient stay and post-discharge based on a standardised 
protocol, provides brief counselling and registers the patient 
with an automated voice recognition follow-up service. This 
follow-up service provides 8 phone calls over 6 months, with 
relapse or low motivation triggering a telephone call from 
a trained practitioner for further support. In the Ottawa 
study a control group of 641 inpatient smokers recruited 
prior to implementation of the OMSC were compared to 
an intervention group of 726 inpatient smokers that were 
treated by the OMSC pathway following implementation 
(after the first 2 months of implementation). The study 
reported a reduction in readmission rates from 38.4% to 
26.7% and a halving of 12-month mortality from 11.4% to 
5.4% in the intervention group compared with the control 
group. Using the risk reductions seen in the Ottawa study, 
it is estimated that implementing a comprehensive opt-out 
tobacco addiction treatment service across NHS secondary 
care in England, would save the NHS approximately £60 
million within 1 year.39 Individual localities have also 
estimated the impact on their local healthcare system to 
support the piloting and commissioning of such services. 
In one study, applying the risk reduction seen in the 
OMSC study to the city of Manchester would result in an 
additional 3,503 patients successfully stopping smoking per 
year, 1,171 readmissions prevented, and 601 lives saved per 
year. For Manchester the estimated healthcare cost savings 
were £1,884,139 per year, and numbers needed to treat 
(NNT) were nine patients to prevent one admission and 17 
patients to prevent one death at 1 year.40
The CURE project (conversation, understand, replace, 
expert and evidence-based treatments) in Manchester 
is the first reported evaluation of the feasibility, uptake 
and impact of a comprehensive smoking ascertainment 
and treatment pilot, based on the Ottawa model, in a UK 
acute medical treatment setting.41 This 6-month pilot at 
a single acute hospital demonstrated that introducing 
the CURE model of systematic stop smoking support 
is feasible, with 92% of adult admissions screened for 
smoking status and 2,393 smokers identified, of whom 
96% were provided with brief advice and 66% prescribed 
cessation pharmacotherapy. A significant component of 
pharmacotherapy was prescribed by frontline clinicians 
utilising a standardised prescribing protocol. Inpatient 
counselling and behavioural interventions with a specialist 
cessation practitioner were completed by 61%; 49% 
completed follow up at 4 weeks and 33% at 12 weeks. The 
intention to treat quit rate at 12 weeks was 22% (Table 9.1) 
at a cost of £183 per quit. 
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This quit rate suggests that if implemented nationally, 
this service model could generate more than 200,000 
successful quits among the more than one million 
smokers admitted to hospitals in England each year.35 
This represents a highly cost-effective intervention and a 
significant return on investment. The RCP estimated that 
implementing comprehensive opt-out tobacco addiction 
treatment services across NHS secondary care would save 
the NHS approximately £60 million within 1 year,39 but this 
estimate was based on uptake of treatment by 27% of 
smokers. In the CURE pilot 61% engaged with the service 
suggesting the NHS savings may be substantially higher. 
The uptake and intention to treat quit rate in the CURE 
pilot compares favourably to published data (Table 9.2). 
Table 9.1 Uptake and impact of the CURE pilot intervention during inpatient admission and follow-up after discharge 
*Quit rate in those patients completing the follow-up assessment and smoking status recorded 
**Quit rate as a proportion of all smokers admitted during the pilot assuming all lost to follow-up have relapsed/continued 
to smoke (intention to treat basis)
Table 9.2 Summary of published outcomes for hospital-based tobacco addiction treatment services
Total number % of all smokers Number of quits Quit rate* 
(% with FU data)
Quit rate** 
(% of all smokers)
All smokers  2,393 100% - - -
Completion of inpatient 
CURE assessment and 
treatment  
1,450 61% - - -
Completion of 2-week 
follow up post-discharge 
1,105 46% - - -
Completion of 4-week 
follow up post-discharge 
1,179 49% 495 42% 21%
Completion of 12-week 
follow up post-discharge 
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9.4.2 Treating pregnant women who smoke
In addition to harming women, smoking in pregnancy is 
associated with increased risks of miscarriage, stillbirth, 
prematurity, low birth weight (LBW), perinatal, neonatal 
and sudden infant death, and poorer infant cognition 
and behavioural outcomes.45–47 Children who live with 
parents who smoke are much more likely to become 
smokers themselves48,49 and when women stop smoking in 
pregnancy this reduces the incidence of low birth weight 
births and neonatal special care admissions.50 Smoking in 
pregnancy is costly for the NHS; on average, until 5 years 
of age, children born to women who smoke cost the NHS 
an extra £222 each (95% CI £17.78–425.83), a UK total 
of £23.3 million (95% CI £1.9–44.7 million).51 Hence, 
permanent cessation by pregnant women benefits them, 
their offspring and families and wider society.  
Smoking in pregnancy is also a major international public 
health problem, with prevalence ranging from 13% to 
25% in high-income countries52–55 and a similar epidemic 
is developing in low- and middle-income countries.56 In 
England in 2017/8, 11% of women smoked at childbirth 
with rates highest in economically deprived areas (the 
highest being Blackpool at 26%), and in England and 
Wales around 94,600 fetuses are exposed to smoking in 
pregnancy annually.57 Pregnancy is probably the most 
motivational life event for encouraging people to try 
stopping smoking; 57% of women who smoked either 
just before or in early pregnancy make a spontaneous 
quit attempt and by the end of pregnancy around 40% 
have stopped.58 Unfortunately, many quitters relapse after 
their child is born; by 3 months approximately 25% of 
spontaneous quitters re-start smoking58 and by 6 months, 
even 46% of those who stopped smoking in pregnancy 
after using cessation support will re-start.59 Health systems, 
therefore, need both to capitalise on pregnant women’s 
motivation to quit by supporting as many as possible to 
succeed, and to prevent smoking relapse after childbirth.
Offering help to pregnant women who smoke is crucially 
important.  In the UK, 2010 NICE guidance PH26,60 which is 
currently being updated, recommends three key principles 
in treating pregnant women who smoke:
 >  engagement – of all pregnant women to identify 
those who smoke
 >  referral – as a default for all women identified as 
smoking
 >  support – for those referred who accept this.
More recently, in 2018 the National Centre for Smoking 
Cessation Training, which is responsible for the quality of 
smoking cessation support provided in the UK, published 
the Standard Treatment Programme for Smoking in 
Pregnancy (STP).61 This clearly delineates how NHS 
providers should support pregnant women who smoke; 
‘standard treatment’ begins in antenatal care settings 
when health professionals engage with all pregnant 
women by asking them to provide exhaled carbon 
monoxide (CO) readings. For this, pregnant women blow 
into a CO monitor and those who have readings of greater 
than 4ppm are referred for smoking cessation support 
unless they specifically decline. Some women who do not 
smoke may still have high expired air CO concentrations; 
such women are unlikely to accept referral for stop 
smoking support and sensitive discussion of potential 
environmental sources of CO such as car or boiler exhaust 
fumes is important. ‘Opt-out’ referrals are readily accepted 
by women undergoing antenatal care62 and double the 
proportions of pregnant women who receive cessation 
support63 and quit smoking.63,64
Both NICE60 and the 2017 Tobacco Control Plan for 
England65 recommend that ‘opt-out’ referrals are offered 
to all women who attend for antenatal care. Ideally, this 
approach should be sensitively applied at all antenatal 
care pathway appointments because, women’s interest 
in cessation support persists throughout pregnancy66 and 
even very organised, early pregnancy referral processes 
may fail to refer substantial numbers of women.63 ‘Opt-out’ 
referrals for smoking cessation support are a key feature of 
the NHS ‘Saving Babies’ Lives’ care bundle for preventing 
stillbirth,67 which defines components of standard 
antenatal care required to reduce stillbirth rates. Smoking 
in pregnancy is strongly associated with stillbirth68 so, using 
a systematic approach to identify women who smoke 
and to support them in stopping is vital to this process. 
Implementation of this care bundle throughout England is 
estimated to have prevented 600 stillbirths annually.69
After successful referral, concerns for the safety of 
medicines in pregnancy limit pregnant women’s available 
treatment options to behavioural support (counselling-
based interventions);50 nicotine replacement therapy 
(NRT);70 self-help71 and cessation-contingent financial 
incentives.50 Of these, intensive behavioural support 
has the strongest evidence base (from 54 randomised 
controlled trials (RCTs)) and increases smoking cessation 
in late pregnancy compared with usual care (average 
risk ratio (RR) 1.44, 95% confidence interval (CI) 1.19 to 
1.73).50 NRT also seems effective; from nine RCTs in 2,336 
women there is low-certainty evidence that NRT increases 
the likelihood of smoking abstinence in later pregnancy 
(RR 1.37, 95% CI 1.08 to 1.74).70 Twelve trials of self-help 
interventions suggest a pooled odds ratio in favour of 
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these promoting cessation of 1.83 (95% CI 1.23-2.73).  
However, to use self-help effectively requires motivation so, 
these interventions may not be appropriate for all women. 
Cessation-contingent financial incentives are a promising 
approach,50 these can help non-pregnant smokers to quit72 
and there is high quality evidence that they are effective 
in pregnancy.50 However, one RCT has investigated the 
impact of incentives as an adjunct to usual care, as these 
might be used in everyday clinical practice.73 This study 
recorded an unusually large intervention effect; 13.9% 
higher quit rates in women offered incentives and the 
relative risk of not smoking at the end of pregnancy was 
2.63 (95% CI 1.73 to 4.01). It was conducted in a single 
stop smoking service and an ongoing trial is attempting to 
replicate findings in multiple settings.74
Clearly, optimal management of smoking in pregnancy 
relies on the NHS making effective cessation treatments 
accessible to pregnant women. Historically, NHS funds 
were specifically hypothecated to help pregnant women 
to stop smoking and in 2011, 79% (121/152) of English 
NHS primary care trusts reported commissioning cessation 
support specifically for pregnant women.75 In 2013, 
protection for smoking cessation budgets ended when local 
authorities (LAs) assumed public health responsibilities 
and LAs began commissioning cessation support in the 
context of substantial austerity. In 2015, only 47.3% 
(72/152) of LAs reported providing stop smoking support 
for pregnant women.76 This decline in available support for 
pregnant women is likely to be the key factor underpinning 
a 57% reduction in the number of pregnant women in 
England who stop smoking with stop smoking services 
(SSS) support annually, from 6,857 in 2011/2 to 3,887 in 
2018/9. However, the 2019 NHS Long Term Plan promises 
smoking cessation support for all pregnant women,77 so a 
proliferation of NHS-provided cessation support is likely. It is 
vital for public health that both NHS and local authority SSS 
are sufficiently maintained and all pregnant women who 
need or want cessation support can receive this.
9.4.3 Treating smoking in people with mental illness 
9.4.3.1 Smoking and mental illness: the need for effective 
interventions
Smoking is a major contributor to health inequalities 
and disparities in life expectancy between people with 
and without a mental health condition.78 An estimated 
12 years of life lost prematurely for women and 16 years 
for men have been attributed to the consequences of 
smoking in people with a mental health condition.79 The 
links between smoking and mental illness are complex 
and include neurobiological, psychosocial and genetic 
factors, not all of which are understood in their entirety.80 
Smoking prevalence and heaviness of tobacco dependency 
are markedly higher in people with a mental illness than 
in those without,78 and although evidence from a UK 
population-level study79 indicates a downward trend in 
prevalence over the last decades (from 44.6% in 1993 to 
34.1% in 2014 in people with a mental health condition, 
compared to 29.3% to 19.6% in those without), smoking 
rates remain approximately 50% higher in this group than 
in the general population. In those with severe mental 
illness (SMI), such as schizophrenia, smoking prevalence 
can reach over 70%.81 In view of major and increasing 
tobacco-related inequalities, the urgency to provide and 
promote effective interventions to treat smoking in people 
with a mental health condition has been recognised in 
UK national policies and guidelines.78,82–84 This subchapter 
summarises the evidence relating to safe and effective 
smoking cessation interventions for people with a mental 
health condition and briefly discusses common barriers to 
addressing smoking in mental health settings. 
9.4.3.2 Treating tobacco dependency in people with a 
mental health condition: perceptions vs evidence
Due to the historic smoking culture in mental health 
disorders85 and other complexities involved in the links 
between smoking and mental illness, there are common 
and persistent misconceptions that people with a mental 
health condition ‘don’t want to quit smoking’, that 
evidence-based smoking cessation treatments used in 
the general population ‘do not work’ for them, or indeed 
that stopping smoking ‘exacerbates mental health 
conditions’.78,85,86 None of these perceptions is supported by 
the evidence. 
A 2017 systematic review87 of 26 trials of pharmacological 
and behavioural interventions for smoking cessation for 
people with SMI concluded that, in line with an earlier 
systematic review,88 people with SMI can successfully quit 
smoking using the same interventions (NRT, bupropion and 
varenicline, combined with behavioural support) shown 
to be effective for the general population. Although it 
was acknowledged that smoking cessation studies in this 
population were sometimes underpowered and generally 
had a high or unclear risk of bias, it was evident that people 
with SMI are willing and able to quit smoking. A lack of 
research on electronic cigarettes for smoking cessation, 
shown to be effective in the general population89 and 
identified as promising for people with a mental health 
condition,90 was identified. Findings from this systematic 
review are in line with results from a subsequent large 
randomised controlled trial evaluating the neuropsychiatric 
safety and efficacy of varenicline, bupropion and nicotine 
patches,91 which included over 8,144 participants with 
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and without common mental health conditions (eg 
depression, anxiety) and SMI in 16 countries and 140 study 
centres. The trial demonstrated that varenicline was more 
effective than placebo, nicotine patch, and bupropion in 
helping smokers quit in both study groups. Comparison of 
treatment efficacy was reported not to differ statistically 
between mental health and non-mental health cohorts. An 
analysis of population-level trends of smoking and quitting 
behaviours in the UK79 supports the above findings, albeit 
limited to common mental health conditions. It included 
several waves of population sample survey data, ranging 
from 7,402 to 10,108 participants per wave. Although the 
odds of successful smoking cessation were significantly 
lower among people with any mental health condition 
in unadjusted analysis, the association was no longer 
significant after adjustment for heavy smoking (0.82, 
95% CI 0.55 to 1.22, p=.317). Importantly, people with a 
common mental health condition were found to be more 
likely to report a desire to quit smoking than those without. 
Varenicline, bupropion and NRT are safe for people with 
a mental health condition.87,91 This counters perceptions 
which are being actively discouraged by the Royal College 
of Psychiatrists90 but are still persistent, that varenicline 
may be contraindicated in this group. Furthermore, in the 
systematic review studies participants’ mental health 
condition did not worsen following smoking cessation,87 
as is still commonly assumed to occur. In view of the 
continuing reluctance of mental health professionals to 
address smoking in their patients92,93 often because of 
concerns over safety, this is an important finding. In fact, a 
systematic review and meta-analysis of longitudinal studies 
of smoking cessation in healthy and clinical populations 
concluded that smoking cessation is associated with 
reduced depression, anxiety and stress, and improved 
positive mood and quality of life compared with continuing 
smoking,94 while a Mendelian randomisation study (a 
research method that provides evidence about putative 
causal relations between modifiable risk factors and 
disease, using genetic variants as natural experiments) 
found evidence that smoking can be causally involved 
in the development of depression or schizophrenia.95 A 
Cochrane review96 to investigate the association between 
smoking cessation and subsequent mental health outcome 
using secondary analysis of trial data is underway. 
9.4.3.3 Tailoring smoking cessation interventions for people 
with SMI
Notwithstanding the evidence that smoking cessation 
treatments recommended for the general population work 
and should be routinely provided for people with a mental 
health condition,83 recommendations for developing 
tailored interventions that address particular needs in 
this population, especially those with SMI, exist.84 There 
is evidence from a prospective cohort study97 using data 
from 654 general practices in England from 2006 onwards 
that smoking cessation prescribing for patients with mental 
health conditions may be declining, and it is recognised 
that people with SMI are less likely than people without 
to access local Stop Smoking Services.98,99 Qualitative 
evidence100 indicates that these services can be perceived 
to be inappropriate by people with SMI, who often do not 
feel adequately supported by smoking cessation advisors 
without mental health training. Another important aspect 
in considering the need for tailored smoking cessation 
interventions for people with SMI is the need to adjust the 
dosage of certain antipsychotic medications (eg clozapine) 
following cessation,78 as drug metabolism decelerates 
when people quit, which can result in toxic blood levels 
of certain medications101 and requires monitoring. The 
evidence related to the development and evaluation of 
bespoke smoking cessation interventions for people with 
SMI is still developing. 
In the UK, the SCIMITAR+ trial102 included 526 patients 
with a documented diagnosis of schizophrenia, delusional 
or psychotic disorder and randomised them to a bespoke 
smoking cessation intervention for people with mental 
illness or usual care. The intervention was based on 
standard pharmacological and behavioural smoking 
cessation support, as recommended by the National Centre 
for Smoking Cessation and Training (NCSCT), and delivered 
by smoking cessation practitioners with mental health 
backgrounds. Adaptations to cater for the needs of people 
with SMI included making several assessments before 
setting a quit date, offering nicotine replacement before 
setting a quit date (ie, ‘cut down to quit’), recognising the 
purpose of smoking in the context of a person’s mental 
illness, providing home visits, providing additional face-to-
face support after an unsuccessful quit attempt or relapse, 
and informing the primary care physician and psychiatrist 
of a successful quit attempt, such that they could review 
doses of antipsychotic medication if metabolism changed 
following cessation. Results demonstrated notably higher 
levels of engagement with the bespoke intervention than 
with usual care. The proportion of participants who quit at 
6 months was significantly higher in the intervention group 
than in the usual care group (32 [14%] of 226 vs 14 [6%] 
of 217; odds ratio (OR) 2.4, 95% CI 1.2 to 4.6; p=0.010), 
though at 12 months this difference was not significant 
(34 [15%] of 223 vs 22 [10%] of 219; OR 1.6, 95% CI 0.9 
to 2.9; p=0·10). Health economic analyses showed that the 
intervention was cost-effective.103 The authors concluded 
that the SCIMITAR+ intervention could serve as a model 
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of bespoke smoking cessation support for people with SMI 
and acknowledge that further research to address the lack 
of long term effectiveness should be undertaken. 
Important steps to ensure that smokers with a mental 
health condition are appropriately supported in the future 
have been taken, both in terms of national policies (see 
also chapter 6.4) and emerging research. Recognising 
and effectively tackling barriers, including prevailing 
misconceptions by health professionals and gaps in the 
evidence (eg further tailoring of behavioural intervention 
content relevant to SMI and smoking; electronic cigarettes 
for smoking cessation in SMI; relapse prevention), will be 
crucial to ensuring further progress. This is particularly 
pertinent in light of the COVID-19 pandemic, as having 
a SMI presents a risk factor for experiencing a new set 
of emerging inequalities in addition to existing ones,104 
including those related to COVID-19 and smoking.105,106   
9.4.5 Smoking among the lesbian, gay, bisexual, 
and transgender community 
In the UK, smoking prevalence is higher among lesbian, gay, 
and bisexual people (LGB) than in the general population. 
The most recent available data from the Annual Population 
Survey107 indicate that smoking prevalence in England in 
2018 was around 1.4 times higher among people who 
identified as gay or lesbian (21.9%) and 1.3 times higher 
among those who identified as bisexual (19.7%) than in 
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Fig 9.6 Current smoking prevalence in adults (18+ years) in England by sexual orientation, 2014-2018.107 
© Annual Population Survey
© Royal College of Physicians 2021
9      Treatment of tobacco addiction
120
There are currently limited data (particularly in the UK) 
on smoking prevalence in trans and non-binary people. 
This failing should improve in the future: there is a project 
to harmonise and improve data collection on sex, gender 
identity and sexual orientation across government 
statistical services in the UK ahead of the 2021 census.108,109 
The data that do exist suggest that these groups are also 
more likely to smoke than cisgender people.110,111 On this 
basis, NICE guidelines published in 2018 identified lesbian, 
gay, bisexual and transgender (LGBT) people as a priority 
for smoking cessation initiatives and services.112
Recent evidence113–115 has shown a narrowing in the 
smoking prevalence gap between the general population 
and some (but not all) LGB groups. However, this has 
not consistently been observed across surveys.116 While 
LGB people are more likely than heterosexual people 
to smoke, both groups appear to be equally motivated 
to stop smoking or likely to make a quit attempt113 and 
differences in smoking rates may in part be due to other 
sociodemographic confounders associated with sexual 
orientation/gender identity.115
9.4.5.1 Barriers to cessation
There are several factors that may contribute to higher 
smoking prevalence and make cessation more difficult 
among sexual minority groups. 
9.4.5.1.1 Discrimination and mental health
Many smokers mistakenly believe that smoking helps to 
relieve stress and report smoking as a means of coping with 
high levels of stress.117,118 For some LGBT people, smoking 
may be a mechanism for coping with ‘minority stress’ caused 
by exposure to prejudice, discrimination, harassment, and 
victimisation.119,120 Homophobia, biphobia, and transphobia 
remain prevalent in schools, the workplace, and healthcare 
services. Quitting smoking may be more difficult, or less of a 
priority, for LGBT people in this context.
LGBT people are disproportionately more likely to 
experience poor mental health due to social pressures 
and prejudices.121 Smoking prevalence among the general 
population with common mental health conditions remains 
around 50% higher than among those without, despite 
their higher desire to quit.122
9.4.5.1.2 Social influence
Smoking is a socially contagious behaviour and is 
initiated and maintained through social networks.123 
For many LGBT people, safe places for social gathering 
have traditionally been bars and similar establishments 
where there is a culture of smoking.124 Because of this, the 
introduction of smoke-free legislation in 2007 may have 
had a disproportionate benefit for this group, resulting in a 
decrease in smoking disparities.113 However, given the high 
levels of social exclusion experienced by sexual minority 
groups, it is also plausible that smoking persists due to fear of 
exclusion from the social group if the behaviour stopped.125,126
9.4.5.1.3 Industry interference 
LGBT smoking has been encouraged by decades of 
targeted marketing from the tobacco industry, with 
companies investing heavily in the promotion and 
depiction of smoking in LGBT media. Other techniques 
have included sponsorship of pride events, silencing 
boycotts with large pay-outs, and giving away free 
cigarettes in LGBT venues.127,128
9.4.5.1.4 Intersectionality with other high-risk  
smoking groups
Those who identify as LGBT are also more likely to belong to 
other groups with higher smoking rates. As mentioned above, 
LGBT people are more likely than heterosexual or cisgender 
people to have mental health problems. They are also more 
likely to be single,129 socio-economically disadvantaged,130 and 
more likely to experience homelessness,131 all of which are 
associated with higher smoking prevalence.
9.4.5.1.5 Engagement in other health-harming behaviours
LGBT people are also more likely than non-LGBT people 
to engage in other health-risk behaviours associated with 
increased risk of smoking, including excessive alcohol use and 
dependence on controlled substances.115,132 There is evidence 
these behaviours are linked to use of LGBT social spaces,133 
echoing the importance of social influence outlined above.
9.4.5.1.6 Difficulty accessing services
LGBT people also face problems accessing health services. 
In January 2016, a report by the Women and Equalities 
Select Committee into ‘transgender equality’ concluded 
that ‘the NHS is letting down trans people’, noting a 
number of areas such as a lack of staff training around 
gender identity and a failure to combat transphobia.134 This 
sentiment is echoed throughout LGBT patient experience 
research which has repeatedly identified sexual orientation 
as a reason for delaying access to services.121 
GP advice to quit smoking is received by more than 
half of smokers visiting their practice in the past year 
and motivates quit attempts.135 Behavioural support 
can increase the likelihood that a quit attempt will be 
successful,136,137 so it is vital that LGBT people feel able to 
access GP and stop smoking services and feel supported 
when they do so. The evidence suggests however that 
among LGBT people this is not always the case.121
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Coming out to healthcare professionals appears to be 
beneficial. One in five LGBT people is not ‘out’ to any 
healthcare professional about their sexual orientation 
when seeking general medical care.121 Across all primary 
care services, the needs of LGBT people are more likely to 
be met when they disclose their sexual orientation and/or 
trans status to their healthcare professionals.138
However, the 2017 LGBT Patient Survey found that only 
53% of LGB people had a positive response to disclosing 
their sexual orientation, while only 44% of trans people 
had a positive response to disclosing their trans status, to 
a healthcare professional.138 A substantial minority (18%) 
of trans people report avoiding medical treatment due to 
fears of insensitivity, misgendering (being referred to as the 
incorrect gender), and discrimination.139
9.4.5.2 Strategies for boosting quit rates
9.4.5.2.1 Making services welcoming for LGBT people
When a service is designed for everyone, it does not 
necessarily cater to the specific needs of every user group. 
As such, services for all smokers may not appeal to LGBT 
smokers. Discrimination or a lack of understanding of LGBT 
issues could prevent a smoker from accessing or returning 
to a service.
It is likely that most LGBT people do not need an LGBT-
specific smoking cessation service. Rather, they need 
the mainstream service to be a safe place for them to 
be themselves, without fear of discrimination, being 
misgendered, or having to explain or justify their identity. 
This potential can be reduced by having staff trained 
in LGBT awareness and providing visible signs of LGBT 
acceptance within services and more broadly in campaigns 
and health initiatives.
There are many simple steps that can be taken to make a 
service visibly LGBT friendly:
 >  displaying LGBT posters and literature in GP receptions, 
pharmacies, etc 
 >  healthcare professionals wearing rainbow lanyards
 >  appropriate posters signposting to LGBT support (as you 
would for carers, or people with mental health conditions)
 >  including LGBT people in campaign communications
 >  amending registration and health forms to ask 
appropriately about sex, gender, and sexual orientation
 >  for events, providing labels that give people the 
chance to share their preferred pronouns (she/her, he/
him, they/them) alongside their name.
It is also important to create an accepting atmosphere by 
ensuring that staff have a relaxed and welcoming attitude 
and avoid assumptions that everyone is heterosexual or 
cisgender (eg assuming that all service users will have 
opposite-sex partners). These simple steps to inclusion can 
act as marks of acceptance, improve engagement with 
services, and boost confidence in service users by breaking 
down perceived barriers.140
9.4.5.2.2 Engaging in LGBT outreach activities
Above and beyond making services LGBT friendly, there 
are other things that can be done to proactively target 
LGBT smokers and offer them the support they need to 
quit. These include working with local LGBT organisations 
to reach the local LGBT community, and working with the 
local LGBT community to embed smoke-free spaces in 
events and festivals (eg prides) and recruit LGBT people 
to stop smoking services. A recent publication by Action 
on Smoking and Health141 provides examples of good 
practice at a local level. For instance, Greater Manchester 
has engaged with local tobacco alliances and tobacco 
control teams to ensure LGBT inequality is a standing item 
on their agendas to raise awareness among policymakers 
and promote action. Another region, Calderdale, working as 
part of Yorkshire Smokefree, has developed a relationship 
with a charity that supports local LGBT people to improve 
co-production and knowledge exchange. Examples of 
their activity include training designated charity staff 
as stop smoking advisors and the charity supporting 
national stop smoking campaigns (eg ‘No Smoking Day’ 
and ‘Stoptober’) to extend the reach of stop smoking 
support to communities who may not access, or look for 
information about, generic stop smoking services.
9.4.5.2.3 Regular monitoring of smoking and quit advice in 
LGBT-focused healthcare provision
Healthcare services that serve members of the LGBT 
community (eg LGBT health centres, HIV clinics) should 
monitor service users’ smoking status and be able to 
direct smokers to appropriate cessation support. Training 
healthcare professionals working in these settings to deliver 
brief advice on smoking could provide an effective, time- 
and resource-efficient intervention142 to LGBT smokers who 
may not otherwise seek professional support for quitting.
9.4.5.2.4 Sexual orientation and trans status monitoring
In terms of evaluation, evidence on the LGBT population 
has traditionally been limited by a lack of routine 
monitoring of sexual orientation in public services.143 The 
Sexual Orientation Monitoring Information Standard 
provides a standardised format for recording the sexual 
orientation of patients/service users.144 Monitoring sexual 
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orientation and trans status is important because it enables 
health and social care bodies to understand the needs 
of the local population better and target services more 
effectively and efficiently. There is a lack of evidence about 
the needs and experiences of LGBT people in general, and 
of trans people in particular. 
Monitoring, correctly implemented, is the best way to 
address this lack of evidence and ensure LGBT people’s 
needs and experiences are heard. Monitoring also gives the 
patient or service user a safe and familiar way to disclose 
their identity. At present, other characteristics such as 
age, ethnicity, and marital status are monitored routinely. 
Additional questions around sexual orientation and trans 
status can be easily integrated into existing demographic 
forms for the purpose of compliance with the Equality Act 
2010 and the Public Sector Equality Duty.
9.4.5.3 Special considerations for subgroups of 
LGBT people who smoke
In providing cessation support to LGBT smokers, certain 
considerations may be relevant for women, trans people, 
and people living with HIV.
9.4.5.3.1 Women
There is some evidence that differences in health-risk 
behaviour between sexual minority and heterosexual 
people are more pronounced in women than men,115,145 
which suggests that other gender-specific influences may 
be implicated. It may be an expression of gender non-
conformity for some LGB women looking to break the 
stereotype that women are less likely to smoke than men.146 
It may also reflect the fact that LGB women are more likely 
than men to experience multiple forms of minority stress,147 
which may increase their propensity to engage in risky 
health behaviours as a coping mechanism. Gender-specific 
tailoring of health messages could help to reduce smoking 
disparities between LGB men and women.
9.4.5.3.2 Trans people
Self-identification is all that is required to be trans, but 
many trans people also seek hormone replacement 
therapy (HRT) as part of their transition process. For 
these people, smoking cessation is particularly important 
because concurrent smoking and hormone use generates 
substantial health risks.148 In the case of trans women 
taking HRT, tobacco use may also reduce the efficacy of 
their treatment. Trans people wishing to undergo gender 
affirming surgery should also be aware of the significant 
risks of smoking during and after any surgery. In general, 
smokers are 30% more likely to die after any surgery and 
more likely to experience major complications such as 
wound infection149 and cardiovascular events.150 Preoperative 
smoking cessation interventions can improve short-term 
cessation and lead to significant health benefits.151
9.4.5.3.3 People living with HIV
Gay, bisexual, and other men who have sex with men are 
the population most affected by HIV. There are higher 
levels of smoking among people with HIV than in the 
general population.152 With modern anti-viral treatment 
regimes, smoking has a much greater impact on life 
expectancy than HIV infection – but the two conditions 
combine to threaten the health of HIV positive smokers.153 
Caution should be taken when prescribing bupropion 
(Zyban) to someone on anti-HIV drugs due to the way the 
two drugs interact.154 Anti-HIV drugs can reduce the level 
of bupropion in the blood and may require a much higher 
dosage to be effective; NICE guidance is to start bupropion 
at the recommended dose and titrate as required.155
9.5 Primary care 
Almost all clinicians will see patients who smoke under 
their care, and current national guidelines recommend that 
clinicians make brief opportunistic interventions to promote 
smoking cessation.156,157 Patients rarely ask clinicians directly 
for help to stop smoking; rather, clinicians raise this, typically 
at the end of a consultation, where they opportunistically 
offer advice or help to stop smoking. All clinicians are 
advised to do this, however, GPs in particular are often seen 
as best placed as they typically have credibility and are well 
trusted by patients. 
9.5.1 Evidence for the effectiveness of 
opportunistic brief interventions
The Cochrane review, Physician advice for smoking cessation, 
grades the evidence as strong that physicians can support 
people to stop smoking – patients who receive advice of 
some form are more likely to stop smoking than those who 
receive no such advice.158 People who stop smoking are at 
substantially lower risks of heart disease in the short term 
and other diseases over the longer term 159 and therefore 
the costs of GP time spent on advice are outweighed by 
the savings that accrue in reduced healthcare costs in the 
medium and long term.160 Thus, it would be rational for any 
clinician heeding this evidence to undertake opportunistic 
interventions to support smoking cessation on every possible 
occasion. Clinicians do not do so, however.
A systematic review aimed to determine what clinicians 
should do during a brief opportunistic intervention 
by reviewing all the opportunistic interventions in the 
Cochrane review described above.26 Some trials randomised 
participants to advice to stop smoking or advice to stop 
smoking plus offering support in achieving abstinence. 
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Offering support led to more participants attempting to 
stop, implying that simply offering support is a motivational 
strategy in itself. Since then, UK policy has adopted an 
approach to opportunistic interventions known as the 3As– 
ask, advise, act. In consultation recordings, however, there 
were no interventions that resembled this sequence.161
9.5.2 The frequency and content of opportunistic 
brief interventions
One common source of data on the occurrence of brief 
interventions is to ask practitioners about what they do, 
how often, and what the prompts are to act or factors 
that demotivate clinicians from doing so. Cancer Research 
UK (CRUK) commissioned such a survey in 2017, including 
1,000 GPs and 1,000 practice nurses.162 Responses between 
the two groups were similar. UK guidance for making 
brief interventions focuses on three actions: asking about 
smoking status, advising on the best way to quit smoking, 
and acting on the response, for example by prescribing or 
offering to refer the patient to a stop smoking service. A total 
of 84% of clinicians reported asking people ‘frequently’ or 
‘always’ about their smoking. A further 87% reported that 
they advised people about smoking frequently or always, 
while 64% acted frequently or always by offering a referral 
or prescribing medication. Self-reported adherence to 
guidelines may overestimate the true frequency with which 
clinicians deliver brief interventions.
Another data source comes from asking people who 
smoke how often GPs speak to them about smoking. The 
best data for this comes from the Smoking Toolkit Study 
(STS), conducted in England.12 Around 30% of smokers 
report receiving any kind of advice on smoking, 20% 
are offered any kind of support, 10% offered referral to 
the stop smoking services, with 5% offered prescription 
medication and only a small number advised to use an 
e-cigarette.27 The prevalence has not changed much over 
time (Fig 9.7). A prior report from the STS suggests the rate 
of intervention has been much the same since 2010. In 
the STS, around two-thirds of people that smoke reported 
visiting the GP each year, thus less than half of everyone 
who smokes and visits a GP receives any advice on smoking. 
On average, people make about five visits a year to their 
GP.163 This would imply that GPs offer smoking advice on 
about one in 10 consultations with people that smoke. It 
is plausible that patients forget receiving advice, so this 
may underestimate the frequency, however CRUK and 
STS data suggest there is a large gap between practitioner 
and patient recall of being offered opportunistic brief 
interventions.
Fig 9.7 Prevalence of receipt of GP advice and support on smoking by past-year smokers in England (2016–2019).27  
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Another method to estimate the frequency of advice, and 
probably the most accurate, is to record consultations. 
In a currently unpublished study, Wheat and colleagues 
examined recorded consultations from the 'One in a 
million' study and the 'Harnessing resources from the 
internet to maximise outcomes from GP consultations 
(HaRI)' study, which recorded consultations completely 
unrelated to smoking.164,165 Five-hundred and nineteen 
adults were included in the study and the true prevalence 
of smoking among these participants was unknown. 
Smoking was discussed in 31 consultations. Assuming a 
smoking prevalence of just under 20%, that represents 
30% of consultations with people who smoke. Typically, 
smoking was raised in the history section of the 
consultation when it was epidemiologically relevant. 
Doctors advised patients about their smoking in 9% of 
consultations with people who smoked and offered some 
kind of support to stop smoking in 18% of consultations. 
Although these methods of estimating the prevalence of 
brief interventions differ, they imply that brief interventions 
are a lot less frequent than guidelines and policy suggests 
they should be. Moreover, there is no evidence that the 
policy initiatives in the past 10 years have had any impact 
on the frequency of brief interventions. 
These reports as well as the international literature paint a 
consistent picture of what clinicians do when they discuss 
smoking in consultations. The CRUK survey documented 
high rates of recording smoking status. The consultation 
recordings show that this occurs most commonly in the 
diagnostic portion of the consultation, when GPs were 
trying to understand the cause of a patient’s symptoms. 
If doctors intervene beyond that, the most common thing 
that they do is advise a person to stop smoking, with 89% 
saying they do this frequently or always. Advising on ways 
to quit smoking was reported by clinicians less frequently, 
with 79% discussing the benefits of the stop smoking 
service and 53% advising about medication. Consultation 
recordings, however, show that doctors’ most common 
action beyond asking about smoking status is advising 
about the smoking status. Both the survey of doctors, 
patients, and consultation recordings show that actively 
offering support to the patient is much less frequent. 
In fact, the consultation recordings showed not a single 
incidence of a clear unambiguous offer of support to quit 
smoking, with most offers being made ‘in theory’. 
Dealing with whatever factors are holding doctors back from 
offering support will be key to improving take-up of cessation 
support. GPs often express negativity towards smoking 
cessation, with common explanations of their reluctance 
that it takes too long, it does not work, and creates conflict 
with patients.166 However, such negativity is likely to belie 
deeper feelings about what medicine is, the professional 
identity of doctors, and the place of preventative medicine 
within that.167,168 This is not easy to address, but one study 
found that GPs who saw themselves as part of a public 
health system seemed more engaged with this kind of work.169
Randomised trials show clearly that connecting people to 
behavioural support rather than leaving them to seek it out 
is many times more effective.170–172 Optimising GP systems 
so that this can be done quickly and easily would greatly 
improve the uptake of smoking cessation support.
9.5.3 Policies to increase the frequency and type 
of brief opportunistic interventions given by GPs
9.5.3.1 Quality and Outcomes Framework 
The main policy interventions in England and Wales 
supporting implementation are guidelines from NICE (or 
SIGN in Scotland) and a pay for performance scheme 
called the Quality and Outcomes Framework (QoF). The 
current QoF rewards GPs financially for offering ‘support 
and treatment’ to every patient that smokes, at least once 
every 2 years, and offering support and treatment every 
year to people with a specified set of common smoking-
related illnesses (except smoking-related cancers), and 
people with serious mental illness at least once a year.
The specification of the QoF changed in 2012 to encourage 
clinicians to offer referral and medication, rather than 
simply offering unspecified ‘advice’ on smoking. Moreover, 
2012 saw the extension of the QoF incentives to everyone 
who smokes rather than only those with smoking-related 
conditions, increasing the proportion of adults covered 
from around 20% to 100%. A paper examined the 
impact of this change, which was unexpectedly modest.173 
According to GP records, the proportion of people advised 
to quit smoking showed a 20% (CI 8% to 31%) increase, 
offers of referrals to stop smoking services increased by 
39% (CI 15% to 62%), and prescriptions of cessation 
medication decreased by -8% (CI -21% to +6%).173 One 
explanation for this disappointing impact lay in the detail 
of the change in QoF. GPs are rewarded by entering certain 
specified codes into a template. One of these, ‘smoking 
advice’, was in place prior to 2012 and not removed on 
re-specifying the activity as ‘support and medication’ 
allowing GPs to claim the payments by offering this 
unspecified advice. In addition, some practices claim the 
payments by writing to or texting their patients, rather than 
offering in-person support. This is unlikely to be as effective, 
as offering support in-person can lead to high take up.
The system that rewards treatment and enhanced 
training in primary care could be optimised to ensure 
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that payments are made only as a result of face-to-face 
encounters and remove codes that allow doctors to offer 
general advice to stop smoking. Instead, doctors should be 
rewarded for offering support and medication, as intended.
9.5.3.2 Systematic treatment of tobacco dependency in 
general practice
In 2020, Cancer Research UK published a report174 of 
modelling to show the potential for health improvement 
that would follow improved frequency and quality of brief 
opportunistic interventions. The modelling used the Lumen 
microsimulation model, which creates a virtual population of 
‘people’ who then ‘age’ each year. Their baseline smoking 
status can change because a ‘person’ can quit, relapse, or 
start smoking for the first time. Moreover, a ‘person’ can 
develop one of 19 of the most common smoking-related 
diseases or die of an unrelated cause. The probability 
of developing a smoking-related disease was obviously 
dependent on current smoking status, using epidemiological 
data for the probabilities of these events occurring.
In the baseline scenario, the modellers examined current 
trends of smoking by simply continuing the past year’s 
smoking prevalence. The projection showed that smoking 
prevalence would reach 5.8% by 2039, which implies 
missing the government target for a smoke-free England 
(<5% prevalence by 2030). 
The team then examined the effect of upgrading the 
frequency and effectiveness of brief interventions given in 
primary care using three different scenarios. All assumed 
that GPs intervened at least once a year with everyone 
who attended an appointment who smoked. (About 75% 
of the population see the GP at least once). One scenario 
assumed that GPs referred people to the stop smoking 
service, a second that they prescribed medication, and a 
third that they did both. 
The modelling suggested that improving frequency and 
quality of brief interventions would have important effects 
on smoking prevalence. Compared with the baseline 
scenario where the prevalence was 8.7% in 2030, supporting 
referral would reduce this to 6.4%, prescribing alone would 
reduce the prevalence to 6.7%, and doing both to 6.2%. 
The latter scenario would reduce the incidence of serious 
smoking-related disease by 15% and premature deaths by 
16% over the next 20 years compared with the baseline. 
This would reduce costs of delivering primary care for people 
with these smoking-related diseases by 8% and reduce 
hospital admissions by 19%. Overall, these reduced incidence 
rates would save 16% of the NHS spend on smoking-related 
disease. This amounts to around 0.4% of the total NHS 
budget annually, which would be saved by increasing the 
frequency and quality of brief interventions.
9.6 The role of e-cigarettes and heated 
tobacco products 
9.6.1 E-cigarettes
E-cigarettes consist of a battery-powered element which 
heats an e-liquid to produce an aerosol, commonly referred 
to as a vapour. E-liquids contain glycerine and/or propylene 
glycol, water, flavours and frequently nicotine. Initially this 
nicotine was present in freebase form but nicotine salt 
e-cigarettes have become more popular since emerging 
on the US market in 2015 with the discovery that the 
addition of benzoic acid to freebase nicotine reduces 
the irritant effects of nicotine in the upper airways thus 
enabling inhalation of higher nicotine content products.175 
E-cigarettes were initially designed to resemble tobacco 
cigarettes but have evolved and now there is a plethora of 
different sizes and shapes (such as memory sticks, pens, 
pebbles, metal boxes) including one-time use disposable 
products, reusable, rechargeable kits with replaceable 
cartridges or pods, or refillable open tanks or pods which 
can sometimes be customised, for example so that 
consumers can change the power. The different devices 
vary in the speed and dose of nicotine delivery and users of 
some models, particularly experienced users, can achieve 
similar blood nicotine levels to smoking.176,177 
E-liquids are typically heated at temperatures of 40–180°C 
compared with 900°C for combustible cigarettes.178 As 
e-cigarette vapour does not involve combustion, experts 
generally agree that they provide a less harmful source of 
nicotine than burning tobacco.3,179–180
In England, e-cigarettes increased in popularity between 
2011 and 2014 but use subsequently plateaued with 
around 6% of adults in England and 5% of 11- to 18-year-
olds reporting current vaping in 2019.181 There are two 
routes to market: consumer and medicinal. All available 
e-cigarettes in the UK are currently consumer products 
and although one product (e-Voke) was licensed as a 
medicine,182 it was never brought to market. E-cigarette 
regulations introduced as a result of the Revised European 
Union Tobacco Products Directive183 were translated 
into UK law under the Tobacco and Related Products 
Regulations 2016184 and are overseen by the Medicines 
and Healthcare Products Regulatory Agency (MHRA). 
These regulations stipulate that nicotine e-cigarettes are 
notified to the MHRA prior to being marketed, and cover 
minimum standards for safety and quality, maximum 
capacities and nicotine strength limits, information 
provision, and a prohibition of all broadcast and cross-
border advertising. There is a mandatory 30% sized health 
warning on all nicotine-containing e-cigarettes and refill 
containers which reads ‘This product contains nicotine 
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which is a highly addictive substance’. Other legislation 
prohibits e-cigarette sales to those under 18 years old, and 
there is also an Advertising Code governing the content of 
e-cigarette advertisements.185 The Code covers a range of 
issues and applies to e-cigarettes that do or do not contain 
nicotine, including ensuring inter alia that: marketing 
communications are socially responsible; content is not 
associated with, or could promote, tobacco products; non-
nicotine users or non-smokers are not encouraged to use 
the products; and the marketing does not appeal to young 
people. Health claims on advertisements are permitted 
but only if supported by robust evidence that the product 
in question possesses the advertised health benefit – to 
our knowledge, to date, no such health claims have been 
made.181 Non-nicotine e-cigarettes are regulated under 
General Product Safety Regulations 2005.186
E-cigarettes have caused controversy, with the main 
contested areas being: long-term health effects given 
they have only been marketed for 15 years; that they may 
attract young people to take up nicotine or smoking (see 
chapter 4); the motives and role of the tobacco industry 
in the e-cigarette market; the extent to which they help 
smokers to stop smoking, particularly given many smokers 
vape alongside continued smoking; and whether they 
encourage ex-smokers to continue using nicotine rather 
than stopping smoking and nicotine use altogether. 
In relation to smoking uptake, prospective studies 
have found that using e-cigarettes is associated with 
an increased risk of tobacco smoking187 but a recent 
systematic review indicated that this evidence was 
limited by publication bias, high attrition and inadequate 
adjustment for potential confounders.188 This relationship 
could therefore be due to common liabilities rather than 
so-called ‘gateway’ theories where the use of one drug 
delivery device leads to another. In support of this, studies 
have also shown that smoking can lead to e-cigarette 
uptake.189 Given the difficulty of controlling for all common 
liabilities, studies have used other methods to assess the 
likelihood of a gateway effect. For example, a study of the 
National Youth Tobacco Survey (NYTS) of US high school 
students using matched controls suggested that from 2014 
to 2017, e-cigarettes may have actually acted as a gateway 
out of smoking rather than a gateway to smoking.190 This 
would be consistent with the decline in cigarette smoking 
over this period while e-cigarette use was increasing. 
In relation to concerns about e-cigarettes leading to 
nicotine uptake among tobacco-naïve users, a further 
analysis of the NYTS from 2017 to 2019 reported that 
among e-cigarette users who had never used any tobacco 
products, frequent use and dependence on e-cigarettes, 
and hence nicotine dependence, were rare.191
E-cigarettes emerged from outside the tobacco industry 
but in recent years tobacco companies have been 
investing in vaping products, both through acquisition and 
developing their own products.192 The tobacco industry has 
a long history of deception with regard to their products 
and their impact,193 which has brought into question their 
motives in the e-cigarette market. Some companies have 
declared that they have entered the e-cigarette market so 
that smokers can switch to them and reduce their harms 
from tobacco.194 However, the same companies continue to 
contest regulations for cigarettes.195 
There have been several systematic reviews of e-cigarettes 
for smoking cessation and their findings vary depending 
on the included studies, their participants, products 
used, outcomes, follow-up periods, how missing data are 
handled and how the studies were synthesised.180 Given 
Cochrane’s robust methodologies including efforts to 
minimise bias,196 the Cochrane review of e-cigarettes and 
smoking cessation, which was last updated in 2020,197 is 
summarised here. To be included in the Cochrane review, 
a minimum of 6 months follow up was required but 
otherwise included studies varied due to different types 
of e-cigarettes used, whether smokers were motivated or 
unmotivated to quit and the extent of behavioural support 
offered. Fifty studies were included overall (35 new studies 
since their 2016 review197). There was moderate-certainty 
evidence, using the GRADE system198, from three RCTs 
including 1,498 participants, that quit rates were higher in 
people randomised to nicotine vaping products compared 
with people randomised to nicotine replacement therapy 
(risk ratio (RR) 1.69, 95% CI 1.25 to 2.27). There was also 
moderate-certainty evidence from three RCTs, including 
802 participants that quit rates were higher in people 
randomised to nicotine vaping products compared with 
non-nicotine vaping products (RR 1.71, 95% CI 1.00 to 
2.92). There was very low-certainty evidence from four 
RCTs, including 2,312 participants, that quit rates were 
higher in people randomised to nicotine vaping products 
compared to behavioural or no support (RR 2.50, 95% CI 
1.24 to 5.04).
Head-to-head trials of different e-cigarette devices or 
the same devices with different nicotine levels or delivery 
systems (eg tanks vs disposables, or nicotine salts vs 
freebase nicotine) have not been carried out. However, 
observational studies have suggested tanks may be more 
effective for smoking cessation.199,200
Support for e-cigarettes being effective for stopping 
smoking also comes from observational studies in England. 
A recent time series analysis of population data from 
2007 to 2018 indicated that greater use of e-cigarettes 
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was associated with higher success of quit attempts.201 
For every 1% increase in the mean point prevalence of 
e-cigarettes, the mean point prevalence of successful 
quit attempts increased by 0.106% (95% CI 0.011, 0.201, 
p=0.029). A further time series analysis of the Smoking 
Toolkit Study from 2007 to 2017 similarly found that 
changes in the prevalence of e-cigarette use in England 
have been positively associated with overall quit rates 
and quit success rates but not clearly associated with the 
prevalence of quit attempts and cigarette consumption. 
The latter study concluded that just over 50,000 additional 
smokers were no longer smoking as a consequence of 
e-cigarette use in a quit attempt in 2017.202
Given concerns about dual use,203 two cohort studies in 
England have examined this using the Smoking Toolkit 
Study data with 6204 and 12205 month follow-up periods 
over 2014–2016 and 2015–2018 respectively. The first 
found reductions in cigarette consumption, significantly 
lower quit attempts but no difference in use of evidence-
based support when making quit attempts among dual 
users with e-cigarettes compared with dual users with 
NRT.204 The second observed higher quit attempts but no 
difference in success rates among dual users of e-cigarettes 
compared with exclusive smokers, whereas differences in 
quit attempts and success were inconclusive across dual 
users of e-cigarettes compared with dual users of NRT.205
With regard to ex-smokers, there is some evidence from the 
UK RCT in stop smoking services that ex-smokers continue 
to vape for longer periods than ex-smokers who used NRT 
to stop, although advice given to recent ex-smokers is to 
use e-cigarettes while there is a danger of relapse.206 A 
cross-sectional study in the UK, Canada, USA and Australia 
found that former smokers who vaped reported higher 
dependence on smoking both before and after stopping, 
yet they had greater confidence in staying quit.207 A unique 
role of e-cigarettes in preventing relapse is emerging from 
UK qualitative research.208,209
E-cigarettes could be especially helpful for groups 
in society where smoking is particularly prevalent or 
dangerous, such as people with mental health problems 
and pregnant women. A recent systematic review of 
vaping among people with mental health conditions 
included 31 studies (three from England and 28 from 
outside of the UK). However, the review identified181 no 
published RCTs evaluating vaping products for smoking 
cessation among smokers with mental health conditions. 
A secondary analysis of one trial that included a sample 
of people with a mental health condition and four single-
group pre-post studies were assessed; in four of these five 
studies participants were not motivated to stop. Complete 
abstinence from smoking was achieved by 7–14% of 
participants between 4 weeks and 12 months follow 
up across the studies. A nationally representative study 
carried out in England since this review found no difference 
between the use of e-cigarettes during a quit attempt 
among those with and without mental health conditions 
and the use of e-cigarettes was similarly successful.210 
The review also identified 17 studies that reported vaping 
prevalence in people with mental health conditions outside 
the UK, with rates of current vaping ranging from 3–20% 
among people with mental health conditions in five 
nationally representative population samples; the authors 
reported that these high rates of vaping likely reflected the 
high prevalence of smoking in this group. More research is 
needed in this area.
A recent review of e-cigarettes in pregnant women181 
included 27 studies (6 from the UK and 21 non-UK). There 
was a lack of evidence on the prevalence of vaping during 
pregnancy in England, although pregnant women who 
vape were likely to do so to stop smoking and vaping was 
rare among those who had not smoked. A prospective 
observational study published after the review found that 
the birthweight of infants born to exclusive e-cigarette 
users was similar to that of non-smokers.211 
9.6.2 Heated tobacco products
A new generation of heated tobacco products (HTPs) 
produced by the tobacco industry entered the market in 
2014; prototypical HTPs had been introduced in the 1980s 
but did not achieve commercial success. These products 
differ from tobacco cigarettes in that they contain tobacco 
but rather than the tobacco being ignited, it is heated 
and thermal decomposition produces an aerosol which 
contains nicotine (see chapter 8). There are several different 
types of HTP, with slightly different mechanisms of action, 
most commonly: IQOS (Philip Morris International) and 
glo (British American Tobacco (BAT)) both of which heat 
tobacco sticks to produce the aerosol; and iFuse (BAT) 
and Ploom Tech (Japan Tobacco International) that heat 
an e-liquid to produce an aerosol which then passes over 
tobacco. Temperatures for heating range depending on 
the mechanism of action from 50–350°C.212 Given these 
temperatures are still lower than those required to burn 
tobacco, it seems likely that HTPs will be less harmful than 
smoking.213 In 2020, the US Food and Drug Administration 
(FDA) stated that switching completely from tobacco 
cigarette smoking to IQOS specifically reduced exposure 
to harmful or potentially harmful chemicals, but not 
that IQOS use reduced the risks of tobacco-related 
diseases or reduced harm relative to continued tobacco 
cigarette smoking.214,215 However, little is known about 
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how easily smokers find it to switch completely to HTPs, 
with no evidence from RCTs carried out by independent 
researchers.213 RCTs comparing the effectiveness of HTPs 
vs e-cigarettes are also warranted. 
IQOS is the most widely available HTP, being marketed 
in over 50 countries216,217 and was introduced in the UK 
in 2016, although use of IQOS in the UK remains low.181 
However, in other countries HTP use quickly became 
popular. For example in Japan, IQOS was introduced in 
2016 and captured 15.5% of the tobacco market over the 
subsequent 3 years.218 Cigarette consumption and sales 
have declined significantly suggesting some switching, 
although the extent to which IQOS and other HTP have 
substituted completely for cigarettes (rather than cigarette 
smokers using IQOS as well) is not known.219 
In the UK, IQOS and other HTPs are regulated by Public 
Health England as specified in the Tobacco and Related 
Products Regulations 2016.184 Advertising is allowed for 
the IQOS device but not the tobacco sticks, and similar to 
e-cigarettes 30% text health warnings were required for 
the packs of tobacco sticks, although the warning differs, 
stating ‘This tobacco product damages your health and 
is addictive’. Unlike e-cigarettes which are taxed as a 
consumer product and hence subject to Value Added Tax 
(currently 20%), following a consultation a separate tax 
category was set for HTPs.220 Initially (July 2019), the tax 
rate was matched with that for hand rolled tobacco, but 
annual tax increases will be smaller to create a differential 
over time.221 
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Key points
>  Tobacco industry interference in tobacco control 
has been identified as the greatest obstacle to the 
implementation of evidence-based measures to reduce 
tobacco use.
>  Tobacco companies employ a range of tactics to attempt 
to eliminate or limit the impact of tobacco control 
policies on their business including delaying, weakening, 
foreclosing, circumventing, avoiding, or overturning the 
proposed policy.
>  The key tactics used by the tobacco industry are 
information management, coalition management, 
influencing policy through lobbying, and litigation.
>  The government ‘Better Regulation’ requirement that 
stakeholders are consulted and involved in an impact 
assessment of proposed public health policies enables 
corporate influence over public health policy and can be 
exploited by the tobacco industry.
>  Rigorous adherence to Article 5.3 of the Framework 
Convention on Tobacco Control across the whole of 
government is more important than ever.  
Recommendations
>  The tobacco industry is excluded from all policymaking 
across government, from meeting with government 
officials and elected representatives, from making gifts 
or payments in kind and from any activity likely to or with 
the potential to promote tobacco use.
>  Minutes and all related documentation arising from 
meetings of national and local government services with 
the tobacco industry and with stakeholders linked to the 
industry are immediately published online. 
>  A lobbying register is established for the disclosure of any 
and all funding sources of individuals or organisations 
lobbying government on tobacco control. 
>  Contributions (monetary or otherwise) from the 
tobacco industry or tobacco-industry funded third party 
organisations to political parties, government officials 
at all levels and All-Party Parliamentary Groups are 
prohibited.
>  Tobacco companies are statutorily required to provide 
information to government on their political activities 
and associated expenditure including the names of 
organisations they fund.
>  A tax or levy on tobacco companies is introduced to 
fund independent tobacco control research, including 
independent testing of tobacco industry product 
contents and emissions.
>  Measures are put in place to mitigate tobacco industry 
tactics on ‘Better Regulation’ including; full disclosure 
of conflicts of interests; exclusion of submissions and 
organisations if rules are broken; and the Regulatory 
Policy Committee (which plays a key role in approving 
impact assessments) being subject to the Freedom of 
Information Act.
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10.1 Introduction
Implementation of effective tobacco control policies 
has major financial implications for the tobacco industry, 
which over many years has employed a range of tactics 
to attempt to eliminate or limit the impact of tobacco 
control policies on their business. Tobacco industry 
interference in tobacco control has been identified as the 
greatest obstacle to the implementation of evidence-
based measures to reduce tobacco use.1 In this chapter, 
tobacco industry tactics to undermine tobacco control 
will be reviewed before discussing the current and future 
challenges posed by the tobacco industry to the UK.
10.2 Tobacco industry interference in UK 
tobacco control
Historically, tobacco companies have enjoyed considerable 
influence over public policy-making in the UK and 
elsewhere, often resulting in a largely self-regulatory 
approach to tobacco control.2,3 However, by the late 
1990s, research on tobacco-related documents began 
to weaken the tobacco industry’s status as a political 
insider. For example, the 1999 House of Commons Health 
Committee enquiry into the tobacco industry and the 2000 
Department of Trade and Industry investigation into the 
involvement of British American Tobacco (BAT) in cigarette 
smuggling both deepened distrust of the industry.2,3 This 
paved the way for an increase in statutory regulation in the 
UK and globally.
The UK is a signatory to the first global health treaty, the 
Framework Convention on Tobacco Control (FCTC), which 
includes a commitment to protect health policy from the 
commercial and vested interests of the tobacco industry.4 
The impact of tobacco industry interference in tobacco 
control is specifically reflected in the development of Article 
5.3 of the FCTC.5 This article, arguably the most unique 
feature of the FCTC, seeks to prevent the inappropriate 
influence of the tobacco industry on policy, stating: ‘in 
setting and implementing their public health policies … 
Parties shall act to protect these policies from commercial 
and other vested interests of the tobacco industry’.5
The UK has successfully implemented and enforced 
comprehensive tobacco policies and is consistently highly 
rated globally for its implementation of the FCTC and 
as having the most robust tobacco-control policies in 
Europe.6,7 In the first Global Tobacco Industry Interference 
Index, which assessed how well governments in 33 
countries during the period January 2017–December 2018 
implemented Article 5.3, the UK scored the highest of the 
33 countries surveyed.8  
Strengths of the UK system included:
 >  excluding the tobacco industry from the government 
bodies that set public health policy and from the FCTC 
Conference of the Parties delegations
 >  requiring the government to publish information on 
meetings with the industry
 >  guidelines stipulating that Foreign and Commonwealth 
Office (FCO) officials must not engage on behalf of the 
industry.
However, subsequent research found evidence that  
more tobacco industry attempts to interfere in 
policymaking were made in 2019 than in the previous year, 
and that the UK’s position had fallen to fourth among the 
now 57 countries participating.9 Examples  
of industry interference included:
 >  industry representatives, or organisations affiliated to the 
industry, participating in informal parliamentary groups
 >  industry promoting its Comprehensive Spending 
Review activity among parliamentarians using 
informal parliamentary groups and direct lobbying
 >  individual backbench parliamentarians in England  
and the devolved administrations attending industry 
social functions.
Successful implementation of Article 5.3 remains 
challenging in the UK and globally with the tobacco 
industry continuously adapting to its changing 
circumstances, in both structure and function. Over 
recent decades, significant progress has been made 
in understanding and exposing the corporate political 
activities of the tobacco industry.10–12 The industry typically 
produces dystopian narratives that proposed policies will 
not work and would instead have several undesirable social 
and economic effects, aiming to convince policymakers 
to decide in its interest, which can mean defeating, 
delaying, weakening, foreclosing, overturning or avoiding 
the proposed policy.12 This work, based on two systematic 
reviews, showed that to construct and disseminate these 
narratives three key strategies are commonly used: 
coalition management, information management, and 
direct involvement in decision-making, such as lobbying, as 
well as two subsidiary strategies: illicit trade, and litigation 
which feed into information management by increasing 
the credibility of the industry’s misleading messages; 
litigation also directly impacts policy outcomes by stopping 
policy adoption or implementation (Fig 10.1).12
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To illustrate the tobacco industries’ use of these strategies 
in the UK we focus on a case study of standardised tobacco 
packaging, one of the most significant policy threats to the 
tobacco industry in recent years which came into force in 
the UK on 20 May 2016.13 
10.2.1 Case study: standardised packaging
Plain, or standardised packaging as it is formally known, 
refers to a policy which mandates the removal of all brand 
images, colours, and messages from tobacco products. 
Tobacco products are instead packaged in the same size, 
shape, style and colour with all brand names and variants 
in the same typeface and font size.14 The objective, as set 
out in the Framework Convention on Tobacco Control, is to 
reduce the attractiveness of tobacco products, increase the 
effectiveness of health warnings, reduce the use of design 
techniques that could mislead consumers and reduce the 
chance of non-smokers starting to smoke.15 
Australia was the first country in the world to introduce 
plain packaging for tobacco products in December 2012, 
and the UK government became the second to pass such 
legislation.13,16 The UK government raised the possibility 
of plain packaging in 2008 and in 2010 made a firmer 
commitment to consult on the proposal,17,18 with the 
legislation finally being approved in March 2015. The time 
period from proposal of the legislation to its approval 
provided the tobacco industry with time to formulate and 
test arguments on how to oppose such proposals and 
implement a well-financed, well-thought-out and hostile 
plan to frustrate the legislation which it has gone on to 
implement elsewhere.19
10.2.1.1 Information management
The oldest arguments were that the proposals were against 
the law. In 2008, in response to the initial UK plans, BAT 
argued that the government’s power to introduce plain 
packaging was constrained by law, including the European 
Convention on Human Rights and the WTO Agreement on 
Trade-Related Aspects of Intellectual Property Rights.20 
The argument that standardised packaging legislation 
breached intellectual property (IP) rights was continued 
despite the industry having been given a legal opinion in 
the 1990s that IP laws gave it no protection.21 Although the 
argument that requiring standardised packaging infringed 
international trade agreements was not thrown out by the 
World Trade Organization (WTO) until 2020, expert legal 
opinion from 2012 had already shown this to be a frivolous 
complaint.22
Fig 10.1 Arguments and techniques used by the Tobacco industry: overview of the Policy Dystopia Model.12 
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Aside from trying to undermine the legal foundation for 
the proposals, and despite clear evidence that marketing 
promotes tobacco use and that the pack was now the key 
form of marketing available to the tobacco industry, the 
industry argued there was simply no credible evidence the 
legislation would work. Alex Parsons from Imperial Tobacco 
told the BBC in 2011: ‘Quite frankly, it is a preposterous 
notion’.23 The managing director of Japan Tobacco 
International (JTI) in the same year said: ‘Put simply, this 
will not work. We hope common sense will prevail’.24 The 
secretary general of the industry trade association, the 
Tobacco Manufacturers’ Association, asserted: ‘There is no 
reliable evidence plain packaging will reduce rates of youth 
smoking.’25
To support its argument that there was ‘no evidence’ 
that standardised packaging would be effective, the 
industry created its own evidence against the measure. 
It commissioned reports from legal firms and academics 
to critique the evidence base for the proposals, but which 
largely misrepresented and attempted to discredit the 
independent evidence which backed these proposals.26,27 
For example, the industry argued that evidence would be 
insufficient  to introduce a policy unless there was evidence 
of a reduction in smoking directly attributable to plain 
packaging, which was neither feasible nor appropriate as 
observational evidence could not be obtained without the 
policy first being introduced.28,29 The use of independent 
organisations to produce reports favourable to industry 
positions is a well-established information management 
tactic and, in this example, BAT commissioned Deloitte to 
produce a report which apparently showed that legislation 
in Australia had been ineffective.30,31 While a subsequent 
independent review of the report found the methodology 
to be weak and containing several important errors, the 
sound bite the report gave to tobacco companies was 
immediate.30 In a study of opposition to standardised 
tobacco packaging during the 3-year period 1 January 
2011 to 31 December 2013 (including the Department 
of Health consultation on standardised packaging for 
tobacco products in 2012), 50 out of 57 publicly available 
research reports used to oppose plain packs could be 
linked to the industry.32 The reports were widely cited in 
industry submissions to the policy consultation, and were 
amplified by the many organisations the industry funded 
to make its arguments more palatable (see coalition 
management).32,33
The industry also tried to argue that not only was the 
proposal unlawful and doomed to fail, but also that 
package branding was not that important.  
Philip Morris’ submission to the 2012 UK consultation 
stated that: ‘There is overwhelming evidence which 
demonstrates that brands and packaging have nothing to 
do with why young people begin smoking.’34 It went on to 
say that it could not be demonstrated that packaging has 
any effect on the decision to smoke.34
There are numerous internal industry documents which 
suggest otherwise. One Rothmans document from 1982 
stated that the company was very aware that every 
customer carried its logo on the package with them all the 
time.35 The document went on to say ‘That package comes 
out many times a day, and every time it is seen makes 
a personal comment about the person who carries and 
shows it’.35
The industry also made baseless claims that other  
countries had either dropped the idea of standardised 
packaging or that it wasn’t working.14,36 For example, a 
national account manager for BAT UK described the 
company's surprise at the government's proposal for plain 
packaging of tobacco products, 'especially given that 
a number of governments around the world, including 
Canada, have already looked closely at this measure  
and have decided it wouldn’t work’.14,36 
Indeed, the industry argued at one point that the UK had 
dropped the idea once already, which was false.14
10.2.1.2 Illicit trade
A particularly fruitful argument the industry used, again 
underpinned by an information management strategy to 
support its case, was that the UK plans for standardised 
packaging would lead to an increase in smuggling. This 
drew upon the idea that plain packs would be easier to 
counterfeit and so the phrase ‘a counterfeiters’ charter’ 
was born and much reproduced.37 This led to the argument 
that standardised packaging would be a boon for criminals. 
The next step in this narrative was that these would not 
be ordinary criminals but terrorists, and hence that plain 
packaging would help to fuel international terrorism. 
Thus in May 2012, Imperial CEO Alison Cooper said: 
‘Do we really want to hand business like this to gangs in 
Eastern Europe funding crime and even, in some cases, 
terrorists?’.38 This led to a story in The Sun, the UK’s 
biggest selling newspaper at the time, which argued that 
‘groups who benefit from such trade include al-Qaeda and 
Hezbollah’.38 There was and is no independent evidence 
that plain packaging increases illicit trade, crime or 
terrorism.39
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The scaremongering on illicit trade found a fertile audience 
in the retail sector who feared further pressure on revenues 
and already tight profit margins.40,41 The industry also 
advanced, among complaints about a ‘nanny state’, 
the ‘slippery slope’ argument whereby it suggested that 
if plain packaging plans were not opposed, then other 
more draconian measures would be introduced.42 Michael 
Prideaux, BAT’s communications director said in 2012: 
‘There is a feeling among the general public that the 
theft of trademarks is a step too far in terms of tobacco 
regulation. Who will be next? I think the libertarian 
argument resonates among people who wouldn’t normally 
take notice of what the tobacco industry say’.43 The 
unfounded claim of trademark theft is also woven in here.
All this occurred despite evidence of tobacco industry 
involvement in tobacco smuggling.44,45 It was underpinned 
and supported by the tobacco industry’s manipulation of 
data on smuggling to exaggerate the scale of the problem 
and scaremonger.3 The industry fed its misleading claims 
and data on the illicit trade into its consultation responses 
and ensured they were widely disseminated in the press, in 
both instances attempting to give the impression that such 
data and claims were independent.3,46,47
10.2.1.3 Coalition management 
The industry often uses other organisations or individuals 
that it funds to make its arguments more palatable and 
credible, to echo its arguments, and to act as media 
spokespeople and give the false impression of widespread 
opposition to the policy.32 In addition to the 12 tobacco or 
packaging companies involved in opposing standardised 
packaging, research identified 109 organisations opposing 
standardised packs, 82 (75%) of which had financial links 
with tobacco industry companies and 20 (18%) of which 
had non-financial links (Fig 10.2). These organisations 
included smokers’ rights groups, public relations and 
Fig 10.2 Number, sector and relationship with TTCs of organisations opposing, or facilitating opposition to, 
standardised packaging in the UK 2011–2013 (excludes tobacco manufacturing, packaging and design companies), 
n=109. PR, public relations; TTC, transnational tobacco company.32 
























































































































































































Business (other companies) Business (associations) Civil society Academia 
State
  None/Unknown (7,6.4%) 
  Non-financial relationships (20, 18.4%) 
  Financial relationships (82, 75.2%)
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lobbying firms, business associations, universities, law firms, 
research consultancies and retail associations. Their links 
with the industry were however rarely transparent.32
The tactic of funding and mobilising third parties and front 
groups – whose links to industry are generally hidden – to 
present the tobacco industry’s case, is a direct response 
by the tobacco industry to Article 5.3 of the FCTC. The 
industry used a very similar approach in opposing revisions 
to the EU Tobacco Products Directive where its leaked 
documents describe third party involvement as ‘key to 
success’ and identify ‘indirect engagement’ as a priority 
over direct engagement.48
‘Better Regulation’ is a system of governance which 
requires, inter alia, that stakeholders, particularly economic 
stakeholders, are consulted during the development of a 
policy and an impact assessment of the proposed policy 
is carried out in part informed by evidence stakeholders 
can submit.49,50 The tobacco industry and its allies 
helped implement Better Regulation in the mid-1990s, 
predicting that it would make it harder for governments 
to enact public health policies.27,51 During the government 
consultation on standardised packaging, the tobacco 
industry, operating in part via its third parties, took 
direct advantage of Better Regulation and ensured the 
government consultation was flooded with responses and 
that such responses promoted the misleading evidence it 
had commissioned, while failing to declare its links to that 
evidence and the third parties involved.3,27,46,52,53 
10.2.1.4 Direct influence on policymaking 
In addition to the largely covert influence on standardised 
packaging legislation outlined above, the industry has also 
engaged in overt lobbying.
In 2010 the Labour government was replaced by a coalition 
of Conservative and Liberal Democrats. Prime minister 
David Cameron, along with several senior colleagues, 
were close to lobbyist Lynton Crosby who has long 
represented tobacco interests.54,55 In 2012, the UK branch 
of Crosby’s consultancy firm started a contract with Philip 
Morris International (PMI), around the same time Crosby 
became the Conservative party's election campaign 
strategist and a month later he chaired a meeting in which 
members of the tobacco industry discussed strategies to 
block the government’s plain packaging plan.55–57 In the 
same year, Forest (Freedom Organisation for the Right to 
Enjoy Smoking Tobacco), which receives almost all of its 
funding from the four major tobacco companies, launched 
the ‘Hands Off Our Packs!’ (HOOPs) campaign to ‘give 
opponents of plain packaging of tobacco a chance to have 
their say’.58,59 At the close of the first UK public consultation 
on plain packaging, Forest announced that 235,000 people 
had signed an anti-plain packaging petition.60 However, 
questions have been raised regarding the legitimacy of the 
signatures, with the Department of Health highlighting 
evidence of falsification.61 JTI launched its own campaign 
which included advertisements in leading broadsheet 
newspapers questioning the evidence underpinning the 
proposed regulation, the allegedly detrimental effects 
of the policy in facilitating illicit trade, and unintended 
impacts on small businesses.62,63 These were timed to 
coincide with political party conferences in the autumn of 
2012.62,64 Imperial Tobacco also attempted to influence 
the views of MPs by buying an advert on the cover of 
The House (a political magazine delivered directly to MPs 
and civil servants each week) which mimicked a warning 
message on tobacco packets and read ‘WARNING Plain 
Packaging: Bad for Business Good for Criminals’ but did 
not declare that it was an advert paid for by Imperial 
Tobacco.19,65
Having carried out a consultation, the government – 
apparently influenced by industry arguments that there 
was insufficient evidence for plain packaging – announced 
that it would wait and see what the situation in Australia 
suggested, supporting the tobacco industry’s hopes of 
delaying and undermining legislative proposals. At the 
end of November 2013, the government announced that 
it had reversed its decision and would again consider the 
introduction of standardised packaging, commissioning 
a review to look into the relevant evidence (the Chantler 
review).66 The Chantler review found it ‘highly likely that 
standardised packaging would serve to reduce the rate of 
children taking up smoking and implausible that it would 
increase the consumption of tobacco’.66 After backbench 
peers, supported by Action on Smoking and Health (ASH) 
and the Smokefree Action Coalition, tabled an amendment 
to the Children and Families Bill to introduce standardised 
packaging, and recognising the amendments had 
sufficient parliamentary support to pass, the government 
adopted the amendments as its own, and in the summer 
of 2014 announced a second consultation with draft 
regulations.14,66 Recognising another opportunity to lobby 
MPs, Forest launched a follow up campaign called ‘No, 
Prime Minister’.67 This campaign invited its followers 
to send a pre-written email both to their local MPs and 
the then prime minister David Cameron, to ‘make your 
feelings against plain packaging known’ and the campaign 
was advertised in The House magazine and a range of 
politically orientated websites and blogs.67–69 Despite this 
opposition, in January 2015 the government announced 
that it would offer a free vote on the proposals and the bill 
was passed in March 2015.13 
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10.2.1.5 Litigation 
Two months after the legislation was passed, PMI, BAT 
and JTI filed lawsuits against the government alleging, 
among other things, breach of international trademark 
rules as well as UK and EU law. Once again evidence 
documenting the industry’s disinformation strategy 
provided pivotal in the dismissal of these lawsuits, with the 
judge concluding that the industry’s evidence ‘does not 
accord with internationally recognised best practice’ (para 
374) and ‘I am of the conclusion that, measured against 
internationally accepted research and evidence standards, 
that evidence, as a generality, was materially below par 
(para 404)’.70 In short, in addition to the active advocacy 
campaign in parliament by ASH and the Smokefree Action 
Coalition, vital evidence on the impact of plain packaging, 
the effective and timely documentation of the tobacco 
industry’s misconduct and disinformation played a key role 
in ensuring plain packaging legislation was both passed 
and upheld. 
10.3 Undermining UK tobacco control policy: 
current and future concerns
Despite the increased understanding of the narratives and 
strategies used by the tobacco industry, continued vigilance 
is required by governments as well as an active civil society 
to expose and counter industry interference in tobacco 
control. Here we give examples and a more detailed case 
study of how the tobacco industry continues to undermine 
tobacco control policies and illustrate some of the current 
challenges in the UK.
Given the EU’s historical involvement in the supply, taxation 
and regulation of tobacco products in the UK, Brexit is 
likely to have an impact on both tobacco control and 
potentially on tobacco industry interference.71,72 EU rules 
relevant to tobacco control are incorporated into UK law 
and will continue to apply to the UK after Brexit. However, 
there is a risk that without the regular EU timetable for 
reviewing and updating tobacco control legislation, 
progress in the UK may become more subject to changing 
political priorities with the potential for tobacco control to 
fall down the agenda.71 This risk is reinforced by previous 
efforts of tobacco companies and their allies to create 
opposition to EU regulations, including those within the EU 
Tobacco Products Directive (TPD), and calls for aspects of 
legislation to be repealed.73,74 Furthermore, several high-
profile members of the current UK government have links 
to the tobacco industry and tobacco industry-funded think 
tanks such as the Institute of Economic Affairs,9 suggesting 
that the government may not be pro-active in working to 
introduce stronger tobacco control regulation. 
10.3.1 Undermining tobacco taxes with industry 
pricing and profitability
Increasing tobacco taxes above inflation and combatting 
illicit trade are core tobacco control strategies in the UK,45 
together they reduce the affordability of tobacco and 
have driven down smoking prevalence for over 20 years 
while also reducing inequalities.75–77 The public health 
benefits of tobacco taxes can be increased further if the 
revenues they generate are reinvested into wider tobacco 
control strategies aimed at reducing smoking prevalence 
and uptake.78,79 While tobacco taxes have been broadly 
successful in the UK, their impact has been undermined 
by the tobacco industry’s gaming of the tax system via its 
pricing tactics and tax avoidance strategies.80,81 These are 
described in detail in chapter 7 but are further explored in 
the context of this chapter. 
Tobacco companies have employed a range of pricing 
strategies to minimise the impact of tobacco taxes on 
tobacco sales, including undershifting taxes (absorbing 
the tax increase) on its cheapest products, overshifting 
taxes (increasing its prices above the tax increase) on 
more expensive products in order to maximise profits, 
and smoothing price increases throughout the year 
to prevent sudden large increases in price that might 
otherwise help stimulate quitting80,82 (see chapter 7). In 
the UK a combination of both under- and overshifting 
and market segmentation has pushed more smokers 
towards cheaper tobacco products, which in turn appears 
to reduce their chance of successfully quitting.81,83–86 
Government responses to these tobacco industry tactics 
have had an impact. For example, the introduction of the 
minimum excise tax in 2017 in response to the growing gap 
between cheap and expensive cigarettes was associated 
with significant decline in sales and in tobacco industry 
revenues.87 However, tobacco companies continue to 
undermine these measures by overshifting tax increases 
at different rates across the product range to keep the 
cheapest tobacco cheaper relative to the more expensive 
products; hand rolled tobacco remains significantly cheaper 
than cigarettes.88 This highlights the need for continued 
strengthening of tax structures to counter tobacco industry 
interference in this crucial tobacco control measure.
Despite having some of the highest tobacco taxes in the 
world, there remains a considerable deficit between the 
economic cost of smoking to the UK economy and the 
money raised from excise duties. For example, in 2017 
the Department of Health estimated that the cost of 
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smoking to the economy was in excess of £11 billion per 
year in England (England accounts for 84% of the total 
UK population), including £5.3 billion to employers, £2.5 
billion to the NHS and £4.1 billion to the wider economy, 
while excise duty from the sale of tobacco products across 
the UK raised £9.5 billion, a deficit of over £1.5 billion.89,90 
This imbalance is particularly shocking given that, despite 
their immense profitability, tobacco companies successfully 
employ a range of tax avoidance strategies in the UK.91 
The very low rates of UK corporation tax paid by tobacco 
companies is a key example. The tobacco industry is 
estimated to make in the region of £1.5 billion in profits per 
year, but Imperial Tobacco, BAT, and Gallaher (a subsidiary 
of JTI), representing the majority of the market share, 
collectively paid just £83.6 million in corporation tax in 
2016.79,90,92 Furthermore, using group relief (the ability to 
offset losses made by one subsidiary against profits made 
by another) the UK subsidiaries of Imperial Tobacco and 
BAT – both headquartered in the UK – lowered their UK 
corporate tax burden by a joint total of £2.5 billion between 
2010 and 2019.91 This stands in stark contrast to far larger 
reported sums paid by the same tobacco companies in 
domestic tax in other countries and overseas profit taxes, 
suggesting that the UK could generate considerable 
government revenue from a more appropriate corporation 
tax surcharge on profits.79,90 This in turn could be used to 
support tobacco control efforts including cessation services 
and mass media campaigns and contribute to offsetting 
the economic cost of smoking to the UK economy.
10.3.2 Next generation products: (re)opening 
doors for the tobacco industry
New consumer tobacco and nicotine products, including 
e-cigarettes and heated tobacco products, generally known 
as next generation products (NGPs), have emerged on 
the market. A key current and future area of concern is the 
tobacco industry’s use of novel NGPs as an opportunity to 
re-engage with policymakers, which has the potential to 
undermine the political consensus that has characterised 
the tobacco control movement and been central to its 
success.93,94 
In the most recent Global Tobacco Industry Interference 
Index the majority of the incidents of tobacco industry 
interference in the UK related to NGPs.9 Many of the 
longstanding techniques used by tobacco companies 
to attempt to engage decision-makers in a dialogue are 
being used, but this time in relation to NGPs. For example, 
in 2017, 2018 and 2019 PMI had a promotional stand at 
the Conservative party conference that showcased its 
heated tobacco product IQOS and Juul, partly owned by 
the cigarette manufacturer Altria, held two closed events 
for MPs and their special advisers at the same conference, 
and sponsored panels at Labour and Conservative party 
events.9,95–97 More recently, in July 2019, a UK MP invited 
fellow members to a PMI event to ‘discover smoking 
statistics for your constituency and how together we can 
deliver a smoke-free future’ (Fig 10.3).98 
Between 2015 and 2019 the UK Vaping Industry 
Association (UKVIA) contributed ‘benefits in kind’ 
of between £66,000 and £74,000 to the All-Party 
Parliamentary Group (APPG) for Vaping (previously the 
APPG for E-cigarettes), which also housed the APPG’s 
secretariat.99,100 UKVIA’s members include tobacco 
companies JTI, Imperial Brands, PMI, and BAT.99 The APPG 
for Vaping’s membership includes MPs and lords from 
both leading political parties, and in 2019 BAT reportedly 
used an APPG meeting to promote initiatives relating to 
their NGPs and as an opportunity to suggest that the 
Department of Health should engage more with the 
industry.101,102
While most forms of tobacco advertising and promotion in 
the UK are banned, tobacco companies are continuously 
innovative in their marketing methods which poses a 
challenge to these bans (see chapter 5). For example, 
tobacco companies increasingly use brand websites, many 
of which offer their products for sale directly to consumers, 
and social media platforms like Instagram, Twitter and 
Facebook as marketing tools to bypass advertising bans 
globally.103–106 A recent example of this was highlighted 
by the UK Advertising Standards Authority (ASA) 2019 
investigation of BAT’s use of social media platforms 
following complaints that BAT’s posts were designed 
to maximise exposure of their products to children, 
Fig 10.3 Invitation to Philip Morris International’s 
summer drop in event at the House of Commons.98 
Used with permission from Stopping Tobacco Organizations and 
Products (STOP)
RSVP smoke-freeUK@pmi.com
Mr Ross Thomson MP 
invites you to Philip Morris Limited's summer drop-in event
Discover smoking statistics for your constituency 
and how together we can deliver a smoke-free future
Tuesday 16th July, 12:30 - 18:00 
Churchill Room, House of Commons
A photo opportunity and refreshments are available
MAKE A CHANGE TODAY, UNSMOKE YOUR WORLD
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teenagers and non-nicotine users in contravention of UK 
advertising regulations.107,108 In December 2019, the ASA 
ruled against British American Tobacco and in a follow-
up statement, Facebook and Instagram announced that 
branded content that promotes goods such as tobacco 
products ‘will not be allowed’.109,110 
10.3.3 Case study: the EU/UK flavourings ban
Flavoured tobacco is used to increase the attractiveness 
and palatability of tobacco smoke.111 Menthol is the most 
widely used flavour, being used in an estimated 21% 
of the UK market with approximately 6 billion menthol 
cigarettes sold in the UK in 2018.112 Regulation of flavours 
is recommended by the WHO FCTC on the grounds that 
menthol cigarettes generate higher levels of nicotine 
dependence, greater difficulty in quitting and create 
misleading perceptions of reduced harm,113–116 and evidence 
that the industry has manipulated the menthol content of 
cigarettes to promote initiation and sustain use.111
In 2014 a ban on the sale of cigarettes with a 
characterising flavour, including menthol, was introduced 
as part of the revised European Tobacco Products 
Directive (EU TPD) which was written into UK law and 
came into force in May 2016.117 An independent survey 
in 2018 suggested that up to 17.5% of menthol smokers 
in England intended to quit (and others to cut back) 
after the menthol ban was implemented.118 This would 
equate to an approximate 3% reduction of the total 
cigarette market in the UK with sales volumes reduced by 
approximately 1 billion sticks per year – a major threat to 
tobacco companies’ revenues.119 Moreover, menthol tobacco 
products are used disproportionately more by younger 
age groups, with evidence suggesting that these products 
promote experimentation and hence indicating that the ban 
threatens the recruitment of the new generation of smokers 
central to the tobacco industry business model.116,120
Leaked PMI documents revealed their opposition to 
‘ingredients bans’ generally and their identification of the 
European menthol ban as a key threat to business, and 
laid out plans for opposition of the EU TPD.121 A range 
of tobacco industry tactics, along the lines outlined in 
this chapter, were employed to delay and weaken the 
TPD.48,122,123 Amid this opposition from the tobacco industry, 
and similar to the one-year ‘sell-through period’ the 
industry was granted when standardised packaging was 
introduced into the UK, manufacturers and retailers were 
granted a 4-year transition period ostensibly to prepare 
for the ban on menthol cigarettes with implementation 
postponed to 2020.117,124 This delay gave the tobacco 
industry time to implement a revised strategy around 
menthol, particularly in countries like the UK with a high 
menthol market share, to take advantage of the delay to 
boost sales; develop new tobacco products and accessories 
to circumvent the law; and to capitalise on the upcoming 
ban to promote other tobacco products.
10.3.3.1 Boosting sales during the phase-out period
The 4 years of delay between introduction of the TPD and 
implementation of the flavourings ban was designated a 
‘phase-out period’ by the European Commission. However, 
data on menthol and capsule cigarette sales show a steep 
increase in the menthol/capsule median market share in 
the UK from 14% in 2014 to 21% in 2018.125 This equates 
to approximately double and quadruple the EU median 
market share in 2014 and 2018, respectively.125 Tobacco 
companies encouraged retailers to sell menthol cigarettes 
right up to the point of implementation with PMI releasing 
statements on plans for ‘buy back’ schemes while BAT and 
JTI offered a potential ‘stock swap’.126,127 This suggests that 
the tobacco industry’s strategy was to use the ‘phase-out 
period’ to achieve the opposite, aiming to prolong and 
increase menthol sales.128,129
As late as May 2020, tobacco companies and their 
front groups were reported to be lobbying for further 
postponement of the ban in the EU, including the tobacco 
industry front group Forest EU which had previously 
described the ban as an ‘unwarranted attack on consumer 
choice that will do little to deter children from smoking’.130 
While these attempts were not successful at the EU level, 
there is concern that the tobacco industry may exploit the 
UK exit from the EU to roll back the flavourings ban after 
the transition period.131,132
10.3.3.2 Circumvention through product innovation
The tobacco industry has a long history of attempting to 
bypass product restrictions80,133 and has attempted to do so in 
relation to the flavourings ban by exploiting the fact that the 
legislation applies only to cigarettes and hand rolling tobacco, 
leaving cigars, cigarillos and pipe tobacco exempt:134–137
 >  JTI launched a 10 pack of cigarillos with menthol 
capsules in the 6 months leading up to the ban.138 
These cigarillos closely resemble cigarettes, were 
launched under JTI’s popular Stirling cigarette 
brand, and were promoted to retailers as a way to 
circumvent the menthol ban.111,137 Cigarillos offered 
further advantages to tobacco companies due to 
them being subject to lower taxes and not covered by 
legislation on branding or minimum pack size under 
UK standardised packs legislation.134 The cigarillos 
were therefore legally allowed to be sold in packs 
of 10, making them approximately half the price 
of the cheapest cigarette packs on the UK market. 
Euromonitor international data covering the period 
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between introduction of the TPD and implementation 
of associated UK law suggests a growth in sales of 
cigarillos, reversing a previous downward trend.13
 >  Imperial Tobacco followed suit by adding a similarly 
priced 10-pack of menthol crushball cigarillos under its 
JPS Players range. Imperial’s UK market manager said 
that this product would: ‘help bridge the gap left by 
the ban’.111,139
 >  BAT, JTI, PMI and Imperial all developed new or 
variation cigarette ranges designed as alternative 
products for menthol users and promoted as ‘for 
adult  smokers who previously preferred menthol’, 
‘menthol reimagined’, ‘the Marlboro menthol blend – 
without methylation’, and to ‘cater for their menthol 
and crushball customers’, respectively.140–143 Tobacco 
companies had between them created 29 new product 
lines to replace menthol products due to be banned.111
 >  Tobacco accessories are also excluded from the current 
TPD regulations when they are not sold within the 
same packaging as tobacco or cigarettes.134,135 Imperial 
Tobacco launched menthol and capsule roll-your-
own (RYO) filter tips and ‘menthol chill’, which could 
encourage menthol cigarette smokers to switch to RYO 
rather than quit.144,145 Most recently, their launch of 
‘menthol chill’ and ‘fresh mint’ ‘flavour infusion cards’ 
allow users a menthol flavour if inserted into factory-
made cigarettes or packs of hand rolling tobacco.146
In short, therefore, each tobacco company has sought 
to circumvent and undermine the menthol ban, using 
approaches that vary according to company market share 
and product range. It appears the ultimate intention is 
to minimise any public health benefit of the ban through 
quitting and reduced uptake and instead use it as an 
opportunity to maximise sales by encouraging switching to 
and uptake of their alternative menthol products.
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Key points
>  If it is accepted that tobacco products are harmful 
and addictive and it would be best if they were not 
manufactured, sold and consumed at all, this gives us 
a basis for evaluating any policy which seeks to reduce 
tobacco consumption and tobacco-related harm, and 
improve the regulation of tobacco products and markets.
>  The first step in any argument about tobacco control 
always focuses on the autonomy of the consumer of the 
tobacco product.
>  The key features of an autonomy-first approach are to 
ensure that people have the information they need to 
make informed decisions and that they are supported in 
the exercise of their autonomy. 
>  Accurate information is not generally known by 
consumers about how harmful, or how addictive, tobacco 
products are, or how dangerous they are to third parties.
>  In a market for an addictive product in which information 
is supplied in inaccurate and misleading ways it is 
arguable that the choice to smoke is framed in such a 
way as to make that choice presumptively unfree.
>  Justice is another crucial ethical principle. It is harmful 
and unjust for the poorest and most vulnerable 
members of our communities to be most at risk of 
smoking-related illness; and it is the easiest element in 
such inequalities to remedy.
>  Tobacco is a product unlike any other, and the usual 
arguments about consumer choice and the freedom 
of citizens to enjoy their pleasures freely without undue 
interference from the state do not apply.
Recommendations
>  The kinds of information and messaging which the 
tobacco industry may use are controlled, such as 
regulation of tobacco use in film and television.
>  The range of signalling to users is widened to include price 
(taxation both to discourage purchase and signal health 
risk), incentives to quit (money and other payments to quit 
or discourage uptake of smoking) and incorporation of 
smoking health advice in general health consultations.
>  There is a focus on reducing the uptake of smoking, and 
supporting and encouraging existing smokers to quit, as 
this is practical and ethical.
11.1 Introduction
The ethical case for tobacco control has been made in 
successive reports from the RCP Tobacco Advisory Group, 
focusing on specific issues of smoking in public places, smoking 
and children, smoking and mental health, and nicotine harm 
reduction as a clinical and public health strategy.
The central ethical issue is that tobacco products, however 
consumed, are directly hazardous to the consumer’s health, 
and that smoking tobacco is hazardous to those around the 
primary consumer. Not only are these products hazardous 
to health, they are addictive. These two factors would be 
the foundation of strong arguments for prohibiting the 
manufacture and sale of such products, were they newly 
introduced to the market. Measures short of prohibition 
have had significant success over the years, but as outlined 
in chapter 10, at every stage the tobacco industry has 
sought to disrupt, discredit and undermine public health 
efforts to reduce uptake of smoking, assist smokers in 
quitting, and promote smoke-free public places. 
So, if it is accepted that given the nature of tobacco 
products as harmful and addictive it would be best if they 
were not manufactured, sold and consumed at all, this 
gives us a basis for evaluating any policy which seeks to 
reduce tobacco consumption and tobacco-related harm, 
and improve the regulation of tobacco products and 
markets. Here we consider the general ethical principles for 
a systematic approach to making smoking obsolete. 
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11.2 Autonomy
The first step in any argument about tobacco control 
always focuses on the autonomy of the consumer of 
the tobacco product. Historically the aim has been to 
persuade current or potential users of tobacco products 
that it is unwise and unsafe to use these products, and 
to stop doing so as soon and as effectively as possible. 
This involves provision of clear, accurate information 
about the effects of tobacco products on users and 
those around them. Such information has become more 
detailed in content and sophisticated in presentation over 
the years, as research has established the harms of these 
products, their addictive nature, the health inequalities 
they enhance, and the deceitful and evasive practices 
of the tobacco industry. Initially, such information was 
provided in a media space in which, ironically, public health 
messages competed for attention with tobacco product 
marketing through advertisements, branding, product 
placement and so forth. Given the scale and sophistication 
of tobacco marketing, the countermeasures against 
public health messaging deployed by the industry, the 
cultural prevalence of smoking and the addictive nature 
of the product, public health messaging could only do so 
much. Numerous steps have been taken over the years 
to equalise the terms of this competition, and indeed to 
enable public health information to dominate. But public 
health campaigns, supported by clinical interventions when 
health professionals are in contact with patients and by 
campaigns in schools, are limited in efficacy while they take 
place in a cultural context in which the meaning of smoking 
is changing only slowly. For instance, while smoking retains a 
certain glamour or signals rebellion and resistance to social 
groups for whom this matters (particularly young people), 
messages about health and harm may fail to land, or be 
rejected for the very same reason they might be thought 
persuasive: ‘Dangerous and disobedient? Yes please!’ 
At this stage in the history of tobacco, it is probably true 
that everyone knows that tobacco products are harmful. 
However, it is not generally known how harmful, or how 
addictive, these products are, or how dangerous they 
are to third parties. And to some extent it is possible that 
the rapid acceptance in the market of e-cigarettes and 
vaping products have muddied the waters, by confusing 
people about the relative safety of different products. 
Information-led approaches are therefore still important, 
and still sit comfortably with an autonomy-first approach. 
There are two key factors involved. First, to ensure that 
people have the information they need to make informed 
decisions and second, that they are supported in the 
exercise of their autonomy. This means ensuring that 
people genuinely can exercise choice, rather than be under 
peer pressure to smoke, be misled about the relative risks, 
or find that the default in a social situation is to explain why 
they are not smoking rather than why they are. An analogy 
here is with a consent-first approach in sex education: much 
sexual health-related harm can be removed or mitigated by 
ensuring that consent is overt, free and explicit as the norm. 
The autonomy-first approach in tobacco control does raise 
the question of whether this means there can be a free 
choice to smoke. The industry and its supporters are very 
keen on arguing that there can, and up to a point, this may 
be so. But only up to a point. In a market for an addictive 
product in which information is supplied in inaccurate and 
misleading ways (for instance through attractive branding, 
or cultural signalling about a purported association 
between smoking and sexiness), it is arguable that the 
choice to smoke is framed in such a way as to make that 
choice presumptively unfree. This suggests that two broad 
approaches may legitimately be tried: one is to control the 
kinds of information and messaging which the industry and 
retailers may use (advertising bans and plain packaging 
are only the start, and other measures such as regulation 
of tobacco use in film and television are reasonable and 
proportionate steps). The other is to widen the range of 
signalling to users beyond express public health messaging 
to include price (taxation both to discourage purchase 
and signal health risk), incentives to quit (money and other 
payments to quit or discourage uptake of smoking) and 
incorporation of smoking health advice in general health 
consultation (eg in routine GP or midwife consultations). 
11.3 Justice
Should we go beyond this autonomy-first approach? 
We consider that the answer to this is yes. Other ethical 
principles are relevant here. The first is justice: noting that 
smoking prevalence is growing most rapidly internationally 
in low- and middle-income countries (LMICs), and 
domestically, that smoking prevalence is strongly inversely 
correlated with income (and social class), there is a direct 
link between inequality in smoking prevalence and 
inequality in health. It is harmful and unjust for the poorest 
and most vulnerable members of our communities to be 
most at risk of smoking-related illness; and it is the easiest 
element in such inequalities to remedy. 
The Cape Town Declaration on Human Rights asserts 
that the manufacture, marketing and sale of tobacco 
are incompatible with the human right to health. The 
ecological burdens are borne by LMICs while the profits 
accrue in the rich world. Almost 90% of all tobacco 
production is concentrated in the developing world. 
Tobacco transnationals based in high-income countries are 
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literally and metaphorically burning the resources and the 
future of the most vulnerable people on our planet.1–4
International measures, such as the Framework 
Convention on Tobacco Control, do exist, but it is essential 
that governments show the will to abide by their legal 
commitments under the convention, and to use diplomatic, 
trade and legal measures to encourage others to do so. 
Central to this is to press governments to recognise that 
health is at the heart of all policy issues, from defence to 
trade to economic development to culture. It is important 
to break the argument that while health matters, economic 
development matters more, and that international 
trade rules and development policy could permit or even 
encourage investment in or protection of tobacco farming, 
processing and manufacture. Countries with significant 
tobacco farming or manufacture economies should be 
encouraged and assisted to shift to the farming and 
production of alternative products.
In the short term, while making smoking obsolete would be 
difficult and will require public and political support, a vision 
which guides a strategy toward these goals is feasible. A 
focus on reducing uptake of smoking, and supporting and 
encouraging quitting among existing smokers, is practical 
and ethical. Tobacco is a product unlike any other, and the 
usual arguments about consumer choice and the freedom 
of citizens to enjoy their pleasures freely without undue 
interference from the state do not apply both because 
tobacco products are harmful and addictive and because 
the industry has demonstrated itself incapable of acting 
honestly and responsibly, repeatedly and worldwide.
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